{"PMC7152447": [["Pleural SpaceThe pleural space is a potential space formed by the parietal and visceral pleura.", [["Pleural", "ANATOMY", 0, 7], ["pleural space", "ANATOMY", 17, 30], ["parietal", "ANATOMY", 66, 74], ["visceral pleura", "ANATOMY", 79, 94], ["pleural space", "MULTI-TISSUE_STRUCTURE", 17, 30], ["parietal", "MULTI-TISSUE_STRUCTURE", 66, 74], ["visceral pleura", "MULTI-TISSUE_STRUCTURE", 79, 94], ["Pleural Space", "PROBLEM", 0, 13], ["Space", "ANATOMY_MODIFIER", 8, 13], ["pleural", "ANATOMY", 17, 24], ["parietal", "ANATOMY_MODIFIER", 66, 74], ["visceral", "ANATOMY_MODIFIER", 79, 87], ["pleura", "ANATOMY", 88, 94]]], ["It normally contains a minimal amount (few milliliters) of serous fluid to facilitate motion of the lungs in relation to the thoracic cavity and to each other, as well as force distribution during normal breathing.1, 2 The pleura is a thin epithelium formed of mesothelial cells overlying a thin basal membrane.", [["serous fluid", "ANATOMY", 59, 71], ["lungs", "ANATOMY", 100, 105], ["thoracic cavity", "ANATOMY", 125, 140], ["pleura", "ANATOMY", 223, 229], ["thin epithelium", "ANATOMY", 235, 250], ["mesothelial cells", "ANATOMY", 261, 278], ["basal membrane", "ANATOMY", 296, 310], ["serous fluid", "ORGANISM_SUBSTANCE", 59, 71], ["lungs", "ORGAN", 100, 105], ["thoracic cavity", "MULTI-TISSUE_STRUCTURE", 125, 140], ["pleura", "ORGAN", 223, 229], ["epithelium", "TISSUE", 240, 250], ["mesothelial cells", "CELL", 261, 278], ["basal membrane", "CELLULAR_COMPONENT", 296, 310], ["mesothelial cells", "CELL_TYPE", 261, 278], ["serous fluid", "PROBLEM", 59, 71], ["a thin epithelium", "PROBLEM", 233, 250], ["mesothelial cells", "PROBLEM", 261, 278], ["a thin basal membrane", "PROBLEM", 289, 310], ["minimal", "OBSERVATION_MODIFIER", 23, 30], ["amount", "OBSERVATION_MODIFIER", 31, 37], ["few", "OBSERVATION_MODIFIER", 39, 42], ["milliliters", "OBSERVATION_MODIFIER", 43, 54], ["serous fluid", "OBSERVATION", 59, 71], ["lungs", "ANATOMY", 100, 105], ["thoracic cavity", "ANATOMY", 125, 140], ["force", "OBSERVATION_MODIFIER", 171, 176], ["distribution", "OBSERVATION_MODIFIER", 177, 189], ["normal breathing", "OBSERVATION", 197, 213], ["pleura", "ANATOMY", 223, 229], ["thin epithelium", "OBSERVATION_MODIFIER", 235, 250], ["mesothelial cells", "OBSERVATION", 261, 278], ["thin", "OBSERVATION_MODIFIER", 291, 295], ["basal", "ANATOMY_MODIFIER", 296, 301], ["membrane", "ANATOMY_MODIFIER", 302, 310]]], ["The partition between the right and left hemithoraces is incomplete in small animals, but unilateral or unevenly distributed disease is common, especially when copious fibrin is present within the pleural space.3", [["right", "ANATOMY", 26, 31], ["left hemithoraces", "ANATOMY", 36, 53], ["pleural space", "ANATOMY", 197, 210], ["hemithoraces", "CANCER", 41, 53], ["fibrin", "GENE_OR_GENE_PRODUCT", 168, 174], ["pleural space", "MULTI-TISSUE_STRUCTURE", 197, 210], ["fibrin", "PROTEIN", 168, 174], ["unilateral or unevenly distributed disease", "PROBLEM", 90, 132], ["copious fibrin", "PROBLEM", 160, 174], ["right", "ANATOMY_MODIFIER", 26, 31], ["left", "ANATOMY_MODIFIER", 36, 40], ["hemithoraces", "ANATOMY", 41, 53], ["incomplete", "OBSERVATION", 57, 67], ["small", "OBSERVATION_MODIFIER", 71, 76], ["animals", "OBSERVATION_MODIFIER", 77, 84], ["unilateral", "OBSERVATION_MODIFIER", 90, 100], ["unevenly", "OBSERVATION_MODIFIER", 104, 112], ["distributed", "OBSERVATION_MODIFIER", 113, 124], ["disease", "OBSERVATION", 125, 132], ["fibrin", "OBSERVATION", 168, 174], ["pleural", "ANATOMY", 197, 204]]]], "26d8effa78a2d56ca3da84be52849c0bec73035c": [["IntroductionThis paper assesses how the timing of the lockdown measures implemented in Switzerland and Germany affects the development of cumulative COVID-19-related hospitalization and death rates.", [["death", "DISEASE", 186, 191], ["the lockdown measures", "TREATMENT", 50, 71], ["cumulative COVID", "TEST", 138, 154], ["death rates", "PROBLEM", 186, 197]]], ["In both countries, the federal governments implemented extensive lockdown measures, including the closure of non-essential shops, schools, childcare centers, cafes, bars, and restaurants.", [["extensive lockdown measures", "TREATMENT", 55, 82]]], ["In Germany, these measures were further enhanced with a ban on gatherings with more than two people decided at federal level and curfews implemented in several states.", [["people", "ORGANISM", 93, 99], ["people", "SPECIES", 93, 99]]], ["With the measures in place for some weeks, both countries report a flattening of the COVID-19 epidemic curve.", [["the COVID", "TEST", 81, 90]]], ["This *Correspondence: henrika.langen@unifr.ch University of Fribourg, Bd. de P\u00e9rolles 90, 1700, Fribourg, Switzerland alone, however, does not necessarily exclusively reflect the impact of the measures, but likely also general time trends in the spread of the virus.", [["the virus", "PROBLEM", 256, 265]]], ["For this reason, this study aims to provide evidence about the causal effects of the German and Swiss measures by exploiting variation (i) in their relative timing due the fact that the epidemic was more advanced in some regions than in others when certain measures came into force and (ii) across regions due to the fact that some measures were only introduced in a subset of regions.IntroductionA range of studies on the impact of COVID-19 response measures focus on predicting the development of the pandemic in terms of infections, hospitalizations, or death rates based on simulating the spread of the virus and calibrating the model as a function of the measures.", [["infections", "DISEASE", 524, 534], ["death", "DISEASE", 557, 562], ["this study", "TEST", 17, 27], ["Swiss measures", "TREATMENT", 96, 110], ["the epidemic", "PROBLEM", 182, 194], ["COVID", "TREATMENT", 433, 438], ["infections", "PROBLEM", 524, 534], ["death rates", "PROBLEM", 557, 568], ["the virus", "TREATMENT", 603, 612], ["infections", "OBSERVATION", 524, 534]]], ["For instance, Koo et al. (2020) provide a simulation study on the COVID-19 outbreak in Singapore and model the development of COVID-19 infections under four potential intervention scenarios.", [["infections", "DISEASE", 135, 145], ["COVID-19", "SPECIES", 126, 134], ["a simulation study", "TEST", 40, 58], ["the COVID", "TREATMENT", 62, 71], ["COVID", "TREATMENT", 126, 131]]], ["Likewise, Bicher et al. (2020) developed an agent-based simulation model to predict the development of infections under different scenarios of lockdown timing and exit strategies out of the lockdown in Austria, finding that delaying the lockdown by 1 week would have translated into an increase of infections by 4 times.", [["infections", "DISEASE", 103, 113], ["infections", "DISEASE", 298, 308], ["an agent", "TREATMENT", 41, 49], ["infections", "PROBLEM", 103, 113], ["lockdown timing", "TREATMENT", 143, 158], ["infections", "PROBLEM", 298, 308], ["infections", "OBSERVATION", 103, 113], ["increase", "OBSERVATION_MODIFIER", 286, 294], ["infections", "OBSERVATION", 298, 308]]], ["Donsimoni et al. (2020) simulate the effect of lockdown timing and duration on the rate of COVID-19 infections and the expected end date of the epidemic in Germany.", [["infections", "DISEASE", 100, 110], ["lockdown timing", "TREATMENT", 47, 62], ["COVID", "TEST", 91, 96], ["infections", "PROBLEM", 100, 110], ["infections", "OBSERVATION", 100, 110]]], ["The study suggests that a complete lift of measures on April 20 would have borne the risk of increasing infection rates.", [["infection", "DISEASE", 104, 113], ["The study", "TEST", 0, 9], ["increasing infection rates", "PROBLEM", 93, 119], ["increasing", "OBSERVATION_MODIFIER", 93, 103], ["infection", "OBSERVATION", 104, 113]]], ["The authors further advise to adopt exit strategies and policies that differ across regions in order to learn about which measures are most effective for containing the epidemic while reducing social and economic costs.IntroductionIn contrast to such simulations, in which empirical data serve for calibrating parameters in prediction models, a growing literature applies policy evaluation methods as outlined in Imbens and Wooldridge (2009) to assess the effectiveness of lockdown measures based on variation across regions and over time.", [["policy evaluation methods", "TEST", 372, 397], ["lockdown measures", "TREATMENT", 473, 490]]], ["Qiu et al. (2020) for instance investigate the influence of socioeconomic factors and COVID-19 response measures on transmission dynamics in China, finding that measures at a local level have a larger impact on the epidemic curve than restricting population flows between cities.", [["socioeconomic factors", "PROTEIN", 60, 81], ["socioeconomic factors", "TREATMENT", 60, 81], ["COVID", "TREATMENT", 86, 91], ["larger", "OBSERVATION_MODIFIER", 194, 200]]], ["Juranek and Zoutman (2020) use an event study approach to assess the effect of the lockdown measures of Denmark and Norway on hospitalizations based on a comparison with Sweden whose measures are comparably lenient.", [["an event study approach", "TEST", 31, 54], ["the lockdown measures", "TREATMENT", 79, 100]]], ["Results suggest that the peak number of hospitalizations would have more than doubled in Denmark and Norway had they followed Sweden's strategy. use a difference-in-differences approach to evaluate lockdown measures (namely shelter in place orders) in the USA by exploiting variation in responses across states and over time.", [["lockdown measures", "TREATMENT", 198, 215], ["peak", "OBSERVATION_MODIFIER", 25, 29]]], ["As a consequence of the measures, they find an important increase (of 5-10%) in the rate at which state residents remained in their homes full-time as well as substantial reductions in cumulative COVID-19 cases (44% after 3 weeks), 1 with early adopting states with a high population density benefiting most.", [["cumulative COVID", "TEST", 185, 201], ["a high population density", "PROBLEM", 266, 291], ["important", "OBSERVATION_MODIFIER", 47, 56], ["increase", "OBSERVATION_MODIFIER", 57, 65], ["high population", "OBSERVATION_MODIFIER", 268, 283], ["density", "OBSERVATION", 284, 291]]], ["See also Fowler et al. (2020) for a related difference-in-differences strategy for the USA that suggests reductions in infections, too, as well as in fatalities.", [["infections", "DISEASE", 119, 129], ["a related difference", "PROBLEM", 34, 54], ["the USA", "TEST", 83, 90], ["infections", "PROBLEM", 119, 129], ["reductions", "OBSERVATION_MODIFIER", 105, 115], ["infections", "OBSERVATION", 119, 129]]], ["Results in Friedson et al. (2020) , who use a synthetic control approach to analyze the measures' effectiveness in California, and , who evaluate the impact 1 The estimated effect on fatalities is also negative but less precise.Introductionof the measures implemented in Texas in an event study framework, point in the same direction.", [["a synthetic control approach", "TREATMENT", 44, 72]]], ["Weber (2020) exploits regional differences in the timing of measures in Germany finding that school closures, prohibition of mass events, and gathering bans and curfews played a major role in reducing the number of confirmed infections, while border closures and shutdowns of the service and retail sector did not show a significant effect.", [["infections", "DISEASE", 225, 235], ["mass events", "PROBLEM", 125, 136], ["infections", "PROBLEM", 225, 235], ["mass", "OBSERVATION", 125, 129], ["infections", "OBSERVATION", 225, 235], ["significant", "OBSERVATION_MODIFIER", 321, 332], ["effect", "OBSERVATION", 333, 339]]], ["Studies on the impact of face mask requirements in public transport, retailers, and public businesses find evidence for a reduction in the spread of the virus through such requirements, see, for example, Mitze et al. (2020) for a synthetic control study on German data and Chernozhukov et al. (2020) , who assess the impact of such requirements in the USA within a causal framework that allows for both direct effects of COVID-19 response measures and indirect effects through behavioral changes.", [["face mask requirements", "TREATMENT", 25, 47], ["a reduction", "PROBLEM", 120, 131], ["the virus", "PROBLEM", 149, 158], ["a synthetic control study", "TEST", 228, 253], ["such requirements", "PROBLEM", 327, 344], ["COVID-19 response measures", "TREATMENT", 421, 447], ["behavioral changes", "PROBLEM", 477, 495], ["reduction", "OBSERVATION_MODIFIER", 122, 131]]], ["Askitas et al. (2020) apply an event study design to assess a range of different response measures across 135 countries and find that canceling public events and restricting gatherings reduce new infections more effectively than mobility restrictions like international travel controls.", [["infections", "DISEASE", 196, 206], ["an event study", "TEST", 28, 42], ["new infections", "PROBLEM", 192, 206], ["new", "OBSERVATION_MODIFIER", 192, 195], ["infections", "OBSERVATION", 196, 206]]], ["This is in line with Bonardi et al. (2020) who consider first difference and AR(1) models based on 184 countries and conclude that lockdown measures generally reduce confirmed infections and fatalities (and even more so if imposed rather earlier than later), while border closures do not show important effects.", [["infections", "DISEASE", 176, 186], ["fatalities", "DISEASE", 191, 201], ["infections", "PROBLEM", 176, 186], ["infections", "OBSERVATION", 176, 186]]], ["Findings in Banholzer et al. (2020) , a study on 20 Western countries in a Bayesian framework, suggest that venue closures and gathering bans are most effective in reducing infections but also attest a significant effect of border closures.IntroductionOur paper contributes to this growing literature by analyzing COVID-19-related hospitalizations and death rates across administrative units over time, namely across counties in the case of Germany and across cantons in the case of Switzerland.", [["infections", "DISEASE", 173, 183], ["death", "DISEASE", 352, 357], ["a study", "TEST", 38, 45], ["venue closures", "TREATMENT", 108, 122], ["reducing infections", "PROBLEM", 164, 183], ["border closures", "TREATMENT", 224, 239], ["analyzing COVID", "TEST", 304, 319], ["death rates", "PROBLEM", 352, 363], ["infections", "OBSERVATION", 173, 183]]], ["We estimate the effect of the relative timing of lockdown measures based on measuring health outcomes relative to the region-specific start of the epidemic and comparing outcomes across regions with earlier and later start dates.", [["lockdown measures", "TREATMENT", 49, 66], ["the epidemic", "PROBLEM", 143, 155]]], ["The start date is defined as the day on which the confirmed regional infections per 10,000 inhabitants exceed 1 for the first time.", [["infections", "DISEASE", 69, 79], ["regional infections", "PROBLEM", 60, 79], ["regional", "OBSERVATION_MODIFIER", 60, 68], ["infections", "OBSERVATION", 69, 79]]], ["In the analysis, we control for regional characteristics (population size and density, age structure, and GDP per capita), initial trends of the epidemic (median age of confirmed infections and initial growth rate of confirmed infections), and other policies selectively introduced prior to the major lockdowns (e.g., a ban on visits to hospitals and retirement homes in some regions).IntroductionLinear regression estimates suggest that for both Switzerland (which also includes the Principality of Liechtenstein as data point) and Germany, a relatively later exposure to the measures entails higher cumulative (2020) 156:10IntroductionPage 3 of 19 hospitalization and death rates on sufficiently advanced region-specific days after the outbreak of the epidemic.", [["infections", "DISEASE", 179, 189], ["infections", "DISEASE", 227, 237], ["death", "DISEASE", 670, 675], ["the analysis", "TEST", 3, 15], ["infections", "PROBLEM", 179, 189], ["infections", "PROBLEM", 227, 237], ["death rates", "PROBLEM", 670, 681], ["population", "OBSERVATION_MODIFIER", 58, 68], ["size", "OBSERVATION_MODIFIER", 69, 73], ["density", "OBSERVATION", 78, 85], ["infections", "OBSERVATION", 179, 189], ["infections", "OBSERVATION", 227, 237]]], ["This suggests that an earlier imposition of measures is more effective than a later one w.r.t. our health outcomes, which is in line with findings in Amuedo-Dorantes et al.Introduction(2020) on the effect of lockdown timing on COVID-19related deaths in Spain.", [["deaths", "DISEASE", 243, 249]]], ["For Germany with its substantially larger number of observations, we also estimate the effect of the relative timing based on doubly robust (DR) estimation, see Robins et al. (1994) and Robins and Rotnitzky (1995) , which is a more flexible approach than exclusively relying on a linear outcome model.", [["a more flexible approach", "TREATMENT", 225, 249], ["substantially", "OBSERVATION_MODIFIER", 21, 34], ["larger", "OBSERVATION_MODIFIER", 35, 41], ["number", "OBSERVATION_MODIFIER", 42, 48]]], ["For Switzerland, we also consider the synthetic control method, see Abadie and Gardeazabal (2003) and Abadie et al. (2010) , to assess for two selected cantons with a relatively late exposure what their counterfactual outcomes would have been under an earlier exposure.", [["the synthetic control method", "TREATMENT", 34, 62]]], ["Both the DR and synthetic control methods corroborate the findings of the linear regression.", [["the linear regression", "PROBLEM", 70, 91], ["linear", "OBSERVATION_MODIFIER", 74, 80], ["regression", "OBSERVATION", 81, 91]]], ["For Germany only, we also evaluate the effect of curfews that were introduced by a subset of German states in addition to the federal lockdown measures and bans of gatherings with more than two individuals.", [["curfews", "TREATMENT", 49, 56], ["the federal lockdown measures", "TREATMENT", 122, 151]]], ["Exploiting this cross-sectional variation while controlling for observed characteristics, neither linear regression nor DR estimation suggests that curfews further reduce hospitalizations and fatalities under the lockdown measures already in place, which is in line with the findings in Bonardi et al. (2020) and Banholzer et al. (2020) .", [["fatalities", "DISEASE", 192, 202], ["DR estimation", "TEST", 120, 133], ["the lockdown measures", "TREATMENT", 209, 230]]], ["Apart from this assessment of the impact of curfews on COVID-19-related death rates, our analysis does not inform about the effectiveness of single social distancing measures implemented as part of the lockdown in Germany and Switzerland.", [["death", "DISEASE", 72, 77], ["this assessment", "TEST", 11, 26], ["COVID", "TEST", 55, 60], ["our analysis", "TEST", 85, 97], ["single social distancing measures", "TREATMENT", 141, 174]]], ["Further, a cost-effectiveness assessment of COVID-19 response measures, which is certainly of great importance for policy makers, is beyond the scope of this paper, as the long-run social and economic consequences of the lockdown cannot be credibly assessed at the current stage.", [["a cost-effectiveness assessment", "TEST", 9, 40], ["COVID", "TEST", 44, 49]]], ["Section 2 provides an overview of the timeline of COVID-19 measures in Switzerland and Germany.", [["COVID", "TREATMENT", 50, 55]]], ["Sections 3 and 4 describe the data and econometric methods used in the analyses.", [["the data", "TEST", 26, 34], ["econometric methods", "TEST", 39, 58]]], ["Section 6 concludes.Timeline of COVID-19 response measuresBoth Germany and Switzerland are federal states with competencies in epidemic control partly belonging to the 26 cantons in Switzerland and the 16 federal states (L\u00e4nder) in Germany.", [["COVID", "TEST", 32, 37]]], ["With competencies fragmented across the federal governments and subfederal authorities, not all measures were implemented in all regions and, if so, not always at the same time.", [["fragmented", "OBSERVATION_MODIFIER", 18, 28]]], ["However, decisions on key COVID-19 response measures were made at the federal level in both countries.Timeline of COVID-19 response measuresIn Switzerland, the first COVID-19 response measure, a ban of events with more than 1000 visitors, was announced and implemented at the federal level on February 28 when there were some 25 confirmed COVID-19 cases (0.03 per 10,000 inhabitants) in Switzerland.", [["COVID", "TEST", 114, 119], ["the first COVID", "TEST", 156, 171], ["COVID", "TEST", 339, 344]]], ["At that point in time, the rate of confirmed infections in Switzerland was at 4.2 per 10,000 inhabitants.", [["infections", "DISEASE", 45, 55], ["infections", "PROBLEM", 45, 55], ["infections", "OBSERVATION", 45, 55]]], ["Due to the two countries' similar schedules of COVID-19 response measures, their geographic proximity, and their economic, cultural, and political interconnection, we include LI as additional data point when investigating the impact of the lockdown measures in Switzerland.Timeline of COVID-19 response measuresIn Germany, first measures at the federal level were implemented between March 9 and March 12.", [["COVID-19 response measures", "TREATMENT", 47, 73], ["the lockdown measures", "TREATMENT", 236, 257], ["COVID", "TEST", 285, 290]]], ["On March 8, when there were some 1000 reported COVID-19 cases (0.12 per 10,000 inhabitants) in Germany, the federal government advised against events with more than 1000 visitors.", [["COVID", "TEST", 47, 52]]], ["The closure of all non-essential retailers, bars, and public events of any kind and the restriction of restaurant opening hours were decided at the federal level on March 16 when the overall rate of confirmed infections reached 1.1 per 10,000 inhabitants.", [["infections", "DISEASE", 209, 219], ["infections", "PROBLEM", 209, 219], ["closure", "OBSERVATION", 4, 11], ["all", "OBSERVATION_MODIFIER", 15, 18], ["non-essential", "OBSERVATION_MODIFIER", 19, 32], ["retailers", "OBSERVATION", 33, 42], ["infections", "OBSERVATION", 209, 219]]], ["Other than in Switzerland and LI, these measures were further enhanced later on.", [["LI", "ANATOMY", 30, 32]]], ["Since April 17, more and more states have made wearing face masks in shops and public transport compulsory, resulting in a nationwide requirement to wear masks in public from April 27 on.", [["face masks", "TREATMENT", 55, 65], ["masks", "TREATMENT", 154, 159]]], ["Meanwhile, lockdown measures have been lifted gradually in Switzerland and Germany, with distinct schedules and exit strategies across countries and states.", [["lockdown measures", "TREATMENT", 11, 28]]], ["For instance, curfews ended in the respective German states around April 27, with the exception of Bavaria, where they ended on May 5.", [["Bavaria", "OBSERVATION", 99, 106]]], ["On May 6, a so-called emergency mechanism was put in place in Germany requiring counties to re-impose lockdown measures locally if the rate of new confirmed infections over 7 days exceeds 5 per 10,000 inhabitants.DataFor Switzerland and LI, data on confirmed COVID-19 infections as well as on COVID-19-related hospitalizations and deaths are amalgamated by the Swiss Federal Office of Public Health (FOPH) and made available to the interuniversity research consortium of the Swiss School of Public Health (www.ssphplus.ch).", [["infections", "DISEASE", 157, 167], ["infections", "DISEASE", 268, 278], ["deaths", "DISEASE", 331, 337], ["lockdown measures", "TREATMENT", 102, 119], ["COVID", "TEST", 259, 264], ["infections", "PROBLEM", 268, 278], ["COVID", "TEST", 293, 298], ["infections", "OBSERVATION", 157, 167], ["infections", "OBSERVATION", 268, 278]]], ["For each confirmed case, the FOPH gathers information on the reporting canton, test date, and patient's age and gender from laboratory declarations.", [["patient", "ORGANISM", 94, 101], ["FOPH", "DNA", 29, 33], ["patient", "SPECIES", 94, 101]]], ["For our analysis, we aggregate the number of confirmed infections, hospitalizations, and fatalities by canton and test date; compute the respective cumulative numbers by canton and date; and complement the data with sociodemographic variables at the cantonal level (and for LI) from the statistical offices of Switzerland and LI.", [["infections", "DISEASE", 55, 65], ["fatalities", "DISEASE", 89, 99], ["our analysis", "TEST", 4, 16], ["infections", "OBSERVATION", 55, 65]]], ["For each of the 26 Swiss cantons and LI, we calculate the rate of cumulative confirmed infections, hospitalizations, and fatalities per 10,000 inhabitants, as well as the median age of those tested positively for COVID-19 prior to the lockdown measures in Switzerland and LI.", [["infections", "DISEASE", 87, 97], ["fatalities", "DISEASE", 121, 131], ["infections", "PROBLEM", 87, 97], ["COVID", "TEST", 213, 218], ["the lockdown measures", "TREATMENT", 231, 252], ["infections", "OBSERVATION", 87, 97], ["LI", "ANATOMY", 272, 274]]], ["Furthermore, we construct indicators for whether a canton has introduced certain additional measures not imposed by the federal government along with variables providing the start date of such canton-level measures as stated in press releases of the respective cantons.DataIn Germany, all confirmed infections and deaths are reported to the Robert Koch Institute (RKI), a federal government agency and research institute for disease control and prevention.", [["infections", "DISEASE", 299, 309], ["deaths", "DISEASE", 314, 320], ["such canton-level measures", "TREATMENT", 188, 214], ["disease control", "TREATMENT", 425, 440], ["infections", "OBSERVATION", 299, 309]]], ["The RKI publishes data on the age group, gender, test date, and county of residence of each validated COVID-19 case reported to the institute.", [["RKI", "DNA", 4, 7]]], ["Similar to Switzerland, we aggregate the data by county (or residential district, respectively) and test date, and compute cumulative confirmed cases and fatalities by county and date.", [["fatalities", "DISEASE", 154, 164]]], ["Figure 1 provides the cumulative numbers of confirmed COVID-19 infections and COVID-19-related deaths per 10,000 inhabitants in Germany (left) as well as cumulative numbers of confirmed infections, hospitalizations, and deaths in Switzerland (right).", [["infections", "DISEASE", 63, 73], ["deaths", "DISEASE", 95, 101], ["infections", "DISEASE", 186, 196], ["deaths", "DISEASE", 220, 226], ["COVID", "TEST", 54, 59], ["COVID", "TEST", 78, 83], ["left", "ANATOMY_MODIFIER", 137, 141], ["infections", "OBSERVATION", 186, 196], ["right", "ANATOMY_MODIFIER", 243, 248]]], ["The figure suggests a flattening of the COVID-19 epidemic curve in both countries after the main COVID-19 measures have been in place for some weeks, which does, however, not necessarily exclusively reflect the causal impact of the measures.", [["the COVID", "TEST", 36, 45], ["the main COVID", "TREATMENT", 88, 102], ["flattening", "OBSERVATION_MODIFIER", 22, 32], ["main", "OBSERVATION_MODIFIER", 92, 96]]], ["As a further descriptive statistic, Fig. 2 provides the overall deaths per 10,000 inhabitants (thus including COVID-19-related mortality) by calendar week in Germany and Switzerland since January 1, 2020 (provisional data).", [["deaths", "DISEASE", 64, 70]]], ["While the increase in mortality in March and April can be linked to the COVID-19 epidemic (a finding that also holds when controlling for the average mortality over 2015-2019), we cannot directly infer how large the increase would have been with and without the lockdown measures.", [["the COVID", "TEST", 68, 77], ["the lockdown measures", "TREATMENT", 258, 279], ["increase", "OBSERVATION_MODIFIER", 10, 18], ["mortality", "OBSERVATION_MODIFIER", 22, 31], ["large", "OBSERVATION_MODIFIER", 206, 211]]], ["For this reason, our analysis aims at shedding light on the causal effect of the measures.Econometric approachIn our analysis, we exploit the fact that the epidemic was more advanced in some regions than in others when the key control measures came into force.", [["our analysis", "TEST", 17, 29], ["the measures", "TREATMENT", 77, 89], ["the epidemic", "PROBLEM", 152, 164], ["epidemic", "OBSERVATION_MODIFIER", 156, 164]]], ["In Switzerland, for instance, Basel-Stadt had already more than 1 confirmed case per 10,000 inhabitants 12 days before the federal lockdown measures were implemented, while other cantons such as St. Gallen were at an earlier stage, reaching 1 confirmed infection per 10,000 inhabitants on the day of the lockdown.", [["infection", "DISEASE", 253, 262], ["St. Gallen", "ORGANISM", 195, 205], ["the federal lockdown measures", "TREATMENT", 119, 148], ["infection", "PROBLEM", 253, 262], ["infection", "OBSERVATION", 253, 262]]], ["In Germany, the county of Heinsberg recorded more than 1 confirmed infection per 10,000 inhabitants already 19 days before the lockdown.", [["infection", "DISEASE", 67, 76], ["infection", "PROBLEM", 67, 76], ["infection", "OBSERVATION", 67, 76]]], ["In several other counties, this level of infections was reached only after the lockdown.Econometric approachFor Germany, we investigate the impact of the lockdown measures as well as the curfew on cumulative deaths per 10,000 inhabitants.", [["infections", "DISEASE", 41, 51], ["deaths", "DISEASE", 208, 214], ["infections", "PROBLEM", 41, 51], ["the lockdown measures", "TREATMENT", 150, 171], ["infections", "OBSERVATION", 41, 51]]], ["For Switzerland and LI, we assess the causal effect of the lockdown on both cumulative hospitalizations and deaths per 10,000 inhabitants.", [["deaths", "DISEASE", 108, 114]]], ["The idea is to quantify the epidemic stage of each canton/county when measures were implemented by defining dates on which the health outcomes are measured relative to the day a canton/county first reached a certain rate of confirmed infections.", [["infections", "DISEASE", 234, 244], ["infections", "PROBLEM", 234, 244], ["infections", "OBSERVATION", 234, 244]]], ["For both Germany and Switzerland, we define the start date of the epidemic as the day when the rate of infections first reached or exceeded 1 infection per 10,000 inhabitants.", [["infections", "DISEASE", 103, 113], ["infection", "DISEASE", 142, 151], ["infections", "PROBLEM", 103, 113], ["1 infection", "PROBLEM", 140, 151], ["infections", "OBSERVATION", 103, 113]]], ["Appendix 1 provides the start states for all Swiss cantons and LI.Econometric approachBesides their obvious relevance for health care, a further motivation to consider hospitalization and death rates as outcomes is that their measurement is likely more robust to differences in testing strategies across regions than the While the share of infections with mild symptoms being detected ceteris paribus likely rises with increased testing, the number of hospitalizations and fatalities gives a better estimate of the severeness of the epidemic in terms of human loss and strains for the health care system.", [["death", "DISEASE", 188, 193], ["infections", "DISEASE", 340, 350], ["ceteris paribus", "ORGANISM", 385, 400], ["human", "ORGANISM", 554, 559], ["human", "SPECIES", 554, 559], ["human", "SPECIES", 554, 559], ["health care", "TREATMENT", 122, 133], ["infections", "PROBLEM", 340, 350], ["mild symptoms", "PROBLEM", 356, 369], ["increased testing", "PROBLEM", 419, 436], ["human loss", "PROBLEM", 554, 564], ["LI", "ANATOMY", 63, 65], ["infections", "OBSERVATION", 340, 350], ["mild", "OBSERVATION_MODIFIER", 356, 360]]], ["As both Germany and Switzerland maintain a system of mandatory health insurance and neither country generally saw their hospitalization capacities exhausted, we would suspect that the number of COVID-19-related hospitalizations in general mirrors well the number of individuals infected with COVID-19 that are in need of hospitalization.", [["COVID-19", "CHEMICAL", 194, 202], ["COVID", "TEST", 194, 199], ["COVID", "TREATMENT", 292, 297]]], ["Nevertheless, a potential concern in our analysis is that the criteria for hospitalizations might not be uniform across regions.", [["our analysis", "TEST", 37, 49]]], ["The same may apply to the measurement of fatalities, i.e., the definition of criteria according to which a decease is attributed to COVID-19.", [["fatalities", "DISEASE", 41, 51], ["COVID-19", "CHEMICAL", 132, 140], ["COVID", "TEST", 132, 137]]], ["If such measurement issues in health outcomes are not systematically associated with the region-specific start date of the epidemic (or more generally, with the policy interventions considered), they do not bias the results of our analysis.", [["such measurement issues in health outcomes", "PROBLEM", 3, 45], ["our analysis", "TEST", 227, 239]]], ["However, if for instance regions with an earlier start date and a more advanced epidemic systematically applied more stringent rules for hospital admissions (e.g., to prevent capacity constraints), this could also entail an underestimation of COVID-19 fatalities due to underreporting deceases at home.", [["fatalities", "DISEASE", 252, 262], ["COVID", "TEST", 243, 248]]], ["In this case, our analysis of the relative timing of measures presented below would likely provide a lower bound of the true effect on (capacity-unconstraint) hospitalizations and fatalities.OLS approachWe compare the average number of cumulative hospitalizations and fatalities per 10,000 inhabitants on canton/county-specific epidemic days across three groups of cantons/counties.", [["fatalities", "DISEASE", 180, 190], ["fatalities", "DISEASE", 268, 278], ["our analysis", "TEST", 14, 26]]], ["Cantons reaching or exceeding 1 confirmed infection per 10,000 inhabitants at most 4 days before the lockdown measures are exposed to the measures at a relatively early stage of the epidemic and constitute the reference group (sample size N = 8).", [["infection", "DISEASE", 42, 51], ["infection", "PROBLEM", 42, 51], ["the lockdown measures", "TREATMENT", 97, 118], ["infection", "OBSERVATION", 42, 51]]], ["Those cantons with at least 1 confirmed infection per 10,000 inhabitants between 5 and 8 days before March 16 (or March 18 in the case of LI) are the intermediate intervention group (N = 11) .", [["infection", "DISEASE", 40, 49], ["infection", "PROBLEM", 40, 49], ["infection", "OBSERVATION", 40, 49]]], ["Those with a canton-specific start date at least 9 days before March 16 are the late intervention group (N = 8).OLS approachFor Germany, we proceed analogously and define the treatment groups based on the days between the countyspecific start of the epidemic and the lockdown according to the retail closures between March 17 and 20, but with somewhat different time brackets.", [["the treatment groups", "TREATMENT", 171, 191]]], ["Counties with at least 1 confirmed infection per 10,000 inhabitants not earlier than 3 days after the implementation of lockdown measures make up the reference group.", [["infection", "DISEASE", 35, 44], ["infection", "PROBLEM", 35, 44], ["lockdown measures", "TREATMENT", 120, 137], ["infection", "OBSERVATION", 35, 44]]], ["However, any effect of the measures can materialize in the outcomes only with a substantial time lag of more than 1.5 weeks (due to incubation time and reporting lags), as also confirmed in our analysis.", [["our analysis", "TEST", 190, 202]]], ["Therefore, confirmed infection rates are not yet influenced by the measures even several days after the lockdown.", [["infection", "DISEASE", 21, 30], ["infection rates", "PROBLEM", 21, 36], ["the lockdown", "TREATMENT", 100, 112], ["infection", "OBSERVATION", 21, 30]]], ["The intermediate intervention group is comprised of all counties with at least 1 confirmed infection per 10,000 inhabitants between 3 days before and 2 days after the lockdown (N = 275).", [["infection", "DISEASE", 91, 100], ["infection", "PROBLEM", 91, 100], ["intermediate", "OBSERVATION_MODIFIER", 4, 16], ["infection", "OBSERVATION", 91, 100]]], ["The late intervention group consists of counties with at least 1 confirmed infection per 10,000 inhabitants more than 3 days before the lockdown (N = 81).OLS approachWe estimate the difference in cumulative death rates, as well as hospitalization rates for Switzerland and LI, between either of the two treatment groups (intermediate and late intervention group) and the reference group by means of an OLS regression with treatment indicators.", [["infection", "DISEASE", 75, 84], ["death", "DISEASE", 207, 212], ["infection", "PROBLEM", 75, 84], ["cumulative death rates", "PROBLEM", 196, 218], ["an OLS regression", "PROBLEM", 399, 416], ["treatment indicators", "TREATMENT", 422, 442], ["late", "OBSERVATION_MODIFIER", 4, 8], ["infection", "OBSERVATION", 75, 84], ["difference", "OBSERVATION_MODIFIER", 182, 192]]], ["We also control for the following canton/county-specific covariates: population size and density, income per capita, age distribution, age structure of positively tested up to the lockdown, the initial canton/county-specific growth trend for confirmed cases, and canton-specific bans on visits in hospitals and retired homes entering into force prior to the lockdown.", [["size", "OBSERVATION_MODIFIER", 80, 84], ["density", "OBSERVATION", 89, 96]]], ["The large number of counties in Germany allows us to further control for past mortality by age group, past mortality rate related to respiratory diseases, and hospital capacities (beds/1000 inhabitants).", [["respiratory", "ANATOMY", 133, 144], ["respiratory diseases", "DISEASE", 133, 153], ["respiratory diseases", "PROBLEM", 133, 153], ["large", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16], ["respiratory diseases", "OBSERVATION", 133, 153]]], ["Appendix 2 provides descriptive statistics of the covariates used in the analysis of the German and Swiss measures for the respective total samples as well as separately for the various intervention groups.OLS approachThough aiming to control for confounders jointly affecting the region-specific epidemic and the health outcomes in a comprehensive way, we cannot completely rule out that some important characteristics are omitted in our analysis.", [["Swiss measures", "TREATMENT", 100, 114], ["the respective total samples", "TREATMENT", 119, 147], ["the various intervention groups", "TREATMENT", 174, 205], ["our analysis", "TEST", 435, 447]]], ["For instance, we cannot directly control for the amount of intergenerational interactions, which is according to Bayer and Kuhn (2020) correlated with the ratio of deaths over confirmed cases and could potentially differ across regions.", [["deaths", "DISEASE", 164, 170]]], ["The OLS regression contains a binary treatment indicator for curfews as well as a range of control variables.", [["a binary treatment", "TREATMENT", 28, 46], ["curfews", "TREATMENT", 61, 68]]], ["The latter include the previously mentioned county-specific characteristics, growth trends and COVID-19 response measures, and in addition the cumulative confirmed infections and death rates on several days prior to the curfews, in order to make regions exposed and not exposed to curfews as similar as possible.", [["infections", "DISEASE", 164, 174], ["death", "DISEASE", 179, 184], ["COVID", "TEST", 95, 100], ["infections", "PROBLEM", 164, 174], ["death rates", "PROBLEM", 179, 190], ["infections", "OBSERVATION", 164, 174]]], ["The OLS specification is provided in Appendix 3, and descriptive statistics for counties with and without curfews in Appendix 2.Doubly robust estimationThe larger number of regions in Germany allows us to also consider a more flexible (so-called semiparametric) evaluation approach based on doubly robust (DR) estimation, see Robins et al. (1994) and Robins and Rotnitzky (1995) .", [["evaluation approach", "TEST", 262, 281], ["Appendix", "ANATOMY", 117, 125], ["larger", "OBSERVATION_MODIFIER", 156, 162], ["number", "OBSERVATION_MODIFIER", 163, 169]]], ["It is based on (i) estimating a logit model for the treatment probability as a function of the covariates as well as a linear model for the outcome as a function of the treatment and the covariates and (ii) using the respective model predictions as plug-in parameters for the estimation of the treatment effects.", [["a logit model", "TREATMENT", 30, 43], ["the treatment", "TREATMENT", 165, 178], ["plug", "TEST", 249, 253], ["the treatment effects", "TREATMENT", 290, 311]]], ["DR provides consistent effect estimates if at least one of the plug-in models is correctly specified and thus relies on less stringent assumptions than OLS.", [["plug", "OBSERVATION", 63, 67]]], ["Using the \"drgee\" package of Zetterqvist and Sj\u00f6lander (2015) for the statistical software \"R, \" we apply DR for estimating the average effect of a binary intervention separately to subsets of counties consisting of the reference group and either the intermediate intervention group or the late intervention group.Synthetic control approachFor Switzerland, we complement the regression analysis with a synthetic control approach, a quantitative case study method suggested in Abadie and Gardeazabal (2003) .", [["Zetterqvist", "TREATMENT", 29, 40], ["a binary intervention", "TREATMENT", 146, 167], ["the late intervention group", "TREATMENT", 286, 313], ["the regression analysis", "TEST", 371, 394], ["a synthetic control approach", "TREATMENT", 400, 428], ["a quantitative case study", "TEST", 430, 455]]], ["The control pool includes all in all 11 cantons that reached 1 confirmed 2 In contrast to the OLS specification provided in Appendix 3, squared variables (i.e., the squares of the population share aged 65+ and of the median age of confirmed infections prior to the lockdown) are not included.", [["infections", "DISEASE", 241, 251], ["infections", "PROBLEM", 241, 251], ["Appendix", "ANATOMY", 124, 132], ["infections", "OBSERVATION", 241, 251]]], ["In addition, the dummy for the number of inhabitants being smaller than 60,000 is replaced by the actual number of inhabitants.Synthetic control approachinfection per 10,000 inhabitants at most 3 days before the lockdown.", [["Synthetic control approachinfection", "TREATMENT", 127, 162], ["smaller", "OBSERVATION_MODIFIER", 59, 66]]], ["Figure 3 reports the mean differences in cumulative fatalities per 10,000 inhabitants between either treatment group and the early intervention group (reference group) per day up to 28 days after the county-specific start date (solid lines) based on the OLS approach.", [["fatalities", "DISEASE", 52, 62], ["solid lines", "CELL", 228, 239], ["treatment group", "TREATMENT", 101, 116], ["the early intervention group", "TREATMENT", 121, 149], ["solid lines)", "TREATMENT", 228, 240], ["the OLS approach", "TREATMENT", 250, 266]]], ["3 It also includes 90% confidence intervals (dashed lines).", [["lines", "CELL", 52, 57], ["dashed lines", "TREATMENT", 45, 57]]], ["The mean differences in fatality rates between the late and the early intervention groups (left) remain close to zero during the first 2.5 weeks of the county-specific epidemic but show a positive and statistically significant tendency thereafter.", [["a positive", "PROBLEM", 186, 196], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["differences", "OBSERVATION_MODIFIER", 9, 20], ["early", "OBSERVATION_MODIFIER", 64, 69], ["left", "ANATOMY_MODIFIER", 91, 95], ["positive", "OBSERVATION", 188, 196], ["significant", "OBSERVATION_MODIFIER", 215, 226], ["tendency", "OBSERVATION", 227, 235]]], ["Also, the difference in death rates between the intermediate and the early intervention groups is statistically significant at the 10% level, but (expectedly) smaller in magnitude.", [["death", "DISEASE", 24, 29], ["the difference in death rates", "PROBLEM", 6, 35], ["difference", "OBSERVATION_MODIFIER", 10, 20], ["death", "OBSERVATION", 24, 29], ["intermediate", "OBSERVATION_MODIFIER", 48, 60], ["early", "OBSERVATION_MODIFIER", 69, 74], ["statistically", "OBSERVATION_MODIFIER", 98, 111], ["significant", "OBSERVATION_MODIFIER", 112, 123], ["smaller", "OBSERVATION_MODIFIER", 159, 166], ["magnitude", "OBSERVATION_MODIFIER", 170, 179]]], ["Overall, the results suggest that the relative timing of measures had a perceptible impact on COVID19-related fatalities in Germany.", [["fatalities", "DISEASE", 110, 120]]], ["We note that Appendix 3 provides the OLS specification with the full list of coefficients on treatments and covariates along with standard errors 28 days after the start of the epidemic.", [["treatments", "TREATMENT", 93, 103], ["covariates", "TREATMENT", 108, 118], ["Appendix", "OBSERVATION", 13, 21]]], ["Concerning the robustness of our findings, we note that estimations without controlling for observed covariates yield qualitatively similar results, see Appendix 4.", [["Appendix", "ANATOMY", 153, 161]]], ["Figure 4 reports the estimates of DR, which are generally similar to OLS, though suggesting an even stronger effect of a late timing of lockdown measures on the death rate.", [["death", "DISEASE", 161, 166], ["lockdown measures", "TREATMENT", 136, 153], ["the death rate", "TEST", 157, 171]]], ["The point estimate suggests that an earlier lockdown With 27% of the German population living in counties with late lockdown timing, a rough back-of-the-envelope calculation based on the OLS point estimates suggests that some 1283 COVID-19-related deaths (2080 when using the DR results) could have been prevented in Germany over the first 4 weeks after lockdown implementation if the counties with late timing had implemented the lockdown early, meaning no later than 3 days before reaching or exceeding the level of 1 confirmed infection per 10,000 inhabitants.", [["deaths", "DISEASE", 248, 254], ["infection", "DISEASE", 530, 539], ["infection", "PROBLEM", 530, 539], ["infection", "OBSERVATION", 530, 539]]], ["If all 275 states with intermediate lockdown timing had implemented the lockdown early, the death toll could have been further reduced by some 1816 (1580 based on DR results).", [["death", "DISEASE", 92, 97]]], ["Figure 5 reports the results of a further OLS regression, in which the treatment indicators for the intermediate and late intervention groups are replaced by the time lag between the county-specific start date of the epidemic and the lockdown, in order to (linearly) estimate the effect of the lag.", [["a further OLS regression", "PROBLEM", 32, 56], ["the intermediate and late intervention groups", "TREATMENT", 96, 141]]], ["This can be interpreted as the average effect of waiting an additional day before implementing the measures.", [["the measures", "TREATMENT", 95, 107]]], ["The point estimates suggest that each additional day without lockdown entails on average 0.04 to 0.05 additional fatalities per 10,000 inhabitants after 1 month of the epidemic, even though the confidence intervals are rather wide (but yet do not include a zero effect).", [["fatalities", "DISEASE", 113, 123]]], ["Again, these results are quite robust to not controlling for covariates, see Appendix 4.GermanyOur results also appear interesting with respect to one key element in the German exit strategy, the so-called emergency mechanism requiring counties to re-impose lockdown measures locally if the rate of new confirmed infections over 7 days exceeds 5 per 10,000 inhabitants.", [["infections", "DISEASE", 313, 323], ["lockdown measures", "TREATMENT", 258, 275], ["Appendix", "ANATOMY", 77, 85], ["infections", "OBSERVATION", 313, 323]]], ["Though the local epidemic start date is based on the cumulative rate of confirmed infections and the threshold of the German policy is based on the 7-day running infection rate, one may want to assess the appropriateness of this threshold in the light of our findings about the importance of lockdown timing.", [["infections", "DISEASE", 82, 92], ["infection", "DISEASE", 162, 171], ["infections", "PROBLEM", 82, 92], ["lockdown timing", "TREATMENT", 292, 307], ["infections", "OBSERVATION", 82, 92]]], ["In fact, the threshold for re-implementing lockdown measures can be regarded as late rather than intermediate or early intervention with respect to our definition, which seems worth considering given the threat of a second wave.", [["re-implementing lockdown measures", "TREATMENT", 27, 60], ["early intervention", "TREATMENT", 113, 131]]], ["However, the situation during the early phase of the epidemic is most likely not comparable to that in a later point in time, where the hope is that larger testing capacities and better policy response lead to an earlier detection and containment of local COVID-19 outbreaks and that the increased awareness in the population entails an adoption of social distancing and hygiene measures that sufficiently slow down the transmission.", [["larger testing capacities", "PROBLEM", 149, 174], ["an earlier detection", "TEST", 210, 230], ["local COVID", "TREATMENT", 250, 261], ["the increased awareness", "PROBLEM", 284, 307], ["hygiene measures", "TREATMENT", 371, 387], ["most likely", "UNCERTAINTY", 65, 76], ["increased", "OBSERVATION_MODIFIER", 288, 297]]], ["Furthermore, the left graph in Fig. 6 provides the OLSbased effects of curfews relative to contact restrictions, i.e., bans of gatherings with more than 2 persons, under all other lockdown measures already in place.", [["all other lockdown measures", "TREATMENT", 170, 197], ["left", "ANATOMY_MODIFIER", 17, 21]]], ["The estimates have a positive sign, which appears counterintuitive as curfews are more restrictive than contact restrictions, but are never statistically significantly different from zero throughout the evaluation window which starts on March 23 and ends 35 days later.", [["a positive sign", "PROBLEM", 19, 34], ["the evaluation window", "TEST", 199, 220], ["positive sign", "OBSERVATION", 21, 34], ["more restrictive", "OBSERVATION_MODIFIER", 82, 98]]], ["The same finding applies to estimation results based on DR, which are shown in the right graph of Fig. 6 .", [["right", "ANATOMY_MODIFIER", 83, 88]]], ["Figure 7 reports the OLS estimates of the mean differences in cumulative hospitalizations (left) and fatalities (right) per 10,000 inhabitants between the late and the early intervention groups up to 44 days after the start of the canton-specific epidemic (solid line), as well as 90% confidence intervals (dashed lines).", [["dashed lines", "TREATMENT", 307, 319], ["left", "ANATOMY_MODIFIER", 91, 95], ["right", "ANATOMY_MODIFIER", 113, 118]]], ["See Appendix 3 for the full OLS specification with the coefficients on treatments and covariates on the last day of the evaluation window and fatalities as outcome variable.Switzerland and LIWe note that the canton of Ticino is excluded from this analysis due to its comparably strong economic and social ties with Northern Italy (which was particularly severely affected by the COVID19 crisis), as this could arguably However, our findings are quite similar when including Ticino in the regression, as well as when not controlling for covariates, see Appendix 5.Switzerland and LIAs for Germany, we see no immediate effect of the relative timing of measures on the health outcomes right after their introduction.", [["treatments", "TREATMENT", 71, 81], ["the evaluation window", "TEST", 116, 137], ["this analysis", "TEST", 242, 255], ["Appendix", "ANATOMY", 552, 560]]], ["However, after about 2 weeks, there is a positive tendency in the effect on cumulative hospitalizations that becomes statistically significant at the 10% level about 2.5 weeks after the start of the cantonspecific epidemic.", [["a positive tendency", "PROBLEM", 39, 58], ["positive", "OBSERVATION_MODIFIER", 41, 49], ["tendency", "OBSERVATION_MODIFIER", 50, 58], ["significant", "OBSERVATION_MODIFIER", 131, 142]]], ["A qualitatively similar pattern is observed for the effect on cumulative deaths, which becomes statistically significant after about 3 weeks.", [["deaths", "DISEASE", 73, 79], ["cumulative deaths", "PROBLEM", 62, 79], ["significant", "OBSERVATION_MODIFIER", 109, 120]]], ["The point estimates suggest an increase of 1 to 2 fatalities per 10,000 inhabitants in the case of a later lockdown, but precision is again low.", [["increase", "OBSERVATION_MODIFIER", 31, 39]]], ["As these two groups are more similar in terms of the relative timing of the measures, differences are less pronounced and never statistically significant in all but one case, which might be due to low statistical power related to the small number of cantons.", [["low statistical power", "PROBLEM", 197, 218], ["less pronounced", "OBSERVATION_MODIFIER", 102, 117], ["significant", "OBSERVATION_MODIFIER", 142, 153], ["small", "OBSERVATION_MODIFIER", 234, 239], ["number", "OBSERVATION_MODIFIER", 240, 246]]], ["4 A rough back-of-the-envelope estimation based on these point estimates suggests that some 333 COVID-19-related deaths and some 764 hospitalizations could have been prevented during the time of the lockdown in Switzerland if the cantons with late timing had implemented the lockdown at most 4 days after reaching or 4 For cumulative fatalities, we also run the OLS regression using an alternative data source based on calculations of the statistics office of the canton of Zurich, available at https://statistik.zh.ch (retrieved on May 15).", [["deaths", "DISEASE", 113, 119], ["COVID", "TEST", 96, 101]]], ["Namely, the late intervention effect turns statistically significant after about 3 weeks with even somewhat higher point estimates (approaching 3) at the end of the evaluation window.", [["the evaluation window", "TEST", 161, 182]]], ["The intermediate intervention effect is again insignificant. exceeding the level of 1 confirmed infection per 10,000 inhabitants.", [["infection", "DISEASE", 96, 105], ["infection", "PROBLEM", 96, 105], ["intermediate", "OBSERVATION_MODIFIER", 4, 16], ["intervention", "OBSERVATION", 17, 29], ["insignificant", "OBSERVATION_MODIFIER", 46, 59], ["infection", "OBSERVATION", 96, 105]]], ["Finally, we report the results of the synthetic control method for two cantons experiencing the lockdown rather late relative to their start date of the epidemic.", [["the synthetic control method", "TREATMENT", 34, 62]]], ["Figure 9 plots the difference in cumulative hospitalizations (left) and deaths (right) per 10,000 inhabitants on a daily base after the canton-specific start date between Basel-Stadt, which was on day 12 of the epidemic when the measures came into force, and its synthetic counterfactual.", [["deaths", "DISEASE", 72, 78], ["left", "ANATOMY_MODIFIER", 62, 66], ["right", "ANATOMY_MODIFIER", 80, 85]]], ["Dots on the solid line imply that the differences are statistically significant at the 10% level according to placebo tests in the control group, in which each of the 11 cantons is considered as (pseudo-)treated in a rotating scheme in order to estimate its (pseudo-)counterfactual based on the remaining 10 cantons.", [["solid line", "ANATOMY", 12, 22], ["solid line", "CELL", 12, 22], ["the solid line", "TREATMENT", 8, 22], ["placebo tests", "TEST", 110, 123], ["a rotating scheme", "TREATMENT", 215, 232], ["solid line", "OBSERVATION", 12, 22], ["significant", "OBSERVATION_MODIFIER", 68, 79]]], ["We, however, note that the estimation of p values might be imprecise, due to the low number of control cantons available for the placebo tests.Switzerland and LIAgain, the relative timing of measures shows no immediate effect on hospitalizations but the difference becomes statistically significant after roughly 2.5 weeks.", [["the placebo tests", "TEST", 125, 142], ["LIAgain", "TREATMENT", 159, 166], ["no", "UNCERTAINTY", 206, 208], ["significant", "OBSERVATION_MODIFIER", 287, 298]]], ["The point estimates suggest that the hospitalization rate in Basel-Stadt could have been reduced by more than 4 hospitalizations if the lockdown measures had been introduced earlier.", [["the hospitalization rate", "TEST", 33, 57], ["the lockdown measures", "TREATMENT", 132, 153], ["reduced", "OBSERVATION_MODIFIER", 89, 96]]], ["Similarily, the fatalities per 10,000 inhabitants could have been reduced by 1 to 2 cases about 1.5 months after the start of the epidemic.", [["reduced", "OBSERVATION_MODIFIER", 66, 73]]], ["As for the OLS analysis, the exact numbers should, however, be interpreted with caution, as they are imprecisely estimated and canton-specific factors not considered in the analysis could play a role as well.", [["canton-specific factors", "PROTEIN", 127, 150], ["the OLS analysis", "TEST", 7, 23]]], ["Albeit the effect on COVID-19-related fatalities is somewhat less pronounced, it turns statistically significant in the final periods of the evaluation window.ConclusionIn this paper, we analyzed the impact of lockdown timing on COVID-19-related fatalities and hospitalizations in Germany and Switzerland.", [["fatalities", "DISEASE", 38, 48], ["fatalities", "DISEASE", 246, 256], ["COVID", "TEST", 21, 26], ["the evaluation window", "TEST", 137, 158], ["COVID", "TEST", 229, 234], ["somewhat", "OBSERVATION_MODIFIER", 52, 60], ["less pronounced", "OBSERVATION_MODIFIER", 61, 76]]], ["For doing so, we exploited the fact that measures differed across regions and that the epidemic was more advanced in some regions than in others when certain measures came into force.", [["the epidemic", "PROBLEM", 83, 95], ["epidemic", "OBSERVATION_MODIFIER", 87, 95], ["more", "OBSERVATION_MODIFIER", 100, 104], ["advanced", "OBSERVATION_MODIFIER", 105, 113]]], ["Using OLS and doubly robust estimation, we compared the development of COVID-19-related hospitalization and death rates-two indicators which are arguably rather robust to regional differences in COVID-19 testing policies-across regions that have been at different epidemic stages when exposed to the lockdown measures.", [["death", "DISEASE", 108, 113], ["COVID", "TEST", 71, 76], ["death rates", "TEST", 108, 119], ["COVID", "TEST", 195, 200], ["the lockdown measures", "TREATMENT", 296, 317]]], ["For Switzerland, we also applied a synthetic control approach to investigate the impact of the relative timing of the lockdown in two selected cantons.", [["a synthetic control approach", "TREATMENT", 33, 61]]], ["In addition, we analyzed the impact of curfews as implemented in some German states on top of the federal ban on gatherings of more than 2 persons based on a cross-regional comparison.ConclusionFor both countries, we found an earlier lockdown to be more effective than a later one, as cumulative hospitalization and fatality rates measured relative to the region-specific start date of the epidemic were higher in regions with a more advanced spread of COVID-19 when the measures came into force.", [["persons", "SPECIES", 139, 146], ["fatality rates", "TEST", 316, 330], ["the epidemic", "PROBLEM", 386, 398], ["COVID", "TEST", 453, 458], ["higher", "OBSERVATION_MODIFIER", 404, 410]]], ["In contrast, our results did not provide evidence for curfews being more effective than bans on gatherings under the other lockdown measures already in place.", [["curfews", "PROBLEM", 54, 61]]]], "a13adbbb240731d746c19395d0d3aed3645d132e": [["IntroductionCoronavirus Disease 2019 (COVID- 19) , which broke out in Wuhan on December 31, 2019, was an emerging, rapidly developing epidemic and a Public Health Emergency of International Concern (PHEIC) that affected people around the world [1, 2] .", [["COVID- 19", "CHEMICAL", 38, 47], ["people", "ORGANISM", 220, 226], ["people", "SPECIES", 220, 226], ["IntroductionCoronavirus Disease", "PROBLEM", 0, 31], ["COVID", "TEST", 38, 43]]], ["According to latest investigations, fever, cough and fatigue are the main symptoms of patients with mild COVID-19 while patients with severe COVID-19 might present with respiratory distress syndrome, shock and sepsis [3] .", [["respiratory", "ANATOMY", 169, 180], ["fever", "DISEASE", 36, 41], ["cough", "DISEASE", 43, 48], ["fatigue", "DISEASE", 53, 60], ["respiratory distress syndrome", "DISEASE", 169, 198], ["shock", "DISEASE", 200, 205], ["sepsis", "DISEASE", 210, 216], ["patients", "ORGANISM", 86, 94], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 120, 128], ["latest investigations", "TEST", 13, 34], ["fever", "PROBLEM", 36, 41], ["cough", "PROBLEM", 43, 48], ["fatigue", "PROBLEM", 53, 60], ["the main symptoms", "PROBLEM", 65, 82], ["mild COVID", "PROBLEM", 100, 110], ["severe COVID", "PROBLEM", 134, 146], ["respiratory distress syndrome", "PROBLEM", 169, 198], ["shock", "PROBLEM", 200, 205], ["sepsis", "PROBLEM", 210, 216], ["mild", "OBSERVATION_MODIFIER", 100, 104], ["respiratory distress", "OBSERVATION", 169, 189], ["shock", "OBSERVATION", 200, 205], ["sepsis", "OBSERVATION", 210, 216]]], ["Both post-traumatic stress disorder (PTSD) and acute stress disorder (ASD) refer to the stress response that occurs after the person suffered a fatal and catastrophic traumatic event that is beyond the individual's capacity [4, 5] .", [["post-traumatic stress disorder", "DISEASE", 5, 35], ["PTSD", "DISEASE", 37, 41], ["acute stress disorder", "DISEASE", 47, 68], ["ASD", "DISEASE", 70, 73], ["person", "SPECIES", 126, 132], ["Both post-traumatic stress disorder", "PROBLEM", 0, 35], ["PTSD", "PROBLEM", 37, 41], ["acute stress disorder", "PROBLEM", 47, 68], ["ASD", "PROBLEM", 70, 73], ["a fatal and catastrophic traumatic event", "PROBLEM", 142, 182], ["post-traumatic stress disorder", "OBSERVATION", 5, 35], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["stress disorder", "OBSERVATION", 53, 68], ["catastrophic", "OBSERVATION_MODIFIER", 154, 166], ["traumatic", "OBSERVATION", 167, 176]]], ["The understanding about COVID-19 has been insufficient yet, and there is no effective treatment plan for it at this stage as vaccines are still testing or trial phases [1] .IntroductionMost current practice to address COVID-19, Isolation and addressing symptomatic treatment is the only option at this stage, isolation and treatment measures would lead to a battery of emotional and behavioral reactions.", [["COVID-19", "CHEMICAL", 24, 32], ["COVID-19", "DNA", 24, 32], ["COVID", "TEST", 24, 29], ["vaccines", "TREATMENT", 125, 133], ["COVID", "TEST", 218, 223], ["Isolation", "TREATMENT", 228, 237], ["symptomatic treatment", "TREATMENT", 253, 274], ["isolation", "TREATMENT", 309, 318], ["treatment measures", "TREATMENT", 323, 341], ["emotional and behavioral reactions", "PROBLEM", 369, 403], ["no", "UNCERTAINTY", 73, 75]]], ["Past evidence suggests that mental disturbance in COVID-19 cases is closely J o u r n a l P r e -p r o o f linked to symptoms coming in survivors after large infectious diseases.IntroductionResearch proved that severe acute respiratory syndrome (SARS) andIntroductionMiddle East respiratory syndrome (MERS) survivors had a higher prevalence of PTSD [6, 7] .", [["COVID", "DISEASE", 50, 55], ["infectious diseases", "DISEASE", 158, 177], ["acute respiratory syndrome", "DISEASE", 218, 244], ["SARS", "DISEASE", 246, 250], ["Middle East respiratory syndrome", "DISEASE", 267, 299], ["MERS", "DISEASE", 301, 305], ["PTSD", "DISEASE", 344, 348], ["mental disturbance", "PROBLEM", 28, 46], ["COVID", "TEST", 50, 55], ["symptoms", "PROBLEM", 117, 125], ["large infectious diseases", "PROBLEM", 152, 177], ["severe acute respiratory syndrome", "PROBLEM", 211, 244], ["SARS)", "PROBLEM", 246, 251], ["IntroductionMiddle East respiratory syndrome", "PROBLEM", 255, 299], ["PTSD", "PROBLEM", 344, 348], ["large", "OBSERVATION_MODIFIER", 152, 157], ["infectious", "OBSERVATION", 158, 168], ["severe", "OBSERVATION_MODIFIER", 211, 217], ["acute", "OBSERVATION_MODIFIER", 218, 223], ["respiratory syndrome", "OBSERVATION", 224, 244], ["Middle", "ANATOMY_MODIFIER", 267, 273], ["respiratory syndrome", "OBSERVATION", 279, 299]]], ["Besides this, individuals with PTSD often suffered from depression and anxiety as well [8] .", [["PTSD", "DISEASE", 31, 35], ["depression", "DISEASE", 56, 66], ["anxiety", "DISEASE", 71, 78], ["PTSD", "PROBLEM", 31, 35], ["depression", "PROBLEM", 56, 66], ["anxiety", "PROBLEM", 71, 78]]], ["The research found that 59 percent of those who fully met the PTSD diagnosis had anxiety disorder and 34.5 % had depression [9] .", [["PTSD", "DISEASE", 62, 66], ["anxiety disorder", "DISEASE", 81, 97], ["depression", "DISEASE", 113, 123], ["anxiety disorder", "PROBLEM", 81, 97], ["depression", "PROBLEM", 113, 123]]], ["According to the investigation results of Ju el, nearly 50% of COVID-19 patients in isolation ward suffered from ASD, along with anxiety, depression, insomnia and other mental and psychological symptoms [10] .IntroductionMoreover, a clinical survey of 68 patients with COVID-19 showed that the anxiety score was (60.20\u00b12.04), the incidence rate was 70.6% (including 32 cases of mild anxiety, 20 cases of moderate anxiety and 3 cases of severe anxiety), the depression score was (64.03\u00b13.21), and the incidence rate was 73 .5% (including 34 cases of mild depression, 15 cases of moderate depression and 1 case of severe depression) among them [11] .", [["ASD", "DISEASE", 113, 116], ["anxiety", "DISEASE", 129, 136], ["depression", "DISEASE", 138, 148], ["insomnia", "DISEASE", 150, 158], ["anxiety", "DISEASE", 294, 301], ["anxiety", "DISEASE", 383, 390], ["anxiety", "DISEASE", 413, 420], ["anxiety", "DISEASE", 443, 450], ["depression", "DISEASE", 457, 467], ["depression", "DISEASE", 554, 564], ["depression", "DISEASE", 587, 597], ["depression", "DISEASE", 619, 629], ["patients", "ORGANISM", 72, 80], ["patients", "ORGANISM", 255, 263], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 255, 263], ["COVID", "TEST", 63, 68], ["ASD", "PROBLEM", 113, 116], ["anxiety", "PROBLEM", 129, 136], ["depression", "PROBLEM", 138, 148], ["insomnia", "PROBLEM", 150, 158], ["other mental and psychological symptoms", "PROBLEM", 163, 202], ["COVID", "TEST", 269, 274], ["the anxiety score", "TEST", 290, 307], ["the incidence rate", "TEST", 326, 344], ["mild anxiety", "PROBLEM", 378, 390], ["moderate anxiety", "PROBLEM", 404, 420], ["severe anxiety", "PROBLEM", 436, 450], ["the depression score", "PROBLEM", 453, 473], ["the incidence rate", "TEST", 496, 514], ["mild depression", "PROBLEM", 549, 564], ["moderate depression", "PROBLEM", 578, 597], ["severe depression)", "PROBLEM", 612, 630], ["severe", "OBSERVATION_MODIFIER", 612, 618], ["depression", "OBSERVATION", 619, 629]]], ["Therefore, patients recovering from COVID-19 are more likely to suffer from PTSD, anxiety and depression.IntroductionUnfortunately\uff0cthere are many limitations to treat mental disorders.IntroductionSerotonin reuptake inhibitors (SSRIs) and Norepinephrine reuptake inhibitors (SNRIs) are commonly used as antidepressants drugs for the treatment of PSTD.", [["PTSD", "DISEASE", 76, 80], ["anxiety", "DISEASE", 82, 89], ["depression", "DISEASE", 94, 104], ["IntroductionSerotonin reuptake inhibitors", "CHEMICAL", 184, 225], ["SSRIs", "CHEMICAL", 227, 232], ["Norepinephrine", "CHEMICAL", 238, 252], ["SNRIs", "CHEMICAL", 274, 279], ["antidepressants", "CHEMICAL", 302, 317], ["PSTD", "DISEASE", 345, 349], ["Norepinephrine", "CHEMICAL", 238, 252], ["patients", "ORGANISM", 11, 19], ["IntroductionSerotonin reuptake inhibitors", "GENE_OR_GENE_PRODUCT", 184, 225], ["SSRIs", "SIMPLE_CHEMICAL", 227, 232], ["Norepinephrine reuptake inhibitors", "SIMPLE_CHEMICAL", 238, 272], ["SNRIs", "SIMPLE_CHEMICAL", 274, 279], ["PSTD", "CANCER", 345, 349], ["patients", "SPECIES", 11, 19], ["COVID", "TEST", 36, 41], ["PTSD", "PROBLEM", 76, 80], ["anxiety", "PROBLEM", 82, 89], ["depression", "PROBLEM", 94, 104], ["mental disorders", "PROBLEM", 167, 183], ["IntroductionSerotonin reuptake inhibitors", "TREATMENT", 184, 225], ["SSRIs)", "TREATMENT", 227, 233], ["Norepinephrine reuptake inhibitors", "TREATMENT", 238, 272], ["SNRIs", "TREATMENT", 274, 279], ["antidepressants drugs", "TREATMENT", 302, 323], ["the treatment of PSTD", "TREATMENT", 328, 349]]], ["However, their clinical application was very limited (more or less 50%), and this treatment regime comes with possible side effects such as headache, dizziness and increased muscle tension [12] .", [["muscle", "ANATOMY", 174, 180], ["headache", "DISEASE", 140, 148], ["dizziness", "DISEASE", 150, 159], ["muscle tension", "DISEASE", 174, 188], ["muscle", "ORGAN", 174, 180], ["this treatment regime", "TREATMENT", 77, 98], ["side effects", "PROBLEM", 119, 131], ["headache", "PROBLEM", 140, 148], ["dizziness", "PROBLEM", 150, 159], ["increased muscle tension", "PROBLEM", 164, 188], ["muscle", "ANATOMY", 174, 180]]], ["Although benzodiazepines had a significant anti-anxiety effects, but because of respiratory inhibition effects of these drugs are not suitable for patients with pulmonary damage related to COVID 19 [10] .", [["respiratory", "ANATOMY", 80, 91], ["pulmonary", "ANATOMY", 161, 170], ["benzodiazepines", "CHEMICAL", 9, 24], ["pulmonary damage", "DISEASE", 161, 177], ["benzodiazepines", "CHEMICAL", 9, 24], ["benzodiazepines", "SIMPLE_CHEMICAL", 9, 24], ["patients", "ORGANISM", 147, 155], ["pulmonary", "ORGAN", 161, 170], ["patients", "SPECIES", 147, 155], ["benzodiazepines", "TREATMENT", 9, 24], ["a significant anti-anxiety effects", "TREATMENT", 29, 63], ["respiratory inhibition effects", "PROBLEM", 80, 110], ["these drugs", "TREATMENT", 114, 125], ["pulmonary damage", "PROBLEM", 161, 177], ["pulmonary", "ANATOMY", 161, 170], ["damage", "OBSERVATION", 171, 177]]], ["On the other sides, TCM therapy has the advantages of multi-pathway and multi-target, and is comparatively safer option.", [["TCM therapy", "TREATMENT", 20, 31], ["multi-pathway", "TREATMENT", 54, 67]]], ["In addition to this, Chinese herbs treat symptoms and deal with causes of disease, and it can remedy the remaining symptoms of COVID-19 at the time of treating J o u r n a l P r e -p r o o f 6 mental disorders.IntroductionIn this review, we were trying to find the pathogenic factors of mental disorders in COVID-19 survivors from the perspective of both western medicine and traditional Chinese medicine theory, and trying to put forward the corresponding TCM treatment plan ( Figure 1 ).Sudden epidemic is the cause of mental illnessBased on the researches, all of sudden and life-threatening events, people would experience the corresponding psychological stress reaction and emotions such as anxiety, fear and loneliness.", [["COVID", "DISEASE", 127, 132], ["anxiety", "DISEASE", 696, 703], ["loneliness", "DISEASE", 714, 724], ["people", "ORGANISM", 603, 609], ["people", "SPECIES", 603, 609], ["Chinese herbs", "TREATMENT", 21, 34], ["symptoms", "PROBLEM", 41, 49], ["disease", "PROBLEM", 74, 81], ["the remaining symptoms", "PROBLEM", 101, 123], ["COVID", "TEST", 127, 132], ["mental disorders", "PROBLEM", 193, 209], ["mental disorders", "PROBLEM", 287, 303], ["Sudden epidemic", "PROBLEM", 489, 504], ["mental illness", "PROBLEM", 521, 535], ["the corresponding psychological stress reaction", "PROBLEM", 627, 674], ["anxiety", "PROBLEM", 696, 703], ["loneliness", "PROBLEM", 714, 724], ["disease", "OBSERVATION", 74, 81]]], ["A small number of people could even suffer into mental distress [13] .", [["people", "ORGANISM", 18, 24], ["people", "SPECIES", 18, 24], ["mental distress", "PROBLEM", 48, 63], ["small", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14]]], ["Studies demonstrated that the prevalence of all kinds of mental illness within 30 months after the outbreak of SARS was 33.3%, and a quarter of the patients had PTSD, while 15.6% underwent depression disorder [14, 15] .", [["illness", "DISEASE", 64, 71], ["SARS", "DISEASE", 111, 115], ["PTSD", "DISEASE", 161, 165], ["depression disorder", "DISEASE", 189, 208], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["mental illness", "PROBLEM", 57, 71], ["SARS", "TEST", 111, 115], ["PTSD", "PROBLEM", 161, 165], ["depression disorder", "PROBLEM", 189, 208]]], ["Besides this, a four-year follow-up of 233 SARS survivors showed that more than 40% claimed to be suffering from mental illness, and 40.3% reported chronic fatigue problem [16] .", [["SARS", "DISEASE", 43, 47], ["illness", "DISEASE", 120, 127], ["fatigue", "DISEASE", 156, 163], ["SARS survivors", "TEST", 43, 57], ["mental illness", "PROBLEM", 113, 127], ["chronic fatigue problem", "PROBLEM", 148, 171], ["chronic", "OBSERVATION_MODIFIER", 148, 155], ["fatigue", "OBSERVATION", 156, 163]]], ["In addition to this, many patients and medical workers went through severe emotional stress during the outbreak period of MERS [7] .", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["severe emotional stress", "PROBLEM", 68, 91]]], ["When the epidemic was controlled, many medical workers and recovered patients would be bothered with anxiety, depression and even PTSD [7] .", [["anxiety", "DISEASE", 101, 108], ["depression", "DISEASE", 110, 120], ["PTSD", "DISEASE", 130, 134], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["anxiety", "PROBLEM", 101, 108], ["depression", "PROBLEM", 110, 120]]], ["COVID-19 is a respiratory infection caused by corona virus that similar to SARS and MERS.", [["respiratory", "ANATOMY", 14, 25], ["COVID-19", "CHEMICAL", 0, 8], ["respiratory infection", "DISEASE", 14, 35], ["SARS", "DISEASE", 75, 79], ["corona virus", "ORGANISM", 46, 58], ["corona virus", "SPECIES", 46, 58], ["COVID", "TEST", 0, 5], ["a respiratory infection", "PROBLEM", 12, 35], ["corona virus", "PROBLEM", 46, 58], ["SARS", "PROBLEM", 75, 79], ["respiratory", "ANATOMY", 14, 25], ["infection", "OBSERVATION", 26, 35], ["corona virus", "OBSERVATION", 46, 58]]], ["An investigation on the basic reproduction number of SARS-CoV-2 transmission proved that the R0 (2.8, 3.9) of SARS-CoV-2 was higher than the R0 (2.2, 3.7) of SARS-CoV, but lower than the R0 (2.0, 6.7) of MERS-CoV, indicating that SARS-COV-2 was a medium-high infectious disease [17] .Sudden epidemic is the cause of mental illnessOn January 30, 2020, the world health organization declared the outbreak of COVID-19 in Wuhan, central China as a Public Health Emergency of International Concern (PHEIC) [18] .", [["SARS", "DISEASE", 53, 57], ["SARS", "DISEASE", 110, 114], ["SARS", "DISEASE", 158, 162], ["SARS", "DISEASE", 230, 234], ["infectious disease", "DISEASE", 259, 277], ["COVID-19", "CHEMICAL", 406, 414], ["SARS-CoV-2", "ORGANISM", 53, 63], ["SARS-CoV-2", "ORGANISM", 110, 120], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 158, 166], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 204, 212], ["SARS-CoV", "SPECIES", 53, 61], ["SARS-CoV", "SPECIES", 110, 118], ["SARS-CoV", "SPECIES", 158, 166], ["MERS-CoV", "SPECIES", 204, 212], ["An investigation", "TEST", 0, 16], ["SARS", "TEST", 53, 57], ["CoV", "TEST", 58, 61], ["the R0", "TEST", 89, 95], ["SARS", "TEST", 110, 114], ["CoV", "TEST", 115, 118], ["SARS", "TEST", 158, 162], ["CoV", "TEST", 163, 166], ["MERS", "TEST", 204, 208], ["CoV", "TEST", 209, 212], ["SARS", "TEST", 230, 234], ["COV", "TEST", 235, 238], ["a medium-high infectious disease", "PROBLEM", 245, 277], ["lower", "ANATOMY_MODIFIER", 172, 177], ["high", "OBSERVATION_MODIFIER", 254, 258], ["infectious", "OBSERVATION", 259, 269]]], ["So far, there is no treatment of covid-19 available and the number of infections continuously increasing.", [["infections", "DISEASE", 70, 80], ["treatment", "TREATMENT", 20, 29], ["covid", "TEST", 33, 38], ["infections", "PROBLEM", 70, 80], ["no", "UNCERTAINTY", 17, 19], ["infections", "OBSERVATION", 70, 80]]], ["Until Thursday, J o u r n a l P r e -p r o o f May 31, 2020, more than 6.15 million people had been infected [19] , i.e. more than the total number of people infected with SARS and MERS.", [["SARS", "DISEASE", 172, 176], ["people", "ORGANISM", 84, 90], ["people", "ORGANISM", 151, 157], ["people", "SPECIES", 84, 90], ["people", "SPECIES", 151, 157], ["SARS", "PROBLEM", 172, 176], ["infected", "OBSERVATION", 100, 108], ["infected", "OBSERVATION", 158, 166]]], ["Therefore, due to the fear of disease, physical discomfort, drug side effects and social isolation, COVID-19 patients might be suffering from loneliness, anger, anxiety, depression, insomnia and PTSD in the period of treatment and isolation [20] .Sudden epidemic is the cause of mental illnessThe investigation suggested that the medical workers infected with COVID19 had varying extent of depression, anxiety and sleep disorders [21] .", [["physical discomfort", "DISEASE", 39, 58], ["loneliness", "DISEASE", 142, 152], ["anger", "DISEASE", 154, 159], ["anxiety", "DISEASE", 161, 168], ["depression", "DISEASE", 170, 180], ["insomnia", "DISEASE", 182, 190], ["PTSD", "DISEASE", 195, 199], ["COVID19", "CHEMICAL", 360, 367], ["depression", "DISEASE", 390, 400], ["anxiety", "DISEASE", 402, 409], ["sleep disorders", "DISEASE", 414, 429], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["disease", "PROBLEM", 30, 37], ["physical discomfort", "PROBLEM", 39, 58], ["drug side effects", "PROBLEM", 60, 77], ["social isolation", "TREATMENT", 82, 98], ["COVID", "TREATMENT", 100, 105], ["anxiety", "PROBLEM", 161, 168], ["depression", "PROBLEM", 170, 180], ["insomnia", "PROBLEM", 182, 190], ["PTSD", "PROBLEM", 195, 199], ["treatment", "TREATMENT", 217, 226], ["isolation", "TREATMENT", 231, 240], ["Sudden epidemic", "PROBLEM", 247, 262], ["mental illness", "PROBLEM", 279, 293], ["depression", "PROBLEM", 390, 400], ["anxiety", "PROBLEM", 402, 409], ["sleep disorders", "PROBLEM", 414, 429], ["disease", "OBSERVATION", 30, 37], ["depression", "OBSERVATION", 390, 400]]], ["A recent study on 714 COVID-19 patients confirmed that the prevalence of significant post-traumatic stress symptoms among the recovered patients was 96.2% [22] .", [["patients", "ORGANISM", 31, 39], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 136, 144], ["A recent study", "TEST", 0, 14], ["COVID", "TEST", 22, 27], ["significant post-traumatic stress symptoms", "PROBLEM", 73, 115]]], ["Furthermore, studies demonstrated that patients with COVID-19 showed higher level of depression, anxiety, and PTSD than people without COVID-19 [23] .Therefore, the mental health of COVID-19 survivors needed to be noticed.The close relationship between inflammatory cytokines and mental diseaseWang el.", [["depression", "DISEASE", 85, 95], ["anxiety", "DISEASE", 97, 104], ["PTSD", "DISEASE", 110, 114], ["COVID-19", "CHEMICAL", 135, 143], ["patients", "ORGANISM", 39, 47], ["inflammatory cytokines", "PROTEIN", 253, 275], ["patients", "SPECIES", 39, 47], ["people", "SPECIES", 120, 126], ["studies", "TEST", 13, 20], ["COVID", "TEST", 53, 58], ["depression", "PROBLEM", 85, 95], ["anxiety", "PROBLEM", 97, 104], ["PTSD", "PROBLEM", 110, 114], ["COVID", "TEST", 135, 140], ["COVID-19 survivors", "TREATMENT", 182, 200], ["inflammatory cytokines", "PROBLEM", 253, 275], ["mental diseaseWang el", "PROBLEM", 280, 301], ["depression", "OBSERVATION", 85, 95], ["inflammatory", "OBSERVATION_MODIFIER", 253, 265], ["cytokines", "OBSERVATION", 266, 275]]], ["[24] analyzed 138 cases of hospitalized COVID-19 patients, and they observed that the number of neutrophils cell were increased in patients.The close relationship between inflammatory cytokines and mental diseaseThat might be related to cytokine storm during the invasion of virus.", [["neutrophils cell", "ANATOMY", 96, 112], ["COVID", "DISEASE", 40, 45], ["patients", "ORGANISM", 49, 57], ["neutrophils cell", "CELL", 96, 112], ["patients", "ORGANISM", 131, 139], ["neutrophils cell", "CELL_TYPE", 96, 112], ["inflammatory cytokines", "PROTEIN", 171, 193], ["cytokine", "PROTEIN", 237, 245], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 131, 139], ["hospitalized COVID", "TEST", 27, 45], ["neutrophils cell", "TEST", 96, 112], ["inflammatory cytokines", "PROBLEM", 171, 193], ["mental disease", "PROBLEM", 198, 212], ["cytokine storm", "PROBLEM", 237, 251], ["the invasion of virus", "PROBLEM", 259, 280], ["neutrophils cell", "OBSERVATION", 96, 112], ["increased", "OBSERVATION_MODIFIER", 118, 127], ["inflammatory", "OBSERVATION_MODIFIER", 171, 183], ["cytokines", "OBSERVATION", 184, 193], ["mental disease", "OBSERVATION", 198, 212], ["might be related to", "UNCERTAINTY", 217, 236], ["cytokine storm", "OBSERVATION", 237, 251]]], ["Recent clinical studies had been done to [25, 26] summarize the clinical characteristics of COVID-19 patients.", [["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["Recent clinical studies", "TEST", 0, 23], ["COVID", "TEST", 92, 97]]], ["It's also proposed that compared with healthy people, COVID-19 patients' lymphocyte count was significantly less.", [["lymphocyte", "ANATOMY", 73, 83], ["people", "ORGANISM", 46, 52], ["COVID-19", "CELL", 54, 62], ["patients", "ORGANISM", 63, 71], ["lymphocyte", "CELL", 73, 83], ["people", "SPECIES", 46, 52], ["patients", "SPECIES", 63, 71], ["COVID", "TEST", 54, 59], ["patients' lymphocyte count", "TEST", 63, 89]]], ["Besides this, their inflammatory factors such as interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10) and the tumor necrosis factor alpha (TNF-\u03b1) were markedly high.", [["tumor", "DISEASE", 148, 153], ["interleukin-1\u03b2", "GENE_OR_GENE_PRODUCT", 49, 63], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 65, 70], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 73, 86], ["IL-6", "GENE_OR_GENE_PRODUCT", 88, 92], ["interleukin-8", "GENE_OR_GENE_PRODUCT", 95, 108], ["IL-8", "GENE_OR_GENE_PRODUCT", 110, 114], ["interleukin-10", "GENE_OR_GENE_PRODUCT", 117, 131], ["IL-10", "GENE_OR_GENE_PRODUCT", 133, 138], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 148, 175], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 177, 182], ["inflammatory factors", "PROTEIN", 20, 40], ["interleukin-1\u03b2 (IL-1\u03b2", "PROTEIN", 49, 70], ["interleukin-6", "PROTEIN", 73, 86], ["interleukin-10", "PROTEIN", 117, 131], ["tumor necrosis factor alpha", "PROTEIN", 148, 175], ["TNF", "PROTEIN", 177, 180], ["their inflammatory factors", "PROBLEM", 14, 40], ["interleukin", "TEST", 49, 60], ["IL", "TEST", 65, 67], ["interleukin", "TEST", 73, 84], ["IL", "TEST", 88, 90], ["interleukin", "TEST", 95, 106], ["IL", "TEST", 110, 112], ["interleukin", "TEST", 117, 128], ["IL", "TEST", 133, 135], ["the tumor necrosis factor alpha", "PROBLEM", 144, 175], ["TNF", "TEST", 177, 180], ["markedly high", "PROBLEM", 189, 202], ["inflammatory", "OBSERVATION_MODIFIER", 20, 32], ["tumor", "OBSERVATION_MODIFIER", 148, 153], ["necrosis", "OBSERVATION", 154, 162], ["high", "OBSERVATION_MODIFIER", 198, 202]]], ["These levels of cytokines were sharper in critically ill patients with pneumonia [26] .", [["critically ill", "DISEASE", 42, 56], ["pneumonia", "DISEASE", 71, 80], ["patients", "ORGANISM", 57, 65], ["cytokines", "PROTEIN", 16, 25], ["patients", "SPECIES", 57, 65], ["pneumonia", "PROBLEM", 71, 80], ["pneumonia", "OBSERVATION", 71, 80]]], ["Therefore, patients with COVID-19 showed signs of immune dysfunction and elevated levels of inflammatory cytokines.The close relationship between inflammatory cytokines and mental diseaseMeanwhile, several researches had provided obvious evidences which indicates that immune system activation, pro-inflammatory cytokines were concern with psychiatric symptoms [27] .", [["immune system", "ANATOMY", 269, 282], ["immune dysfunction", "DISEASE", 50, 68], ["psychiatric", "DISEASE", 340, 351], ["patients", "ORGANISM", 11, 19], ["inflammatory cytokines", "PROTEIN", 92, 114], ["inflammatory cytokines", "PROTEIN", 146, 168], ["pro-inflammatory cytokines", "PROTEIN", 295, 321], ["patients", "SPECIES", 11, 19], ["COVID", "TEST", 25, 30], ["immune dysfunction", "PROBLEM", 50, 68], ["elevated levels of inflammatory cytokines", "PROBLEM", 73, 114], ["inflammatory cytokines", "PROBLEM", 146, 168], ["mental disease", "PROBLEM", 173, 187], ["immune system activation", "PROBLEM", 269, 293], ["pro-inflammatory cytokines", "PROBLEM", 295, 321], ["psychiatric symptoms", "PROBLEM", 340, 360], ["immune dysfunction", "OBSERVATION", 50, 68], ["elevated", "OBSERVATION_MODIFIER", 73, 81], ["inflammatory cytokines", "OBSERVATION", 92, 114], ["inflammatory", "OBSERVATION_MODIFIER", 146, 158], ["cytokines", "OBSERVATION", 159, 168], ["mental disease", "OBSERVATION", 173, 187]]], ["Consequently, patients with J o u r n a l P r e -p r o o f 8 COVID-19 could have a higher propensity to be attacked by mental disorders than normal people.", [["patients", "ORGANISM", 14, 22], ["people", "ORGANISM", 148, 154], ["patients", "SPECIES", 14, 22], ["people", "SPECIES", 148, 154], ["mental disorders", "PROBLEM", 119, 135]]], ["There was evidence to support the cross-correlation between cytokine levels and depression risk in many diseases [28] .", [["depression", "DISEASE", 80, 90], ["cytokine", "PROTEIN", 60, 68], ["cytokine levels", "TEST", 60, 75], ["depression risk in many diseases", "PROBLEM", 80, 112]]], ["Along with this, depression may be related to infectious diseases which had been supported by the conclusion of relevant studies [29] .", [["depression", "DISEASE", 17, 27], ["depression", "PROBLEM", 17, 27], ["infectious diseases", "PROBLEM", 46, 65], ["relevant studies", "TEST", 112, 128], ["depression", "OBSERVATION", 17, 27], ["may be related to", "UNCERTAINTY", 28, 45], ["infectious", "OBSERVATION", 46, 56]]], ["In addition, a meta-analysis which brought into 54 studies demonstrated that levels of pro-inflammatory cytokines, especially IL-1\u03b2, IL-6, and TNF-\u03b1, were associated with depressive symptoms [30] .", [["depressive symptoms", "DISEASE", 171, 190], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 126, 131], ["IL-6", "GENE_OR_GENE_PRODUCT", 133, 137], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 143, 148], ["pro-inflammatory cytokines", "PROTEIN", 87, 113], ["IL", "PROTEIN", 126, 128], ["IL-6", "PROTEIN", 133, 137], ["TNF", "PROTEIN", 143, 146], ["a meta-analysis", "TEST", 13, 28], ["pro-inflammatory cytokines", "TEST", 87, 113], ["IL", "TEST", 126, 128], ["IL", "TEST", 133, 135], ["TNF", "TEST", 143, 146], ["depressive symptoms", "PROBLEM", 171, 190], ["pro-inflammatory cytokines", "OBSERVATION", 87, 113]]], ["An excessive dose of interleukin-1beta had been affirmed to be associated with neuro-inflammatory degenerative diseases and mental disorders [31] .", [["degenerative diseases", "DISEASE", 98, 119], ["mental disorders", "DISEASE", 124, 140], ["interleukin-1beta", "GENE_OR_GENE_PRODUCT", 21, 38], ["interleukin-1beta", "PROTEIN", 21, 38], ["An excessive dose of interleukin-1beta", "TREATMENT", 0, 38], ["neuro-inflammatory degenerative diseases", "PROBLEM", 79, 119], ["mental disorders", "PROBLEM", 124, 140], ["excessive", "OBSERVATION_MODIFIER", 3, 12], ["inflammatory", "OBSERVATION_MODIFIER", 85, 97]]], ["Shim el. stated that lateral ventricular IL-1\u03b2 could induce anxiety-like behavior in rats [32] .", [["lateral ventricular", "ANATOMY", 21, 40], ["anxiety", "DISEASE", 60, 67], ["ventricular", "MULTI-TISSUE_STRUCTURE", 29, 40], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 41, 46], ["rats", "ORGANISM", 85, 89], ["lateral ventricular IL-1\u03b2", "PROTEIN", 21, 46], ["rats", "SPECIES", 85, 89], ["lateral ventricular IL", "TREATMENT", 21, 43], ["anxiety", "PROBLEM", 60, 67], ["lateral ventricular", "ANATOMY", 21, 40]]], ["Moreover, systematic reviews had also found that higher levels of interleukin 6, interleukin 1beta, and TNF-\u03b1 were interrelated with PTSD [33] .", [["PTSD", "DISEASE", 133, 137], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 66, 79], ["interleukin 1beta", "GENE_OR_GENE_PRODUCT", 81, 98], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 104, 109], ["interleukin 6", "PROTEIN", 66, 79], ["interleukin 1beta", "PROTEIN", 81, 98], ["TNF", "PROTEIN", 104, 107], ["interleukin", "TEST", 66, 77], ["interleukin 1beta", "TEST", 81, 98], ["TNF", "TEST", 104, 107], ["PTSD", "PROBLEM", 133, 137]]], ["As a result, it is necessary to pay close attention to their mental health during and after the treatment.The pathogenesis explained by traditional Chinese Medicine theoryTraditional Chinese medicine doctors named highly infectious and easily prevalent disease as \"Yi disease\", which meant epidemic, and considered its etiology as \"Yi Qi\" [34] .", [["the treatment", "TREATMENT", 92, 105], ["Yi disease\"", "PROBLEM", 265, 276]]], ["Thus, in accordance with TCM theory, COVID-19 pertained to the category of \"Yi disease\" [35] .", [["COVID-19", "DNA", 37, 45]]], ["Referring to the theory of TCM, \"Yi Qi\" entered the human body from the mouth and nose, while the mouth connected the spleen as well as the whole digestive system, and the nose linked the lung as well as the total respiratory system [36] .", [["body", "ANATOMY", 58, 62], ["mouth", "ANATOMY", 72, 77], ["nose", "ANATOMY", 82, 86], ["mouth", "ANATOMY", 98, 103], ["spleen", "ANATOMY", 118, 124], ["digestive system", "ANATOMY", 146, 162], ["nose", "ANATOMY", 172, 176], ["lung", "ANATOMY", 188, 192], ["human", "ORGANISM", 52, 57], ["body", "ORGANISM_SUBDIVISION", 58, 62], ["mouth", "ORGANISM_SUBDIVISION", 72, 77], ["nose", "ORGANISM_SUBDIVISION", 82, 86], ["mouth", "ORGANISM_SUBDIVISION", 98, 103], ["spleen", "ORGAN", 118, 124], ["digestive", "ORGAN", 146, 155], ["system", "ANATOMICAL_SYSTEM", 156, 162], ["nose", "ORGAN", 172, 176], ["lung", "ORGAN", 188, 192], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["mouth", "ANATOMY", 72, 77], ["nose", "ANATOMY", 82, 86], ["spleen", "ANATOMY", 118, 124], ["lung", "ANATOMY", 188, 192]]], ["While, COVID-19 in the infected patients would first affect the lung and spleen, leading to abnormal function of lung and spleen, and triggering a series of digestive and respiratory symptoms [36] .", [["lung", "ANATOMY", 64, 68], ["spleen", "ANATOMY", 73, 79], ["lung", "ANATOMY", 113, 117], ["spleen", "ANATOMY", 122, 128], ["digestive", "ANATOMY", 157, 166], ["respiratory", "ANATOMY", 171, 182], ["COVID-19", "CHEMICAL", 7, 15], ["digestive and respiratory symptoms", "DISEASE", 157, 191], ["COVID-19", "GENE_OR_GENE_PRODUCT", 7, 15], ["patients", "ORGANISM", 32, 40], ["lung", "ORGAN", 64, 68], ["spleen", "ORGAN", 73, 79], ["lung", "ORGAN", 113, 117], ["spleen", "ORGAN", 122, 128], ["digestive", "ORGAN", 157, 166], ["COVID-19", "DNA", 7, 15], ["patients", "SPECIES", 32, 40], ["COVID", "TEST", 7, 12], ["abnormal function of lung and spleen", "PROBLEM", 92, 128], ["digestive and respiratory symptoms", "PROBLEM", 157, 191], ["infected", "OBSERVATION", 23, 31], ["lung", "ANATOMY", 64, 68], ["spleen", "ANATOMY", 73, 79], ["abnormal", "OBSERVATION_MODIFIER", 92, 100], ["function", "OBSERVATION", 101, 109], ["lung", "ANATOMY", 113, 117], ["spleen", "ANATOMY", 122, 128]]], ["The above statements were consistent with the clinical reports that patients with COVID-19 had not only respiratory symptoms, but also metabolic disorder symptoms such as diarrhea and vomiting [37] .The pathogenesis explained by traditional Chinese Medicine theoryThe harmonious and consistent unity of body and emotion was the stand J o u r n a l P r e -p r o o f point of TCM.", [["respiratory", "ANATOMY", 104, 115], ["body", "ANATOMY", 303, 307], ["respiratory symptoms", "DISEASE", 104, 124], ["metabolic disorder", "DISEASE", 135, 153], ["diarrhea", "DISEASE", 171, 179], ["vomiting", "DISEASE", 184, 192], ["patients", "ORGANISM", 68, 76], ["body", "ORGANISM_SUBDIVISION", 303, 307], ["TCM", "CELL_TYPE", 374, 377], ["patients", "SPECIES", 68, 76], ["COVID", "TEST", 82, 87], ["respiratory symptoms", "PROBLEM", 104, 124], ["metabolic disorder symptoms", "PROBLEM", 135, 162], ["diarrhea", "PROBLEM", 171, 179], ["vomiting", "PROBLEM", 184, 192], ["TCM", "PROBLEM", 374, 377], ["consistent with", "UNCERTAINTY", 26, 41]]], ["Therefore, the emotions of patient were concerned with the function of Five Organs (heart, liver, spleen, lungs and kidneys) [38] .", [["Organs", "ANATOMY", 76, 82], ["heart", "ANATOMY", 84, 89], ["liver", "ANATOMY", 91, 96], ["spleen", "ANATOMY", 98, 104], ["lungs", "ANATOMY", 106, 111], ["kidneys", "ANATOMY", 116, 123], ["patient", "ORGANISM", 27, 34], ["Organs", "ORGAN", 76, 82], ["heart", "ORGAN", 84, 89], ["liver", "ORGAN", 91, 96], ["spleen", "ORGAN", 98, 104], ["lungs", "ORGAN", 106, 111], ["kidneys", "ORGAN", 116, 123], ["patient", "SPECIES", 27, 34], ["heart", "ANATOMY", 84, 89], ["liver", "ANATOMY", 91, 96], ["spleen", "ANATOMY", 98, 104], ["lungs", "ANATOMY", 106, 111], ["kidneys", "ANATOMY", 116, 123]]], ["Seven main emotions in TCM (anger, joy, worry, thinking, sadness, fear, shock) were regulated by the state of function of the Five Organs, meaning that the Five Organs control the generation and change of Seven emotions.", [["Organs", "ANATOMY", 131, 137], ["Organs", "ANATOMY", 161, 167], ["shock", "DISEASE", 72, 77], ["Organs", "ORGAN", 131, 137], ["Organs", "ORGAN", 161, 167], ["sadness", "PROBLEM", 57, 64], ["shock", "PROBLEM", 72, 77], ["main", "OBSERVATION_MODIFIER", 6, 10], ["emotions", "OBSERVATION", 11, 19]]], ["When the status of Five Organs changed, the moods changed accordingly [38] .", [["Organs", "ANATOMY", 24, 30], ["Organs", "ORGAN", 24, 30]]], ["The lung controlled worry and sadness, while the spleen controlled thinking [39] .", [["lung", "ANATOMY", 4, 8], ["spleen", "ANATOMY", 49, 55], ["lung", "ORGAN", 4, 8], ["spleen", "ORGAN", 49, 55], ["sadness", "PROBLEM", 30, 37], ["lung", "ANATOMY", 4, 8], ["spleen", "ANATOMY", 49, 55]]], ["As a result, once lung and spleen was invaded by \"Yi Qi\", the moods controlled by them would also be abnormal.", [["lung", "ANATOMY", 18, 22], ["spleen", "ANATOMY", 27, 33], ["lung", "ORGAN", 18, 22], ["spleen", "ORGAN", 27, 33], ["lung", "ANATOMY", 18, 22], ["spleen", "ANATOMY", 27, 33]]], ["Then, the patients would be bothered with sadness, or they could be tired of over thinking.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["sadness", "PROBLEM", 42, 49]]], ["Consequently, there was a tendency that the COVID-19 survivors suffered from psychological disorders.The pathogenesis explained by traditional Chinese Medicine theoryAdditionally, there was a view in the TCM theory that the diseases with sign of fever could cause the loss of Yin fluid in human body [34] .", [["body", "ANATOMY", 295, 299], ["psychological disorders", "DISEASE", 77, 100], ["fever", "DISEASE", 246, 251], ["human", "ORGANISM", 289, 294], ["human", "SPECIES", 289, 294], ["human", "SPECIES", 289, 294], ["the COVID", "TEST", 40, 49], ["psychological disorders", "PROBLEM", 77, 100], ["the diseases", "PROBLEM", 220, 232], ["fever", "PROBLEM", 246, 251], ["the loss of Yin fluid in human body", "PROBLEM", 264, 299], ["Yin fluid", "OBSERVATION", 276, 285]]], ["Yin fluid referred to body fluid and blood [40] .", [["body fluid", "ANATOMY", 22, 32], ["blood", "ANATOMY", 37, 42], ["body fluid", "ORGANISM_SUBSTANCE", 22, 32], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["Yin fluid", "TEST", 0, 9], ["body fluid", "TEST", 22, 32], ["blood", "TEST", 37, 42], ["fluid", "OBSERVATION", 4, 9]]], ["During the development of COVID-19, \"Yi Qi\" could cause internal heat in body resulting in the symptom of fever that consumed yin fluid.", [["body", "ANATOMY", 73, 77], ["fever", "DISEASE", 106, 111], ["COVID-19", "CELL", 26, 34], ["body", "ORGANISM_SUBDIVISION", 73, 77], ["COVID", "TEST", 26, 31], ["internal heat in body", "PROBLEM", 56, 77], ["fever", "PROBLEM", 106, 111]]], ["As a result, the balance of Yin and Yang was broken and the deficiency of Yin led to the relative excess of Yang.", [["Yin", "CHEMICAL", 74, 77], ["Yin", "GENE_OR_GENE_PRODUCT", 28, 31], ["Yang", "GENE_OR_GENE_PRODUCT", 36, 40], ["the deficiency of Yin", "PROBLEM", 56, 77], ["Yang", "OBSERVATION", 108, 112]]], ["Yin was supposed to be cold while Yang was considered hot.", [["cold", "PROBLEM", 23, 27], ["supposed to be", "UNCERTAINTY", 8, 22]]], ["Then the relative excess of Yang could make the internal body hotter than normal, which contributed to the internal heat and Yin deficiency syndrome. anxious and grim [42] .Synopsis of Prescriptions of the Golden Chamber is a classic book ofTCM, which provided a record of \"Lily disease\" caused by internal heat and Yin deficiency in heart and lung.", [["body", "ANATOMY", 57, 61], ["heart", "ANATOMY", 334, 339], ["lung", "ANATOMY", 344, 348], ["anxious", "DISEASE", 150, 157], ["Lily disease", "DISEASE", 274, 286], ["body", "ORGANISM_SUBDIVISION", 57, 61], ["Yin", "GENE_OR_GENE_PRODUCT", 316, 319], ["heart", "ORGAN", 334, 339], ["lung", "ORGAN", 344, 348], ["the internal heat", "PROBLEM", 103, 120], ["Yin deficiency syndrome", "PROBLEM", 125, 148], ["anxious", "PROBLEM", 150, 157], ["Lily disease", "PROBLEM", 274, 286], ["internal heat and Yin deficiency in heart and lung", "PROBLEM", 298, 348], ["internal heat", "ANATOMY", 107, 120], ["Yin deficiency", "OBSERVATION", 125, 139], ["syndrome", "OBSERVATION", 140, 148], ["Golden Chamber", "OBSERVATION", 206, 220], ["Lily disease", "OBSERVATION", 274, 286], ["Yin deficiency", "OBSERVATION", 316, 330], ["heart", "ANATOMY", 334, 339], ["lung", "ANATOMY", 344, 348]]], ["The main symptoms were willingness to eat, loss of appetite, daily in a bad mental, less words, fatigue but unable to sleep, unable to walk.", [["loss of appetite", "DISEASE", 43, 59], ["fatigue", "DISEASE", 96, 103], ["The main symptoms", "PROBLEM", 0, 17], ["loss of appetite", "PROBLEM", 43, 59], ["fatigue", "PROBLEM", 96, 103], ["unable to sleep", "PROBLEM", 108, 123], ["unable to walk", "PROBLEM", 125, 139], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["They concluded that a series of symptoms could appears including psychological abnormalities; paresthesia and eating behavior abnormalities [43] .", [["paresthesia", "DISEASE", 94, 105], ["eating behavior abnormalities", "DISEASE", 110, 139], ["symptoms", "PROBLEM", 32, 40], ["psychological abnormalities", "PROBLEM", 65, 92], ["paresthesia", "PROBLEM", 94, 105], ["eating behavior abnormalities", "PROBLEM", 110, 139]]], ["These symptoms were very similar to those of depression [44] .Synopsis of Prescriptions of the Golden Chamber is a classic book ofAnother classic book of TCM Typhoid fever theory recorded an opinion that after fever, internal heat had not been cleaned, which contributed to \"deficient dysphoria disease\", an internal heat disease due to deficiency of Yin.Synopsis of Prescriptions of the Golden Chamber is a classic book ofThe symptoms of \"deficient dysphoria \" such as insomnia, restlessness were consistent with the clinical manifestations of anxiety [45] .Synopsis of Prescriptions of the Golden Chamber is a classic book of\"Lily disease\" can be characterized by wandering mind and confusing the illusion and reality, which was similar to PTSD patients' traumatic memory forced into mind to reproduce the event scene in the form of flashbacks or nightmares, compelling them repeatedly to experience the emotion and feeling of that time.", [["depression", "DISEASE", 45, 55], ["Typhoid fever", "DISEASE", 158, 171], ["fever", "DISEASE", 210, 215], ["dysphoria disease", "DISEASE", 285, 302], ["internal heat disease", "DISEASE", 308, 329], ["dysphoria", "DISEASE", 450, 459], ["insomnia", "DISEASE", 470, 478], ["anxiety", "DISEASE", 545, 552], ["Lily disease", "DISEASE", 628, 640], ["PTSD", "DISEASE", 742, 746], ["Yin", "GENE_OR_GENE_PRODUCT", 351, 354], ["patients", "ORGANISM", 747, 755], ["Yin", "PROTEIN", 351, 354], ["patients", "SPECIES", 747, 755], ["These symptoms", "PROBLEM", 0, 14], ["depression", "PROBLEM", 45, 55], ["TCM Typhoid fever", "PROBLEM", 154, 171], ["fever", "PROBLEM", 210, 215], ["internal heat", "PROBLEM", 217, 230], ["\"deficient dysphoria disease\"", "PROBLEM", 274, 303], ["an internal heat disease", "PROBLEM", 305, 329], ["deficiency of Yin", "PROBLEM", 337, 354], ["The symptoms", "PROBLEM", 423, 435], ["\"deficient dysphoria", "PROBLEM", 439, 459], ["insomnia", "PROBLEM", 470, 478], ["restlessness", "PROBLEM", 480, 492], ["anxiety", "PROBLEM", 545, 552], ["Lily disease", "PROBLEM", 628, 640], ["flashbacks", "PROBLEM", 835, 845], ["nightmares", "PROBLEM", 849, 859], ["internal heat disease", "OBSERVATION", 308, 329], ["Golden Chamber", "OBSERVATION", 592, 606], ["Lily disease", "OBSERVATION", 628, 640]]], ["On the basis of concept and clinical manifestations of PTSD, Guo also considered PTSD as a kind of \"Lily disease\", and proposed PTSD of heart-lung Yin deficiency syndrome type [46] .", [["heart", "ANATOMY", 136, 141], ["lung", "ANATOMY", 142, 146], ["PTSD", "DISEASE", 55, 59], ["PTSD", "DISEASE", 81, 85], ["Lily disease", "DISEASE", 100, 112], ["PTSD", "DISEASE", 128, 132], ["heart-lung Yin deficiency syndrome", "DISEASE", 136, 170], ["heart", "ORGAN", 136, 141], ["lung", "ORGAN", 142, 146], ["PTSD", "PROBLEM", 55, 59], ["PTSD", "PROBLEM", 81, 85], ["Lily disease\"", "PROBLEM", 100, 113], ["heart-lung Yin deficiency syndrome", "PROBLEM", 136, 170], ["heart", "ANATOMY", 136, 141], ["lung", "ANATOMY", 142, 146], ["Yin deficiency", "OBSERVATION", 147, 161]]], ["By adding Anemarrhena asphodeloides Bge., the heat-clearing function of the decoction could be strengthened, making it more suitable for those who were already diagnosed as internal heat and Yin deficiency syndrome with more heat.Synopsis of Prescriptions of the Golden Chamber is a classic book ofGanmai Dazao Decoction was indicated for \"Hysteria disease\", whose symptoms were sadness, crying, mood disorders, and abnormal behavior, Decoction combined with Flupentixol and Melitracen Tablets in the treatment of menopausal depression and found that the total clinical effective rate of the combined group was significantly higher than that of the single group [51] .Synopsis of Prescriptions of the Golden Chamber is a classic book ofFurthermore, Lily Bulb and Rehmannia Decoction was able to alleviate the symptoms of depression patients with Yin deficiency and internal heat syndrome remarkably and long-term administration was not harmful [52] .", [["Yin deficiency syndrome", "DISEASE", 191, 214], ["Ganmai Dazao Decoction", "CHEMICAL", 298, 320], ["Hysteria disease", "DISEASE", 340, 356], ["sadness, crying", "DISEASE", 379, 394], ["mood disorders", "DISEASE", 396, 410], ["abnormal behavior", "DISEASE", 416, 433], ["Flupentixol", "CHEMICAL", 459, 470], ["Melitracen", "CHEMICAL", 475, 485], ["menopausal depression", "DISEASE", 514, 535], ["depression", "DISEASE", 821, 831], ["Yin deficiency", "DISEASE", 846, 860], ["internal heat syndrome", "DISEASE", 865, 887], ["Flupentixol", "CHEMICAL", 459, 470], ["Melitracen", "CHEMICAL", 475, 485], ["Anemarrhena asphodeloides", "ORGANISM", 10, 35], ["Flupentixol", "SIMPLE_CHEMICAL", 459, 470], ["Melitracen Tablets", "SIMPLE_CHEMICAL", 475, 493], ["patients", "ORGANISM", 832, 840], ["Anemarrhena asphodeloides", "SPECIES", 10, 35], ["patients", "SPECIES", 832, 840], ["Anemarrhena asphodeloides", "SPECIES", 10, 35], ["the decoction", "TREATMENT", 72, 85], ["internal heat", "PROBLEM", 173, 186], ["Yin deficiency syndrome", "PROBLEM", 191, 214], ["Ganmai Dazao Decoction", "TREATMENT", 298, 320], ["Hysteria disease\"", "PROBLEM", 340, 357], ["whose symptoms", "PROBLEM", 359, 373], ["sadness", "PROBLEM", 379, 386], ["crying", "PROBLEM", 388, 394], ["mood disorders", "PROBLEM", 396, 410], ["abnormal behavior", "PROBLEM", 416, 433], ["Decoction", "TREATMENT", 435, 444], ["Flupentixol", "TREATMENT", 459, 470], ["Melitracen Tablets", "TREATMENT", 475, 493], ["menopausal depression", "PROBLEM", 514, 535], ["Lily Bulb", "TREATMENT", 749, 758], ["Rehmannia Decoction", "TREATMENT", 763, 782], ["the symptoms", "PROBLEM", 805, 817], ["depression", "PROBLEM", 821, 831], ["Yin deficiency", "PROBLEM", 846, 860], ["internal heat syndrome", "PROBLEM", 865, 887], ["long-term administration", "TREATMENT", 903, 927], ["Yin deficiency", "OBSERVATION", 191, 205], ["Golden Chamber", "OBSERVATION", 701, 715], ["Lily Bulb", "ANATOMY", 749, 758], ["Rehmannia Decoction", "OBSERVATION", 763, 782], ["heat syndrome", "OBSERVATION", 874, 887]]], ["In J o u r n a l P r e -p r o o f addition, the investigation used Lily Bulb and Rehmannia Decoction combined with fluoxetine for 6 weeks, confirmed that it was able to reduce the anxiety somatization factor and sleep factor, and the efficacy was more obvious than single modern depression intervention medicine [53] .", [["fluoxetine", "CHEMICAL", 115, 125], ["anxiety", "DISEASE", 180, 187], ["somatization", "DISEASE", 188, 200], ["depression", "DISEASE", 279, 289], ["fluoxetine", "CHEMICAL", 115, 125], ["fluoxetine", "SIMPLE_CHEMICAL", 115, 125], ["the investigation", "TEST", 44, 61], ["Lily Bulb", "TREATMENT", 67, 76], ["Rehmannia Decoction", "TREATMENT", 81, 100], ["fluoxetine", "TREATMENT", 115, 125], ["the anxiety somatization factor", "PROBLEM", 176, 207], ["sleep factor", "PROBLEM", 212, 224], ["single modern depression intervention medicine", "TREATMENT", 265, 311], ["Rehmannia Decoction", "OBSERVATION", 81, 100]]], ["Yan el. adopted Ganmai Dazao Decoction combined with Lily Bulb and Rhizoma Anemarrhena Decoction to treat depression.", [["Ganmai Dazao Decoction", "CHEMICAL", 16, 38], ["Anemarrhena Decoction", "CHEMICAL", 75, 96], ["depression", "DISEASE", 106, 116], ["Ganmai Dazao Decoction", "TREATMENT", 16, 38], ["Lily Bulb", "TREATMENT", 53, 62], ["Rhizoma Anemarrhena Decoction", "TREATMENT", 67, 96], ["depression", "PROBLEM", 106, 116], ["Bulb", "ANATOMY", 58, 62], ["Rhizoma Anemarrhena", "OBSERVATION", 67, 86]]], ["Compared with conventional modern medicine, the decoctions were safer and the incidence of adverse reactions was less [54] . patients with initial severe depression, which mechanism may be related to the regulation of monoamines and amino acid neurotransmitters, the regulation of immune inflammation, and the reduction of the level of inflammatory factors [56] .Synopsis of Prescriptions of the Golden Chamber is a classic book ofIn addition to this, some animal experiments had been carried out to explore the antidepressant pharmacological mechanism of above decoctions.Synopsis of Prescriptions of the Golden Chamber is a classic book ofAfter Lily Bulb and Rehmannia Decoction intervention, the content of monoamine such as neurotransmitters norepinephrine (NE), 5-hydroxytryptamine (5-HT) and dopamine (DA) were greatly increased in the hippocampus of CUMS rats, and the activity of monoamine oxidase was significantly reduced [57] .", [["hippocampus", "ANATOMY", 842, 853], ["depression", "DISEASE", 154, 164], ["amino acid", "CHEMICAL", 233, 243], ["inflammation", "DISEASE", 288, 300], ["antidepressant", "CHEMICAL", 512, 526], ["norepinephrine", "CHEMICAL", 746, 760], ["NE", "CHEMICAL", 762, 764], ["5-hydroxytryptamine", "CHEMICAL", 767, 786], ["5-HT", "CHEMICAL", 788, 792], ["dopamine", "CHEMICAL", 798, 806], ["DA", "CHEMICAL", 808, 810], ["monoamines", "CHEMICAL", 218, 228], ["amino acid", "CHEMICAL", 233, 243], ["monoamine", "CHEMICAL", 710, 719], ["norepinephrine", "CHEMICAL", 746, 760], ["5-hydroxytryptamine", "CHEMICAL", 767, 786], ["5-HT", "CHEMICAL", 788, 792], ["dopamine", "CHEMICAL", 798, 806], ["monoamine", "CHEMICAL", 888, 897], ["patients", "ORGANISM", 125, 133], ["monoamines", "SIMPLE_CHEMICAL", 218, 228], ["amino acid", "AMINO_ACID", 233, 243], ["monoamine", "SIMPLE_CHEMICAL", 710, 719], ["norepinephrine", "SIMPLE_CHEMICAL", 746, 760], ["NE", "SIMPLE_CHEMICAL", 762, 764], ["5-hydroxytryptamine", "SIMPLE_CHEMICAL", 767, 786], ["5-HT", "SIMPLE_CHEMICAL", 788, 792], ["dopamine", "SIMPLE_CHEMICAL", 798, 806], ["DA", "SIMPLE_CHEMICAL", 808, 810], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 842, 853], ["CUMS rats", "ORGANISM", 857, 866], ["monoamine oxidase", "GENE_OR_GENE_PRODUCT", 888, 905], ["inflammatory factors", "PROTEIN", 336, 356], ["monoamine oxidase", "PROTEIN", 888, 905], ["patients", "SPECIES", 125, 133], ["rats", "SPECIES", 862, 866], ["the decoctions", "TREATMENT", 44, 58], ["adverse reactions", "PROBLEM", 91, 108], ["initial severe depression", "PROBLEM", 139, 164], ["monoamines", "TREATMENT", 218, 228], ["amino acid neurotransmitters", "TREATMENT", 233, 261], ["immune inflammation", "PROBLEM", 281, 300], ["inflammatory factors", "PROBLEM", 336, 356], ["above decoctions", "TREATMENT", 556, 572], ["Lily Bulb", "TREATMENT", 647, 656], ["Rehmannia Decoction intervention", "TREATMENT", 661, 693], ["monoamine", "TREATMENT", 710, 719], ["neurotransmitters norepinephrine (NE)", "TREATMENT", 728, 765], ["hydroxytryptamine", "TREATMENT", 769, 786], ["dopamine (DA)", "TREATMENT", 798, 811], ["monoamine oxidase", "TEST", 888, 905], ["severe", "OBSERVATION_MODIFIER", 147, 153], ["depression", "OBSERVATION", 154, 164], ["may be related to", "UNCERTAINTY", 182, 199], ["immune inflammation", "OBSERVATION", 281, 300], ["reduction", "OBSERVATION_MODIFIER", 310, 319], ["inflammatory", "OBSERVATION_MODIFIER", 336, 348], ["Golden Chamber", "OBSERVATION", 606, 620], ["Rehmannia Decoction", "OBSERVATION", 661, 680], ["increased", "OBSERVATION_MODIFIER", 825, 834], ["hippocampus", "ANATOMY", 842, 853], ["CUMS", "OBSERVATION", 857, 861]]], ["Bi el. treated depressed rats with Ganmai Dazao Decoction, and the results showed that it could significantly improve the depressed behavioral characteristics of rats, and significantly increase the activity and content of neurotransmitters 5-HT and NE in the brain of rats [58] .Synopsis of Prescriptions of the Golden Chamber is a classic book ofStudy confirmed that Ganmai Dazao Decoction could significantly improve the depression-like behavior of CUMS rats by regulating HPA axis elevation and protecting hippocampus injury [59] .", [["brain", "ANATOMY", 260, 265], ["hippocampus", "ANATOMY", 510, 521], ["depressed", "DISEASE", 15, 24], ["Ganmai Dazao Decoction", "CHEMICAL", 35, 57], ["depressed", "DISEASE", 122, 131], ["5-HT", "CHEMICAL", 241, 245], ["NE", "CHEMICAL", 250, 252], ["Ganmai Dazao Decoction", "CHEMICAL", 369, 391], ["depression", "DISEASE", 424, 434], ["hippocampus injury", "DISEASE", 510, 528], ["5-HT", "CHEMICAL", 241, 245], ["rats", "ORGANISM", 25, 29], ["rats", "ORGANISM", 162, 166], ["5-HT", "SIMPLE_CHEMICAL", 241, 245], ["NE", "SIMPLE_CHEMICAL", 250, 252], ["brain", "ORGAN", 260, 265], ["rats", "ORGANISM", 269, 273], ["rats", "ORGANISM", 457, 461], ["hippocampus", "ORGAN", 510, 521], ["NE", "PROTEIN", 250, 252], ["rats", "SPECIES", 25, 29], ["rats", "SPECIES", 162, 166], ["rats", "SPECIES", 269, 273], ["rats", "SPECIES", 457, 461], ["depressed rats", "PROBLEM", 15, 29], ["Ganmai Dazao Decoction", "TREATMENT", 35, 57], ["the depressed behavioral characteristics of rats", "PROBLEM", 118, 166], ["neurotransmitters", "TEST", 223, 240], ["Ganmai Dazao Decoction", "TREATMENT", 369, 391], ["the depression", "PROBLEM", 420, 434], ["CUMS rats", "PROBLEM", 452, 461], ["regulating HPA axis elevation", "PROBLEM", 465, 494], ["protecting hippocampus injury", "PROBLEM", 499, 528], ["increase", "OBSERVATION_MODIFIER", 186, 194], ["activity", "OBSERVATION_MODIFIER", 199, 207], ["brain", "ANATOMY", 260, 265], ["hippocampus", "ANATOMY", 510, 521]]], ["The intervention of Lily Bulb and J o u r n a l P r e -p r o o f increase the content of monoamine neurotransmitters in the brain of depression animal model [60] .", [["brain", "ANATOMY", 124, 129], ["depression", "DISEASE", 133, 143], ["monoamine", "CHEMICAL", 89, 98], ["monoamine", "SIMPLE_CHEMICAL", 89, 98], ["brain", "ORGAN", 124, 129], ["monoamine neurotransmitters", "PROBLEM", 89, 116], ["depression", "PROBLEM", 133, 143], ["brain", "ANATOMY", 124, 129]]], ["Besides this, research proposed that Lily Bulb and Rhizoma Anemarrhena Decoction could alleviate the loss of pleasure and despair in depressed rats, and promote the remodeling of neurons.", [["neurons", "ANATOMY", 179, 186], ["Anemarrhena", "CHEMICAL", 59, 70], ["loss of pleasure and despair", "DISEASE", 101, 129], ["depressed", "DISEASE", 133, 142], ["rats", "ORGANISM", 143, 147], ["neurons", "CELL", 179, 186], ["rats", "SPECIES", 143, 147], ["Lily Bulb", "PROBLEM", 37, 46], ["Rhizoma Anemarrhena Decoction", "TREATMENT", 51, 80], ["the loss of pleasure", "PROBLEM", 97, 117], ["despair in depressed rats", "PROBLEM", 122, 147], ["Bulb", "OBSERVATION_MODIFIER", 42, 46], ["Rhizoma", "OBSERVATION_MODIFIER", 51, 58], ["neurons", "ANATOMY", 179, 186]]], ["The mechanism behind this was related to inhibiting the hyperfunction of HPA axis and up-regulating the expression of BDNF mRNA in hippocampus of depressed rats [61] .", [["hippocampus", "ANATOMY", 131, 142], ["depressed", "DISEASE", 146, 155], ["HPA axis", "GENE_OR_GENE_PRODUCT", 73, 81], ["BDNF", "GENE_OR_GENE_PRODUCT", 118, 122], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 131, 142], ["rats", "ORGANISM", 156, 160], ["BDNF mRNA", "RNA", 118, 127], ["rats", "SPECIES", 156, 160], ["the hyperfunction of HPA axis", "PROBLEM", 52, 81], ["depressed rats", "PROBLEM", 146, 160], ["hyperfunction", "OBSERVATION", 56, 69], ["hippocampus", "ANATOMY", 131, 142], ["depressed", "OBSERVATION_MODIFIER", 146, 155]]], ["Previous evidence showed that antidepressant mechanism of Lily Bulb and Rhizoma Anemarrhena Decoction was also related to up-regulation of monoamine transmitters in serum and cerebral cortex [62] .Synopsis of Prescriptions of the Golden Chamber is a classic book ofFurthermore, there are some experiments about active compounds of these decoctions.", [["serum", "ANATOMY", 165, 170], ["cerebral cortex", "ANATOMY", 175, 190], ["antidepressant", "CHEMICAL", 30, 44], ["Anemarrhena", "CHEMICAL", 80, 91], ["monoamine", "CHEMICAL", 139, 148], ["monoamine", "SIMPLE_CHEMICAL", 139, 148], ["serum", "ORGANISM_SUBSTANCE", 165, 170], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 175, 190], ["Lily Bulb", "PROBLEM", 58, 67], ["Rhizoma Anemarrhena Decoction", "PROBLEM", 72, 101], ["monoamine transmitters in serum and cerebral cortex", "PROBLEM", 139, 190], ["these decoctions", "TREATMENT", 331, 347], ["Lily Bulb", "ANATOMY", 58, 67], ["Rhizoma", "OBSERVATION_MODIFIER", 72, 79], ["cerebral cortex", "ANATOMY", 175, 190]]], ["Evidence from Guo el. confirmed that lily saponins, as the main component of Lilii Bulbus, could relieve depression symptoms, whose effect might be related to the increased level of monoamine neurotransmitters in brain and the hyperfunction inhibition of HPA axis [63] .", [["brain", "ANATOMY", 213, 218], ["lily saponins", "CHEMICAL", 37, 50], ["depression", "DISEASE", 105, 115], ["saponins", "CHEMICAL", 42, 50], ["monoamine", "CHEMICAL", 182, 191], ["lily saponins", "SIMPLE_CHEMICAL", 37, 50], ["Lilii Bulbus", "ORGANISM", 77, 89], ["monoamine neurotransmitters", "GENE_OR_GENE_PRODUCT", 182, 209], ["brain", "ORGAN", 213, 218], ["Guo el.", "TEST", 14, 21], ["lily saponins", "PROBLEM", 37, 50], ["depression symptoms", "PROBLEM", 105, 124], ["the increased level of monoamine neurotransmitters in brain", "PROBLEM", 159, 218], ["lily saponins", "OBSERVATION", 37, 50], ["main", "OBSERVATION_MODIFIER", 59, 63], ["Lilii Bulbus", "ANATOMY", 77, 89], ["brain", "ANATOMY", 213, 218], ["hyperfunction", "OBSERVATION", 227, 240]]], ["Research suggested that lily saponins treated depression with irritable bowel syndrome by synergistically regulating the content of brain-gut peptide and the function of 5-HT nervous system in blood, stomach and intestine [47] .", [["bowel", "ANATOMY", 72, 77], ["brain", "ANATOMY", 132, 137], ["5-HT nervous system", "ANATOMY", 170, 189], ["blood", "ANATOMY", 193, 198], ["stomach", "ANATOMY", 200, 207], ["intestine", "ANATOMY", 212, 221], ["lily saponins", "CHEMICAL", 24, 37], ["depression", "DISEASE", 46, 56], ["irritable bowel syndrome", "DISEASE", 62, 86], ["5-HT", "CHEMICAL", 170, 174], ["saponins", "CHEMICAL", 29, 37], ["5-HT", "CHEMICAL", 170, 174], ["bowel", "ORGAN", 72, 77], ["brain", "ORGAN", 132, 137], ["5-HT nervous system", "ANATOMICAL_SYSTEM", 170, 189], ["blood", "ORGANISM_SUBSTANCE", 193, 198], ["stomach", "ORGAN", 200, 207], ["intestine", "ORGAN", 212, 221], ["lily saponins", "PROBLEM", 24, 37], ["depression", "PROBLEM", 46, 56], ["irritable bowel syndrome", "PROBLEM", 62, 86], ["saponins treated", "OBSERVATION", 29, 45], ["bowel", "ANATOMY", 72, 77], ["brain", "ANATOMY", 132, 137], ["gut", "ANATOMY", 138, 141], ["blood", "ANATOMY", 193, 198], ["stomach", "ANATOMY", 200, 207], ["intestine", "ANATOMY", 212, 221]]], ["Further, in the alcohol extract of Rehmannia glutinosa Linosch is one of the main effective components with higher content of it.", [["alcohol", "CHEMICAL", 16, 23], ["Rehmannia glutinosa", "CHEMICAL", 35, 54], ["alcohol", "CHEMICAL", 16, 23], ["alcohol", "SIMPLE_CHEMICAL", 16, 23], ["Rehmannia glutinosa", "ORGANISM", 35, 54], ["Linosch", "ORGANISM", 55, 62], ["Rehmannia glutinosa", "SPECIES", 35, 54], ["Rehmannia glutinosa", "SPECIES", 35, 54], ["Rehmannia glutinosa Linosch", "OBSERVATION", 35, 62], ["one", "OBSERVATION_MODIFIER", 66, 69], ["main", "OBSERVATION_MODIFIER", 77, 81], ["effective", "OBSERVATION_MODIFIER", 82, 91], ["higher content", "OBSERVATION", 108, 122]]], ["Study proved that catalpol had more remarkable antidepressant effect by involving monoamine nervous system than other ingredients in Rehmannia glutinosa Linosch [64] . reduced the contents of TNF-\u03b1, IL-1\u03b2 and IL-6 in mouse brain tissue for anti-inflammatory treatment of depression [66] .Synopsis of Prescriptions of the Golden Chamber is a classic book ofTherefore, these three TCM decoctions can be applied to the treatment of depression.AnxietySuanzaoren Decoction\uff0cHuang lian E jiao Decoction, Zhizi Chi Decoction, were used for anxiety of internal heat and Yin deficiency syndrome ( Table 2) .AnxietyThey were recorded in Typhoid fever theory, and were classic decoctions for Meng el.", [["monoamine nervous system", "ANATOMY", 82, 106], ["brain tissue", "ANATOMY", 223, 235], ["catalpol", "CHEMICAL", 18, 26], ["antidepressant", "CHEMICAL", 47, 61], ["depression", "DISEASE", 271, 281], ["depression", "DISEASE", 429, 439], ["Anxiety", "DISEASE", 440, 447], ["Suanzaoren Decoction", "CHEMICAL", 447, 467], ["anxiety", "DISEASE", 532, 539], ["Yin deficiency syndrome", "DISEASE", 561, 584], ["Anxiety", "DISEASE", 597, 604], ["Typhoid fever", "DISEASE", 626, 639], ["catalpol", "CHEMICAL", 18, 26], ["monoamine", "CHEMICAL", 82, 91], ["catalpol", "SIMPLE_CHEMICAL", 18, 26], ["monoamine nervous system", "ANATOMICAL_SYSTEM", 82, 106], ["Rehmannia glutinosa", "ORGANISM", 133, 152], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 192, 197], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 199, 204], ["IL-6", "GENE_OR_GENE_PRODUCT", 209, 213], ["mouse", "ORGANISM", 217, 222], ["brain tissue", "TISSUE", 223, 235], ["TNF", "PROTEIN", 192, 195], ["IL-1\u03b2", "PROTEIN", 199, 204], ["IL-6", "PROTEIN", 209, 213], ["Rehmannia glutinosa", "SPECIES", 133, 152], ["mouse", "SPECIES", 217, 222], ["Rehmannia glutinosa", "SPECIES", 133, 152], ["mouse", "SPECIES", 217, 222], ["catalpol", "TREATMENT", 18, 26], ["monoamine nervous system", "PROBLEM", 82, 106], ["TNF", "TEST", 192, 195], ["IL", "TEST", 199, 201], ["IL", "TREATMENT", 209, 211], ["anti-inflammatory treatment", "TREATMENT", 240, 267], ["depression", "PROBLEM", 271, 281], ["these three TCM decoctions", "TREATMENT", 367, 393], ["depression", "PROBLEM", 429, 439], ["Anxiety", "PROBLEM", 440, 447], ["Suanzaoren Decoction", "TREATMENT", 447, 467], ["Huang lian E jiao Decoction", "TREATMENT", 468, 495], ["Zhizi Chi Decoction", "TREATMENT", 497, 516], ["anxiety", "PROBLEM", 532, 539], ["internal heat", "PROBLEM", 543, 556], ["Yin deficiency syndrome", "PROBLEM", 561, 584], ["Anxiety", "PROBLEM", 597, 604], ["Typhoid fever theory", "PROBLEM", 626, 646], ["Rehmannia glutinosa", "ANATOMY", 133, 152], ["TNF", "ANATOMY", 192, 195], ["brain tissue", "ANATOMY", 223, 235], ["Golden Chamber", "OBSERVATION", 321, 335], ["depression", "OBSERVATION", 429, 439], ["internal heat", "ANATOMY", 543, 556], ["Yin deficiency", "OBSERVATION", 561, 575]]], ["[67] randomly divided 90 patients with generalized anxiety disorder into the observation group and the control group with 45 cases each, the observation group was treated with modified Suanzaoren Decoction, and the positive control group was treated with estazolam, the results proved that the total effective rates of the observation group and the control group were 91.11% and 75.56% respectively, suggesting that modified Suanzaoren Decoction was more appropriate than modern medicine in the treatment of generalized anxiety disorder.", [["anxiety disorder", "DISEASE", 51, 67], ["Suanzaoren Decoction", "CHEMICAL", 185, 205], ["estazolam", "CHEMICAL", 255, 264], ["Suanzaoren Decoction", "CHEMICAL", 425, 445], ["anxiety disorder", "DISEASE", 520, 536], ["estazolam", "CHEMICAL", 255, 264], ["patients", "ORGANISM", 25, 33], ["estazolam", "SIMPLE_CHEMICAL", 255, 264], ["patients", "SPECIES", 25, 33], ["generalized anxiety disorder", "PROBLEM", 39, 67], ["modified Suanzaoren Decoction", "TREATMENT", 176, 205], ["estazolam", "TREATMENT", 255, 264], ["modified Suanzaoren Decoction", "TREATMENT", 416, 445], ["modern medicine", "TREATMENT", 472, 487], ["generalized anxiety disorder", "PROBLEM", 508, 536], ["generalized", "OBSERVATION_MODIFIER", 508, 519], ["anxiety", "OBSERVATION", 520, 527]]], ["[68] analyzed the clinical effect of modified Suanzaoren Decoction on cancer patients who met the CCMD-3 anxiety diagnosis standard, the total effective rate of clinical effect was higher than that of the control group and no adverse reactions were found.", [["cancer", "ANATOMY", 70, 76], ["Suanzaoren Decoction", "CHEMICAL", 46, 66], ["cancer", "DISEASE", 70, 76], ["anxiety", "DISEASE", 105, 112], ["cancer", "CANCER", 70, 76], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["modified Suanzaoren Decoction", "TREATMENT", 37, 66], ["adverse reactions", "PROBLEM", 226, 243]]], ["It indicating that modified Suanzaoren Decoction can significantly improve the mild and moderate anxiety of cancer patients.", [["cancer", "ANATOMY", 108, 114], ["Suanzaoren Decoction", "CHEMICAL", 28, 48], ["anxiety", "DISEASE", 97, 104], ["cancer", "DISEASE", 108, 114], ["cancer", "CANCER", 108, 114], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["modified Suanzaoren Decoction", "TREATMENT", 19, 48], ["the mild and moderate anxiety of cancer patients", "PROBLEM", 75, 123], ["mild", "OBSERVATION_MODIFIER", 79, 83], ["moderate", "OBSERVATION_MODIFIER", 88, 96], ["cancer", "OBSERVATION", 108, 114]]], ["It was proved that the ant-anxiety effect of Suanzaoren Decoction might be related to the increase of NO concentration in blood and the decrease of IL-1\u03b2, TNF-\u03b1 in serum [69] .AnxietyZhang el.", [["blood", "ANATOMY", 122, 127], ["serum", "ANATOMY", 164, 169], ["Suanzaoren Decoction", "CHEMICAL", 45, 65], ["NO", "CHEMICAL", 102, 104], ["Anxiety", "DISEASE", 176, 183], ["NO", "CHEMICAL", 102, 104], ["NO", "SIMPLE_CHEMICAL", 102, 104], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 148, 153], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 155, 160], ["serum", "ORGANISM_SUBSTANCE", 164, 169], ["IL-1\u03b2", "PROTEIN", 148, 153], ["TNF", "PROTEIN", 155, 158], ["the ant-anxiety effect", "TREATMENT", 19, 41], ["Suanzaoren Decoction", "TREATMENT", 45, 65], ["concentration in blood", "PROBLEM", 105, 127], ["IL", "TEST", 148, 150], ["TNF", "TEST", 155, 158], ["serum", "TEST", 164, 169], ["Anxiety", "PROBLEM", 176, 183], ["decrease", "OBSERVATION_MODIFIER", 136, 144]]], ["[70] selected 60 patients with generalized anxiety, and randomly divided them into treatment group (30 cases) treated with Huanglian E jiao and Decoction, and control group (30 cases) that treated with lorazepam.", [["anxiety", "DISEASE", 43, 50], ["lorazepam", "CHEMICAL", 202, 211], ["lorazepam", "CHEMICAL", 202, 211], ["patients", "ORGANISM", 17, 25], ["lorazepam", "SIMPLE_CHEMICAL", 202, 211], ["patients", "SPECIES", 17, 25], ["generalized anxiety", "PROBLEM", 31, 50], ["Huanglian E jiao", "TREATMENT", 123, 139], ["Decoction", "TREATMENT", 144, 153], ["lorazepam", "TREATMENT", 202, 211]]], ["The total effective rate of the treatment group was 93.33% and that of the control group was 73.33% at the fourth week of treatment.", [["the treatment group", "TREATMENT", 28, 47], ["treatment", "TREATMENT", 122, 131], ["total", "OBSERVATION_MODIFIER", 4, 9], ["effective", "OBSERVATION_MODIFIER", 10, 19]]], ["And the treatment effect of the decoction was more lasting and the adverse reactions were less than that of lorazepam.", [["lorazepam", "CHEMICAL", 108, 117], ["lorazepam", "CHEMICAL", 108, 117], ["lorazepam", "SIMPLE_CHEMICAL", 108, 117], ["the decoction", "PROBLEM", 28, 41], ["the adverse reactions", "PROBLEM", 63, 84], ["lorazepam", "TREATMENT", 108, 117], ["decoction", "OBSERVATION", 32, 41]]], ["Huanglian E jiao Decoction had a better curative effect and fewer adverse reactions than fluvoxamine in the treatment of anxiety that pertained to yin deficiency and fire hyperactivity Syndrome [71] .", [["fluvoxamine", "CHEMICAL", 89, 100], ["anxiety", "DISEASE", 121, 128], ["yin deficiency", "DISEASE", 147, 161], ["hyperactivity", "DISEASE", 171, 184], ["fluvoxamine", "CHEMICAL", 89, 100], ["fluvoxamine", "SIMPLE_CHEMICAL", 89, 100], ["Huanglian E jiao Decoction", "TREATMENT", 0, 26], ["fewer adverse reactions", "PROBLEM", 60, 83], ["fluvoxamine", "TREATMENT", 89, 100], ["anxiety", "PROBLEM", 121, 128], ["yin deficiency", "PROBLEM", 147, 161], ["fire hyperactivity Syndrome", "PROBLEM", 166, 193]]], ["Liu el. reported 50 cases of anxiety treated with Zhizi Chi Decoction, and the total effective rate was 96% [72] .AnxietyIn addition, study confirmed that Suanzaoren Decoction combined with Zhizi Chi Decoction was more effective than diazepam in the treatment of anxiety disorder, and the relapse rate after cessation of the medication was lower [73] .", [["anxiety", "DISEASE", 29, 36], ["Zhizi Chi Decoction", "CHEMICAL", 50, 69], ["Anxiety", "DISEASE", 114, 121], ["Suanzaoren Decoction", "CHEMICAL", 155, 175], ["Zhizi Chi Decoction", "CHEMICAL", 190, 209], ["diazepam", "CHEMICAL", 234, 242], ["anxiety disorder", "DISEASE", 263, 279], ["diazepam", "CHEMICAL", 234, 242], ["Suanzaoren Decoction", "SIMPLE_CHEMICAL", 155, 175], ["diazepam", "SIMPLE_CHEMICAL", 234, 242], ["anxiety", "PROBLEM", 29, 36], ["Zhizi Chi Decoction", "TREATMENT", 50, 69], ["the total effective rate", "TEST", 75, 99], ["Anxiety", "PROBLEM", 114, 121], ["study", "TEST", 134, 139], ["Suanzaoren Decoction", "TREATMENT", 155, 175], ["Zhizi Chi Decoction", "TREATMENT", 190, 209], ["diazepam", "TREATMENT", 234, 242], ["anxiety disorder", "PROBLEM", 263, 279], ["the medication", "TREATMENT", 321, 335], ["more effective", "OBSERVATION_MODIFIER", 214, 228]]], ["Liu el. applied Suanzaoren Decoction combined with Zhizi Chi Decoction to the treatment of 60 cases of anxiety insomnia, and consequently the symptoms of anxiety and insomnia were significantly improved [74] .AnxietyMeanwhile, there are some reports about the therapeutic mechanism and effective compounds of the above decoction.", [["Suanzaoren Decoction", "CHEMICAL", 16, 36], ["anxiety insomnia", "DISEASE", 103, 119], ["anxiety", "DISEASE", 154, 161], ["insomnia", "DISEASE", 166, 174], ["Anxiety", "DISEASE", 209, 216], ["Suanzaoren Decoction", "TREATMENT", 16, 36], ["Zhizi Chi Decoction", "TREATMENT", 51, 70], ["anxiety insomnia", "PROBLEM", 103, 119], ["the symptoms", "PROBLEM", 138, 150], ["anxiety", "PROBLEM", 154, 161], ["insomnia", "PROBLEM", 166, 174], ["Anxiety", "PROBLEM", 209, 216], ["the above decoction", "TREATMENT", 309, 328]]], ["Researches considered that the anti-anxiety effects of Suanzaoren Decoction and Huanglian E jiao Decoction were both related to the increase of \u03b3-GABAA level [75, 76] .", [["Suanzaoren Decoction", "CHEMICAL", 55, 75], ["GABAA", "CHEMICAL", 146, 151], ["\u03b3-GABAA", "GENE_OR_GENE_PRODUCT", 144, 151], ["the anti-anxiety effects", "TREATMENT", 27, 51], ["Suanzaoren Decoction", "TREATMENT", 55, 75], ["Huanglian E jiao Decoction", "TREATMENT", 80, 106]]], ["Besides, Suanzaoren Decoction also decreased the release of NE in hippocampus and inhibited the synthesis of 5-HT [76] .", [["hippocampus", "ANATOMY", 66, 77], ["Suanzaoren Decoction", "CHEMICAL", 9, 29], ["NE", "CHEMICAL", 60, 62], ["5-HT", "CHEMICAL", 109, 113], ["5-HT", "CHEMICAL", 109, 113], ["NE", "SIMPLE_CHEMICAL", 60, 62], ["hippocampus", "ORGAN", 66, 77], ["5-HT", "SIMPLE_CHEMICAL", 109, 113], ["NE", "PROTEIN", 60, 62], ["Suanzaoren Decoction", "TREATMENT", 9, 29], ["NE in hippocampus", "TREATMENT", 60, 77], ["the synthesis", "TEST", 92, 105], ["decreased", "OBSERVATION_MODIFIER", 35, 44], ["hippocampus", "ANATOMY", 66, 77]]], ["Sanjoinine A isolated from Zizyphi Spinosi Semen had been proved to be concerned the GABA ergic transmission [77] .", [["Sanjoinine A", "CHEMICAL", 0, 12], ["GABA", "CHEMICAL", 85, 89], ["Sanjoinine A", "CHEMICAL", 0, 12], ["GABA", "CHEMICAL", 85, 89], ["Sanjoinine A", "SIMPLE_CHEMICAL", 0, 12], ["Zizyphi Spinosi Semen", "ORGANISM", 27, 48], ["GABA", "SIMPLE_CHEMICAL", 85, 89], ["Zizyphi Spinosi", "SPECIES", 27, 42]]], ["In addition, study confirmed that berberine which was the main component of Coptidis Rhizoma in Huanglian E jiao Decoction could regulate the expression of monoamine neurotransmitters and their metabolites and 5 -HT receptors to resist anxiety [79] .", [["berberine", "CHEMICAL", 34, 43], ["5 -HT", "CHEMICAL", 210, 215], ["anxiety", "DISEASE", 236, 243], ["berberine", "CHEMICAL", 34, 43], ["monoamine", "CHEMICAL", 156, 165], ["5 -HT", "CHEMICAL", 210, 215], ["berberine", "SIMPLE_CHEMICAL", 34, 43], ["Coptidis Rhizoma", "ORGANISM", 76, 92], ["monoamine neurotransmitters", "GENE_OR_GENE_PRODUCT", 156, 183], ["5 -HT receptors", "GENE_OR_GENE_PRODUCT", 210, 225], ["study", "TEST", 13, 18], ["berberine", "TREATMENT", 34, 43], ["Coptidis Rhizoma", "TREATMENT", 76, 92], ["Huanglian E jiao Decoction", "TREATMENT", 96, 122], ["monoamine neurotransmitters", "TREATMENT", 156, 183], ["their metabolites", "TEST", 188, 205], ["anxiety", "PROBLEM", 236, 243], ["berberine", "OBSERVATION", 34, 43], ["main", "OBSERVATION_MODIFIER", 58, 62], ["component", "OBSERVATION_MODIFIER", 63, 72], ["Coptidis Rhizoma", "OBSERVATION", 76, 92]]], ["Baicalin and wogonin isolated from Scutellariae Radix both perform anti-anxiety effects mediated by \u03b3-GABAA [80, 81] .", [["Baicalin", "CHEMICAL", 0, 8], ["wogonin", "CHEMICAL", 13, 20], ["Scutellariae Radix", "CHEMICAL", 35, 53], ["\u03b3-GABAA", "CHEMICAL", 100, 107], ["Baicalin", "CHEMICAL", 0, 8], ["wogonin", "CHEMICAL", 13, 20], ["Baicalin", "SIMPLE_CHEMICAL", 0, 8], ["wogonin", "SIMPLE_CHEMICAL", 13, 20], ["Scutellariae Radix", "ORGANISM", 35, 53], ["\u03b3-GABAA", "GENE_OR_GENE_PRODUCT", 100, 107], ["Baicalin", "TREATMENT", 0, 8], ["wogonin", "TREATMENT", 13, 20], ["Scutellariae Radix", "TREATMENT", 35, 53], ["anti-anxiety effects", "TREATMENT", 67, 87], ["wogonin", "OBSERVATION_MODIFIER", 13, 20], ["Scutellariae Radix", "OBSERVATION_MODIFIER", 35, 53]]], ["Moreover, A research mentioned that geniposides, as the main component of Gardeniae Fructus water extract, was one of the anti-anxiety components of Gardeniae Fructus [82] .AnxietyComplementarily, mixed anxiety-depression disorder (MAD) was also a common comorbid psychiatric disorder that frequently-observed with PTSD [83] .", [["geniposides", "CHEMICAL", 36, 47], ["Gardeniae Fructus water extract", "CHEMICAL", 74, 105], ["anxiety-depression disorder", "DISEASE", 203, 230], ["MAD", "DISEASE", 232, 235], ["psychiatric disorder", "DISEASE", 264, 284], ["PTSD", "DISEASE", 315, 319], ["geniposides", "CHEMICAL", 36, 47], ["geniposides", "SIMPLE_CHEMICAL", 36, 47], ["Gardeniae Fructus water extract", "TREATMENT", 74, 105], ["Gardeniae Fructus", "PROBLEM", 149, 166], ["AnxietyComplementarily", "PROBLEM", 173, 195], ["mixed anxiety", "PROBLEM", 197, 210], ["depression disorder", "PROBLEM", 211, 230], ["a common comorbid psychiatric disorder", "PROBLEM", 246, 284], ["PTSD", "PROBLEM", 315, 319], ["main", "OBSERVATION_MODIFIER", 56, 60], ["component", "OBSERVATION_MODIFIER", 61, 70], ["Gardeniae", "OBSERVATION_MODIFIER", 74, 83], ["Fructus water", "OBSERVATION", 84, 97]]], ["Thus, COVID-19 survivors may suffer from MAD.", [["MAD", "DISEASE", 41, 44], ["COVID", "TREATMENT", 6, 11]]], ["The above three kinds of decoctions have been proved to be effective in treating depression [84] .AnxietyIn conclusion COVID-19 survivors with anxiety could be treated with the above three decoctions, and patients with insomnia and MAD could also take the decoctions.Post-traumatic stress disorderLily Bulb and Rehmannia Decoction and Guilu Erxian Decoction were the decoctions for PTSD of internal heat and Yin deficiency syndrome ( Table 3) .Post-traumatic stress disorderMost of the researches on the treatment of PTSD with Chinese herbal medicine were done on animal but the less clinical studies were reported.Post-traumatic stress disorderResearch suggested that patients with PTSD of Yin deficiency of heart and lung Syndrome were suitable to be treated with Lily Bulb and Rehmannia Decoction.", [["heart", "ANATOMY", 709, 714], ["lung", "ANATOMY", 719, 723], ["depression", "DISEASE", 81, 91], ["anxiety", "DISEASE", 143, 150], ["insomnia", "DISEASE", 219, 227], ["MAD", "DISEASE", 232, 235], ["PTSD", "DISEASE", 382, 386], ["Yin deficiency syndrome", "DISEASE", 408, 431], ["traumatic stress disorder", "DISEASE", 449, 474], ["PTSD", "DISEASE", 517, 521], ["traumatic stress disorder", "DISEASE", 620, 645], ["PTSD", "DISEASE", 683, 687], ["heart and lung Syndrome", "DISEASE", 709, 732], ["patients", "ORGANISM", 205, 213], ["patients", "ORGANISM", 669, 677], ["heart", "ORGAN", 709, 714], ["lung", "ORGAN", 719, 723], ["patients", "SPECIES", 205, 213], ["patients", "SPECIES", 669, 677], ["decoctions", "TREATMENT", 25, 35], ["depression", "PROBLEM", 81, 91], ["AnxietyIn conclusion COVID", "TREATMENT", 98, 124], ["anxiety", "PROBLEM", 143, 150], ["insomnia", "PROBLEM", 219, 227], ["traumatic stress disorderLily Bulb", "PROBLEM", 272, 306], ["Rehmannia Decoction", "TREATMENT", 311, 330], ["Guilu Erxian Decoction", "TREATMENT", 335, 357], ["the decoctions", "TREATMENT", 363, 377], ["PTSD", "PROBLEM", 382, 386], ["internal heat", "PROBLEM", 390, 403], ["Yin deficiency syndrome", "PROBLEM", 408, 431], ["Post-traumatic stress disorder", "PROBLEM", 444, 474], ["PTSD", "PROBLEM", 517, 521], ["Chinese herbal medicine", "TREATMENT", 527, 550], ["Post-traumatic stress disorder", "PROBLEM", 615, 645], ["PTSD", "PROBLEM", 683, 687], ["Yin deficiency of heart and lung Syndrome", "PROBLEM", 691, 732], ["Lily Bulb", "TREATMENT", 766, 775], ["Rehmannia Decoction", "TREATMENT", 780, 799], ["traumatic", "OBSERVATION_MODIFIER", 272, 281], ["stress", "OBSERVATION", 282, 288], ["Bulb", "ANATOMY", 302, 306], ["Rehmannia Decoction", "OBSERVATION", 311, 330], ["internal heat", "ANATOMY", 390, 403], ["Yin deficiency", "OBSERVATION", 408, 422], ["traumatic stress disorder", "OBSERVATION", 449, 474], ["traumatic stress disorder", "OBSERVATION", 620, 645], ["Yin deficiency", "OBSERVATION", 691, 705], ["heart", "ANATOMY", 709, 714], ["lung", "ANATOMY", 719, 723], ["Syndrome", "OBSERVATION", 724, 732], ["Rehmannia Decoction", "OBSERVATION", 780, 799]]], ["As they showed lung dryness symptoms such as lung heat cough, which are also a common symptom in the convalescence of COVID-19.", [["lung", "ANATOMY", 15, 19], ["lung", "ANATOMY", 45, 49], ["lung dryness", "DISEASE", 15, 27], ["lung heat cough", "DISEASE", 45, 60], ["lung", "ORGAN", 15, 19], ["lung", "ORGAN", 45, 49], ["lung dryness symptoms", "PROBLEM", 15, 36], ["lung heat cough", "PROBLEM", 45, 60], ["a common symptom", "PROBLEM", 77, 93], ["COVID", "TEST", 118, 123], ["lung", "ANATOMY", 15, 19], ["dryness", "OBSERVATION", 20, 27], ["lung", "ANATOMY", 45, 49], ["heat", "OBSERVATION_MODIFIER", 50, 54], ["cough", "OBSERVATION", 55, 60]]], ["It was suggested to add Tuber Raidix Ophiopogonis (ophiopogon japonicas), Liquorice Root Radix Glycyrrhizae (licorice) in the decoction [46] .", [["Liquorice Root Radix Glycyrrhizae", "CHEMICAL", 74, 107], ["licorice", "CHEMICAL", 109, 117], ["ophiopogon japonicas", "ORGANISM", 51, 71], ["licorice", "ORGANISM_SUBDIVISION", 109, 117], ["ophiopogon japonicas", "SPECIES", 51, 71], ["Tuber Raidix Ophiopogonis (ophiopogon japonicas", "TREATMENT", 24, 71], ["Liquorice Root Radix Glycyrrhizae (licorice", "TREATMENT", 74, 117], ["Root Radix", "ANATOMY", 84, 94]]], ["Meanwhile, if patients had insomnia, they can add Ziziphus spinosa Hu and Radix Pseudostellariae (Heterophylly Falsesatarwort Root) [46] .", [["insomnia", "DISEASE", 27, 35], ["patients", "ORGANISM", 14, 22], ["Ziziphus spinosa", "ORGANISM", 50, 66], ["Hu", "ORGANISM", 67, 69], ["Radix Pseudostellariae", "ORGANISM", 74, 96], ["patients", "SPECIES", 14, 22], ["Ziziphus spinosa", "SPECIES", 50, 66], ["Ziziphus spinosa", "SPECIES", 50, 66], ["Radix Pseudostellariae (Heterophylly Falsesatarwort Root)", "SPECIES", 74, 131], ["insomnia", "PROBLEM", 27, 35], ["Radix Pseudostellariae (Heterophylly Falsesatarwort Root", "TREATMENT", 74, 130], ["Radix Pseudostellariae", "ANATOMY", 74, 96]]], ["Furthermore, the investigation confirmed that Lily Bulb and Rehmannia Decoction could up regulate 5-HT level in hippocampus and deal with the symptoms of PTSD [85] .Post-traumatic stress disorderThe results demonstrated that Lily Bulb and Rehmannia Decoction down regulated the expression of glucocorticoid receptor (GR) in hippocampus, up regulated the expression of glucocorticoid receptor (MR), and improve the symptoms of PTSD in rats [86] .Post-traumatic stress disorderGuilu Erxian Decoction was composed of antler gum, tortoise plate gum, ginseng and wolfberry fruit which nourished Yin.", [["hippocampus", "ANATOMY", 112, 123], ["hippocampus", "ANATOMY", 324, 335], ["Rehmannia", "CHEMICAL", 60, 69], ["5-HT", "CHEMICAL", 98, 102], ["PTSD", "DISEASE", 154, 158], ["traumatic stress disorder", "DISEASE", 170, 195], ["PTSD", "DISEASE", 426, 430], ["traumatic stress disorder", "DISEASE", 450, 475], ["Guilu Erxian Decoction", "CHEMICAL", 475, 497], ["antler gum, tortoise plate gum", "CHEMICAL", 514, 544], ["5-HT", "CHEMICAL", 98, 102], ["5-HT", "GENE_OR_GENE_PRODUCT", 98, 102], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 112, 123], ["Rehmannia Decoction", "ORGANISM", 239, 258], ["glucocorticoid receptor", "GENE_OR_GENE_PRODUCT", 292, 315], ["GR", "GENE_OR_GENE_PRODUCT", 317, 319], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 324, 335], ["glucocorticoid receptor", "GENE_OR_GENE_PRODUCT", 368, 391], ["rats", "ORGANISM", 434, 438], ["antler gum", "ORGANISM_SUBSTANCE", 514, 524], ["tortoise", "ORGANISM", 526, 534], ["ginseng", "ORGANISM", 546, 553], ["glucocorticoid receptor", "PROTEIN", 292, 315], ["GR", "PROTEIN", 317, 319], ["glucocorticoid receptor", "PROTEIN", 368, 391], ["MR", "PROTEIN", 393, 395], ["rats", "SPECIES", 434, 438], ["ginseng", "SPECIES", 546, 553], ["wolfberry", "SPECIES", 558, 567], ["the investigation", "TEST", 13, 30], ["Lily Bulb", "TREATMENT", 46, 55], ["Rehmannia Decoction", "TREATMENT", 60, 79], ["the symptoms", "PROBLEM", 138, 150], ["PTSD", "PROBLEM", 154, 158], ["Post-traumatic stress disorder", "PROBLEM", 165, 195], ["Lily Bulb", "PROBLEM", 225, 234], ["Rehmannia Decoction", "TREATMENT", 239, 258], ["glucocorticoid receptor", "TREATMENT", 292, 315], ["the symptoms", "PROBLEM", 410, 422], ["PTSD", "PROBLEM", 426, 430], ["Post-traumatic stress disorder", "PROBLEM", 445, 475], ["Guilu Erxian Decoction", "TREATMENT", 475, 497], ["antler gum", "PROBLEM", 514, 524], ["tortoise plate gum", "TREATMENT", 526, 544], ["Lily Bulb", "ANATOMY", 46, 55], ["Rehmannia Decoction", "OBSERVATION", 60, 79], ["hippocampus", "ANATOMY", 112, 123], ["traumatic stress disorder", "OBSERVATION", 170, 195], ["Lily Bulb", "OBSERVATION", 225, 234], ["Rehmannia Decoction", "OBSERVATION", 239, 258], ["glucocorticoid receptor", "OBSERVATION", 292, 315], ["hippocampus", "ANATOMY", 324, 335], ["traumatic stress disorder", "OBSERVATION", 450, 475], ["antler gum", "ANATOMY", 514, 524], ["tortoise plate", "OBSERVATION", 526, 540]]], ["Li el. demonstrated that Guilu Erxian Decoction may play an anti-PTSD role by regulating synaptic plasticity, anti-apoptosis, anti-inflammation and promoting fear memory extinction through network pharmacology [87] .", [["synaptic", "ANATOMY", 89, 97], ["Li", "CHEMICAL", 0, 2], ["Guilu Erxian Decoction", "TREATMENT", 25, 47], ["anti-apoptosis", "TREATMENT", 110, 124], ["anti-inflammation", "TREATMENT", 126, 143]]], ["Moreover, researches had confirmed that the therapeutic mechanism of was to regulating the function of the HPA axis, the expression of GR and 5-HT receptors in the hippocampus to improve the emotional and behavioral abnormalities in PTSD rats [88, 89] .", [["hippocampus", "ANATOMY", 164, 175], ["5-HT", "CHEMICAL", 142, 146], ["behavioral abnormalities", "DISEASE", 205, 229], ["PTSD", "DISEASE", 233, 237], ["5-HT", "CHEMICAL", 142, 146], ["GR", "GENE_OR_GENE_PRODUCT", 135, 137], ["5-HT receptors", "GENE_OR_GENE_PRODUCT", 142, 156], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 164, 175], ["rats", "ORGANISM", 238, 242], ["GR", "PROTEIN", 135, 137], ["5-HT receptors", "PROTEIN", 142, 156], ["rats", "SPECIES", 238, 242], ["GR and 5-HT receptors", "TREATMENT", 135, 156], ["the emotional and behavioral abnormalities", "PROBLEM", 187, 229], ["PTSD rats", "TEST", 233, 242], ["HPA axis", "ANATOMY", 107, 115], ["hippocampus", "ANATOMY", 164, 175]]], ["Besides this, study confirmed that Lycium barbarum polysaccharide in Guilu Erxian Decoction can reduce the level of cortisol in serum to improve the symptoms of PTSD [90] .", [["serum", "ANATOMY", 128, 133], ["Lycium barbarum polysaccharide", "CHEMICAL", 35, 65], ["Guilu Erxian Decoction", "CHEMICAL", 69, 91], ["cortisol", "CHEMICAL", 116, 124], ["PTSD", "DISEASE", 161, 165], ["cortisol", "CHEMICAL", 116, 124], ["Lycium barbarum", "ORGANISM", 35, 50], ["Guilu Erxian Decoction", "ORGANISM", 69, 91], ["cortisol", "SIMPLE_CHEMICAL", 116, 124], ["serum", "ORGANISM_SUBSTANCE", 128, 133], ["Lycium barbarum", "SPECIES", 35, 50], ["Lycium barbarum", "SPECIES", 35, 50], ["study", "TEST", 14, 19], ["Lycium barbarum polysaccharide", "TREATMENT", 35, 65], ["Guilu Erxian Decoction", "TREATMENT", 69, 91], ["cortisol in serum", "TEST", 116, 133], ["the symptoms", "PROBLEM", 145, 157], ["PTSD", "PROBLEM", 161, 165]]], ["Previous evidence showed that ginsenoside Rg2 can regulate the function of HPA axis to treat PTSD [91] .Consequently\uff0cPTSD patients could be treated with the two decoctions.", [["ginsenoside Rg2", "CHEMICAL", 30, 45], ["PTSD", "DISEASE", 93, 97], ["PTSD", "DISEASE", 117, 121], ["ginsenoside Rg2", "CHEMICAL", 30, 45], ["ginsenoside Rg2", "GENE_OR_GENE_PRODUCT", 30, 45], ["HPA axis", "GENE_OR_GENE_PRODUCT", 75, 83], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["ginsenoside Rg2", "PROBLEM", 30, 45], ["PTSD", "PROBLEM", 93, 97], ["the two decoctions", "TREATMENT", 153, 171], ["ginsenoside Rg2", "OBSERVATION", 30, 45]]], ["We strictly disclosed that all funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.", [["the study", "TEST", 54, 63], ["data collection", "TEST", 72, 87], ["analysis", "TEST", 92, 100]]]], "bf1d95ada5ce959db1a171eba72b349366a6748b": [["BackgroundThe underlying pathophysiology of malaria is not well understood despite considerable and prolonged international research effort.", [["malaria", "DISEASE", 44, 51], ["malaria", "PROBLEM", 44, 51], ["malaria", "OBSERVATION", 44, 51]]], ["This effort is largely driven by the need to reduce the impact of Plasmodium falciparum on human life, particularly in African children [1, 2] .", [["Plasmodium falciparum", "DISEASE", 66, 87], ["Plasmodium falciparum", "ORGANISM", 66, 87], ["human", "ORGANISM", 91, 96], ["children", "ORGANISM", 127, 135], ["Plasmodium falciparum", "SPECIES", 66, 87], ["human", "SPECIES", 91, 96], ["children", "SPECIES", 127, 135], ["Plasmodium falciparum", "SPECIES", 66, 87], ["human", "SPECIES", 91, 96], ["Plasmodium falciparum on human life", "TREATMENT", 66, 101]]], ["Part of the difficulty in studying the pathophysiology of P. falciparum malaria is the lack of a permissive animal model and a comparator disease in man.", [["P. falciparum malaria", "DISEASE", 58, 79], ["P. falciparum", "ORGANISM", 58, 71], ["man", "ORGANISM", 149, 152], ["P. falciparum", "SPECIES", 58, 71], ["man", "SPECIES", 149, 152], ["P. falciparum", "SPECIES", 58, 71], ["P. falciparum malaria", "PROBLEM", 58, 79], ["a comparator disease", "PROBLEM", 125, 145], ["falciparum malaria", "OBSERVATION", 61, 79]]], ["With the recent discovery of severe malaria, caused by the zoonotic parasite Plasmodium knowlesi in the human population of Southeast Asia [3, 4] , it is now possible to link findings in primates and humans through this common agent.BackgroundIn the natural primate hosts (long and pig-tailed macaques), P. knowlesi causes asymptomatic low-grade parasitism.", [["malaria", "DISEASE", 36, 43], ["Plasmodium knowlesi", "DISEASE", 77, 96], ["P. knowlesi", "DISEASE", 304, 315], ["low-grade parasitism", "DISEASE", 336, 356], ["Plasmodium knowlesi", "ORGANISM", 77, 96], ["human", "ORGANISM", 104, 109], ["primates", "ORGANISM", 187, 195], ["humans", "ORGANISM", 200, 206], ["primate", "ORGANISM", 258, 265], ["long", "ORGANISM_SUBDIVISION", 273, 277], ["pig-tailed macaques", "ORGANISM", 282, 301], ["P. knowlesi", "ORGANISM", 304, 315], ["Plasmodium knowlesi", "SPECIES", 77, 96], ["human", "SPECIES", 104, 109], ["humans", "SPECIES", 200, 206], ["pig", "SPECIES", 282, 285], ["macaques", "SPECIES", 293, 301], ["P. knowlesi", "SPECIES", 304, 315], ["Plasmodium knowlesi", "SPECIES", 77, 96], ["human", "SPECIES", 104, 109], ["humans", "SPECIES", 200, 206], ["pig-tailed macaques", "SPECIES", 282, 301], ["P. knowlesi", "SPECIES", 304, 315], ["severe malaria", "PROBLEM", 29, 43], ["the zoonotic parasite Plasmodium knowlesi", "PROBLEM", 55, 96], ["long and pig-tailed macaques", "TREATMENT", 273, 301], ["asymptomatic low-grade parasitism", "PROBLEM", 323, 356], ["severe", "OBSERVATION_MODIFIER", 29, 35], ["malaria", "OBSERVATION", 36, 43], ["low-grade", "OBSERVATION_MODIFIER", 336, 345], ["parasitism", "OBSERVATION", 346, 356]]], ["In contrast, hyperparasitaemia and death ensue in the well-used Rhesus experimental model [5] .", [["hyperparasitaemia", "DISEASE", 13, 30], ["death", "DISEASE", 35, 40], ["hyperparasitaemia", "PROBLEM", 13, 30], ["death", "PROBLEM", 35, 40]]], ["Consequently, there is much information on experimental P. knowlesi malaria, including organ pathology in various animal models [6] [7] [8] .", [["organ", "ANATOMY", 87, 92], ["P. knowlesi malaria", "DISEASE", 56, 75], ["P. knowlesi", "ORGANISM", 56, 67], ["organ", "ORGAN", 87, 92], ["P. knowlesi", "SPECIES", 56, 67], ["P. knowlesi", "SPECIES", 56, 67], ["experimental P. knowlesi malaria", "PROBLEM", 43, 75], ["organ pathology", "TEST", 87, 102]]], ["Natural P. knowlesi infections of humans were formerly missed because of morphological similarity with Plasmodium malariae [9, 10] .", [["P. knowlesi infections", "DISEASE", 8, 30], ["Plasmodium malariae", "DISEASE", 103, 122], ["P. knowlesi", "ORGANISM", 8, 19], ["humans", "ORGANISM", 34, 40], ["Plasmodium malariae", "ORGANISM", 103, 122], ["P. knowlesi", "SPECIES", 8, 19], ["humans", "SPECIES", 34, 40], ["P. knowlesi", "SPECIES", 8, 19], ["humans", "SPECIES", 34, 40], ["Plasmodium malariae", "SPECIES", 103, 122], ["Natural P. knowlesi infections of humans", "PROBLEM", 0, 40], ["Plasmodium malariae", "PROBLEM", 103, 122]]], ["Now clinical descriptions of knowlesi malaria encompass a spectrum of disease ranging from uncomplicated to fatal malaria [3, 4] .BackgroundThe pathophysiology of severe knowlesi malaria in humans is undescribed, but nonetheless important for several reasons.", [["knowlesi malaria", "DISEASE", 29, 45], ["malaria", "DISEASE", 114, 121], ["knowlesi malaria", "DISEASE", 170, 186], ["knowlesi", "ORGANISM", 29, 37], ["humans", "ORGANISM", 190, 196], ["humans", "SPECIES", 190, 196], ["humans", "SPECIES", 190, 196], ["knowlesi malaria", "PROBLEM", 29, 45], ["disease", "PROBLEM", 70, 77], ["fatal malaria", "PROBLEM", 108, 121], ["severe knowlesi malaria in humans", "PROBLEM", 163, 196], ["knowlesi malaria", "OBSERVATION", 29, 45], ["disease", "OBSERVATION", 70, 77], ["fatal", "OBSERVATION_MODIFIER", 108, 113], ["malaria", "OBSERVATION", 114, 121], ["severe", "OBSERVATION_MODIFIER", 163, 169], ["knowlesi", "OBSERVATION_MODIFIER", 170, 178], ["malaria", "OBSERVATION", 179, 186]]], ["First, to provide improved guidelines for the diagnosis, treatment and management of severe knowlesi cases.", [["knowlesi", "DISEASE", 92, 100], ["treatment", "TREATMENT", 57, 66], ["management", "TREATMENT", 71, 81], ["severe knowlesi cases", "PROBLEM", 85, 106], ["severe", "OBSERVATION_MODIFIER", 85, 91]]], ["Secondly, when severe knowlesi infection is compared with severe falciparum malaria, this can help clarify determinants of severe disease.", [["knowlesi infection", "DISEASE", 22, 40], ["falciparum malaria", "DISEASE", 65, 83], ["severe knowlesi infection", "PROBLEM", 15, 40], ["severe falciparum malaria", "PROBLEM", 58, 83], ["severe disease", "PROBLEM", 123, 137], ["severe", "OBSERVATION_MODIFIER", 15, 21], ["knowlesi", "OBSERVATION_MODIFIER", 22, 30], ["infection", "OBSERVATION", 31, 40], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["falciparum", "OBSERVATION_MODIFIER", 65, 75], ["malaria", "OBSERVATION", 76, 83], ["severe", "OBSERVATION_MODIFIER", 123, 129], ["disease", "OBSERVATION", 130, 137]]], ["Thirdly, it is possible that we are observing a P. knowlesi vertebrate host switch from Southeast Asian macaques to a fullblown emergence into the human population [11, 12] .", [["P. knowlesi", "DISEASE", 48, 59], ["P. knowlesi", "ORGANISM", 48, 59], ["macaques", "ORGANISM", 104, 112], ["human", "ORGANISM", 147, 152], ["P. knowlesi", "SPECIES", 48, 59], ["Asian macaques", "SPECIES", 98, 112], ["human", "SPECIES", 147, 152], ["P. knowlesi", "SPECIES", 48, 59], ["Asian macaques", "SPECIES", 98, 112], ["human", "SPECIES", 147, 152], ["a P. knowlesi vertebrate host switch", "TREATMENT", 46, 82], ["Southeast Asian macaques", "TREATMENT", 88, 112]]], ["Therefore, it is important to understand properly the disease caused by P. knowlesi to assist strategies to reduce health-impacts if human-to-human transmission of this virulent pathogen is established.BackgroundThe clinical, laboratory and, for the first time, postmortem findings in a fatal case of knowlesi malaria are reported here.", [["P. knowlesi", "DISEASE", 72, 83], ["knowlesi malaria", "DISEASE", 301, 317], ["P. knowlesi", "ORGANISM", 72, 83], ["human", "ORGANISM", 133, 138], ["human", "ORGANISM", 142, 147], ["knowlesi", "ORGANISM", 301, 309], ["P. knowlesi", "SPECIES", 72, 83], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 142, 147], ["P. knowlesi", "SPECIES", 72, 83], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 142, 147], ["this virulent pathogen", "PROBLEM", 164, 186], ["knowlesi malaria", "PROBLEM", 301, 317], ["knowlesi malaria", "OBSERVATION", 301, 317]]], ["The histopathology in various organs is explained within the context of P. knowlesi biology and comparisons with the salient features made with what is known of the pathophysiology of severe falciparum malaria [13] [14] [15] [16] .History and examinationA forty year-old male was brought to the Queen Elizabeth Hospital, Kota Kinabalu, Sabah (8.30 am) in a state of collapse.", [["organs", "ANATOMY", 30, 36], ["P. knowlesi", "DISEASE", 72, 83], ["falciparum malaria", "DISEASE", 191, 209], ["[13] [14] [15]", "CHEMICAL", 210, 224], ["organs", "ORGAN", 30, 36], ["P. knowlesi", "ORGANISM", 72, 83], ["[13] [14] [15] [16]", "SIMPLE_CHEMICAL", 210, 229], ["male", "ORGANISM", 271, 275], ["P. knowlesi", "SPECIES", 72, 83], ["P. knowlesi", "SPECIES", 72, 83], ["severe falciparum malaria", "PROBLEM", 184, 209], ["collapse", "PROBLEM", 366, 374], ["collapse", "OBSERVATION", 366, 374]]], ["He was unable to give a history himself or to stand.", [["He", "ORGANISM", 0, 2]]], ["On examination his blood pressure was unrecordable and oxygen saturations were recorded as low.History and examinationThe patient had no past medical history.", [["blood", "ANATOMY", 19, 24], ["oxygen", "CHEMICAL", 55, 61], ["oxygen", "CHEMICAL", 55, 61], ["blood", "ORGANISM_SUBSTANCE", 19, 24], ["oxygen", "SIMPLE_CHEMICAL", 55, 61], ["patient", "ORGANISM", 122, 129], ["patient", "SPECIES", 122, 129], ["examination", "TEST", 3, 14], ["his blood pressure", "TEST", 15, 33], ["oxygen saturations", "TEST", 55, 73], ["examination", "TEST", 107, 118], ["oxygen saturations", "OBSERVATION", 55, 73]]], ["Ten days after leaving the jungle he experienced the onset of fever and body aches.", [["body", "ANATOMY", 72, 76], ["fever", "DISEASE", 62, 67], ["body aches", "DISEASE", 72, 82], ["body", "ORGANISM_SUBDIVISION", 72, 76], ["aches", "ORGANISM_SUBDIVISION", 77, 82], ["fever", "PROBLEM", 62, 67], ["body aches", "PROBLEM", 72, 82], ["fever", "OBSERVATION", 62, 67]]], ["Two days later, he sought treatment at a government outpatient clinic continuing to complain of fever and myalgia.", [["fever", "DISEASE", 96, 101], ["myalgia", "DISEASE", 106, 113], ["fever", "PROBLEM", 96, 101], ["myalgia", "PROBLEM", 106, 113], ["fever", "OBSERVATION", 96, 101], ["myalgia", "OBSERVATION", 106, 113]]], ["A specific diagnosis was not made and he was able to work although he developed rashes the next day.", [["rashes", "DISEASE", 80, 86], ["rashes", "PROBLEM", 80, 86], ["rashes", "OBSERVATION", 80, 86]]], ["He remained unwell for the next two days, when he presented in a state of collapse and had developed abdominal pain.History and examinationResuscitation measures were begun and the patient was immediately intubated, given adrenaline/atropine and sodium bicarbonate.", [["abdominal", "ANATOMY", 101, 110], ["abdominal pain", "DISEASE", 101, 115], ["adrenaline", "CHEMICAL", 222, 232], ["atropine", "CHEMICAL", 233, 241], ["sodium bicarbonate", "CHEMICAL", 246, 264], ["adrenaline", "CHEMICAL", 222, 232], ["atropine", "CHEMICAL", 233, 241], ["sodium bicarbonate", "CHEMICAL", 246, 264], ["abdominal", "ORGANISM_SUBDIVISION", 101, 110], ["patient", "ORGANISM", 181, 188], ["adrenaline", "SIMPLE_CHEMICAL", 222, 232], ["atropine", "SIMPLE_CHEMICAL", 233, 241], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 246, 264], ["patient", "SPECIES", 181, 188], ["unwell", "PROBLEM", 12, 18], ["collapse", "PROBLEM", 74, 82], ["abdominal pain", "PROBLEM", 101, 115], ["examinationResuscitation measures", "TEST", 128, 161], ["adrenaline", "TREATMENT", 222, 232], ["atropine", "TREATMENT", 233, 241], ["sodium bicarbonate", "TREATMENT", 246, 264], ["unwell", "OBSERVATION", 12, 18], ["collapse", "OBSERVATION", 74, 82], ["abdominal", "ANATOMY", 101, 110], ["pain", "OBSERVATION", 111, 115]]], ["On examination and after resuscitation measures his vital signs were: symmetrical air entry into lungs, BP 58/44 mm Hg, pulse rate 40-50 per minute with poor peripheral perfusion and cyanosis.", [["lungs", "ANATOMY", 97, 102], ["cyanosis", "DISEASE", 183, 191], ["Hg", "CHEMICAL", 116, 118], ["lungs", "ORGAN", 97, 102], ["peripheral", "TISSUE", 158, 168], ["examination", "TEST", 3, 14], ["resuscitation measures", "TEST", 25, 47], ["his vital signs", "TEST", 48, 63], ["BP", "TEST", 104, 106], ["Hg", "TEST", 116, 118], ["pulse rate", "TEST", 120, 130], ["poor peripheral perfusion", "PROBLEM", 153, 178], ["cyanosis", "PROBLEM", 183, 191], ["lungs", "ANATOMY", 97, 102], ["peripheral perfusion", "OBSERVATION", 158, 178], ["cyanosis", "OBSERVATION", 183, 191]]], ["Heart sounds were normal.", [["Heart", "ANATOMY", 0, 5], ["Heart", "ORGAN", 0, 5], ["sounds", "OBSERVATION", 6, 12], ["normal", "OBSERVATION", 18, 24]]], ["He had generalized petechiae and his abdomen was tense and distended.History and examinationResuscitation measures continued for one hour, during which time \"coffee grounds\" were observed in the nasogastric aspirate.", [["petechiae", "ANATOMY", 19, 28], ["abdomen", "ANATOMY", 37, 44], ["nasogastric aspirate", "ANATOMY", 195, 215], ["petechiae", "DISEASE", 19, 28], ["petechiae", "PATHOLOGICAL_FORMATION", 19, 28], ["abdomen", "ORGAN", 37, 44], ["nasogastric aspirate", "MULTI-TISSUE_STRUCTURE", 195, 215], ["generalized petechiae", "PROBLEM", 7, 28], ["tense", "PROBLEM", 49, 54], ["distended", "PROBLEM", 59, 68], ["examinationResuscitation measures", "TEST", 81, 114], ["the nasogastric aspirate", "TEST", 191, 215], ["generalized", "OBSERVATION_MODIFIER", 7, 18], ["petechiae", "OBSERVATION", 19, 28], ["abdomen", "ANATOMY", 37, 44], ["tense", "OBSERVATION", 49, 54], ["distended", "OBSERVATION", 59, 68], ["nasogastric", "ANATOMY", 195, 206], ["aspirate", "OBSERVATION", 207, 215]]], ["The patient became asystolic after one hour and although cardiopulmonary resuscitation was given for a further 20 minutes, there was no response.", [["cardiopulmonary", "ANATOMY", 57, 72], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["asystolic", "PROBLEM", 19, 28], ["cardiopulmonary resuscitation", "TREATMENT", 57, 86], ["no", "UNCERTAINTY", 133, 135]]], ["The patient was pronounced dead two hours after admission.History and examinationDengue haemorrhagic shock was suspected and a post-mortem examination was performed approximately 24 hours later.Laboratory findingsLaboratory results are summarized in Table 1 .", [["Dengue haemorrhagic shock", "DISEASE", 81, 106], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["examination", "TEST", 70, 81], ["Dengue haemorrhagic shock", "PROBLEM", 81, 106], ["a post-mortem examination", "TEST", 125, 150], ["Laboratory findings", "TEST", 194, 213], ["haemorrhagic", "OBSERVATION_MODIFIER", 88, 100], ["shock", "OBSERVATION", 101, 106]]], ["The patient was not anemic, but was thrombocytopenic and had an eosinophilia.", [["anemic", "DISEASE", 20, 26], ["thrombocytopenic", "DISEASE", 36, 52], ["eosinophilia", "DISEASE", 64, 76], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["anemic", "PROBLEM", 20, 26], ["thrombocytopenic", "PROBLEM", 36, 52], ["an eosinophilia", "PROBLEM", 61, 76], ["not", "UNCERTAINTY", 16, 19], ["anemic", "OBSERVATION", 20, 26], ["thrombocytopenic", "OBSERVATION", 36, 52], ["eosinophilia", "OBSERVATION", 64, 76]]], ["He was also hyponatraemic and had elevated blood urea, potassium, lactate dehydrogenase and amino transferase values.", [["blood", "ANATOMY", 43, 48], ["urea", "CHEMICAL", 49, 53], ["potassium", "CHEMICAL", 55, 64], ["lactate", "CHEMICAL", 66, 73], ["urea", "CHEMICAL", 49, 53], ["potassium", "CHEMICAL", 55, 64], ["lactate", "CHEMICAL", 66, 73], ["amino", "CHEMICAL", 92, 97], ["He", "ORGANISM", 0, 2], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["urea", "SIMPLE_CHEMICAL", 49, 53], ["potassium", "SIMPLE_CHEMICAL", 55, 64], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 66, 87], ["amino transferase", "GENE_OR_GENE_PRODUCT", 92, 109], ["lactate dehydrogenase", "PROTEIN", 66, 87], ["amino transferase", "PROTEIN", 92, 109], ["hyponatraemic", "PROBLEM", 12, 25], ["elevated blood urea", "PROBLEM", 34, 53], ["potassium", "TEST", 55, 64], ["lactate dehydrogenase", "TEST", 66, 87], ["amino transferase values", "TEST", 92, 116]]], ["Serum creatinine was not available.", [["Serum", "ANATOMY", 0, 5], ["creatinine", "CHEMICAL", 6, 16], ["creatinine", "CHEMICAL", 6, 16], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["creatinine", "SIMPLE_CHEMICAL", 6, 16], ["Serum creatinine", "TEST", 0, 16]]], ["A blood sample taken 24 hours post-mortem showed >10% of erythrocytes infected with predominantly pigmented parasites ( Figure 1a ).", [["blood sample", "ANATOMY", 2, 14], ["erythrocytes", "ANATOMY", 57, 69], ["blood", "ORGANISM_SUBSTANCE", 2, 7], ["erythrocytes", "CELL", 57, 69], ["erythrocytes", "CELL_TYPE", 57, 69], ["A blood sample", "TEST", 0, 14], ["erythrocytes infected", "PROBLEM", 57, 78], ["predominantly pigmented parasites", "PROBLEM", 84, 117], ["erythrocytes", "ANATOMY", 57, 69], ["infected", "OBSERVATION", 70, 78], ["predominantly", "OBSERVATION_MODIFIER", 84, 97], ["pigmented parasites", "OBSERVATION", 98, 117]]], ["Heavily pigmented monocytes were also present ( Figure 1b ).", [["pigmented monocytes", "ANATOMY", 8, 27], ["monocytes", "CELL", 18, 27], ["pigmented monocytes", "CELL_TYPE", 8, 27], ["Heavily pigmented monocytes", "PROBLEM", 0, 27], ["pigmented monocytes", "OBSERVATION", 8, 27]]], ["Plasmodium knowlesi, as a single species infection, was confirmed by nested-PCR [9] .", [["Plasmodium knowlesi", "DISEASE", 0, 19], ["infection", "DISEASE", 41, 50], ["Plasmodium knowlesi", "ORGANISM", 0, 19], ["Plasmodium knowlesi", "SPECIES", 0, 19], ["Plasmodium knowlesi", "SPECIES", 0, 19], ["Plasmodium knowlesi", "PROBLEM", 0, 19], ["a single species infection", "PROBLEM", 24, 50], ["infection", "OBSERVATION", 41, 50]]], ["Post-mortem dengue serology was negative (Table 1 ) and dengue, respiratory syncytial virus and enterovirus were not isolated in organ samples.Post-mortem examinationExternal examination showed a well-nourished adult male.", [["organ samples", "ANATOMY", 129, 142], ["dengue", "DISEASE", 12, 18], ["dengue", "DISEASE", 56, 62], ["respiratory syncytial virus", "DISEASE", 64, 91], ["respiratory syncytial virus", "ORGANISM", 64, 91], ["enterovirus", "ORGANISM", 96, 107], ["organ samples", "CANCER", 129, 142], ["respiratory syncytial virus", "SPECIES", 64, 91], ["dengue", "SPECIES", 56, 62], ["respiratory syncytial virus", "SPECIES", 64, 91], ["Post-mortem dengue serology", "TEST", 0, 27], ["dengue", "PROBLEM", 56, 62], ["respiratory syncytial virus", "PROBLEM", 64, 91], ["enterovirus", "PROBLEM", 96, 107], ["Post-mortem examination", "TEST", 143, 166], ["External examination", "TEST", 166, 186], ["respiratory syncytial", "ANATOMY", 64, 85]]], ["The conjunctivae showed tinges of jaundice and the right eye had subconjunctival haemorrhages.", [["conjunctivae", "ANATOMY", 4, 16], ["right eye", "ANATOMY", 51, 60], ["subconjunctival", "ANATOMY", 65, 80], ["jaundice", "DISEASE", 34, 42], ["haemorrhages", "DISEASE", 81, 93], ["conjunctivae", "CANCER", 4, 16], ["eye", "ORGAN", 57, 60], ["tinges of jaundice", "PROBLEM", 24, 42], ["subconjunctival haemorrhages", "PROBLEM", 65, 93], ["conjunctivae", "ANATOMY", 4, 16], ["tinges", "OBSERVATION_MODIFIER", 24, 30], ["jaundice", "OBSERVATION", 34, 42], ["right", "ANATOMY_MODIFIER", 51, 56], ["eye", "ANATOMY", 57, 60], ["subconjunctival", "ANATOMY", 65, 80], ["haemorrhages", "OBSERVATION", 81, 93]]], ["There were multiple petechial haemorrhages on the body and venepuncture sites were associated with marked bruising.", [["petechial", "ANATOMY", 20, 29], ["body", "ANATOMY", 50, 54], ["venepuncture sites", "ANATOMY", 59, 77], ["haemorrhages", "DISEASE", 30, 42], ["bruising", "DISEASE", 106, 114], ["petechial haemorrhages", "PATHOLOGICAL_FORMATION", 20, 42], ["body", "ORGANISM_SUBDIVISION", 50, 54], ["venepuncture sites", "MULTI-TISSUE_STRUCTURE", 59, 77], ["multiple petechial haemorrhages on the body and venepuncture sites", "PROBLEM", 11, 77], ["marked bruising", "PROBLEM", 99, 114], ["multiple", "OBSERVATION_MODIFIER", 11, 19], ["petechial", "OBSERVATION_MODIFIER", 20, 29], ["haemorrhages", "OBSERVATION", 30, 42], ["body", "ANATOMY", 50, 54], ["marked", "OBSERVATION_MODIFIER", 99, 105], ["bruising", "OBSERVATION", 106, 114]]], ["Coffee ground material was noted in the mouth.", [["mouth", "ANATOMY", 40, 45], ["mouth", "ORGANISM_SUBDIVISION", 40, 45], ["Coffee ground material", "PROBLEM", 0, 22], ["ground material", "OBSERVATION", 7, 22], ["mouth", "ANATOMY", 40, 45]]], ["Internal examination revealed no tissue oedema or excess fluid in the body cavities.Macroscopic pathologyThe external surfaces of the cerebrum were dusky.", [["tissue", "ANATOMY", 33, 39], ["fluid", "ANATOMY", 57, 62], ["body cavities", "ANATOMY", 70, 83], ["cerebrum", "ANATOMY", 134, 142], ["oedema", "DISEASE", 40, 46], ["tissue", "TISSUE", 33, 39], ["fluid", "ORGANISM_SUBSTANCE", 57, 62], ["body cavities", "MULTI-TISSUE_STRUCTURE", 70, 83], ["external surfaces", "MULTI-TISSUE_STRUCTURE", 109, 126], ["cerebrum", "ORGAN", 134, 142], ["Internal examination", "TEST", 0, 20], ["tissue oedema", "PROBLEM", 33, 46], ["excess fluid in the body cavities", "PROBLEM", 50, 83], ["Macroscopic pathology", "TEST", 84, 105], ["dusky", "PROBLEM", 148, 153], ["no", "UNCERTAINTY", 30, 32], ["tissue", "ANATOMY", 33, 39], ["oedema", "OBSERVATION", 40, 46], ["excess", "OBSERVATION_MODIFIER", 50, 56], ["fluid", "OBSERVATION", 57, 62], ["body", "ANATOMY", 70, 74], ["cavities", "ANATOMY_MODIFIER", 75, 83], ["pathology", "OBSERVATION", 96, 105], ["external", "ANATOMY_MODIFIER", 109, 117], ["surfaces", "ANATOMY_MODIFIER", 118, 126], ["cerebrum", "ANATOMY", 134, 142], ["dusky", "OBSERVATION", 148, 153]]], ["The cut sections showed multiple petechial haemorrhages.", [["sections", "ANATOMY", 8, 16], ["petechial", "ANATOMY", 33, 42], ["haemorrhages", "DISEASE", 43, 55], ["petechial haemorrhages", "PATHOLOGICAL_FORMATION", 33, 55], ["The cut sections", "TEST", 0, 16], ["multiple petechial haemorrhages", "PROBLEM", 24, 55], ["multiple", "OBSERVATION_MODIFIER", 24, 32], ["petechial", "OBSERVATION_MODIFIER", 33, 42], ["haemorrhages", "OBSERVATION", 43, 55]]], ["The cerebellum also showed petechial haemorrhages externally and on multiple cut sections (Figure 2a and 2b).", [["cerebellum", "ANATOMY", 4, 14], ["petechial", "ANATOMY", 27, 36], ["sections", "ANATOMY", 81, 89], ["haemorrhages", "DISEASE", 37, 49], ["cerebellum", "ORGAN", 4, 14], ["petechial haemorrhages", "PROBLEM", 27, 49], ["multiple cut sections", "TEST", 68, 89], ["cerebellum", "ANATOMY", 4, 14], ["petechial", "OBSERVATION_MODIFIER", 27, 36], ["haemorrhages", "OBSERVATION", 37, 49]]], ["The brain stem and upper spinal chord were grossly normal.", [["brain stem", "ANATOMY", 4, 14], ["upper spinal chord", "ANATOMY", 19, 37], ["brain stem", "CANCER", 4, 14], ["upper", "ORGAN", 19, 24], ["spinal chord", "ORGAN", 25, 37], ["brain", "ANATOMY", 4, 9], ["stem", "ANATOMY_MODIFIER", 10, 14], ["upper", "ANATOMY_MODIFIER", 19, 24], ["spinal chord", "ANATOMY", 25, 37], ["grossly", "OBSERVATION_MODIFIER", 43, 50], ["normal", "OBSERVATION", 51, 57]]], ["Both lungs were heavy (weighing on the right 720 g and left 690 g) and cut sections were congested Figure 1 Thin blood film showing mostly late trophozoites of P. knowlesi in poorly defined erythrocytes (1a) and heavily pigmented monocyte (1b).", [["lungs", "ANATOMY", 5, 10], ["sections", "ANATOMY", 75, 83], ["blood", "ANATOMY", 113, 118], ["erythrocytes", "ANATOMY", 190, 202], ["pigmented monocyte", "ANATOMY", 220, 238], ["P. knowlesi", "DISEASE", 160, 171], ["lungs", "ORGAN", 5, 10], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["trophozoites", "ORGANISM_SUBSTANCE", 144, 156], ["erythrocytes", "CELL", 190, 202], ["monocyte", "CELL", 230, 238], ["erythrocytes", "CELL_TYPE", 190, 202], ["heavily pigmented monocyte", "CELL_TYPE", 212, 238], ["P. knowlesi", "SPECIES", 160, 171], ["P. knowlesi", "SPECIES", 160, 171], ["cut sections", "TEST", 71, 83], ["Thin blood film", "TEST", 108, 123], ["mostly late trophozoites", "PROBLEM", 132, 156], ["P. knowlesi", "PROBLEM", 160, 171], ["heavily pigmented monocyte", "TEST", 212, 238], ["lungs", "ANATOMY", 5, 10], ["heavy", "OBSERVATION", 16, 21], ["left", "ANATOMY_MODIFIER", 55, 59], ["late trophozoites", "OBSERVATION_MODIFIER", 139, 156], ["poorly defined", "OBSERVATION_MODIFIER", 175, 189], ["erythrocytes", "OBSERVATION", 190, 202], ["heavily", "OBSERVATION_MODIFIER", 212, 219], ["pigmented monocyte", "OBSERVATION", 220, 238]]], ["Note that the blood film was prepared 24 hours post mortem and shows red cell ghosts, particularly among parasite infected red blood cells.Macroscopic pathologyand 'beefy' in appearance.", [["blood", "ANATOMY", 14, 19], ["red cell", "ANATOMY", 69, 77], ["red blood cells", "ANATOMY", 123, 138], ["blood film", "ORGANISM_SUBSTANCE", 14, 24], ["red cell", "CELL", 69, 77], ["red blood cells", "CELL", 123, 138], ["red cell ghosts", "CELL_TYPE", 69, 84], ["parasite infected red blood cells", "CELL_TYPE", 105, 138], ["the blood film", "TEST", 10, 24], ["red cell ghosts", "PROBLEM", 69, 84], ["parasite infected red blood cells", "PROBLEM", 105, 138], ["Macroscopic pathologyand 'beefy' in appearance", "PROBLEM", 139, 185], ["red cell ghosts", "OBSERVATION", 69, 84], ["parasite", "OBSERVATION_MODIFIER", 105, 113], ["infected", "OBSERVATION", 114, 122], ["blood cells", "OBSERVATION", 127, 138], ["beefy", "OBSERVATION", 165, 170]]], ["Petechial haemorrhages were present on the endocardium with extensive subendocardial haemorrhages involving the left ventricular wall.", [["endocardium", "ANATOMY", 43, 54], ["subendocardial", "ANATOMY", 70, 84], ["left ventricular wall", "ANATOMY", 112, 133], ["haemorrhages", "DISEASE", 10, 22], ["subendocardial haemorrhages", "DISEASE", 70, 97], ["endocardium", "MULTI-TISSUE_STRUCTURE", 43, 54], ["subendocardial haemorrhages", "PATHOLOGICAL_FORMATION", 70, 97], ["ventricular wall", "MULTI-TISSUE_STRUCTURE", 117, 133], ["Petechial haemorrhages", "PROBLEM", 0, 22], ["extensive subendocardial haemorrhages involving the left ventricular wall", "PROBLEM", 60, 133], ["haemorrhages", "OBSERVATION", 10, 22], ["endocardium", "ANATOMY", 43, 54], ["extensive", "OBSERVATION_MODIFIER", 60, 69], ["subendocardial", "ANATOMY_MODIFIER", 70, 84], ["haemorrhages", "OBSERVATION", 85, 97], ["left ventricular", "ANATOMY", 112, 128], ["wall", "ANATOMY_MODIFIER", 129, 133]]], ["The haemorrhages were most prominent at the apex of the heart.", [["heart", "ANATOMY", 56, 61], ["haemorrhages", "DISEASE", 4, 16], ["heart", "ORGAN", 56, 61], ["The haemorrhages", "PROBLEM", 0, 16], ["haemorrhages", "OBSERVATION", 4, 16], ["most prominent", "OBSERVATION_MODIFIER", 22, 36], ["apex", "ANATOMY_MODIFIER", 44, 48], ["heart", "ANATOMY", 56, 61]]], ["The liver (2640 g) and spleen (340 g) were markedly enlarged.", [["liver", "ANATOMY", 4, 9], ["spleen", "ANATOMY", 23, 29], ["liver", "ORGAN", 4, 9], ["spleen", "ORGAN", 23, 29], ["spleen", "TEST", 23, 29], ["markedly enlarged", "PROBLEM", 43, 60], ["liver", "ANATOMY", 4, 9], ["spleen", "ANATOMY", 23, 29], ["markedly", "OBSERVATION_MODIFIER", 43, 51], ["enlarged", "OBSERVATION", 52, 60]]], ["The cut surfaces of the spleen were soft and friable.", [["spleen", "ANATOMY", 24, 30], ["spleen", "ORGAN", 24, 30], ["friable", "PROBLEM", 45, 52], ["cut", "OBSERVATION_MODIFIER", 4, 7], ["surfaces", "OBSERVATION_MODIFIER", 8, 16], ["spleen", "ANATOMY", 24, 30], ["soft", "OBSERVATION", 36, 40], ["friable", "OBSERVATION", 45, 52]]], ["The gallbladder, pancreas and kidneys were grossly normal.Microscopic pathologyHaematoxylin and eosin stained sections from various organs were available for examination.", [["gallbladder", "ANATOMY", 4, 15], ["pancreas", "ANATOMY", 17, 25], ["kidneys", "ANATOMY", 30, 37], ["sections", "ANATOMY", 110, 118], ["organs", "ANATOMY", 132, 138], ["Haematoxylin", "CHEMICAL", 79, 91], ["eosin", "CHEMICAL", 96, 101], ["gallbladder", "ORGAN", 4, 15], ["pancreas", "ORGAN", 17, 25], ["kidneys", "ORGAN", 30, 37], ["Haematoxylin", "SIMPLE_CHEMICAL", 79, 91], ["eosin", "GENE_OR_GENE_PRODUCT", 96, 101], ["organs", "ORGAN", 132, 138], ["Microscopic pathology", "TEST", 58, 79], ["Haematoxylin", "TEST", 79, 91], ["eosin stained sections", "TEST", 96, 118], ["examination", "TEST", 158, 169], ["gallbladder", "ANATOMY", 4, 15], ["pancreas", "ANATOMY", 17, 25], ["kidneys", "ANATOMY", 30, 37], ["grossly", "OBSERVATION_MODIFIER", 43, 50], ["normal", "OBSERVATION", 51, 57], ["pathology", "OBSERVATION", 70, 79]]], ["Parasitized red blood cells (PRBC) were abundant although parasite bodies were obscured by haemozoin (malaria) pigment.", [["red blood cells", "ANATOMY", 12, 27], ["PRBC", "ANATOMY", 29, 33], ["parasite bodies", "ANATOMY", 58, 73], ["haemozoin", "CHEMICAL", 91, 100], ["malaria", "DISEASE", 102, 109], ["red blood cells", "CELL", 12, 27], ["PRBC", "CELL", 29, 33], ["haemozoin", "SIMPLE_CHEMICAL", 91, 100], ["Parasitized red blood cells", "CELL_TYPE", 0, 27], ["PRBC", "CELL_TYPE", 29, 33], ["Parasitized red blood cells", "TEST", 0, 27], ["PRBC", "TEST", 29, 33], ["parasite bodies", "PROBLEM", 58, 73], ["haemozoin (malaria) pigment", "PROBLEM", 91, 118], ["blood cells", "OBSERVATION", 16, 27], ["parasite bodies", "OBSERVATION", 58, 73]]], ["Chemical removal of pigment and oil immersion (\u00d71,000) magnification revealed trophozoites that were discernibly bigger than those of P. falciparum.", [["oil", "ANATOMY", 32, 35], ["trophozoites", "ANATOMY", 78, 90], ["P. falciparum", "DISEASE", 134, 147], ["pigment", "TISSUE", 20, 27], ["oil", "ORGANISM_SUBSTANCE", 32, 35], ["trophozoites", "CELL", 78, 90], ["P. falciparum", "ORGANISM", 134, 147], ["P. falciparum", "SPECIES", 134, 147], ["P. falciparum", "SPECIES", 134, 147], ["Chemical removal of pigment and oil immersion", "TREATMENT", 0, 45], ["trophozoites", "PROBLEM", 78, 90], ["P. falciparum", "PROBLEM", 134, 147], ["removal", "OBSERVATION", 9, 16], ["pigment", "OBSERVATION_MODIFIER", 20, 27], ["oil", "OBSERVATION_MODIFIER", 32, 35], ["trophozoites", "OBSERVATION", 78, 90], ["bigger", "OBSERVATION_MODIFIER", 113, 119], ["falciparum", "OBSERVATION", 137, 147]]], ["Immunohistochemistry stained sections from the brain were Plasmodium anti-aldolase positive ( Figure 3 ) and negative for P. falciparumspecific staining [17] .Microscopic pathologyMany petechial haemorrhages (up to 600 \u03bcm diameter) arising from the rupture of the small vessels of the cerebrum and cerebellum were observed (Figures 4a and 4b ) Sequestration of PRBC was evident within small blood vessels (Figures 4c and 4d ).", [["sections", "ANATOMY", 29, 37], ["brain", "ANATOMY", 47, 52], ["petechial", "ANATOMY", 185, 194], ["small vessels", "ANATOMY", 264, 277], ["cerebrum", "ANATOMY", 285, 293], ["cerebellum", "ANATOMY", 298, 308], ["PRBC", "ANATOMY", 361, 365], ["blood vessels", "ANATOMY", 391, 404], ["haemorrhages", "DISEASE", 195, 207], ["rupture", "DISEASE", 249, 256], ["brain", "ORGAN", 47, 52], ["Plasmodium", "ORGANISM", 58, 68], ["anti-aldolase", "GENE_OR_GENE_PRODUCT", 69, 82], ["petechial haemorrhages", "PATHOLOGICAL_FORMATION", 185, 207], ["small vessels", "MULTI-TISSUE_STRUCTURE", 264, 277], ["cerebrum", "ORGAN", 285, 293], ["cerebellum", "ORGAN", 298, 308], ["PRBC", "CELL", 361, 365], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 391, 404], ["PRBC", "CELL_TYPE", 361, 365], ["Immunohistochemistry stained sections", "TEST", 0, 37], ["the brain", "TEST", 43, 52], ["Plasmodium anti-aldolase", "TEST", 58, 82], ["P. falciparumspecific staining", "PROBLEM", 122, 152], ["Microscopic pathology", "TEST", 159, 180], ["Many petechial haemorrhages", "PROBLEM", 180, 207], ["PRBC", "TREATMENT", 361, 365], ["small blood vessels", "PROBLEM", 385, 404], ["brain", "ANATOMY", 47, 52], ["pathology", "OBSERVATION", 171, 180], ["petechial", "OBSERVATION_MODIFIER", 185, 194], ["haemorrhages", "OBSERVATION", 195, 207], ["up to 600 \u03bcm diameter", "OBSERVATION_MODIFIER", 209, 230], ["rupture", "OBSERVATION", 249, 256], ["small", "ANATOMY_MODIFIER", 264, 269], ["vessels", "ANATOMY", 270, 277], ["cerebrum", "ANATOMY", 285, 293], ["cerebellum", "ANATOMY", 298, 308], ["PRBC", "OBSERVATION", 361, 365], ["small", "OBSERVATION_MODIFIER", 385, 390], ["blood vessels", "ANATOMY", 391, 404]]], ["Congested larger vessels and areas of haemorrhage showed considerable amounts of malaria pigment (Figures 4e and 4f ).", [["vessels", "ANATOMY", 17, 24], ["haemorrhage", "DISEASE", 38, 49], ["malaria", "DISEASE", 81, 88], ["vessels", "MULTI-TISSUE_STRUCTURE", 17, 24], ["Congested larger vessels", "PROBLEM", 0, 24], ["haemorrhage", "PROBLEM", 38, 49], ["malaria pigment", "PROBLEM", 81, 96], ["larger", "OBSERVATION_MODIFIER", 10, 16], ["vessels", "ANATOMY", 17, 24], ["areas", "OBSERVATION_MODIFIER", 29, 34], ["haemorrhage", "OBSERVATION", 38, 49], ["considerable", "OBSERVATION_MODIFIER", 57, 69], ["amounts", "OBSERVATION_MODIFIER", 70, 77], ["malaria pigment", "OBSERVATION", 81, 96]]], ["Clumps of platelets or evidence of thrombi in vessels were not seen.", [["platelets", "ANATOMY", 10, 19], ["thrombi", "ANATOMY", 35, 42], ["vessels", "ANATOMY", 46, 53], ["thrombi", "DISEASE", 35, 42], ["platelets", "CELL", 10, 19], ["vessels", "MULTI-TISSUE_STRUCTURE", 46, 53], ["platelets", "CELL_TYPE", 10, 19], ["Clumps of platelets", "PROBLEM", 0, 19], ["thrombi in vessels", "PROBLEM", 35, 53], ["platelets", "OBSERVATION", 10, 19], ["evidence of", "UNCERTAINTY", 23, 34], ["thrombi", "OBSERVATION", 35, 42], ["vessels", "ANATOMY", 46, 53], ["not seen", "UNCERTAINTY", 59, 67]]], ["There was no evidence of vasculitis or perivascular chronic inflammatory reaction in the brain or any other organ examined (heart, kidney, liver, adrenal gland and spleen).", [["perivascular", "ANATOMY", 39, 51], ["brain", "ANATOMY", 89, 94], ["organ", "ANATOMY", 108, 113], ["heart", "ANATOMY", 124, 129], ["kidney", "ANATOMY", 131, 137], ["liver", "ANATOMY", 139, 144], ["adrenal gland", "ANATOMY", 146, 159], ["spleen", "ANATOMY", 164, 170], ["vasculitis", "DISEASE", 25, 35], ["brain", "ORGAN", 89, 94], ["organ", "ORGAN", 108, 113], ["heart", "ORGAN", 124, 129], ["kidney", "ORGAN", 131, 137], ["liver", "ORGAN", 139, 144], ["adrenal gland", "MULTI-TISSUE_STRUCTURE", 146, 159], ["spleen", "ORGAN", 164, 170], ["vasculitis", "PROBLEM", 25, 35], ["perivascular chronic inflammatory reaction in the brain", "PROBLEM", 39, 94], ["no evidence of", "UNCERTAINTY", 10, 24], ["vasculitis", "OBSERVATION", 25, 35], ["perivascular", "ANATOMY_MODIFIER", 39, 51], ["chronic", "OBSERVATION_MODIFIER", 52, 59], ["inflammatory", "OBSERVATION", 60, 72], ["brain", "ANATOMY", 89, 94], ["heart", "ANATOMY", 124, 129], ["kidney", "ANATOMY", 131, 137], ["liver", "ANATOMY", 139, 144], ["adrenal gland", "ANATOMY", 146, 159], ["spleen", "ANATOMY", 164, 170]]], ["There was no evidence of perivascular or diffuse parenchymal oedema in the brain.", [["perivascular", "ANATOMY", 25, 37], ["parenchymal", "ANATOMY", 49, 60], ["brain", "ANATOMY", 75, 80], ["oedema", "DISEASE", 61, 67], ["perivascular", "IMMATERIAL_ANATOMICAL_ENTITY", 25, 37], ["parenchymal oedema", "PATHOLOGICAL_FORMATION", 49, 67], ["brain", "ORGAN", 75, 80], ["perivascular or diffuse parenchymal oedema in the brain", "PROBLEM", 25, 80], ["no evidence of", "UNCERTAINTY", 10, 24], ["perivascular", "ANATOMY_MODIFIER", 25, 37], ["diffuse", "OBSERVATION_MODIFIER", 41, 48], ["parenchymal", "ANATOMY_MODIFIER", 49, 60], ["oedema", "OBSERVATION", 61, 67], ["brain", "ANATOMY", 75, 80]]], ["Diffuse astrocytosis or microgliosis was not observed, nor was there evidence for acute gliotic reactions about the haemorrhages.", [["astrocytosis", "DISEASE", 8, 20], ["microgliosis", "DISEASE", 24, 36], ["haemorrhages", "DISEASE", 116, 128], ["Diffuse astrocytosis", "PROBLEM", 0, 20], ["microgliosis", "PROBLEM", 24, 36], ["acute gliotic reactions", "PROBLEM", 82, 105], ["the haemorrhages", "PROBLEM", 112, 128], ["astrocytosis", "OBSERVATION", 8, 20], ["microgliosis", "OBSERVATION", 24, 36], ["evidence for", "UNCERTAINTY", 69, 81], ["acute", "OBSERVATION_MODIFIER", 82, 87], ["gliotic", "OBSERVATION", 88, 95], ["haemorrhages", "OBSERVATION", 116, 128]]], ["There was no aggregation of polymorphs in the vessels, no perivascular inflammation, nor generalized encephalitis.", [["vessels", "ANATOMY", 46, 53], ["perivascular", "ANATOMY", 58, 70], ["inflammation", "DISEASE", 71, 83], ["encephalitis", "DISEASE", 101, 113], ["vessels", "MULTI-TISSUE_STRUCTURE", 46, 53], ["perivascular", "IMMATERIAL_ANATOMICAL_ENTITY", 58, 70], ["aggregation of polymorphs in the vessels", "PROBLEM", 13, 53], ["perivascular inflammation", "PROBLEM", 58, 83], ["generalized encephalitis", "PROBLEM", 89, 113], ["no", "UNCERTAINTY", 10, 12], ["aggregation", "OBSERVATION", 13, 24], ["polymorphs", "OBSERVATION", 28, 38], ["vessels", "ANATOMY", 46, 53], ["no", "UNCERTAINTY", 55, 57], ["perivascular", "ANATOMY_MODIFIER", 58, 70], ["inflammation", "OBSERVATION", 71, 83], ["nor", "UNCERTAINTY", 85, 88], ["generalized", "OBSERVATION_MODIFIER", 89, 100], ["encephalitis", "OBSERVATION", 101, 113]]], ["There was no diffuse thrombotic microangiopathy, but within one haemorrhage there was probably some fibrin at the site of the vessel.", [["vessel", "ANATOMY", 126, 132], ["thrombotic microangiopathy", "DISEASE", 21, 47], ["haemorrhage", "DISEASE", 64, 75], ["fibrin", "GENE_OR_GENE_PRODUCT", 100, 106], ["vessel", "MULTI-TISSUE_STRUCTURE", 126, 132], ["fibrin", "PROTEIN", 100, 106], ["diffuse thrombotic microangiopathy", "PROBLEM", 13, 47], ["one haemorrhage", "PROBLEM", 60, 75], ["some fibrin", "PROBLEM", 95, 106], ["no", "UNCERTAINTY", 10, 12], ["diffuse", "OBSERVATION_MODIFIER", 13, 20], ["thrombotic", "OBSERVATION_MODIFIER", 21, 31], ["microangiopathy", "OBSERVATION", 32, 47], ["haemorrhage", "OBSERVATION", 64, 75], ["probably", "UNCERTAINTY", 86, 94], ["some", "OBSERVATION_MODIFIER", 95, 99], ["fibrin", "OBSERVATION", 100, 106], ["site", "ANATOMY_MODIFIER", 114, 118], ["vessel", "ANATOMY", 126, 132]]], ["Immunohistochemistry of sections from the brain was negative for CD54 (which stains intercellular adhesion molecule-1, ICAM-1).", [["sections", "ANATOMY", 24, 32], ["brain", "ANATOMY", 42, 47], ["sections", "MULTI-TISSUE_STRUCTURE", 24, 32], ["brain", "ORGAN", 42, 47], ["CD54", "GENE_OR_GENE_PRODUCT", 65, 69], ["intercellular adhesion molecule-1", "GENE_OR_GENE_PRODUCT", 84, 117], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 119, 125], ["CD54", "PROTEIN", 65, 69], ["intercellular adhesion molecule-1", "PROTEIN", 84, 117], ["ICAM", "PROTEIN", 119, 123], ["Immunohistochemistry of sections from the brain", "TEST", 0, 47], ["CD54", "PROBLEM", 65, 69], ["intercellular adhesion molecule", "TEST", 84, 115], ["ICAM", "TEST", 119, 123], ["brain", "ANATOMY", 42, 47], ["negative for", "UNCERTAINTY", 52, 64]]], ["Figure 2 Gross appearance of the brain.", [["brain", "ANATOMY", 33, 38], ["brain", "ORGAN", 33, 38], ["Gross", "OBSERVATION_MODIFIER", 9, 14], ["brain", "ANATOMY", 33, 38]]], ["The outer surface appears dusky with petechial haemorrhages seen on the outer surface of the cerebellum (2a).", [["outer surface", "ANATOMY", 4, 17], ["petechial", "ANATOMY", 37, 46], ["outer surface", "ANATOMY", 72, 85], ["cerebellum", "ANATOMY", 93, 103], ["haemorrhages", "DISEASE", 47, 59], ["outer surface", "CELLULAR_COMPONENT", 4, 17], ["petechial haemorrhages", "PATHOLOGICAL_FORMATION", 37, 59], ["outer surface", "CELLULAR_COMPONENT", 72, 85], ["cerebellum", "ORGAN", 93, 103], ["dusky", "PROBLEM", 26, 31], ["petechial haemorrhages", "PROBLEM", 37, 59], ["outer", "ANATOMY_MODIFIER", 4, 9], ["surface", "OBSERVATION_MODIFIER", 10, 17], ["dusky", "OBSERVATION_MODIFIER", 26, 31], ["petechial", "OBSERVATION_MODIFIER", 37, 46], ["haemorrhages", "OBSERVATION", 47, 59], ["outer", "ANATOMY_MODIFIER", 72, 77], ["surface", "ANATOMY_MODIFIER", 78, 85], ["cerebellum", "ANATOMY", 93, 103]]], ["Cut section of the cerebellum with multiple petechial haemorrhages seen within the cerebellar grey matter (2b).Figure 3Plasmodium-specific anti-aldolase immunohistochemistry stained sections from the brain.", [["cerebellum", "ANATOMY", 19, 29], ["petechial", "ANATOMY", 44, 53], ["cerebellar grey matter", "ANATOMY", 83, 105], ["sections", "ANATOMY", 182, 190], ["brain", "ANATOMY", 200, 205], ["haemorrhages", "DISEASE", 54, 66], ["cerebellum", "ORGAN", 19, 29], ["petechial haemorrhages", "PATHOLOGICAL_FORMATION", 44, 66], ["anti-aldolase", "GENE_OR_GENE_PRODUCT", 139, 152], ["brain", "ORGAN", 200, 205], ["anti-aldolase", "PROTEIN", 139, 152], ["multiple petechial haemorrhages", "PROBLEM", 35, 66], ["Figure 3Plasmodium", "TEST", 111, 129], ["cerebellum", "ANATOMY", 19, 29], ["multiple", "OBSERVATION_MODIFIER", 35, 43], ["petechial", "OBSERVATION_MODIFIER", 44, 53], ["haemorrhages", "OBSERVATION", 54, 66], ["cerebellar grey matter", "ANATOMY", 83, 105], ["brain", "ANATOMY", 200, 205]]], ["Parasites appear red.Figure 3Although sections from the spleen showed some autolysis, expansion of the red pulp and atrophy of the white pulp was noted.", [["sections", "ANATOMY", 38, 46], ["spleen", "ANATOMY", 56, 62], ["red pulp", "ANATOMY", 103, 111], ["white pulp", "ANATOMY", 131, 141], ["atrophy", "DISEASE", 116, 123], ["Parasites", "CELL", 0, 9], ["3Although sections", "MULTI-TISSUE_STRUCTURE", 28, 46], ["spleen", "ORGAN", 56, 62], ["red", "TISSUE", 103, 106], ["pulp", "TISSUE", 107, 111], ["pulp", "TISSUE", 137, 141], ["Parasites", "PROBLEM", 0, 9], ["some autolysis", "PROBLEM", 70, 84], ["the red pulp", "PROBLEM", 99, 111], ["atrophy of the white pulp", "PROBLEM", 116, 141], ["red", "OBSERVATION", 17, 20], ["spleen", "ANATOMY", 56, 62], ["some", "OBSERVATION_MODIFIER", 70, 74], ["autolysis", "OBSERVATION", 75, 84], ["expansion", "OBSERVATION_MODIFIER", 86, 95], ["red pulp", "OBSERVATION", 103, 111], ["atrophy", "OBSERVATION", 116, 123], ["white pulp", "OBSERVATION", 131, 141]]], ["Germinal centers were not observed.", [["Germinal centers", "ANATOMY", 0, 16], ["Germinal centers", "CANCER", 0, 16], ["not observed", "UNCERTAINTY", 22, 34]]], ["Abundant pigment-containing macrophages and some haemophaghocytosis was evident in the red pulp and parasitized red cells were plentiful (Figure 5a ).", [["pigment", "ANATOMY", 9, 16], ["macrophages", "ANATOMY", 28, 39], ["red pulp", "ANATOMY", 87, 95], ["red cells", "ANATOMY", 112, 121], ["haemophaghocytosis", "DISEASE", 49, 67], ["macrophages", "CELL", 28, 39], ["pulp", "TISSUE", 91, 95], ["red cells", "CELL", 112, 121], ["macrophages", "CELL_TYPE", 28, 39], ["red pulp", "CELL_TYPE", 87, 95], ["parasitized red cells", "CELL_TYPE", 100, 121], ["Abundant pigment-containing macrophages", "PROBLEM", 0, 39], ["some haemophaghocytosis", "PROBLEM", 44, 67], ["parasitized red cells", "PROBLEM", 100, 121], ["pigment", "OBSERVATION", 9, 16], ["macrophages", "ANATOMY", 28, 39], ["some", "OBSERVATION_MODIFIER", 44, 48], ["haemophaghocytosis", "OBSERVATION", 49, 67], ["red pulp", "ANATOMY", 87, 95], ["parasitized red cells", "OBSERVATION", 100, 121]]], ["There was no necrosis or fibrin deposition in the spleen.Figure 3There were many PRBC's in the liver sinusoids with haemozoin pigment in Kupffer cells and evidence of haemophagocytosis.", [["spleen", "ANATOMY", 50, 56], ["PRBC", "ANATOMY", 81, 85], ["liver sinusoids", "ANATOMY", 95, 110], ["Kupffer cells", "ANATOMY", 137, 150], ["necrosis", "DISEASE", 13, 21], ["haemophagocytosis", "DISEASE", 167, 184], ["fibrin", "GENE_OR_GENE_PRODUCT", 25, 31], ["spleen", "ORGAN", 50, 56], ["PRBC", "CELL", 81, 85], ["liver sinusoids", "TISSUE", 95, 110], ["haemozoin pigment", "CELL", 116, 133], ["Kupffer cells", "CELL", 137, 150], ["fibrin", "PROTEIN", 25, 31], ["PRBC", "CELL_TYPE", 81, 85], ["Kupffer cells", "CELL_TYPE", 137, 150], ["necrosis", "PROBLEM", 13, 21], ["fibrin deposition in the spleen", "PROBLEM", 25, 56], ["many PRBC's", "TREATMENT", 76, 87], ["the liver sinusoids", "TREATMENT", 91, 110], ["haemozoin pigment in Kupffer cells", "TREATMENT", 116, 150], ["haemophagocytosis", "PROBLEM", 167, 184], ["no", "UNCERTAINTY", 10, 12], ["necrosis", "OBSERVATION", 13, 21], ["fibrin deposition", "OBSERVATION", 25, 42], ["spleen", "ANATOMY", 50, 56], ["liver", "ANATOMY", 95, 100], ["sinusoids", "ANATOMY_MODIFIER", 101, 110], ["haemozoin pigment", "OBSERVATION", 116, 133], ["Kupffer cells", "OBSERVATION", 137, 150], ["evidence of", "UNCERTAINTY", 155, 166], ["haemophagocytosis", "OBSERVATION", 167, 184]]], ["The portal tracts and sinusoids had moderate chronic lymphoplasmacytic inflammation.", [["portal tracts", "ANATOMY", 4, 17], ["sinusoids", "ANATOMY", 22, 31], ["inflammation", "DISEASE", 71, 83], ["portal tracts", "MULTI-TISSUE_STRUCTURE", 4, 17], ["sinusoids", "MULTI-TISSUE_STRUCTURE", 22, 31], ["lymphoplasmacytic inflammation", "PATHOLOGICAL_FORMATION", 53, 83], ["moderate chronic lymphoplasmacytic inflammation", "PROBLEM", 36, 83], ["portal tracts", "ANATOMY", 4, 17], ["sinusoids", "ANATOMY", 22, 31], ["moderate", "OBSERVATION_MODIFIER", 36, 44], ["chronic", "OBSERVATION_MODIFIER", 45, 52], ["lymphoplasmacytic inflammation", "OBSERVATION", 53, 83]]], ["Overall the liver was non-cirrhotic but with severe macrovesicular steatosis.", [["liver", "ANATOMY", 12, 17], ["non-cirrhotic", "DISEASE", 22, 35], ["steatosis", "DISEASE", 67, 76], ["liver", "ORGAN", 12, 17], ["non-cirrhotic", "PROBLEM", 22, 35], ["severe macrovesicular steatosis", "PROBLEM", 45, 76], ["liver", "ANATOMY", 12, 17], ["non-cirrhotic", "OBSERVATION", 22, 35], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["macrovesicular", "OBSERVATION_MODIFIER", 52, 66], ["steatosis", "OBSERVATION", 67, 76]]], ["No cholestasis, regional necrosis or thrombotic microangiopathy was observed (Figure 5b) .Figure 3The renal cortex showed dilated and congested blood vessels.", [["renal cortex", "ANATOMY", 102, 114], ["blood vessels", "ANATOMY", 144, 157], ["cholestasis", "DISEASE", 3, 14], ["necrosis", "DISEASE", 25, 33], ["thrombotic microangiopathy", "DISEASE", 37, 63], ["renal cortex", "CANCER", 102, 114], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 144, 157], ["cholestasis", "PROBLEM", 3, 14], ["regional necrosis", "PROBLEM", 16, 33], ["thrombotic microangiopathy", "PROBLEM", 37, 63], ["dilated and congested blood vessels", "PROBLEM", 122, 157], ["cholestasis", "OBSERVATION", 3, 14], ["regional", "OBSERVATION_MODIFIER", 16, 24], ["necrosis", "OBSERVATION", 25, 33], ["thrombotic", "OBSERVATION_MODIFIER", 37, 47], ["microangiopathy", "OBSERVATION", 48, 63], ["renal", "ANATOMY", 102, 107], ["cortex", "ANATOMY_MODIFIER", 108, 114], ["dilated", "OBSERVATION", 122, 129], ["congested", "OBSERVATION", 134, 143], ["blood vessels", "OBSERVATION", 144, 157]]], ["Many PRBC were observed within glomerular capillaries with pigment deposition in the mesangium.", [["PRBC", "ANATOMY", 5, 9], ["glomerular capillaries", "ANATOMY", 31, 53], ["pigment", "ANATOMY", 59, 66], ["mesangium", "ANATOMY", 85, 94], ["PRBC", "CELL", 5, 9], ["glomerular capillaries", "TISSUE", 31, 53], ["pigment", "TISSUE", 59, 66], ["mesangium", "TISSUE", 85, 94], ["PRBC", "CELL_TYPE", 5, 9], ["Many PRBC", "TREATMENT", 0, 9], ["pigment deposition in the mesangium", "PROBLEM", 59, 94], ["PRBC", "OBSERVATION", 5, 9], ["glomerular capillaries", "OBSERVATION", 31, 53], ["pigment deposition", "OBSERVATION", 59, 77], ["mesangium", "ANATOMY", 85, 94]]], ["There was no evidence of thrombotic microangiopathy (disseminated intravascular coagulation, DIC).", [["intravascular", "ANATOMY", 66, 79], ["thrombotic microangiopathy", "DISEASE", 25, 51], ["disseminated intravascular coagulation", "DISEASE", 53, 91], ["DIC", "DISEASE", 93, 96], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 66, 79], ["thrombotic microangiopathy", "PROBLEM", 25, 51], ["disseminated intravascular coagulation", "PROBLEM", 53, 91], ["DIC", "PROBLEM", 93, 96], ["no evidence of", "UNCERTAINTY", 10, 24], ["thrombotic", "OBSERVATION_MODIFIER", 25, 35], ["microangiopathy", "OBSERVATION", 36, 51], ["disseminated", "OBSERVATION_MODIFIER", 53, 65], ["intravascular coagulation", "OBSERVATION", 66, 91]]], ["The tubules showed acute tubular necrosis and regeneration.", [["tubules", "ANATOMY", 4, 11], ["tubular", "ANATOMY", 25, 32], ["necrosis", "DISEASE", 33, 41], ["tubules", "TISSUE", 4, 11], ["tubular", "TISSUE", 25, 32], ["acute tubular necrosis", "PROBLEM", 19, 41], ["regeneration", "PROBLEM", 46, 58], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["tubular", "ANATOMY_MODIFIER", 25, 32], ["necrosis", "OBSERVATION", 33, 41], ["regeneration", "OBSERVATION_MODIFIER", 46, 58]]], ["There were a small number of eosinophilic intra-tubular casts (Figure 5c) .Figure 3Sequestration of PRBC's was evident in the small vessels of the heart (Figure 5d ).", [["small vessels", "ANATOMY", 126, 139], ["heart", "ANATOMY", 147, 152], ["PRBC", "CELL", 100, 104], ["small vessels", "MULTI-TISSUE_STRUCTURE", 126, 139], ["heart", "ORGAN", 147, 152], ["PRBC", "CELL_TYPE", 100, 104], ["eosinophilic intra-tubular casts", "PROBLEM", 29, 61], ["PRBC's", "TREATMENT", 100, 106], ["small", "OBSERVATION_MODIFIER", 13, 18], ["number", "OBSERVATION_MODIFIER", 19, 25], ["eosinophilic", "OBSERVATION_MODIFIER", 29, 41], ["intra-tubular casts", "OBSERVATION", 42, 61], ["small vessels", "ANATOMY", 126, 139], ["heart", "ANATOMY", 147, 152]]], ["Endothelial cells were prominent as sometimes observed in patients with sepsis whose cells are responding to generalized stimuli [18] .", [["Endothelial cells", "ANATOMY", 0, 17], ["cells", "ANATOMY", 85, 90], ["sepsis", "DISEASE", 72, 78], ["Endothelial cells", "CELL", 0, 17], ["patients", "ORGANISM", 58, 66], ["cells", "CELL", 85, 90], ["Endothelial cells", "CELL_TYPE", 0, 17], ["patients", "SPECIES", 58, 66], ["Endothelial cells", "PROBLEM", 0, 17], ["sepsis whose cells", "PROBLEM", 72, 90], ["generalized stimuli", "TEST", 109, 128], ["sepsis", "OBSERVATION", 72, 78]]], ["There was no evidence of myocarditis and the heart muscle fibers appeared normal.", [["heart muscle fibers", "ANATOMY", 45, 64], ["myocarditis", "DISEASE", 25, 36], ["heart muscle fibers", "TISSUE", 45, 64], ["myocarditis", "PROBLEM", 25, 36], ["no evidence of", "UNCERTAINTY", 10, 24], ["myocarditis", "OBSERVATION", 25, 36], ["heart muscle", "ANATOMY", 45, 57], ["fibers", "ANATOMY_MODIFIER", 58, 64], ["normal", "OBSERVATION", 74, 80]]], ["There was focal petechial haemorrhage in the subendocardium, which may relate to resuscitation, or be secondary to malaria.Figure 3The adrenal gland appeared active with eosinophilic cytoplasm in the fasciculata layer with no evidence of PRBC sequestration or of parenchymal haemorrhage.", [["petechial", "ANATOMY", 16, 25], ["subendocardium", "ANATOMY", 45, 59], ["adrenal gland", "ANATOMY", 135, 148], ["eosinophilic cytoplasm", "ANATOMY", 170, 192], ["fasciculata layer", "ANATOMY", 200, 217], ["PRBC", "ANATOMY", 238, 242], ["parenchymal", "ANATOMY", 263, 274], ["haemorrhage", "DISEASE", 26, 37], ["malaria", "DISEASE", 115, 122], ["parenchymal haemorrhage", "DISEASE", 263, 286], ["subendocardium", "MULTI-TISSUE_STRUCTURE", 45, 59], ["adrenal gland", "ORGAN", 135, 148], ["eosinophilic", "ORGANISM_SUBSTANCE", 170, 182], ["cytoplasm", "ORGANISM_SUBSTANCE", 183, 192], ["fasciculata layer", "CANCER", 200, 217], ["PRBC", "CELL", 238, 242], ["parenchymal haemorrhage", "PATHOLOGICAL_FORMATION", 263, 286], ["focal petechial haemorrhage in the subendocardium", "PROBLEM", 10, 59], ["resuscitation", "TREATMENT", 81, 94], ["malaria", "PROBLEM", 115, 122], ["eosinophilic cytoplasm in the fasciculata layer", "PROBLEM", 170, 217], ["PRBC sequestration", "PROBLEM", 238, 256], ["parenchymal haemorrhage", "PROBLEM", 263, 286], ["focal", "OBSERVATION_MODIFIER", 10, 15], ["petechial", "OBSERVATION_MODIFIER", 16, 25], ["haemorrhage", "OBSERVATION", 26, 37], ["subendocardium", "ANATOMY", 45, 59], ["may relate to", "UNCERTAINTY", 67, 80], ["resuscitation", "OBSERVATION", 81, 94], ["malaria", "OBSERVATION", 115, 122], ["adrenal gland", "ANATOMY", 135, 148], ["active", "OBSERVATION_MODIFIER", 158, 164], ["eosinophilic cytoplasm", "OBSERVATION", 170, 192], ["fasciculata layer", "OBSERVATION", 200, 217], ["no evidence of", "UNCERTAINTY", 223, 237], ["PRBC sequestration", "OBSERVATION", 238, 256], ["parenchymal", "ANATOMY_MODIFIER", 263, 274], ["haemorrhage", "OBSERVATION", 275, 286]]], ["Samples of lung, intestine or bone marrow were not available for histopathology examination.Figure 3The overall picture was one of systemic malaria infection with multi-organ damage, particularly in the brain where there was much vascular rupture and petechial haemorrhaging.ConclusionsFatal human knowlesi malaria has hitherto not been reported at post-mortem, so this report may increase our understanding of severe and fatal malaria whatever species cause these syndromes.", [["Samples", "ANATOMY", 0, 7], ["lung", "ANATOMY", 11, 15], ["intestine", "ANATOMY", 17, 26], ["bone marrow", "ANATOMY", 30, 41], ["multi-organ", "ANATOMY", 163, 174], ["brain", "ANATOMY", 203, 208], ["vascular", "ANATOMY", 230, 238], ["petechial", "ANATOMY", 251, 260], ["malaria infection", "DISEASE", 140, 157], ["multi-organ damage", "DISEASE", 163, 181], ["vascular rupture", "DISEASE", 230, 246], ["haemorrhaging", "DISEASE", 261, 274], ["human knowlesi malaria", "DISEASE", 292, 314], ["malaria", "DISEASE", 428, 435], ["lung", "ORGAN", 11, 15], ["intestine", "ORGAN", 17, 26], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 30, 41], ["multi-organ", "ORGAN", 163, 174], ["brain", "ORGAN", 203, 208], ["vascular", "MULTI-TISSUE_STRUCTURE", 230, 238], ["human", "ORGANISM", 292, 297], ["human", "SPECIES", 292, 297], ["human knowlesi", "SPECIES", 292, 306], ["Samples of lung, intestine or bone marrow", "TEST", 0, 41], ["histopathology examination", "TEST", 65, 91], ["systemic malaria infection", "PROBLEM", 131, 157], ["multi-organ damage", "PROBLEM", 163, 181], ["much vascular rupture", "PROBLEM", 225, 246], ["petechial haemorrhaging", "PROBLEM", 251, 274], ["Fatal human knowlesi malaria", "PROBLEM", 286, 314], ["severe and fatal malaria", "PROBLEM", 411, 435], ["these syndromes", "PROBLEM", 459, 474], ["lung", "ANATOMY", 11, 15], ["intestine", "ANATOMY", 17, 26], ["bone marrow", "ANATOMY", 30, 41], ["systemic", "OBSERVATION_MODIFIER", 131, 139], ["malaria", "OBSERVATION_MODIFIER", 140, 147], ["infection", "OBSERVATION", 148, 157], ["multi-organ damage", "OBSERVATION", 163, 181], ["brain", "ANATOMY", 203, 208], ["vascular", "ANATOMY", 230, 238], ["rupture", "OBSERVATION", 239, 246], ["petechial", "OBSERVATION_MODIFIER", 251, 260], ["haemorrhaging", "OBSERVATION", 261, 274], ["severe", "OBSERVATION_MODIFIER", 411, 417], ["fatal", "OBSERVATION_MODIFIER", 422, 427], ["malaria", "OBSERVATION", 428, 435]]], ["Interestingly, vivax malaria is also becoming recognized as causing severe and sometimes fatal infection in a significant proportion of individuals, suggesting re-evaluation of the dogma that falciparum infection may be the only important cause of fatal disease [19] [20] [21] .ConclusionsThe WHO classification for severe falciparum malaria would have included this individual because he had several qualifying features including hyperparasitaemia (~10% infected erythrocytes), renal impairment, jaundice and ARDS, although coma was not prominent in the history [3, 4, 22] .", [["erythrocytes", "ANATOMY", 464, 476], ["renal", "ANATOMY", 479, 484], ["vivax malaria", "DISEASE", 15, 28], ["infection", "DISEASE", 95, 104], ["falciparum infection", "DISEASE", 192, 212], ["falciparum malaria", "DISEASE", 323, 341], ["hyperparasitaemia", "DISEASE", 431, 448], ["infected erythrocytes", "DISEASE", 455, 476], ["renal impairment", "DISEASE", 479, 495], ["jaundice", "DISEASE", 497, 505], ["ARDS", "DISEASE", 510, 514], ["coma", "DISEASE", 525, 529], ["vivax malaria", "ORGANISM", 15, 28], ["falciparum", "ORGANISM", 192, 202], ["erythrocytes", "CELL", 464, 476], ["renal", "ORGAN", 479, 484], ["vivax malaria", "PROBLEM", 15, 28], ["sometimes fatal infection", "PROBLEM", 79, 104], ["falciparum infection", "PROBLEM", 192, 212], ["fatal disease", "PROBLEM", 248, 261], ["severe falciparum malaria", "PROBLEM", 316, 341], ["hyperparasitaemia", "PROBLEM", 431, 448], ["infected erythrocytes)", "PROBLEM", 455, 477], ["renal impairment", "PROBLEM", 479, 495], ["jaundice", "PROBLEM", 497, 505], ["ARDS", "PROBLEM", 510, 514], ["coma", "PROBLEM", 525, 529], ["vivax malaria", "OBSERVATION", 15, 28], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["fatal", "OBSERVATION_MODIFIER", 89, 94], ["infection", "OBSERVATION", 95, 104], ["severe", "OBSERVATION_MODIFIER", 316, 322], ["falciparum", "OBSERVATION", 323, 333], ["renal", "ANATOMY", 479, 484], ["impairment", "OBSERVATION", 485, 495], ["jaundice", "OBSERVATION", 497, 505], ["ARDS", "OBSERVATION", 510, 514], ["prominent", "OBSERVATION_MODIFIER", 538, 547]]], ["Commonly, dengue haemorrhagic fever can cause some of these signs, but was excluded by investigations.", [["dengue haemorrhagic fever", "DISEASE", 10, 35], ["dengue haemorrhagic fever", "PROBLEM", 10, 35], ["these signs", "PROBLEM", 54, 65]]], ["Co-infection of knowlesi with falciparum was also excluded by specific PCR and immunohistochemical examination.ConclusionsThe beefy appearance of lung tissue in this case is consistent with respiratory distress syndrome, but could not be confirmed histologically.", [["lung tissue", "ANATOMY", 146, 157], ["respiratory", "ANATOMY", 190, 201], ["knowlesi with falciparum", "DISEASE", 16, 40], ["respiratory distress syndrome", "DISEASE", 190, 219], ["knowlesi", "ORGANISM", 16, 24], ["falciparum", "ORGANISM", 30, 40], ["lung tissue", "TISSUE", 146, 157], ["Co-infection of knowlesi", "PROBLEM", 0, 24], ["falciparum", "PROBLEM", 30, 40], ["specific PCR", "TEST", 62, 74], ["immunohistochemical examination", "TEST", 79, 110], ["lung tissue", "PROBLEM", 146, 157], ["respiratory distress syndrome", "PROBLEM", 190, 219], ["beefy", "OBSERVATION", 126, 131], ["lung", "ANATOMY", 146, 150], ["tissue", "OBSERVATION", 151, 157], ["consistent with", "UNCERTAINTY", 174, 189], ["respiratory", "OBSERVATION", 190, 201], ["distress syndrome", "OBSERVATION", 202, 219], ["could not be confirmed", "UNCERTAINTY", 225, 247]]], ["Changes in the kidney of some recovering areas of acute tubular injury are consistent with the observation of renal impairment reported in other severe cases of knowlesi malaria [3] and an underlying process of acute tubular necrosis related to systemic shock.", [["kidney", "ANATOMY", 15, 21], ["tubular", "ANATOMY", 56, 63], ["renal", "ANATOMY", 110, 115], ["tubular", "ANATOMY", 217, 224], ["acute tubular injury", "DISEASE", 50, 70], ["renal impairment", "DISEASE", 110, 126], ["knowlesi malaria", "DISEASE", 161, 177], ["acute tubular necrosis", "DISEASE", 211, 233], ["systemic shock", "DISEASE", 245, 259], ["kidney", "ORGAN", 15, 21], ["tubular", "MULTI-TISSUE_STRUCTURE", 56, 63], ["renal", "ORGAN", 110, 115], ["tubular", "MULTI-TISSUE_STRUCTURE", 217, 224], ["Changes in the kidney", "PROBLEM", 0, 21], ["acute tubular injury", "PROBLEM", 50, 70], ["renal impairment", "PROBLEM", 110, 126], ["knowlesi malaria", "PROBLEM", 161, 177], ["acute tubular necrosis", "PROBLEM", 211, 233], ["systemic shock", "PROBLEM", 245, 259], ["kidney", "ANATOMY", 15, 21], ["some", "OBSERVATION_MODIFIER", 25, 29], ["recovering", "OBSERVATION_MODIFIER", 30, 40], ["areas", "OBSERVATION_MODIFIER", 41, 46], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["tubular injury", "OBSERVATION", 56, 70], ["consistent with", "UNCERTAINTY", 75, 90], ["renal", "ANATOMY", 110, 115], ["impairment", "OBSERVATION", 116, 126], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["knowlesi malaria", "OBSERVATION", 161, 177], ["acute", "OBSERVATION_MODIFIER", 211, 216], ["tubular", "ANATOMY_MODIFIER", 217, 224], ["necrosis", "OBSERVATION", 225, 233], ["systemic", "OBSERVATION_MODIFIER", 245, 253], ["shock", "OBSERVATION", 254, 259]]], ["There was disorganized white pulp in spleen perhaps as part of a wider stress response [18] .ConclusionsDespite the absence of antecedent established coma, cerebral pathology in this case is very similar to that observed in fatal falciparum infections, confirming that it was important to exclude this co-infection.", [["white pulp", "ANATOMY", 23, 33], ["spleen", "ANATOMY", 37, 43], ["cerebral", "ANATOMY", 156, 164], ["coma", "DISEASE", 150, 154], ["falciparum infections", "DISEASE", 230, 251], ["white pulp", "TISSUE", 23, 33], ["spleen", "ORGAN", 37, 43], ["cerebral", "ORGAN", 156, 164], ["disorganized white pulp in spleen", "PROBLEM", 10, 43], ["a wider stress response", "PROBLEM", 63, 86], ["antecedent established coma", "PROBLEM", 127, 154], ["cerebral pathology", "PROBLEM", 156, 174], ["fatal falciparum infections", "PROBLEM", 224, 251], ["this co-infection", "PROBLEM", 297, 314], ["disorganized", "OBSERVATION_MODIFIER", 10, 22], ["white pulp", "OBSERVATION", 23, 33], ["spleen", "ANATOMY", 37, 43], ["cerebral", "ANATOMY", 156, 164], ["pathology", "OBSERVATION", 165, 174], ["fatal", "OBSERVATION_MODIFIER", 224, 229], ["falciparum", "OBSERVATION_MODIFIER", 230, 240], ["infections", "OBSERVATION", 241, 251], ["co-infection", "OBSERVATION", 302, 314]]], ["Although there was obvious accumulation/sequestration of infected erythrocytes in capillaries and venules, there were also some differences between these appearances and those seen with fatal falciparum infections.", [["erythrocytes", "ANATOMY", 66, 78], ["capillaries", "ANATOMY", 82, 93], ["venules", "ANATOMY", 98, 105], ["falciparum infections", "DISEASE", 192, 213], ["erythrocytes", "CELL", 66, 78], ["capillaries", "TISSUE", 82, 93], ["venules", "MULTI-TISSUE_STRUCTURE", 98, 105], ["infected erythrocytes", "CELL_TYPE", 57, 78], ["obvious accumulation/sequestration", "PROBLEM", 19, 53], ["infected erythrocytes in capillaries and venules", "PROBLEM", 57, 105], ["fatal falciparum infections", "PROBLEM", 186, 213], ["obvious", "OBSERVATION_MODIFIER", 19, 26], ["accumulation", "OBSERVATION_MODIFIER", 27, 39], ["sequestration", "OBSERVATION_MODIFIER", 40, 53], ["infected erythrocytes", "OBSERVATION", 57, 78], ["capillaries", "ANATOMY_MODIFIER", 82, 93], ["venules", "ANATOMY", 98, 105], ["some", "OBSERVATION_MODIFIER", 123, 127], ["differences", "OBSERVATION_MODIFIER", 128, 139], ["fatal", "OBSERVATION_MODIFIER", 186, 191], ["falciparum", "OBSERVATION_MODIFIER", 192, 202], ["infections", "OBSERVATION", 203, 213]]], ["For example, there was no platelet clumping, no notable thrombi, and uninfected erythrocytes were also interspersed with infected cells.", [["platelet", "ANATOMY", 26, 34], ["thrombi", "ANATOMY", 56, 63], ["erythrocytes", "ANATOMY", 80, 92], ["cells", "ANATOMY", 130, 135], ["thrombi", "DISEASE", 56, 63], ["platelet", "CELL", 26, 34], ["thrombi", "PATHOLOGICAL_FORMATION", 56, 63], ["erythrocytes", "CELL", 80, 92], ["cells", "CELL", 130, 135], ["uninfected erythrocytes", "CELL_TYPE", 69, 92], ["infected cells", "CELL_TYPE", 121, 135], ["platelet clumping", "PROBLEM", 26, 43], ["notable thrombi", "PROBLEM", 48, 63], ["uninfected erythrocytes", "PROBLEM", 69, 92], ["infected cells", "PROBLEM", 121, 135], ["no", "UNCERTAINTY", 23, 25], ["platelet clumping", "OBSERVATION", 26, 43], ["no", "UNCERTAINTY", 45, 47], ["notable", "OBSERVATION_MODIFIER", 48, 55], ["thrombi", "OBSERVATION", 56, 63], ["uninfected erythrocytes", "OBSERVATION", 69, 92], ["infected cells", "OBSERVATION", 121, 135]]], ["Neither was up-regulation of ICAM-1 expression detected in endothelial cells, suggesting that the mechanism of sequestration/accumulation of infected erythrocytes in knowlesi infections needs further investigation.", [["endothelial cells", "ANATOMY", 59, 76], ["erythrocytes", "ANATOMY", 150, 162], ["knowlesi infections", "DISEASE", 166, 185], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 29, 35], ["endothelial cells", "CELL", 59, 76], ["erythrocytes", "CELL", 150, 162], ["knowlesi", "ORGANISM", 166, 174], ["ICAM", "PROTEIN", 29, 33], ["endothelial cells", "CELL_TYPE", 59, 76], ["infected erythrocytes", "CELL_TYPE", 141, 162], ["ICAM", "TEST", 29, 33], ["endothelial cells", "PROBLEM", 59, 76], ["sequestration", "PROBLEM", 111, 124], ["infected erythrocytes", "PROBLEM", 141, 162], ["knowlesi infections", "PROBLEM", 166, 185], ["further investigation", "TEST", 192, 213], ["endothelial cells", "ANATOMY", 59, 76], ["sequestration", "OBSERVATION", 111, 124], ["infected erythrocytes", "OBSERVATION", 141, 162], ["knowlesi infections", "OBSERVATION", 166, 185]]], ["In falciparum cerebral malaria, display of ICAM-1 by up regulated endothelial cells mediates adhesion to parasitized red cells [19] .ConclusionsHyperparasitaemia is a marker of severe falciparum malaria.", [["cerebral", "ANATOMY", 14, 22], ["endothelial cells", "ANATOMY", 66, 83], ["red cells", "ANATOMY", 117, 126], ["falciparum cerebral malaria", "DISEASE", 3, 30], ["Hyperparasitaemia", "DISEASE", 144, 161], ["falciparum malaria", "DISEASE", 184, 202], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 43, 49], ["endothelial cells", "CELL", 66, 83], ["red cells", "CELL", 117, 126], ["ICAM-1", "PROTEIN", 43, 49], ["endothelial cells", "CELL_TYPE", 66, 83], ["parasitized red cells", "CELL_TYPE", 105, 126], ["falciparum cerebral malaria", "PROBLEM", 3, 30], ["ICAM", "TEST", 43, 47], ["parasitized red cells", "TEST", 105, 126], ["severe falciparum malaria", "PROBLEM", 177, 202], ["falciparum", "OBSERVATION", 3, 13], ["cerebral", "ANATOMY", 14, 22], ["malaria", "OBSERVATION", 23, 30], ["endothelial cells", "OBSERVATION", 66, 83], ["parasitized red cells", "OBSERVATION", 105, 126], ["severe", "OBSERVATION_MODIFIER", 177, 183], ["falciparum", "OBSERVATION_MODIFIER", 184, 194], ["malaria", "OBSERVATION", 195, 202]]], ["It is also apparent in severe knowlesi infections [3] , but is less commonly observed with severe vivax malaria.", [["knowlesi infections", "DISEASE", 30, 49], ["vivax malaria", "DISEASE", 98, 111], ["severe knowlesi infections", "PROBLEM", 23, 49], ["severe vivax malaria", "PROBLEM", 91, 111], ["severe", "OBSERVATION_MODIFIER", 23, 29], ["knowlesi", "OBSERVATION_MODIFIER", 30, 38], ["infections", "OBSERVATION", 39, 49], ["less commonly", "OBSERVATION_MODIFIER", 63, 76], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["vivax malaria", "OBSERVATION", 98, 111]]], ["The 24 hr replicative cycle of asexual knowlesi may contribute to the rapidity with which hyperparasitaemia and clinical complications ensue.", [["asexual knowlesi", "DISEASE", 31, 47], ["hyperparasitaemia", "DISEASE", 90, 107], ["knowlesi", "ORGANISM", 39, 47], ["asexual knowlesi", "PROBLEM", 31, 47], ["the rapidity", "PROBLEM", 66, 78], ["hyperparasitaemia", "PROBLEM", 90, 107], ["clinical complications", "PROBLEM", 112, 134]]], ["This shorter cycle compared with falciparum and vivax infections may overcome the reduced multiplicative capacity associated with the fewer merozoites generated by P. knowlesi (up to 16 per mature schizont) compared with P. falciparum (up to 36).", [["schizont", "ANATOMY", 197, 205], ["falciparum and vivax infections", "DISEASE", 33, 64], ["P. knowlesi", "DISEASE", 164, 175], ["P. falciparum", "DISEASE", 221, 234], ["vivax", "ORGANISM", 48, 53], ["P. knowlesi", "ORGANISM", 164, 175], ["P. falciparum", "ORGANISM", 221, 234], ["P. knowlesi", "SPECIES", 164, 175], ["P. falciparum", "SPECIES", 221, 234], ["P. knowlesi", "SPECIES", 164, 175], ["P. falciparum", "SPECIES", 221, 234], ["falciparum", "PROBLEM", 33, 43], ["vivax infections", "PROBLEM", 48, 64], ["the reduced multiplicative capacity", "PROBLEM", 78, 113], ["the fewer merozoites", "PROBLEM", 130, 150], ["P. knowlesi", "PROBLEM", 164, 175], ["P. falciparum", "PROBLEM", 221, 234]]], ["Although up to 24 merozoites per schizont have been observed in Plasmodium vivax, parasitaemia is restricted to reticulocytes by limitation of invasion pathways in this species, rather than merozoite number.ConclusionsHyperparasitaemia in falciparum malaria is often explained by protection of late stage parasites from the filtering action of the spleen.", [["schizont", "ANATOMY", 33, 41], ["reticulocytes", "ANATOMY", 112, 125], ["spleen", "ANATOMY", 348, 354], ["Plasmodium vivax", "DISEASE", 64, 80], ["parasitaemia", "DISEASE", 82, 94], ["Hyperparasitaemia", "DISEASE", 218, 235], ["falciparum malaria", "DISEASE", 239, 257], ["merozoites", "CELL", 18, 28], ["schizont", "CELL", 33, 41], ["Plasmodium vivax", "ORGANISM", 64, 80], ["reticulocytes", "CELL", 112, 125], ["falciparum", "ORGANISM", 239, 249], ["spleen", "ORGAN", 348, 354], ["reticulocytes", "CELL_TYPE", 112, 125], ["Plasmodium vivax", "SPECIES", 64, 80], ["Plasmodium vivax", "SPECIES", 64, 80], ["Plasmodium vivax", "PROBLEM", 64, 80], ["parasitaemia", "PROBLEM", 82, 94], ["invasion pathways", "PROBLEM", 143, 160], ["Hyperparasitaemia in falciparum malaria", "PROBLEM", 218, 257], ["late stage parasites", "PROBLEM", 294, 314], ["invasion", "OBSERVATION", 143, 151], ["falciparum malaria", "OBSERVATION", 239, 257], ["late stage", "OBSERVATION_MODIFIER", 294, 304], ["parasites", "OBSERVATION", 305, 314], ["filtering", "OBSERVATION", 324, 333], ["spleen", "ANATOMY", 348, 354]]], ["Unlike P. falciparum infections, all asexual developmental stages are seen in the peripheral circulation of knowlesi-infected patients [10] .", [["P. falciparum infections", "DISEASE", 7, 31], ["knowlesi-infected", "DISEASE", 108, 125], ["P. falciparum", "ORGANISM", 7, 20], ["peripheral circulation", "MULTI-TISSUE_STRUCTURE", 82, 104], ["patients", "ORGANISM", 126, 134], ["P. falciparum", "SPECIES", 7, 20], ["patients", "SPECIES", 126, 134], ["P. falciparum", "SPECIES", 7, 20], ["P. falciparum infections", "PROBLEM", 7, 31], ["all asexual developmental stages", "PROBLEM", 33, 65], ["falciparum infections", "OBSERVATION", 10, 31], ["peripheral", "ANATOMY_MODIFIER", 82, 92], ["circulation", "ANATOMY", 93, 104]]], ["Hyperparasitaemia in knowlesi malaria may not be modulated by splenic clearance in a similar manner as suggested for other non-sequestering human infections.ConclusionsAs with many fatal cases of falciparum malaria, malaria pigment was evident in blood films and was present in circulating leucocytes (~40%), tissue sections and organ specific macrophages.", [["splenic", "ANATOMY", 62, 69], ["blood", "ANATOMY", 247, 252], ["leucocytes", "ANATOMY", 290, 300], ["tissue sections", "ANATOMY", 309, 324], ["organ", "ANATOMY", 329, 334], ["macrophages", "ANATOMY", 344, 355], ["Hyperparasitaemia", "DISEASE", 0, 17], ["knowlesi malaria", "DISEASE", 21, 37], ["infections", "DISEASE", 146, 156], ["falciparum malaria", "DISEASE", 196, 214], ["malaria", "DISEASE", 216, 223], ["knowlesi", "ORGANISM", 21, 29], ["splenic", "ORGAN", 62, 69], ["human", "ORGANISM", 140, 145], ["blood films", "ORGANISM_SUBSTANCE", 247, 258], ["leucocytes", "CELL", 290, 300], ["tissue sections", "TISSUE", 309, 324], ["organ", "ORGAN", 329, 334], ["macrophages", "CELL", 344, 355], ["circulating leucocytes", "CELL_TYPE", 278, 300], ["organ specific macrophages", "CELL_TYPE", 329, 355], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 140, 145], ["Hyperparasitaemia", "PROBLEM", 0, 17], ["knowlesi malaria", "PROBLEM", 21, 37], ["splenic clearance", "TEST", 62, 79], ["other non-sequestering human infections", "PROBLEM", 117, 156], ["falciparum malaria", "PROBLEM", 196, 214], ["malaria pigment", "PROBLEM", 216, 231], ["blood films", "TEST", 247, 258], ["circulating leucocytes", "TEST", 278, 300], ["tissue sections", "TEST", 309, 324], ["knowlesi malaria", "OBSERVATION", 21, 37], ["may not be", "UNCERTAINTY", 38, 48], ["splenic", "ANATOMY", 62, 69], ["clearance", "OBSERVATION", 70, 79], ["infections", "OBSERVATION", 146, 156], ["many", "OBSERVATION_MODIFIER", 176, 180], ["fatal", "OBSERVATION_MODIFIER", 181, 186], ["falciparum malaria", "OBSERVATION", 196, 214], ["malaria pigment", "OBSERVATION", 216, 231], ["circulating leucocytes", "ANATOMY", 278, 300], ["organ", "ANATOMY", 329, 334], ["macrophages", "OBSERVATION", 344, 355]]], ["Reticuloendothelial changes in both liver and spleen were associated with pigment, accumulation of red cells and laden macrophages, and some inflammation in liver portal tracts was observed.", [["Reticuloendothelial", "ANATOMY", 0, 19], ["liver", "ANATOMY", 36, 41], ["spleen", "ANATOMY", 46, 52], ["pigment", "ANATOMY", 74, 81], ["red cells", "ANATOMY", 99, 108], ["macrophages", "ANATOMY", 119, 130], ["liver portal tracts", "ANATOMY", 157, 176], ["inflammation", "DISEASE", 141, 153], ["liver portal tracts", "DISEASE", 157, 176], ["Reticuloendothelial", "CELL", 0, 19], ["liver", "ORGAN", 36, 41], ["spleen", "ORGAN", 46, 52], ["red cells", "CELL", 99, 108], ["laden macrophages", "CELL", 113, 130], ["liver portal tracts", "MULTI-TISSUE_STRUCTURE", 157, 176], ["red cells", "CELL_TYPE", 99, 108], ["laden macrophages", "CELL_TYPE", 113, 130], ["Reticuloendothelial changes in both liver and spleen", "PROBLEM", 0, 52], ["pigment, accumulation of red cells and laden macrophages", "PROBLEM", 74, 130], ["some inflammation in liver portal tracts", "PROBLEM", 136, 176], ["both", "ANATOMY_MODIFIER", 31, 35], ["liver", "ANATOMY", 36, 41], ["spleen", "ANATOMY", 46, 52], ["pigment", "OBSERVATION_MODIFIER", 74, 81], ["accumulation", "OBSERVATION_MODIFIER", 83, 95], ["red cells", "OBSERVATION", 99, 108], ["laden macrophages", "OBSERVATION", 113, 130], ["some", "OBSERVATION_MODIFIER", 136, 140], ["inflammation", "OBSERVATION", 141, 153], ["liver", "ANATOMY", 157, 162], ["portal tracts", "ANATOMY", 163, 176]]], ["Circulating pigment has been variably implicated as an indicator of poor prognosis for falciparum malaria [23] [24] [25] and there is evidence to support pigmentinduced immuno-suppression, particularly of pigmentladen macrophages and monocytes [26] [27] [28] .", [["pigmentladen macrophages", "ANATOMY", 205, 229], ["monocytes", "ANATOMY", 234, 243], ["falciparum malaria", "DISEASE", 87, 105], ["pigmentladen macrophages", "CELL", 205, 229], ["monocytes", "CELL", 234, 243], ["pigmentladen macrophages", "CELL_TYPE", 205, 229], ["monocytes", "CELL_TYPE", 234, 243], ["falciparum malaria", "PROBLEM", 87, 105], ["pigmentladen macrophages", "PROBLEM", 205, 229], ["monocytes", "TEST", 234, 243]]], ["It may be that the associations between parasitaemia, pigmentaemia and disease severity are more quantifiable in knowlesi compared with falciparum infections, where pigmented parasites are sequestered from peripheral blood samples and, therefore, unreliably quantifiable.", [["peripheral blood samples", "ANATOMY", 206, 230], ["parasitaemia", "DISEASE", 40, 52], ["pigmentaemia", "DISEASE", 54, 66], ["knowlesi", "DISEASE", 113, 121], ["falciparum infections", "DISEASE", 136, 157], ["knowlesi", "ORGANISM", 113, 121], ["parasites", "ORGANISM", 175, 184], ["peripheral blood samples", "ORGANISM_SUBSTANCE", 206, 230], ["parasitaemia", "PROBLEM", 40, 52], ["pigmentaemia", "PROBLEM", 54, 66], ["disease severity", "PROBLEM", 71, 87], ["knowlesi", "PROBLEM", 113, 121], ["falciparum infections", "PROBLEM", 136, 157], ["pigmented parasites", "PROBLEM", 165, 184], ["peripheral blood samples", "TEST", 206, 230], ["pigmented", "OBSERVATION_MODIFIER", 165, 174], ["parasites", "OBSERVATION", 175, 184]]], ["In vivax malaria, pigment in parasites often appears more dispersed and it is rarely reported as a correlate of disease [29] .ConclusionsAmong the malaria parasites of humans, cytoadherence is purportedly unique to P. falciparum, resulting in sequestration of all but early trophozoite stages in falciparum malaria.", [["vivax malaria", "DISEASE", 3, 16], ["malaria parasites", "DISEASE", 147, 164], ["P. falciparum", "DISEASE", 215, 228], ["falciparum malaria", "DISEASE", 296, 314], ["humans", "ORGANISM", 168, 174], ["P. falciparum", "ORGANISM", 215, 228], ["falciparum malaria", "ORGANISM", 296, 314], ["humans", "SPECIES", 168, 174], ["P. falciparum", "SPECIES", 215, 228], ["humans", "SPECIES", 168, 174], ["P. falciparum", "SPECIES", 215, 228], ["vivax malaria", "PROBLEM", 3, 16], ["pigment in parasites", "PROBLEM", 18, 38], ["disease", "PROBLEM", 112, 119], ["the malaria parasites of humans", "PROBLEM", 143, 174], ["P. falciparum", "PROBLEM", 215, 228], ["early trophozoite stages", "PROBLEM", 268, 292], ["falciparum malaria", "PROBLEM", 296, 314], ["vivax", "OBSERVATION_MODIFIER", 3, 8], ["malaria", "OBSERVATION", 9, 16], ["pigment", "OBSERVATION_MODIFIER", 18, 25], ["parasites", "OBSERVATION_MODIFIER", 29, 38], ["more dispersed", "OBSERVATION_MODIFIER", 53, 67], ["malaria", "OBSERVATION", 147, 154], ["sequestration", "OBSERVATION", 243, 256], ["early", "OBSERVATION_MODIFIER", 268, 273], ["trophozoite", "OBSERVATION_MODIFIER", 274, 285], ["falciparum malaria", "OBSERVATION", 296, 314]]], ["Cytoadherence is often implicated in malaria pathology and is mediated by the expression of variable var gene products (of the PfEMP-1 family) at the surface of infected host red blood cells with concomitant expression of post-capillary endothelial cell receptors [15, [30] [31] [32] .", [["surface", "ANATOMY", 150, 157], ["red blood cells", "ANATOMY", 175, 190], ["post-capillary endothelial cell", "ANATOMY", 222, 253], ["Cytoadherence", "DISEASE", 0, 13], ["malaria", "DISEASE", 37, 44], ["PfEMP-1", "GENE_OR_GENE_PRODUCT", 127, 134], ["surface", "CELLULAR_COMPONENT", 150, 157], ["red blood cells", "CELL", 175, 190], ["endothelial cell", "CELL", 237, 253], ["variable var gene products", "PROTEIN", 92, 118], ["PfEMP-1 family", "PROTEIN", 127, 141], ["infected host red blood cells", "CELL_TYPE", 161, 190], ["post-capillary endothelial cell receptors", "PROTEIN", 222, 263], ["Cytoadherence", "PROBLEM", 0, 13], ["malaria pathology", "PROBLEM", 37, 54], ["variable var gene products", "TREATMENT", 92, 118], ["red blood cells", "TEST", 175, 190], ["post-capillary endothelial cell receptors", "TEST", 222, 263], ["malaria", "OBSERVATION", 37, 44], ["post-capillary endothelial cell", "OBSERVATION", 222, 253]]], ["Although not easily quantifiable, partial sequestration was observed in this fatal case of knowlesi malaria as evidenced by an abundance of large pigment bearing parasites on the blood film obtained post-mortem and as accumulations in the microvasculature.", [["blood film", "ANATOMY", 179, 189], ["microvasculature", "ANATOMY", 239, 255], ["knowlesi malaria", "DISEASE", 91, 107], ["knowlesi", "ORGANISM", 91, 99], ["blood film", "MULTI-TISSUE_STRUCTURE", 179, 189], ["microvasculature", "TISSUE", 239, 255], ["partial sequestration", "PROBLEM", 34, 55], ["knowlesi malaria", "PROBLEM", 91, 107], ["large pigment bearing parasites", "PROBLEM", 140, 171], ["the blood film", "TEST", 175, 189], ["accumulations in the microvasculature", "PROBLEM", 218, 255], ["partial", "OBSERVATION_MODIFIER", 34, 41], ["sequestration", "OBSERVATION", 42, 55], ["knowlesi malaria", "OBSERVATION", 91, 107], ["abundance", "OBSERVATION_MODIFIER", 127, 136], ["large", "OBSERVATION_MODIFIER", 140, 145], ["pigment bearing parasites", "OBSERVATION", 146, 171], ["microvasculature", "ANATOMY", 239, 255]]], ["We hypothesize that partial sequestration may be due to P. knowlesi infected cell agglutination mediated by variant surface antigens of P. knowlesi SICA var genes (orthologues of the PfEMP-1 family) [33, 34] .", [["cell", "ANATOMY", 77, 81], ["surface", "ANATOMY", 116, 123], ["P. knowlesi infected", "DISEASE", 56, 76], ["P. knowlesi", "ORGANISM", 56, 67], ["cell", "CELL", 77, 81], ["P. knowlesi", "ORGANISM", 136, 147], ["SICA var", "GENE_OR_GENE_PRODUCT", 148, 156], ["PfEMP-1", "GENE_OR_GENE_PRODUCT", 183, 190], ["variant surface antigens", "PROTEIN", 108, 132], ["P. knowlesi SICA var genes", "DNA", 136, 162], ["PfEMP-1 family", "DNA", 183, 197], ["P. knowlesi", "SPECIES", 56, 67], ["P. knowlesi", "SPECIES", 136, 147], ["P. knowlesi", "SPECIES", 56, 67], ["P. knowlesi", "SPECIES", 136, 147], ["partial sequestration", "PROBLEM", 20, 41], ["P. knowlesi infected cell agglutination", "PROBLEM", 56, 95], ["partial sequestration", "OBSERVATION", 20, 41], ["may be due to", "UNCERTAINTY", 42, 55], ["infected cell agglutination", "OBSERVATION", 68, 95]]], ["Importantly, in this fatal case of P. knowlesi, up-regulation of ICAM-1 was not detected, nor was there evidence for cytoadherence as parasitized cells were not marginalized and were interspersed with uninfected erythrocytes in smaller vessels.ConclusionsCerebral malaria and severe acute anaemia are often peculiar to falciparum infection while organ, respiratory and metabolic dysfunction are common with severe knowlesi, vivax and other forms of severe falciparum infection [3, 4, 19, [35] [36] [37] [38] [39] [40] .", [["cells", "ANATOMY", 146, 151], ["erythrocytes", "ANATOMY", 212, 224], ["vessels", "ANATOMY", 236, 243], ["Cerebral", "ANATOMY", 255, 263], ["organ", "ANATOMY", 346, 351], ["respiratory", "ANATOMY", 353, 364], ["P. knowlesi", "DISEASE", 35, 46], ["Cerebral malaria", "DISEASE", 255, 271], ["anaemia", "DISEASE", 289, 296], ["falciparum infection", "DISEASE", 319, 339], ["respiratory and metabolic dysfunction", "DISEASE", 353, 390], ["knowlesi, vivax", "DISEASE", 414, 429], ["falciparum infection", "DISEASE", 456, 476], ["P. knowlesi", "ORGANISM", 35, 46], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 65, 71], ["cells", "CELL", 146, 151], ["erythrocytes", "CELL", 212, 224], ["vessels", "MULTI-TISSUE_STRUCTURE", 236, 243], ["organ", "ORGAN", 346, 351], ["[35] [36] [37] [38] [39", "SIMPLE_CHEMICAL", 488, 511], ["ICAM", "PROTEIN", 65, 69], ["parasitized cells", "CELL_TYPE", 134, 151], ["uninfected erythrocytes", "CELL_TYPE", 201, 224], ["P. knowlesi", "SPECIES", 35, 46], ["P. knowlesi", "SPECIES", 35, 46], ["P. knowlesi", "PROBLEM", 35, 46], ["ICAM", "TEST", 65, 69], ["cytoadherence", "PROBLEM", 117, 130], ["parasitized cells", "PROBLEM", 134, 151], ["uninfected erythrocytes in smaller vessels", "PROBLEM", 201, 243], ["Cerebral malaria", "PROBLEM", 255, 271], ["severe acute anaemia", "PROBLEM", 276, 296], ["falciparum infection", "PROBLEM", 319, 339], ["respiratory and metabolic dysfunction", "PROBLEM", 353, 390], ["severe knowlesi", "PROBLEM", 407, 422], ["vivax", "PROBLEM", 424, 429], ["severe falciparum infection", "PROBLEM", 449, 476], ["evidence for", "UNCERTAINTY", 104, 116], ["uninfected erythrocytes", "OBSERVATION", 201, 224], ["smaller", "OBSERVATION_MODIFIER", 228, 235], ["vessels", "ANATOMY", 236, 243], ["Cerebral", "ANATOMY", 255, 263], ["malaria", "OBSERVATION", 264, 271], ["severe", "OBSERVATION_MODIFIER", 276, 282], ["acute", "OBSERVATION_MODIFIER", 283, 288], ["anaemia", "OBSERVATION", 289, 296], ["falciparum", "OBSERVATION_MODIFIER", 319, 329], ["infection", "OBSERVATION", 330, 339], ["metabolic dysfunction", "OBSERVATION", 369, 390], ["severe", "OBSERVATION_MODIFIER", 449, 455], ["falciparum", "OBSERVATION", 456, 466]]], ["Although late stages of parasites may be visible in the blood in falciparum infections, they are rare and associated with a poor prognosis.", [["blood", "ANATOMY", 56, 61], ["falciparum infections", "DISEASE", 65, 86], ["parasites", "CELL", 24, 33], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["falciparum", "ORGANISM", 65, 75], ["parasites", "PROBLEM", 24, 33], ["the blood in falciparum infections", "PROBLEM", 52, 86], ["late stages", "OBSERVATION_MODIFIER", 9, 20], ["parasites", "OBSERVATION", 24, 33], ["may be", "UNCERTAINTY", 34, 40], ["visible", "OBSERVATION_MODIFIER", 41, 48], ["blood", "ANATOMY", 56, 61], ["falciparum infections", "OBSERVATION", 65, 86]]], ["Testing the relative contribution of virulence factors to the development of severe malaria including, cytoadherence, hyperparasitaemia, cerebral malaria, organ failure, metabolic and respiratory dysfunction and anaemia was previously difficult without comparative information from severe malaria caused by another species [16, [41] [42] [43] [44] .", [["cerebral", "ANATOMY", 137, 145], ["organ", "ANATOMY", 155, 160], ["respiratory", "ANATOMY", 184, 195], ["malaria", "DISEASE", 84, 91], ["hyperparasitaemia", "DISEASE", 118, 135], ["cerebral malaria", "DISEASE", 137, 153], ["organ failure", "DISEASE", 155, 168], ["metabolic and respiratory dysfunction", "DISEASE", 170, 207], ["anaemia", "DISEASE", 212, 219], ["malaria", "DISEASE", 289, 296], ["cerebral", "ORGAN", 137, 145], ["organ", "ORGAN", 155, 160], ["[41] [42] [43", "SIMPLE_CHEMICAL", 328, 341], ["virulence factors", "PROTEIN", 37, 54], ["virulence factors", "PROBLEM", 37, 54], ["severe malaria", "PROBLEM", 77, 91], ["cytoadherence", "PROBLEM", 103, 116], ["hyperparasitaemia", "PROBLEM", 118, 135], ["cerebral malaria", "PROBLEM", 137, 153], ["organ failure", "PROBLEM", 155, 168], ["metabolic and respiratory dysfunction", "PROBLEM", 170, 207], ["anaemia", "PROBLEM", 212, 219], ["severe malaria", "PROBLEM", 282, 296], ["another species", "TEST", 307, 322], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["malaria", "OBSERVATION", 84, 91], ["cerebral", "ANATOMY", 137, 145], ["malaria", "OBSERVATION", 146, 153], ["organ", "ANATOMY", 155, 160], ["failure", "OBSERVATION", 161, 168], ["respiratory dysfunction", "OBSERVATION", 184, 207], ["anaemia", "OBSERVATION", 212, 219], ["severe", "OBSERVATION_MODIFIER", 282, 288], ["malaria", "OBSERVATION", 289, 296]]], ["Severe and fatal cases of knowlesi malaria will add much needed perspective to what is known of malaria pathophysiology.ConclusionsThe need to develop knowlesi-specific diagnosis, treatment and management guidelines is urgent.", [["knowlesi malaria", "DISEASE", 26, 42], ["malaria", "DISEASE", 96, 103], ["Severe and fatal cases", "PROBLEM", 0, 22], ["knowlesi malaria", "PROBLEM", 26, 42], ["malaria pathophysiology", "PROBLEM", 96, 119], ["treatment", "TREATMENT", 180, 189], ["management guidelines", "TREATMENT", 194, 215], ["fatal", "OBSERVATION_MODIFIER", 11, 16], ["knowlesi malaria", "OBSERVATION", 26, 42], ["malaria", "OBSERVATION", 96, 103]]], ["A recent prospective clinical study in Sarawak Malaysian Borneo revealed that approximately 1:10 patients infected with P. knowlesi present with or develop severe symptoms and 1-2% of cases are fatal [4] .", [["P. knowlesi", "DISEASE", 120, 131], ["patients", "ORGANISM", 97, 105], ["P. knowlesi", "ORGANISM", 120, 131], ["patients", "SPECIES", 97, 105], ["P. knowlesi", "SPECIES", 120, 131], ["P. knowlesi", "SPECIES", 120, 131], ["A recent prospective clinical study", "TEST", 0, 35], ["severe symptoms", "PROBLEM", 156, 171], ["severe", "OBSERVATION_MODIFIER", 156, 162]]], ["Complications in survivors included ARDS, liver or renal dysfunction, hypotension with or without parasitaemia >100,000/uL.", [["liver", "ANATOMY", 42, 47], ["renal", "ANATOMY", 51, 56], ["ARDS", "DISEASE", 36, 40], ["liver or renal dysfunction", "DISEASE", 42, 68], ["hypotension", "DISEASE", 70, 81], ["parasitaemia", "DISEASE", 98, 110], ["liver", "ORGAN", 42, 47], ["renal", "ORGAN", 51, 56], ["Complications in survivors", "PROBLEM", 0, 26], ["ARDS", "PROBLEM", 36, 40], ["renal dysfunction", "PROBLEM", 51, 68], ["hypotension", "PROBLEM", 70, 81], ["parasitaemia", "PROBLEM", 98, 110], ["ARDS", "OBSERVATION", 36, 40], ["liver", "ANATOMY", 42, 47], ["renal", "ANATOMY", 51, 56], ["dysfunction", "OBSERVATION", 57, 68], ["hypotension", "OBSERVATION", 70, 81]]], ["Complications in all fatal knowlesi cases had either clinical or laboratory evidence of abdominal pain, combined hepatorenal dysfunction and hyperparasitaemia [3, 4] .", [["abdominal", "ANATOMY", 88, 97], ["hepatorenal", "ANATOMY", 113, 124], ["knowlesi", "DISEASE", 27, 35], ["abdominal pain", "DISEASE", 88, 102], ["hepatorenal dysfunction", "DISEASE", 113, 136], ["hyperparasitaemia", "DISEASE", 141, 158], ["abdominal", "ORGANISM_SUBDIVISION", 88, 97], ["Complications in all fatal knowlesi cases", "PROBLEM", 0, 41], ["abdominal pain", "PROBLEM", 88, 102], ["combined hepatorenal dysfunction", "PROBLEM", 104, 136], ["hyperparasitaemia", "PROBLEM", 141, 158], ["abdominal", "ANATOMY", 88, 97], ["pain", "OBSERVATION", 98, 102], ["hepatorenal dysfunction", "OBSERVATION", 113, 136]]], ["There is a prospect that P. knowlesi may emerge as a human pathogen beyond its current zoonotic manifestations [11, 12] , specific surveillance, control and clinical guidelines are necessary to contain potential larger outbreaks.ConsentApproval to use this case for educational purposes was obtained from the Deputy Director for Health, Sabah State Department of Health, Ministry of Health, Malaysia.", [["P. knowlesi", "DISEASE", 25, 36], ["P. knowlesi", "ORGANISM", 25, 36], ["human", "ORGANISM", 53, 58], ["P. knowlesi", "SPECIES", 25, 36], ["human", "SPECIES", 53, 58], ["P. knowlesi", "SPECIES", 25, 36], ["human", "SPECIES", 53, 58], ["P. knowlesi", "PROBLEM", 25, 36], ["a human pathogen", "PROBLEM", 51, 67], ["specific surveillance", "TEST", 122, 143], ["potential larger outbreaks", "PROBLEM", 202, 228], ["larger", "OBSERVATION_MODIFIER", 212, 218], ["outbreaks", "OBSERVATION", 219, 228]]]], "PMC7357401": [["IntroductionCoronaviruses are enveloped viruses with non-segmented positive-sense RNA, widely distributed in humans and animals12.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 12, 25], ["humans", "ORGANISM", 109, 115], ["non-segmented positive-sense RNA", "RNA", 53, 85], ["humans", "SPECIES", 109, 115], ["humans", "SPECIES", 109, 115], ["non-segmented positive-sense RNA", "PROBLEM", 53, 85], ["sense RNA", "OBSERVATION", 76, 85], ["widely", "OBSERVATION_MODIFIER", 87, 93], ["distributed", "OBSERVATION_MODIFIER", 94, 105]]], ["Initially, infections caused by several human coronaviruses (HCoVs) were only mild and hence were considered as neglected pathogens.", [["infections", "DISEASE", 11, 21], ["human", "ORGANISM", 40, 45], ["coronaviruses", "ORGANISM", 46, 59], ["HCoVs", "CANCER", 61, 66], ["human", "SPECIES", 40, 45], ["human coronaviruses", "SPECIES", 40, 59], ["infections", "PROBLEM", 11, 21], ["several human coronaviruses (HCoVs)", "PROBLEM", 32, 67], ["neglected pathogens", "PROBLEM", 112, 131], ["infections", "OBSERVATION", 11, 21], ["mild", "OBSERVATION_MODIFIER", 78, 82]]], ["After the emergence of highly pathogenic severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) (2002 and 2003) and Middle East respiratory syndrome coronavirus (MERS-CoV, 2012)3, it has become obvious that coronaviruses can cross the species barrier and cause life-challenging infections in human, thus needing greater attention than the initial HCoVs4.IntroductionRecently, another pathogenic HCoV was identified in Wuhan, People's Republic of China, which was initially named as 2019 novel coronavirus (2019-nCoV)5.", [["acute respiratory syndrome coronavirus", "DISEASE", 48, 86], ["Middle East respiratory syndrome coronavirus", "DISEASE", 122, 166], ["infections", "DISEASE", 284, 294], ["severe acute respiratory syndrome coronavirus 1", "ORGANISM", 41, 88], ["SARS-CoV-1", "ORGANISM", 90, 100], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 122, 166], ["MERS-CoV", "ORGANISM", 168, 176], ["coronaviruses", "ORGANISM", 213, 226], ["human", "ORGANISM", 298, 303], ["HCoVs4", "GENE_OR_GENE_PRODUCT", 353, 359], ["HCoV", "CANCER", 401, 405], ["HCoVs4", "PROTEIN", 353, 359], ["coronavirus 1", "SPECIES", 75, 88], ["CoV-1", "SPECIES", 95, 100], ["human", "SPECIES", 298, 303], ["coronavirus", "SPECIES", 499, 510], ["severe acute respiratory syndrome coronavirus 1", "SPECIES", 41, 88], ["SARS-CoV-1", "SPECIES", 90, 100], ["Middle East respiratory syndrome coronavirus (MERS-CoV", "SPECIES", 122, 176], ["human", "SPECIES", 298, 303], ["HCoV", "SPECIES", 401, 405], ["highly pathogenic severe acute respiratory syndrome coronavirus", "PROBLEM", 23, 86], ["SARS-CoV", "TEST", 90, 98], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 122, 166], ["coronaviruses", "PROBLEM", 213, 226], ["challenging infections in human", "PROBLEM", 272, 303], ["another pathogenic HCoV", "PROBLEM", 382, 405], ["novel coronavirus", "TEST", 493, 510], ["pathogenic", "OBSERVATION_MODIFIER", 30, 40], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["respiratory syndrome", "OBSERVATION", 54, 74], ["Middle", "ANATOMY_MODIFIER", 122, 128], ["respiratory syndrome", "OBSERVATION", 134, 154], ["coronaviruses", "OBSERVATION", 213, 226], ["challenging", "OBSERVATION_MODIFIER", 272, 283], ["infections", "OBSERVATION", 284, 294]]], ["But later, it has been named as SARS-CoV-2 by the International Committee on Taxonomy of Viruses (ICTV)6.", [["SARS", "DISEASE", 32, 36], ["Viruses (ICTV)", "TREATMENT", 89, 103]]], ["This virus causes coronavirus disease 2019 (COVID-19).", [["coronavirus disease", "DISEASE", 18, 37], ["coronavirus", "ORGANISM", 18, 29], ["This virus", "PROBLEM", 0, 10], ["coronavirus disease", "PROBLEM", 18, 37], ["COVID", "TEST", 44, 49], ["coronavirus disease", "OBSERVATION", 18, 37]]], ["The clinical presentation of infection ranges from asymptomatic to very severe pneumonia with acute respiratory distress syndrome, septic shock and multi-organ failure resulting in death7.", [["respiratory", "ANATOMY", 100, 111], ["multi-organ", "ANATOMY", 148, 159], ["infection", "DISEASE", 29, 38], ["pneumonia", "DISEASE", 79, 88], ["acute respiratory distress syndrome", "DISEASE", 94, 129], ["septic shock", "DISEASE", 131, 143], ["multi-organ failure", "DISEASE", 148, 167], ["infection ranges", "PROBLEM", 29, 45], ["very severe pneumonia", "PROBLEM", 67, 88], ["acute respiratory distress syndrome", "PROBLEM", 94, 129], ["septic shock", "PROBLEM", 131, 143], ["multi-organ failure", "PROBLEM", 148, 167], ["death7", "PROBLEM", 181, 187], ["infection", "OBSERVATION", 29, 38], ["very", "OBSERVATION_MODIFIER", 67, 71], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["pneumonia", "OBSERVATION", 79, 88], ["acute", "OBSERVATION_MODIFIER", 94, 99], ["respiratory distress syndrome", "OBSERVATION", 100, 129], ["septic shock", "OBSERVATION", 131, 143], ["multi-organ", "ANATOMY", 148, 159], ["failure", "OBSERVATION", 160, 167]]], ["As of March 2020, SARS-CoV-2 has spread to more than 203 countries of various regions including Africa, America, Europe, South East Asia and Western Pacific alarming public health authorities around the world8.IntroductionSince, the first case reported on December 31, 2019, the WHO has been notified with more than 100,000 confirmed cases including 3,380 deaths globally as on March 6, 2020, of whom 90 per cent (3,045) were from China itself, while the remaining 10 per cent (335) were from other countries9.", [["SARS", "DISEASE", 18, 22], ["deaths", "DISEASE", 356, 362], ["SARS-CoV", "SPECIES", 18, 26], ["SARS", "PROBLEM", 18, 22]]], ["The SARS-CoV-2 is now one of the top-priority pathogens to be dealt with, because of high fatality rate in severe cases, spread in a wide geographical area, lack of control measures and knowledge gaps in its epidemiology, immunity and pathogenesis.", [["SARS", "DISEASE", 4, 8], ["SARS-CoV-2", "ORGANISM", 4, 14], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["high fatality rate in severe cases", "PROBLEM", 85, 119], ["a wide geographical area", "PROBLEM", 131, 155], ["pathogenesis", "PROBLEM", 235, 247], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["wide", "OBSERVATION_MODIFIER", 133, 137]]], ["Currently, there are no licensed vaccines or therapies specific to COVID-19.", [["licensed vaccines", "TREATMENT", 24, 41], ["therapies", "TREATMENT", 45, 54], ["COVID", "TEST", 67, 72], ["no", "UNCERTAINTY", 21, 23]]], ["Hence, the WHO has initially declared COVID-19 as the global public health emergency10 and subsequently as pandemic11.IntroductionBecause of the rapid spread of this virus, it has become necessary to enhance laboratory capabilities to provide immediate diagnostic assistance as the load of samples from suspected patients is increasing on a daily basis and existing laboratories cannot meet the demands.", [["samples", "ANATOMY", 290, 297], ["patients", "ORGANISM", 313, 321], ["patients", "SPECIES", 313, 321], ["COVID", "TEST", 38, 43], ["the rapid spread of this virus", "PROBLEM", 141, 171], ["rapid", "OBSERVATION_MODIFIER", 145, 150], ["spread", "OBSERVATION_MODIFIER", 151, 157], ["increasing", "OBSERVATION_MODIFIER", 325, 335]]], ["The objective of this review is to highlight various requirements for the diagnostic laboratories involved in the testing of SARS-CoV-2 and also describe measures to mitigate the risk factors involved in laboratories that are providing molecular diagnosis, so that more laboratories become available for providing quick diagnosis under all safety precautions.Sample of choiceCoronaviruses are mainly responsible for respiratory tract infections resulting in symptoms such as common flu.", [["respiratory tract", "ANATOMY", 416, 433], ["SARS", "DISEASE", 125, 129], ["respiratory tract infections", "DISEASE", 416, 444], ["SARS-CoV-2", "ORGANISM", 125, 135], ["choiceCoronaviruses", "GENE_OR_GENE_PRODUCT", 369, 388], ["tract", "ORGANISM_SUBDIVISION", 428, 433], ["SARS-CoV", "SPECIES", 125, 133], ["the diagnostic laboratories", "TEST", 70, 97], ["the testing", "TEST", 110, 121], ["the risk factors", "PROBLEM", 175, 191], ["all safety precautions", "TREATMENT", 336, 358], ["Sample of choiceCoronaviruses", "PROBLEM", 359, 388], ["respiratory tract infections", "PROBLEM", 416, 444], ["symptoms", "PROBLEM", 458, 466], ["common flu", "PROBLEM", 475, 485], ["mainly responsible for", "UNCERTAINTY", 393, 415]]], ["Choice of sample for detection will be respiratory samples including clinical material from the upper and lower respiratory tracts depending on the symptoms and condition of the patient1213.", [["sample", "ANATOMY", 10, 16], ["respiratory samples", "ANATOMY", 39, 58], ["lower respiratory tracts", "ANATOMY", 106, 130], ["upper", "ORGANISM_SUBDIVISION", 96, 101], ["lower", "ORGANISM_SUBDIVISION", 106, 111], ["respiratory tracts", "ORGANISM_SUBDIVISION", 112, 130], ["patient", "ORGANISM", 178, 185], ["patient", "SPECIES", 178, 185], ["detection", "TEST", 21, 30], ["respiratory samples", "TEST", 39, 58], ["clinical material from the upper and lower respiratory tracts", "PROBLEM", 69, 130], ["the symptoms", "PROBLEM", 144, 156], ["upper", "ANATOMY_MODIFIER", 96, 101], ["lower", "ANATOMY_MODIFIER", 106, 111], ["respiratory tracts", "ANATOMY", 112, 130]]], ["For SARS-CoV-2, shedding patterns are not well understood and further investigations are required to understand the timing, compartmentalization and magnitude of virus shedding.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 4, 14], ["SARS-CoV", "SPECIES", 4, 12], ["SARS", "PROBLEM", 4, 8], ["further investigations", "TEST", 62, 84], ["virus shedding", "PROBLEM", 162, 176]]], ["However, the virus may be detectable in other specimens including blood and urine as in cases of SARS-CoV-1 and MERS-CoV141516.", [["specimens", "ANATOMY", 46, 55], ["blood", "ANATOMY", 66, 71], ["urine", "ANATOMY", 76, 81], ["SARS", "DISEASE", 97, 101], ["specimens", "TISSUE", 46, 55], ["blood", "ORGANISM_SUBSTANCE", 66, 71], ["urine", "ORGANISM_SUBSTANCE", 76, 81], ["MERS-CoV141516", "GENE_OR_GENE_PRODUCT", 112, 126], ["SARS-CoV-1", "SPECIES", 97, 107], ["the virus", "PROBLEM", 9, 18], ["other specimens", "TEST", 40, 55], ["blood and urine", "TEST", 66, 81], ["SARS", "PROBLEM", 97, 101], ["CoV", "TEST", 102, 105], ["virus", "OBSERVATION", 13, 18], ["may be", "UNCERTAINTY", 19, 25]]], ["The mean incubation period for SARS-CoV-2 is 5.2 days; however, it may vary widely depending on severity of illness17.Specimen collectionOnly trained staff should be allowed for appropriate specimen collection, storage, packaging and transport, ensuring that adequate standard operating procedures in consonance with the national or the WHO guidelines18 are in use, and all specimens should be treated as potentially infectious.DiagnosisSuspected cases should be tested for the virus with nucleic acid amplification tests, such as real-time reverse transcription - polymerase chain reaction (RT-PCR) with confirmation by nucleic acid sequencing when needed.", [["specimen", "ANATOMY", 190, 198], ["specimens", "ANATOMY", 374, 383], ["SARS", "DISEASE", 31, 35], ["nucleic acid", "CHEMICAL", 489, 501], ["nucleic acid", "CHEMICAL", 621, 633], ["SARS-CoV", "SPECIES", 31, 39], ["SARS", "PROBLEM", 31, 35], ["CoV", "TEST", 36, 39], ["illness", "PROBLEM", 108, 115], ["packaging", "TREATMENT", 220, 229], ["infectious", "PROBLEM", 417, 427], ["the virus", "PROBLEM", 474, 483], ["nucleic acid amplification tests", "TEST", 489, 521], ["polymerase chain reaction", "PROBLEM", 565, 590], ["nucleic acid sequencing", "TEST", 621, 644], ["infectious", "OBSERVATION", 417, 427]]], ["Viral RNA extraction should be done in a biosafety cabinet in a BSL-2 or equivalent facility, which will be used further for amplification of genes targeted including nucleocapsid (N), spike (S), envelope (E), and RNA-dependent RNA polymerase (RdRp)18.", [["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 167, 183], ["spike (S)", "GENE_OR_GENE_PRODUCT", 185, 194], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 214, 242], ["nucleocapsid (N), spike (S), envelope (E)", "RNA", 167, 208], ["RNA-dependent RNA polymerase (RdRp)18", "PROTEIN", 214, 251], ["Viral RNA extraction", "TREATMENT", 0, 20], ["RNA-dependent RNA polymerase (RdRp)", "TREATMENT", 214, 249]]], ["Serological tests are still under development, and once these become available, field surveys will aid in better understanding of the outbreak, implementation of control measures and also understanding cross-reactivity with other viruses.Infrastructure neededSuspected samples should be handled at initial phase in a biosafety cabinet by well-trained staff with respect to standard BSL-2 facility.", [["samples", "ANATOMY", 269, 276], ["Serological tests", "TEST", 0, 17], ["implementation of control measures", "TREATMENT", 144, 178], ["other viruses", "PROBLEM", 224, 237]]], ["National guidelines on laboratory biosafety should be followed in all circumstances19.", [["laboratory biosafety", "TREATMENT", 23, 43]]], ["At present, very limited information is available on the risk posed by COVID-19, therefore, all procedures should be undertaken based on risk assessment.Infrastructure neededSpecimen handling for molecular testing of COVID-19 would require BSL-2 or equivalent facilities.", [["all procedures", "TREATMENT", 92, 106], ["risk assessment", "TEST", 137, 152], ["Specimen handling", "TEST", 174, 191], ["molecular testing", "TEST", 196, 213], ["COVID", "TEST", 217, 222]]], ["These facilities include separate hand and eye wash sinks, and these also need to have automatic door locking systems.", [["hand", "ANATOMY", 34, 38], ["eye", "ANATOMY", 43, 46], ["hand", "ORGANISM_SUBDIVISION", 34, 38], ["eye", "ORGAN", 43, 46], ["automatic door locking systems", "TREATMENT", 87, 117], ["eye", "ANATOMY", 43, 46]]], ["The BSL-2 laboratories should have access to facility of decontamination, including an autoclave19.Infrastructure neededIt is recommended that good microbiological laboratory practices and universal precautions must be followed in all laboratories where primary specimens (such as sputum, throat swab, nasopharyngeal swab, oropharyngeal swab, and stool) that may contain SARS-CoV-2 virus, are handled.", [["primary specimens", "ANATOMY", 254, 271], ["sputum", "ANATOMY", 281, 287], ["throat swab", "ANATOMY", 289, 300], ["nasopharyngeal swab", "ANATOMY", 302, 321], ["oropharyngeal swab", "ANATOMY", 323, 341], ["stool", "ANATOMY", 347, 352], ["specimens", "CANCER", 262, 271], ["throat", "ORGANISM_SUBDIVISION", 289, 295], ["swab", "ORGANISM_SUBDIVISION", 296, 300], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 302, 321], ["oropharyngeal swab", "MULTI-TISSUE_STRUCTURE", 323, 341], ["stool", "ORGANISM_SUBDIVISION", 347, 352], ["SARS-CoV-2 virus", "ORGANISM", 371, 387], ["CoV-2 virus", "SPECIES", 376, 387], ["SARS-CoV-2 virus", "SPECIES", 371, 387], ["decontamination", "TREATMENT", 57, 72], ["an autoclave19", "TREATMENT", 84, 98], ["universal precautions", "TREATMENT", 189, 210], ["primary specimens", "TEST", 254, 271], ["sputum", "TEST", 281, 287], ["throat swab", "TEST", 289, 300], ["nasopharyngeal swab", "TEST", 302, 321], ["oropharyngeal swab", "TEST", 323, 341], ["SARS", "PROBLEM", 371, 375]]], ["While working with suspected patient's samples, laboratory personnel should be supervised by staff competent in handling infectious agents and related standard procedures19.", [["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36]]], ["The list of basic laboratory equipment and reagents required for providing laboratory diagnosis for COVID-19 is provided in Table I.Biosafety measuresIn most cases, SARS-CoV-2 is transmitted from human to human through inhalation or deposition on mucosal surfaces of large respiratory droplets.", [["mucosal", "ANATOMY", 247, 254], ["respiratory droplets", "ANATOMY", 273, 293], ["SARS", "DISEASE", 165, 169], ["SARS-CoV-2", "ORGANISM", 165, 175], ["human", "ORGANISM", 196, 201], ["human", "ORGANISM", 205, 210], ["mucosal", "PATHOLOGICAL_FORMATION", 247, 254], ["human", "SPECIES", 196, 201], ["human", "SPECIES", 205, 210], ["SARS-CoV", "SPECIES", 165, 173], ["human", "SPECIES", 196, 201], ["human", "SPECIES", 205, 210], ["COVID", "TEST", 100, 105], ["large respiratory droplets", "PROBLEM", 267, 293], ["mucosal surfaces", "OBSERVATION_MODIFIER", 247, 263], ["large", "OBSERVATION_MODIFIER", 267, 272], ["respiratory droplets", "OBSERVATION", 273, 293]]], ["Other routes identified are contact with contaminated fomites and inhalation of aerosol, generated during handling of large volumes, etc20.", [["etc20", "PROTEIN", 133, 138], ["inhalation of aerosol", "TREATMENT", 66, 87], ["large", "OBSERVATION_MODIFIER", 118, 123]]], ["For the laboratories involved in the diagnosis of COVID-19, it is necessary that staff should be well trained in the implementation of appropriate biosafety measures.", [["the laboratories", "TEST", 4, 20], ["COVID", "TEST", 50, 55], ["appropriate biosafety measures", "TREATMENT", 135, 165]]], ["The rational, correct and consistent use of available personal protective equipment (PPE) and appropriate hand hygiene help to reduce the spread of the pathogens.", [["hand", "ANATOMY", 106, 110], ["hand", "ORGANISM_SUBDIVISION", 106, 110], ["available personal protective equipment (PPE)", "TREATMENT", 44, 89], ["appropriate hand hygiene", "TREATMENT", 94, 118], ["the pathogens", "PROBLEM", 148, 161]]], ["Though PPE is considered as a primary prevention strategy, it should not be completely relied upon for complete prevention for virus transmission.", [["PPE", "PROBLEM", 7, 10], ["a primary prevention strategy", "TREATMENT", 28, 57], ["virus transmission", "PROBLEM", 127, 145]]], ["The effectiveness of PPE depends upon proper handling of PPEs by trained staff, hand hygiene practices and human factor21222324.", [["hand", "ANATOMY", 80, 84], ["PPEs", "SIMPLE_CHEMICAL", 57, 61], ["hand", "ORGANISM_SUBDIVISION", 80, 84], ["human", "ORGANISM", 107, 112], ["human factor21222324", "PROTEIN", 107, 127], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 107, 112], ["PPE", "PROBLEM", 21, 24]]], ["Immunization policy for influenza would also help in giving protection to laboratory workers and reduce the suspicion of the staff to be getting infection in such emergency situation.", [["influenza", "DISEASE", 24, 33], ["infection", "DISEASE", 145, 154], ["Immunization policy", "TREATMENT", 0, 19], ["influenza", "PROBLEM", 24, 33], ["infection", "PROBLEM", 145, 154]]], ["Basic biosafety requirements for the laboratories that include important features of procedures and processes to be followed during processing the samples for COVID-19 laboratory diagnosis are provided in Table II.Biosafety measuresBiorisk assessment carried out for individual laboratory personnel and to the community with regard to providing molecular diagnosis for COVID-19 is provided in the Figure This biorisk assessment will also provide guidance for the future laboratories that are opting to provide laboratory diagnosis for this infection.", [["infection", "DISEASE", 540, 549], ["the laboratories", "TEST", 33, 49], ["COVID", "TEST", 159, 164], ["Biosafety measures", "TREATMENT", 214, 232], ["Biorisk assessment", "TEST", 232, 250], ["COVID", "TEST", 369, 374], ["this infection", "PROBLEM", 535, 549], ["infection", "OBSERVATION", 540, 549]]]], "d8aaf27d93846eafe92b5655f5dfd17a33998b51": [["IntroductionAs classified by the International Committee for Taxonomy of Viruses (ICTV), coronaviruses (CoV) are a member of the genus Coronavirus in the Coronaviridae family (Gorbalenya et al., 2020) .", [["coronaviruses", "ORGANISM", 89, 102], ["CoV", "ORGANISM", 104, 107], ["Coronavirus", "GENE_OR_GENE_PRODUCT", 135, 146], ["ICTV", "SPECIES", 82, 86], ["CoV", "SPECIES", 104, 107], ["Viruses", "PROBLEM", 73, 80], ["coronaviruses", "PROBLEM", 89, 102], ["Viruses", "OBSERVATION", 73, 80], ["genus Coronavirus", "OBSERVATION", 129, 146]]], ["Pleomorphism is seen in the RNA of all CoVs viral strains, characterized by having crown-shaped peplomers 80-160 nm in size (Fehr et al., 2017; Fehr and Perlman, 2015; Sahin et al., 2020) .", [["Pleomorphism", "DISEASE", 0, 12], ["CoVs", "GENE_OR_GENE_PRODUCT", 39, 43], ["Pleomorphism", "PROBLEM", 0, 12], ["all CoVs viral strains", "PROBLEM", 35, 57], ["crown-shaped peplomers", "PROBLEM", 83, 105], ["RNA", "ANATOMY_MODIFIER", 28, 31], ["all CoVs", "ANATOMY", 35, 43], ["viral strains", "OBSERVATION", 44, 57], ["crown", "OBSERVATION_MODIFIER", 83, 88], ["shaped", "OBSERVATION_MODIFIER", 89, 95], ["peplomers", "OBSERVATION_MODIFIER", 96, 105], ["160 nm", "OBSERVATION_MODIFIER", 109, 115], ["size", "OBSERVATION_MODIFIER", 119, 123]]], ["The viruses have a positive-sense, single-stranded ribonucleic acid (RNA) genome with a length in the range of 26-32 kilobases (kb) hence containing the biggest RNA of viral genome (Ahmad and Rodriguez-Morales, 2020; Fehr et al., 2017; Roosa et al., 2020) .IntroductionRecombination of CoVs occur at intensely high rates since there are constant development of transcription errors and RNA-related RNA polymerase (RdRP) vaults (Sahin et al., 2020) .", [["ribonucleic acid", "CHEMICAL", 51, 67], ["CoVs", "GENE_OR_GENE_PRODUCT", 286, 290], ["positive-sense, single-stranded ribonucleic acid", "RNA", 19, 67], ["viral genome", "DNA", 168, 180], ["CoVs", "DNA", 286, 290], ["RNA polymerase", "PROTEIN", 398, 412], ["RdRP", "PROTEIN", 414, 418], ["single-stranded ribonucleic acid (RNA) genome", "PROBLEM", 35, 80], ["a length", "TEST", 86, 94], ["viral genome", "PROBLEM", 168, 180], ["CoVs", "PROBLEM", 286, 290], ["transcription errors", "PROBLEM", 361, 381], ["RNA", "TEST", 386, 389], ["RNA polymerase (RdRP) vaults", "PROBLEM", 398, 426], ["viruses", "OBSERVATION", 4, 11], ["positive", "OBSERVATION", 19, 27], ["ribonucleic acid", "OBSERVATION", 51, 67], ["length", "OBSERVATION_MODIFIER", 88, 94], ["biggest", "OBSERVATION_MODIFIER", 153, 160], ["viral genome", "OBSERVATION", 168, 180], ["transcription errors", "OBSERVATION", 361, 381]]], ["Such a high mutation rate renders coronaviruses zoonotic pathogens found in humans and a variety of animals with a wide-ranging clinical properties, from an symptomless period to the need for hospital care in the intensive care unit, which causes infections in the respiratory, gastrointestinal, hepatic, and neurologic systems (Desforges et al., 2019; Fehr et al., 2017; Roosa et al., 2020; Rothan and Byrareddy, 2020) .", [["respiratory", "ANATOMY", 265, 276], ["gastrointestinal", "ANATOMY", 278, 294], ["hepatic", "ANATOMY", 296, 303], ["neurologic", "ANATOMY", 309, 319], ["coronaviruses zoonotic pathogens", "DISEASE", 34, 66], ["infections", "DISEASE", 247, 257], ["respiratory, gastrointestinal, hepatic, and neurologic systems", "DISEASE", 265, 327], ["humans", "ORGANISM", 76, 82], ["gastrointestinal", "ANATOMICAL_SYSTEM", 278, 294], ["hepatic", "MULTI-TISSUE_STRUCTURE", 296, 303], ["humans", "SPECIES", 76, 82], ["humans", "SPECIES", 76, 82], ["a high mutation rate", "PROBLEM", 5, 25], ["coronaviruses zoonotic pathogens", "PROBLEM", 34, 66], ["hospital care", "TREATMENT", 192, 205], ["infections in the respiratory, gastrointestinal, hepatic, and neurologic systems", "PROBLEM", 247, 327], ["infections", "OBSERVATION", 247, 257], ["respiratory", "ANATOMY", 265, 276], ["gastrointestinal", "ANATOMY", 278, 294], ["hepatic", "ANATOMY", 296, 303]]], ["The viruses are sometimes capable of causing more severe disease in young, elderly, or immunocompromised people (Rothan and Byrareddy, 2020; Tang et al., 2020) .", [["people", "ORGANISM", 105, 111], ["people", "SPECIES", 105, 111], ["more severe disease", "PROBLEM", 45, 64], ["viruses", "OBSERVATION", 4, 11], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["disease", "OBSERVATION", 57, 64]]], ["These viral strains are subdivided into four major subclasses of alpha, beta, gamma, and delta.", [["alpha", "GENE_OR_GENE_PRODUCT", 65, 70], ["beta", "GENE_OR_GENE_PRODUCT", 72, 76], ["gamma", "GENE_OR_GENE_PRODUCT", 78, 83], ["delta", "GENE_OR_GENE_PRODUCT", 89, 94], ["alpha, beta, gamma, and delta", "PROTEIN", 65, 94], ["These viral strains", "PROBLEM", 0, 19], ["alpha", "TEST", 65, 70], ["viral strains", "OBSERVATION", 6, 19]]], ["Alpha and beta coronaviruses have their mammalian (bats) origins, whereas gamma and delta coronaviruses are of swine and avian origins (Burrell et al., 2017; Tao et al., 2017; Wang et al., 2019) .", [["Alpha", "GENE_OR_GENE_PRODUCT", 0, 5], ["beta", "GENE_OR_GENE_PRODUCT", 10, 14], ["gamma and delta coronaviruses", "ORGANISM", 74, 103], ["Alpha and beta coronaviruses", "PROTEIN", 0, 28], ["swine", "SPECIES", 111, 116], ["swine", "SPECIES", 111, 116], ["Alpha and beta coronaviruses", "PROBLEM", 0, 28], ["beta coronaviruses", "OBSERVATION", 10, 28]]], ["In humans, infection is caused by seven coronaviruses, namely HCoV-229E (alpha coronavirus), HCoV-NL63 (alpha coronavirus), HCoV-OC43 (beta coronavirus), HCoV-HKU1 (beta coronavirus), Middle East Respiratory Syndrome, or MERS-CoV (beta coronavirus), Severe Acute Respiratory Syndrome, or SARS-CoV (beta coronavirus) (Burrell et al., 2017) , and the Novel Coronavirus (2019-nCoV) detected recently in 2019 Lippi et al., 2020) , known as SARS-CoV-2, which causes the Coronavirus Virus Disease of 2019 .", [["infection", "DISEASE", 11, 20], ["Middle East Respiratory Syndrome", "DISEASE", 184, 216], ["MERS-CoV (beta coronavirus)", "DISEASE", 221, 248], ["Acute Respiratory Syndrome", "DISEASE", 257, 283], ["SARS-CoV (beta coronavirus", "DISEASE", 288, 314], ["humans", "ORGANISM", 3, 9], ["HCoV-229E", "ORGANISM", 62, 71], ["alpha coronavirus", "ORGANISM", 73, 90], ["HCoV-NL63", "ORGANISM", 93, 102], ["alpha coronavirus", "ORGANISM", 104, 121], ["HCoV-OC43", "ORGANISM", 124, 133], ["beta coronavirus", "ORGANISM", 135, 151], ["HCoV-HKU1", "ORGANISM", 154, 163], ["beta coronavirus", "ORGANISM", 165, 181], ["Middle East Respiratory", "ORGANISM", 184, 207], ["MERS-CoV", "ORGANISM", 221, 229], ["beta coronavirus", "ORGANISM", 231, 247], ["SARS-CoV", "ORGANISM", 288, 296], ["beta coronavirus", "ORGANISM", 298, 314], ["SARS-CoV-2", "ORGANISM", 436, 446], ["humans", "SPECIES", 3, 9], ["beta coronavirus", "SPECIES", 135, 151], ["beta coronavirus", "SPECIES", 165, 181], ["MERS-CoV", "SPECIES", 221, 229], ["beta coronavirus", "SPECIES", 231, 247], ["beta coronavirus", "SPECIES", 298, 314], ["humans", "SPECIES", 3, 9], ["HCoV-229E (alpha coronavirus", "SPECIES", 62, 90], ["HCoV-NL63 (alpha coronavirus", "SPECIES", 93, 121], ["HCoV-OC43 (beta coronavirus", "SPECIES", 124, 151], ["HCoV-HKU1 (beta coronavirus", "SPECIES", 154, 181], ["Middle East Respiratory Syndrome", "SPECIES", 184, 216], ["MERS-CoV (beta coronavirus", "SPECIES", 221, 247], ["SARS-CoV (beta coronavirus", "SPECIES", 288, 314], ["SARS-CoV-2", "SPECIES", 436, 446], ["infection", "PROBLEM", 11, 20], ["seven coronaviruses", "PROBLEM", 34, 53], ["HCoV", "TEST", 62, 66], ["alpha coronavirus", "TEST", 73, 90], ["HCoV", "TEST", 93, 97], ["alpha coronavirus", "TEST", 104, 121], ["HCoV", "TEST", 124, 128], ["OC43", "TEST", 129, 133], ["beta coronavirus", "TEST", 135, 151], ["HCoV", "TEST", 154, 158], ["HKU1", "PROBLEM", 159, 163], ["beta coronavirus)", "PROBLEM", 165, 182], ["Middle East Respiratory Syndrome", "PROBLEM", 184, 216], ["MERS", "PROBLEM", 221, 225], ["CoV (beta coronavirus)", "PROBLEM", 226, 248], ["Severe Acute Respiratory Syndrome", "PROBLEM", 250, 283], ["SARS", "PROBLEM", 288, 292], ["CoV (beta coronavirus", "PROBLEM", 293, 314], ["the Novel Coronavirus", "PROBLEM", 345, 366], ["CoV", "TEST", 441, 444], ["the Coronavirus Virus Disease", "PROBLEM", 461, 490], ["infection", "OBSERVATION", 11, 20], ["Middle", "ANATOMY_MODIFIER", 184, 190], ["Respiratory Syndrome", "OBSERVATION", 196, 216], ["Severe", "OBSERVATION_MODIFIER", 250, 256], ["Acute", "OBSERVATION_MODIFIER", 257, 262], ["Respiratory Syndrome", "OBSERVATION", 263, 283], ["Coronavirus Virus", "OBSERVATION", 465, 482]]], ["Four of seven common human CoVs (HCoVs) result in common self-limited upper respiratory diseases: HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1 (Chang et al., 2020) .", [["respiratory", "ANATOMY", 76, 87], ["respiratory diseases", "DISEASE", 76, 96], ["human", "ORGANISM", 21, 26], ["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["HCoVs", "GENE_OR_GENE_PRODUCT", 33, 38], ["HCoV-229E", "CELL", 98, 107], ["HCoV-OC43", "CELL", 109, 118], ["HCoV-NL63", "CELL", 120, 129], ["human CoVs", "PROTEIN", 21, 31], ["HCoVs", "PROTEIN", 33, 38], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 21, 26], ["HCoV-229E", "SPECIES", 98, 107], ["limited upper respiratory diseases", "PROBLEM", 62, 96], ["HCoV", "TEST", 98, 102], ["HCoV", "TEST", 109, 113], ["OC43", "TEST", 114, 118], ["HCoV", "TEST", 120, 124], ["HCoV", "TEST", 135, 139], ["upper", "ANATOMY_MODIFIER", 70, 75], ["respiratory", "ANATOMY", 76, 87], ["diseases", "OBSERVATION", 88, 96]]], ["Of more than 60 coronaviruses (CoVs) isolates obtained from bats (BtCoV), the majority belong to the genus betacoronavirus.", [["coronaviruses", "ORGANISM", 16, 29], ["CoVs", "GENE_OR_GENE_PRODUCT", 31, 35], ["betacoronavirus", "CANCER", 107, 122], ["60 coronaviruses (CoVs) isolates", "PROBLEM", 13, 45], ["genus betacoronavirus", "OBSERVATION", 101, 122]]], ["Bats function as huge (and very movable) CoV sources; most of bat species possess their specific exclusive BtCoV, which suggests that they have coevolved over a highly prolonged history (Payne, 2017) .", [["Bats", "CELL", 0, 4], ["bat species", "ORGANISM", 62, 73], ["BtCoV", "GENE_OR_GENE_PRODUCT", 107, 112], ["BtCoV", "PROTEIN", 107, 112], ["huge (and very movable) CoV sources", "PROBLEM", 17, 52], ["bat species", "PROBLEM", 62, 73], ["huge", "OBSERVATION_MODIFIER", 17, 21]]], ["In humans, coronaviruses fall into the range of viruses causing the common cold and also more serious respiratory diseases, specially, severe acute respiratory syndrome (SARS, 2002) and the Middle East respiratory syndrome (MERS, 2014) , both of which are zoonotic diseases initially detected by the culture of viruses from patients with common colds in the mid-1960s (Li et al., 2019; Lu et al., 2020) .The host of SARS-CoV-2As suggested by evolutionary assays by the use of ORF1a/1b, S, and N genes, SARS-CoV-2 is probably a new coronavirus with independent transfer from animals to humans (Chen et al., 2020a; Lai et al., 2020) .", [["respiratory", "ANATOMY", 102, 113], ["respiratory diseases", "DISEASE", 102, 122], ["acute respiratory syndrome", "DISEASE", 142, 168], ["SARS", "DISEASE", 170, 174], ["Middle East respiratory syndrome", "DISEASE", 190, 222], ["zoonotic diseases", "DISEASE", 256, 273], ["colds", "DISEASE", 345, 350], ["humans", "ORGANISM", 3, 9], ["coronaviruses", "ORGANISM", 11, 24], ["patients", "ORGANISM", 324, 332], ["SARS-CoV-2As", "ORGANISM", 416, 428], ["ORF1a/1b", "GENE_OR_GENE_PRODUCT", 476, 484], ["S", "GENE_OR_GENE_PRODUCT", 486, 487], ["SARS-CoV-2", "ORGANISM", 502, 512], ["coronavirus", "ORGANISM", 531, 542], ["humans", "ORGANISM", 585, 591], ["SARS-CoV-2As", "DNA", 416, 428], ["ORF1a/1b, S, and N genes", "DNA", 476, 500], ["humans", "SPECIES", 3, 9], ["patients", "SPECIES", 324, 332], ["humans", "SPECIES", 585, 591], ["humans", "SPECIES", 3, 9], ["SARS-CoV-2As", "SPECIES", 416, 428], ["SARS-CoV", "SPECIES", 502, 510], ["humans", "SPECIES", 585, 591], ["coronaviruses fall", "PROBLEM", 11, 29], ["viruses", "PROBLEM", 48, 55], ["the common cold", "PROBLEM", 64, 79], ["serious respiratory diseases", "PROBLEM", 94, 122], ["severe acute respiratory syndrome", "PROBLEM", 135, 168], ["the Middle East respiratory syndrome", "PROBLEM", 186, 222], ["zoonotic diseases", "PROBLEM", 256, 273], ["the culture", "TEST", 296, 307], ["viruses", "PROBLEM", 311, 318], ["common colds", "PROBLEM", 338, 350], ["SARS", "PROBLEM", 416, 420], ["ORF1a", "TEST", 476, 481], ["SARS", "PROBLEM", 502, 506], ["a new coronavirus", "PROBLEM", 525, 542], ["coronaviruses", "OBSERVATION", 11, 24], ["viruses", "OBSERVATION", 48, 55], ["more", "OBSERVATION_MODIFIER", 89, 93], ["serious", "OBSERVATION_MODIFIER", 94, 101], ["respiratory diseases", "OBSERVATION", 102, 122], ["severe", "OBSERVATION_MODIFIER", 135, 141], ["acute", "OBSERVATION_MODIFIER", 142, 147], ["respiratory syndrome", "OBSERVATION", 148, 168], ["Middle", "ANATOMY_MODIFIER", 190, 196], ["respiratory syndrome", "OBSERVATION", 202, 222], ["zoonotic", "OBSERVATION_MODIFIER", 256, 264], ["diseases", "OBSERVATION", 265, 273], ["new", "OBSERVATION_MODIFIER", 527, 530], ["coronavirus", "OBSERVATION", 531, 542]]], ["A close identity was established between SARS-CoV-2 and two bat-SARS-like CoV (bat-SL-CoV ZC45 and bat-SL-CoV ZXC21), particularly the sequence identities of the E gene in bat-SL-CoV ZC45 (GenBank accession no. MG772933.1). bat-SL-CoVZXC21The host of SARS-CoV-2(GenBank accession no. MG772934.1) existed 98.7% among 13 gene sites, but it was more apart from SARS-CoV (~79 % similarity) and Middle East respiratory syndrome coronavirus (MERS-CoV) (~50% resemblance) (Jiang et al., 2020; Lu et al., 2020; Ren et al., 2020 ).", [["MG772933.1", "CHEMICAL", 211, 221], ["MG772934.1", "CHEMICAL", 284, 294], ["SARS", "DISEASE", 358, 362], ["Middle East respiratory syndrome coronavirus", "DISEASE", 390, 434], ["SARS-CoV-2", "ORGANISM", 41, 51], ["bat-SARS-like CoV", "ORGANISM", 60, 77], ["bat-SL-CoV ZC45", "ORGANISM", 79, 94], ["bat-SL-CoV ZXC21", "ORGANISM", 99, 115], ["E", "GENE_OR_GENE_PRODUCT", 162, 163], ["bat-SL-CoV ZC45", "ORGANISM", 172, 187], ["SARS-CoV-2", "ORGANISM", 251, 261], ["SARS-CoV", "ORGANISM", 358, 366], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 390, 434], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 436, 444], ["SARS-like CoV (bat-SL-CoV ZC45", "DNA", 64, 94], ["bat", "DNA", 99, 102], ["SL", "DNA", 103, 105], ["CoV ZXC21", "DNA", 106, 115], ["E gene", "DNA", 162, 168], ["bat-SL-CoV ZC45", "DNA", 172, 187], ["SARS-CoV-2", "DNA", 251, 261], ["13 gene sites", "DNA", 316, 329], ["SARS-CoV", "SPECIES", 41, 49], ["bat-SL-CoV", "SPECIES", 172, 182], ["SARS-CoV", "SPECIES", 251, 259], ["SARS-CoV", "SPECIES", 358, 366], ["Middle East respiratory syndrome coronavirus", "SPECIES", 390, 434], ["MERS-CoV", "SPECIES", 436, 444], ["A close identity", "TEST", 0, 16], ["SARS", "TEST", 41, 45], ["CoV", "TEST", 46, 49], ["two bat", "TEST", 56, 63], ["SARS", "TEST", 64, 68], ["CoV", "TEST", 74, 77], ["bat", "TEST", 79, 82], ["SL", "TEST", 83, 85], ["ZC45", "TEST", 90, 94], ["bat", "TEST", 99, 102], ["SL-CoV ZXC21)", "TREATMENT", 103, 116], ["SARS", "PROBLEM", 358, 362], ["CoV", "TEST", 363, 366], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 390, 434], ["Middle", "ANATOMY_MODIFIER", 390, 396], ["respiratory syndrome", "OBSERVATION", 402, 422]]], ["An analysis of data obtained from the initial outburst using a full-length genome study revealed that the SARS-CoV-2 sequence had a 79.5 % sequence identity in common with SARS-CoV (Zhou et al., 2020) .The host of SARS-CoV-2Sequence and phylogenetic analyses illustrated that SARS-CoV-2 had a longer spike protein, a dissimilar relative phylogeny of the complete RNA-reliant RNA polymerase gene, and a differing apparent genetic distance (Ahmed et al., 2020; Zhou et al., 2020) , indicating that SARS-CoV-2 is a novel betacoronavirus, not the SARS-CoV (Ahmed et al., 2020) .", [["SARS", "DISEASE", 106, 110], ["SARS", "DISEASE", 172, 176], ["SARS", "DISEASE", 496, 500], ["SARS-CoV", "ORGANISM", 214, 222], ["SARS-CoV-2", "ORGANISM", 276, 286], ["SARS-CoV-2", "ORGANISM", 496, 506], ["betacoronavirus", "CANCER", 518, 533], ["SARS-CoV", "ORGANISM", 543, 551], ["SARS-CoV-2 sequence", "DNA", 106, 125], ["SARS-CoV-2Sequence", "DNA", 214, 232], ["SARS-CoV-2", "DNA", 276, 286], ["RNA polymerase gene", "DNA", 375, 394], ["SARS-CoV", "SPECIES", 106, 114], ["SARS-CoV", "SPECIES", 172, 180], ["SARS-CoV", "SPECIES", 214, 222], ["SARS-CoV", "SPECIES", 276, 284], ["SARS-CoV", "SPECIES", 496, 504], ["SARS-CoV", "SPECIES", 543, 551], ["An analysis of data", "TEST", 0, 19], ["a full-length genome study", "TEST", 61, 87], ["the SARS", "TEST", 102, 110], ["SARS", "TEST", 214, 218], ["CoV", "TEST", 219, 222], ["phylogenetic analyses", "TEST", 237, 258], ["SARS", "TEST", 276, 280], ["CoV", "TEST", 281, 284], ["a longer spike protein", "PROBLEM", 291, 313], ["SARS", "PROBLEM", 496, 500], ["a novel betacoronavirus", "PROBLEM", 510, 533]]], ["Nevertheless, SARS-CoV-2 and SARS have a common ancestor to the bat HKU9-1 coronavirus (Xu et al., 2020c) .", [["SARS", "DISEASE", 29, 33], ["SARS-CoV-2", "ORGANISM", 14, 24], ["bat", "ORGANISM", 64, 67], ["HKU9-1 coronavirus", "ORGANISM", 68, 86], ["HKU9-1 coronavirus", "SPECIES", 68, 86], ["SARS-CoV", "SPECIES", 14, 22], ["bat HKU9-1 coronavirus", "SPECIES", 64, 86], ["SARS", "TEST", 14, 18], ["CoV", "TEST", 19, 22], ["SARS", "PROBLEM", 29, 33]]], ["In Wuhan, SARS-CoV-2 is a member of the genera beta coronavirus and genome analysis indicates that SARS-CoV-2 has closer relations to bat-SARS-like (SL)-ZC45 and bat-SL-ZXC21 (Zhou et al., 2020) .", [["SARS", "DISEASE", 10, 14], ["SARS-CoV-2", "ORGANISM", 10, 20], ["beta coronavirus", "ORGANISM", 47, 63], ["SARS-CoV-2", "ORGANISM", 99, 109], ["bat-SARS-like (SL)-ZC45", "ORGANISM", 134, 157], ["bat", "ORGANISM", 162, 165], ["SARS-CoV", "SPECIES", 10, 18], ["beta coronavirus", "SPECIES", 47, 63], ["SARS-CoV", "SPECIES", 99, 107], ["the genera beta coronavirus", "PROBLEM", 36, 63], ["genome analysis", "TEST", 68, 83], ["SARS", "PROBLEM", 99, 103], ["SARS", "PROBLEM", 138, 142], ["bat", "ANATOMY", 162, 165]]], ["Even so, the dissimilarities are also possibly suggestive of additional intermediate hosts present between bats and humans.", [["humans", "ORGANISM", 116, 122], ["humans", "SPECIES", 116, 122], ["humans", "SPECIES", 116, 122], ["possibly suggestive of", "UNCERTAINTY", 38, 60], ["intermediate hosts", "OBSERVATION", 72, 90]]], ["An investigational group observed that 70% of pangolins possessed \u03b2-CoV.", [["pangolins", "GENE_OR_GENE_PRODUCT", 46, 55], ["\u03b2-CoV", "GENE_OR_GENE_PRODUCT", 66, 71], ["\u03b2-CoV", "PROTEIN", 66, 71], ["\u03b2-CoV", "SPECIES", 66, 71], ["CoV", "PROBLEM", 68, 71]]], ["A coronavirus isolate obtained from the pangolins contained a genome with a high similarity to that from SARS-CoV-2, and a genome sequence resemblance of 99 % indicates that pangolin is likely the intermediate host of SARS-CoV-2 (Peng et al., 2020b) .Diseases caused by CoronavirusesAmong the seven subtypes of coronaviruses capable of infecting humans, beta-coronaviruses can possibly induce serious disease and mortalities.", [["SARS", "DISEASE", 105, 109], ["pangolin", "CHEMICAL", 174, 182], ["SARS", "DISEASE", 218, 222], ["Diseases", "DISEASE", 251, 259], ["coronavirus", "ORGANISM", 2, 13], ["pangolins", "GENE_OR_GENE_PRODUCT", 40, 49], ["SARS-CoV-2", "ORGANISM", 105, 115], ["pangolin", "GENE_OR_GENE_PRODUCT", 174, 182], ["SARS-CoV-2", "ORGANISM", 218, 228], ["coronaviruses", "ORGANISM", 311, 324], ["humans", "ORGANISM", 346, 352], ["beta-coronaviruses", "GENE_OR_GENE_PRODUCT", 354, 372], ["pangolins", "DNA", 40, 49], ["SARS-CoV-2", "DNA", 105, 115], ["coronavirus", "SPECIES", 2, 13], ["humans", "SPECIES", 346, 352], ["A coronavirus", "SPECIES", 0, 13], ["SARS-CoV", "SPECIES", 105, 113], ["SARS-CoV", "SPECIES", 218, 226], ["humans", "SPECIES", 346, 352], ["A coronavirus isolate", "TEST", 0, 21], ["SARS", "TEST", 105, 109], ["CoV", "TEST", 110, 113], ["a genome sequence resemblance", "TEST", 121, 150], ["CoV", "TEST", 223, 226], ["Diseases", "PROBLEM", 251, 259], ["Coronaviruses", "PROBLEM", 270, 283], ["coronaviruses", "PROBLEM", 311, 324], ["infecting humans", "PROBLEM", 336, 352], ["serious disease and mortalities", "PROBLEM", 393, 424], ["coronavirus isolate", "OBSERVATION", 2, 21], ["Coronaviruses", "OBSERVATION", 270, 283], ["coronaviruses", "OBSERVATION", 311, 324]]], ["The initial isolates of coronaviruses were obtained from fowls with respiratory disease (infective bronchitis) in the 1930s (Burrell et al., 2017) .", [["respiratory", "ANATOMY", 68, 79], ["respiratory disease", "DISEASE", 68, 87], ["infective bronchitis", "DISEASE", 89, 109], ["coronaviruses", "ORGANISM", 24, 37], ["fowls", "ORGANISM_SUBDIVISION", 57, 62], ["fowls", "SPECIES", 57, 62], ["coronaviruses", "PROBLEM", 24, 37], ["respiratory disease (infective bronchitis", "PROBLEM", 68, 109], ["coronaviruses", "OBSERVATION", 24, 37], ["respiratory disease", "OBSERVATION", 68, 87], ["infective", "OBSERVATION_MODIFIER", 89, 98], ["bronchitis", "OBSERVATION", 99, 109]]], ["Until 2002, human coronaviruses (HCoVs) were linked only to mild respiratory tract disease, which were estimated to cause 15 %-25 % of the entire common colds (Geller et al., 2012) .", [["respiratory tract", "ANATOMY", 65, 82], ["respiratory tract disease", "DISEASE", 65, 90], ["colds", "DISEASE", 153, 158], ["human", "ORGANISM", 12, 17], ["coronaviruses", "ORGANISM", 18, 31], ["HCoVs", "CANCER", 33, 38], ["tract", "ORGANISM_SUBDIVISION", 77, 82], ["human", "SPECIES", 12, 17], ["human coronaviruses", "SPECIES", 12, 31], ["HCoVs", "SPECIES", 33, 38], ["mild respiratory tract disease", "PROBLEM", 60, 90], ["mild", "OBSERVATION_MODIFIER", 60, 64], ["respiratory tract", "ANATOMY", 65, 82]]], ["This underwent a change in 2002 upon identification of a human coronavirus as the causative agent of an emerging disease named SARS.", [["coronavirus", "DISEASE", 63, 74], ["SARS", "DISEASE", 127, 131], ["human", "ORGANISM", 57, 62], ["human", "SPECIES", 57, 62], ["human coronavirus", "SPECIES", 57, 74], ["a human coronavirus", "PROBLEM", 55, 74]]], ["The SARS spread was taken under control, but a different new CoV isolate was collected from patients admitted to hospitals with severe respiratory disease in Saudi Arabia during 2014 (Fehr et al., 2017; Roosa et al., 2020; Zumla and Hui, 2014) .", [["respiratory", "ANATOMY", 135, 146], ["SARS", "DISEASE", 4, 8], ["respiratory disease", "DISEASE", 135, 154], ["CoV", "ORGANISM", 61, 64], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["The SARS spread", "PROBLEM", 0, 15], ["a different new CoV isolate", "PROBLEM", 45, 72], ["severe respiratory disease", "PROBLEM", 128, 154], ["severe", "OBSERVATION_MODIFIER", 128, 134], ["respiratory disease", "OBSERVATION", 135, 154]]], ["Since the majority of affected patients were the inhabitants or travellers to Middle East countries, the newly detected disease was termed MERS and the causative coronavirus was named HCoV-MERS (Zumla and Hui, 2014) .", [["patients", "ORGANISM", 31, 39], ["coronavirus", "ORGANISM", 162, 173], ["patients", "SPECIES", 31, 39], ["the newly detected disease", "PROBLEM", 101, 127], ["the causative coronavirus", "PROBLEM", 148, 173], ["disease", "OBSERVATION", 120, 127]]], ["The transmission of most animal and human CoVs occurs via the faecal-oral path, and their primary proliferation place is in epithelial cells, in which virus reproduction induces local respiratory symptoms or diarrhoea (Burrell et al., 2017 ).", [["oral", "ANATOMY", 69, 73], ["epithelial cells", "ANATOMY", 124, 140], ["respiratory", "ANATOMY", 184, 195], ["respiratory symptoms", "DISEASE", 184, 204], ["diarrhoea", "DISEASE", 208, 217], ["human", "ORGANISM", 36, 41], ["CoVs", "GENE_OR_GENE_PRODUCT", 42, 46], ["faecal", "ORGANISM_SUBSTANCE", 62, 68], ["oral", "ORGANISM_SUBDIVISION", 69, 73], ["epithelial cells", "CELL", 124, 140], ["epithelial cells", "CELL_TYPE", 124, 140], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["human CoVs", "PROBLEM", 36, 46], ["epithelial cells", "PROBLEM", 124, 140], ["local respiratory symptoms", "PROBLEM", 178, 204], ["diarrhoea", "PROBLEM", 208, 217], ["primary proliferation", "OBSERVATION", 90, 111], ["epithelial cells", "OBSERVATION", 124, 140]]], ["Additionally, these viruses are able to induce co-infection in the situation of public-derived bacterial pneumonia (Lai et al., 2020) .The transmission routesDue to the relationship of the SARS-CoV-2 to the genus betacoronavirus, the diseases and transmission paths for the genus are depicted in Figure 1 . and not yet confirmed) (Burrell et al., 2017; MacLachlan and Dubovi, 2017) for betacronovirus except SARS-CoV-2The transmission routesThe usual spread paths of the novel coronavirus are spreading directly (cough, sneeze, and droplet inhalation transmission) and contact transmission (contact with oral, nasal, and eye mucous membranes) (Otter et al., 2016; Peng et al., 2020b; Tellier et al., 2019) .", [["oral", "ANATOMY", 604, 608], ["nasal", "ANATOMY", 610, 615], ["eye mucous membranes", "ANATOMY", 621, 641], ["co-infection", "DISEASE", 47, 59], ["pneumonia", "DISEASE", 105, 114], ["SARS", "DISEASE", 189, 193], ["coronavirus", "DISEASE", 477, 488], ["cough", "DISEASE", 513, 518], ["SARS-CoV-2", "ORGANISM", 189, 199], ["coronavirus", "ORGANISM", 477, 488], ["oral", "ORGANISM_SUBDIVISION", 604, 608], ["nasal", "MULTI-TISSUE_STRUCTURE", 610, 615], ["eye mucous membranes", "MULTI-TISSUE_STRUCTURE", 621, 641], ["coronavirus", "SPECIES", 477, 488], ["SARS-CoV", "SPECIES", 189, 197], ["these viruses", "PROBLEM", 14, 27], ["co-infection", "PROBLEM", 47, 59], ["public-derived bacterial pneumonia", "PROBLEM", 80, 114], ["the SARS", "PROBLEM", 185, 193], ["the genus betacoronavirus", "PROBLEM", 203, 228], ["the diseases", "PROBLEM", 230, 242], ["betacronovirus", "PROBLEM", 386, 400], ["SARS-CoV", "PROBLEM", 408, 416], ["the novel coronavirus", "PROBLEM", 467, 488], ["viruses", "OBSERVATION", 20, 27], ["bacterial", "OBSERVATION_MODIFIER", 95, 104], ["pneumonia", "OBSERVATION", 105, 114], ["genus betacoronavirus", "ANATOMY", 207, 228], ["diseases", "OBSERVATION", 234, 242], ["nasal", "ANATOMY", 610, 615], ["eye", "ANATOMY", 621, 624], ["mucous membranes", "ANATOMY", 625, 641]]], ["Eye contact can likely pave the ground effectively for the viral entry into the body (Peng et al., 2020a; Peng et al., 2020b; .", [["body", "ANATOMY", 80, 84], ["body", "ORGANISM_SUBDIVISION", 80, 84], ["body", "ANATOMY", 80, 84]]], ["Despite an insignificant risk of contract with SARS-CoV-2 from the faeces of a patient, there are proofs indicating that SARS-CoV-2 is likely to result in enteric contagion and be found in faeces (Gu et al., 2020) .", [["faeces", "ANATOMY", 67, 73], ["SARS", "DISEASE", 47, 51], ["SARS", "DISEASE", 121, 125], ["enteric contagion", "DISEASE", 155, 172], ["CoV-2", "ORGANISM", 52, 57], ["faeces", "ORGANISM_SUBDIVISION", 67, 73], ["patient", "ORGANISM", 79, 86], ["SARS-CoV-2", "ORGANISM", 121, 131], ["faeces", "ORGANISM_SUBSTANCE", 189, 195], ["patient", "SPECIES", 79, 86], ["SARS-CoV", "SPECIES", 47, 55], ["SARS", "PROBLEM", 47, 51], ["SARS", "PROBLEM", 121, 125], ["enteric contagion", "PROBLEM", 155, 172], ["insignificant", "OBSERVATION_MODIFIER", 11, 24]]], ["About 2-10% of patients with established COVID-19 manifested with diarrhoea two reports indicated that SARS-CoV-2 viral RNA segments were detected in the stool of COVID-19 patients (Chen et al., 2020b; Huang et al., 2020; Wang et al., 2020a; Wang et al., 2019) .", [["stool", "ANATOMY", 154, 159], ["diarrhoea", "DISEASE", 66, 75], ["SARS", "DISEASE", 103, 107], ["patients", "ORGANISM", 15, 23], ["SARS-CoV-2", "ORGANISM", 103, 113], ["stool", "ORGANISM_SUBSTANCE", 154, 159], ["patients", "ORGANISM", 172, 180], ["SARS-CoV-2 viral RNA segments", "DNA", 103, 132], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 172, 180], ["COVID", "TEST", 41, 46], ["diarrhoea", "PROBLEM", 66, 75], ["SARS", "PROBLEM", 103, 107], ["CoV", "TEST", 108, 111], ["2 viral RNA segments", "PROBLEM", 112, 132], ["stool", "ANATOMY", 154, 159]]], ["Up to now, there is only one report on the culture of SARS-CoV-2 from a single stool sample (Holshue et al., 2020) .", [["stool sample", "ANATOMY", 79, 91], ["SARS", "DISEASE", 54, 58], ["SARS-CoV-2", "ORGANISM", 54, 64], ["SARS-CoV", "SPECIES", 54, 62], ["the culture", "TEST", 39, 50], ["SARS", "PROBLEM", 54, 58], ["CoV", "TEST", 59, 62], ["a single stool sample", "TEST", 70, 91]]], ["Investigations observing viral nucleic acids in these patients, additional studies are required to discover the existence of viral elements and nucleic acid levels for demonstrating faecal-oral contagion (Xiao et al., 2020) .The transmission routesMoreover, research has demonstrated that respiratory viruses are transmittable among individuals via contacting directly or indirectly, or coarse or small droplets, and SARS-CoV-2 is transmittable through direct or indirect salivary route .", [["oral", "ANATOMY", 189, 193], ["salivary", "ANATOMY", 472, 480], ["nucleic acids", "CHEMICAL", 31, 44], ["nucleic acid", "CHEMICAL", 144, 156], ["faecal-oral contagion", "DISEASE", 182, 203], ["respiratory viruses", "DISEASE", 289, 308], ["SARS", "DISEASE", 417, 421], ["patients", "ORGANISM", 54, 62], ["nucleic acid", "SIMPLE_CHEMICAL", 144, 156], ["faecal", "ORGANISM_SUBDIVISION", 182, 188], ["oral", "ORGANISM_SUBDIVISION", 189, 193], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 417, 427], ["salivary route", "MULTI-TISSUE_STRUCTURE", 472, 486], ["viral elements", "DNA", 125, 139], ["patients", "SPECIES", 54, 62], ["Investigations", "TEST", 0, 14], ["viral nucleic acids", "TEST", 25, 44], ["additional studies", "TEST", 64, 82], ["viral elements", "PROBLEM", 125, 139], ["nucleic acid levels", "TEST", 144, 163], ["respiratory viruses", "PROBLEM", 289, 308], ["coarse or small droplets", "PROBLEM", 387, 411], ["SARS", "TEST", 417, 421], ["CoV", "TEST", 422, 425], ["viral elements", "OBSERVATION", 125, 139], ["respiratory viruses", "OBSERVATION", 289, 308], ["small", "OBSERVATION_MODIFIER", 397, 402], ["droplets", "OBSERVATION", 403, 411]]], ["As shown by a study in 2010, the likelihood of transmitting influenza by aerosols could be reduced by improving ventilation design and prevention of generating aerosols (Wong et al., 2010) .", [["influenza", "DISEASE", 60, 69], ["influenza", "ORGANISM", 60, 69], ["a study", "TEST", 12, 19], ["transmitting influenza by aerosols", "PROBLEM", 47, 81], ["influenza", "OBSERVATION", 60, 69]]], ["Research suggests that SARS-CoV-2 is probably air-transmitted via aerosols produce during therapeutic actions (Huang et al., 2020; van Doremalen et al., 2020; Wax and Christian, 2020) .", [["SARS", "DISEASE", 23, 27], ["SARS-CoV-2", "ORGANISM", 23, 33], ["SARS", "PROBLEM", 23, 27], ["SARS", "OBSERVATION", 23, 27], ["probably", "UNCERTAINTY", 37, 45]]], ["Remarkably, a case of 2019-nCoV infection reported in Germany reveals that SARS-CoV-2 may also transmitted via contacting with symptomless patients (Rothe et al., 2020) .", [["infection", "DISEASE", 32, 41], ["SARS", "DISEASE", 75, 79], ["2019-nCoV", "ORGANISM", 22, 31], ["SARS-CoV-2", "ORGANISM", 75, 85], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["SARS-CoV", "SPECIES", 75, 83], ["nCoV infection", "PROBLEM", 27, 41], ["infection", "OBSERVATION", 32, 41]]], ["Even so, transmissions through aerosol and faecal-oral routes are those making people concerned, necessitating to be confirmed with additional studies.", [["oral", "ANATOMY", 50, 54], ["oral", "ORGANISM_SUBDIVISION", 50, 54], ["people", "ORGANISM", 79, 85], ["people", "SPECIES", 79, 85], ["aerosol and faecal", "TREATMENT", 31, 49], ["additional studies", "TEST", 132, 150]]], ["Fomite transmission, i.e. viral dissemination via a material, including a door handgrip, door-bell, or inhalator, also has a critical contribution to the virus spread (Kraay et al., 2018; WHO, 2020) .", [["the virus spread", "PROBLEM", 150, 166], ["viral dissemination", "OBSERVATION", 26, 45]]], ["Additionally, postnatal infection with SARS-CoV-2-borne pneumonia in neonates could be boosted by the contact levels of faecal infection, aerosol transmission, and contacting closely with the mother (Meng et al., 2020) .", [["faecal", "ANATOMY", 120, 126], ["infection", "DISEASE", 24, 33], ["SARS", "DISEASE", 39, 43], ["pneumonia", "DISEASE", 56, 65], ["faecal infection", "DISEASE", 120, 136], ["SARS-CoV-2", "ORGANISM", 39, 49], ["neonates", "ORGANISM", 69, 77], ["faecal", "ORGANISM_SUBSTANCE", 120, 126], ["CoV-2", "SPECIES", 44, 49], ["SARS-CoV", "SPECIES", 39, 47], ["postnatal infection", "PROBLEM", 14, 33], ["SARS", "PROBLEM", 39, 43], ["CoV", "PROBLEM", 44, 47], ["borne pneumonia in neonates", "PROBLEM", 50, 77], ["faecal infection", "PROBLEM", 120, 136], ["aerosol transmission", "TREATMENT", 138, 158], ["postnatal", "OBSERVATION_MODIFIER", 14, 23], ["infection", "OBSERVATION", 24, 33], ["pneumonia", "OBSERVATION", 56, 65], ["faecal infection", "OBSERVATION", 120, 136]]], ["Up to now, no investigations are available reporting COVID-19 transmission via exposure to blood (Zhou et al., 2020) .Environmental transmission possibilityBesides public movement and person-to-person connections, viral contagion and survivability can be impacted by environmental players (e.g., influenza), but no research has yet studied the topic about this new pathogen.", [["blood", "ANATOMY", 91, 96], ["viral contagion", "DISEASE", 214, 229], ["influenza", "DISEASE", 296, 305], ["COVID-19", "GENE_OR_GENE_PRODUCT", 53, 61], ["blood", "ORGANISM_SUBSTANCE", 91, 96], ["person", "SPECIES", 184, 190], ["COVID", "TEST", 53, 58], ["influenza", "PROBLEM", 296, 305], ["this new pathogen", "PROBLEM", 356, 373], ["possibility", "UNCERTAINTY", 145, 156]]], ["Absolute humidity, described as the water content in ambient air, is a robust determining factor in the environment for other viral spreads (Hoseinzadeh et al., 2017; Wolkoff, 2018; Yang and Marr, 2012) .", [["Absolute humidity", "PROBLEM", 0, 17], ["ambient air", "OBSERVATION", 53, 64]]], ["For instance, influenza viruses live lengthier on surfaces or in droplets in cold and dry air, which increases the possibility of succeeding contagion.", [["lengthier", "CHEMICAL", 37, 46], ["influenza viruses", "ORGANISM", 14, 31], ["influenza viruses", "PROBLEM", 14, 31], ["air", "OBSERVATION", 90, 93]]], ["It is, therefore, imperative to apprehend the impacts of environmental elements on the progressive outburst to endorse making decisions on controlling the disease, particularly in places in which there is a likely underestimation of the transmission risk, including in moist and warmer areas.", [["the disease", "PROBLEM", 151, 162], ["the transmission risk", "PROBLEM", 233, 254], ["disease", "OBSERVATION", 155, 162], ["likely", "UNCERTAINTY", 207, 213], ["underestimation", "OBSERVATION_MODIFIER", 214, 229], ["moist", "OBSERVATION_MODIFIER", 269, 274]]], ["This paper focuses on drinking water, sewage systems, solid waste, and ambient air as potential paths of contagion in the environment.Transmission by drinking waterAs a tiny infective agent, a virus proliferates only within the organismal living cells but not within contaminated cells, or in the event of contaminating cells.", [["cells", "ANATOMY", 246, 251], ["cells", "ANATOMY", 280, 285], ["cells", "ANATOMY", 320, 325], ["cells", "CELL", 246, 251], ["cells", "CELL", 280, 285], ["cells", "CELL", 320, 325], ["organismal living cells", "CELL_TYPE", 228, 251], ["contaminated cells", "CELL_TYPE", 267, 285], ["contaminating cells", "CELL_TYPE", 306, 325], ["solid waste", "TREATMENT", 54, 65], ["a tiny infective agent", "PROBLEM", 167, 189], ["a virus proliferates", "PROBLEM", 191, 211], ["contaminating cells", "PROBLEM", 306, 325], ["tiny", "OBSERVATION_MODIFIER", 169, 173], ["infective", "OBSERVATION_MODIFIER", 174, 183], ["organismal living cells", "OBSERVATION", 228, 251], ["contaminated cells", "OBSERVATION", 267, 285], ["contaminating cells", "OBSERVATION", 306, 325]]], ["Viruses are found independently in the form of particles.", [["Viruses", "PROBLEM", 0, 7], ["particles", "OBSERVATION", 47, 56]]], ["Waterborne viruses are different with regard to their genome contents and capsid proteins, but such viruses have some common attributes making them of specific interest concerning the risk of disease endemics related to drinking water infections (Gall et al., 2015) .", [["infections", "DISEASE", 235, 245], ["capsid proteins", "PROTEIN", 74, 89], ["Waterborne viruses", "PROBLEM", 0, 18], ["capsid proteins", "PROBLEM", 74, 89], ["such viruses", "PROBLEM", 95, 107], ["disease endemics", "PROBLEM", 192, 208], ["viruses", "OBSERVATION", 11, 18], ["capsid proteins", "OBSERVATION", 74, 89], ["disease", "OBSERVATION", 192, 199]]], ["Water-spread viral pathogens, categorized in terms of moderate to high health importance by the WHO, consist of adenovirus, astrovirus, hepatitis A and E viruses, rotavirus, norovirus, and other caliciviruses, as well as enteroviruses including coxsackieviruses and polioviruses (Gall et al., 2015) .", [["astrovirus, hepatitis A", "DISEASE", 124, 147], ["rotavirus, norovirus, and other caliciviruses", "DISEASE", 163, 208], ["enteroviruses", "DISEASE", 221, 234], ["adenovirus", "ORGANISM", 112, 122], ["astrovirus", "ORGANISM", 124, 134], ["hepatitis A and E viruses", "ORGANISM", 136, 161], ["rotavirus", "ORGANISM", 163, 172], ["norovirus", "ORGANISM", 174, 183], ["enteroviruses", "ORGANISM", 221, 234], ["hepatitis A", "SPECIES", 136, 147], ["E viruses", "SPECIES", 152, 161], ["Water-spread viral pathogens", "PROBLEM", 0, 28], ["adenovirus", "PROBLEM", 112, 122], ["astrovirus", "PROBLEM", 124, 134], ["hepatitis A", "PROBLEM", 136, 147], ["E viruses", "PROBLEM", 152, 161], ["rotavirus", "PROBLEM", 163, 172], ["norovirus", "PROBLEM", 174, 183], ["other caliciviruses", "PROBLEM", 189, 208], ["enteroviruses", "PROBLEM", 221, 234], ["coxsackieviruses", "PROBLEM", 245, 261], ["polioviruses", "PROBLEM", 266, 278], ["moderate", "OBSERVATION_MODIFIER", 54, 62]]], ["Also, viruses of urine urinary excretion (e.g. polyomaviruses and cytomegalovirus) have the potential to be disseminated via water (Gall et al., 2015; Goetsch et al., 2018; WHO, 2011) .", [["urine urinary", "ANATOMY", 17, 30], ["urine", "ORGANISM_SUBSTANCE", 17, 22], ["urinary", "ORGANISM_SUBSTANCE", 23, 30], ["polyomaviruses", "ORGANISM", 47, 61], ["cytomegalovirus", "ORGANISM", 66, 81], ["urine urinary excretion", "TEST", 17, 40], ["polyomaviruses", "PROBLEM", 47, 61], ["cytomegalovirus", "PROBLEM", 66, 81], ["viruses", "OBSERVATION", 6, 13], ["urine urinary", "ANATOMY", 17, 30]]], ["Other viruses (e.g. influenza and coronaviruses) have been considered as organisms being transmittable via drinking water, but there is indecisive evidence (Gall et al., 2015; WHO, 2011) .", [["influenza and coronaviruses", "DISEASE", 20, 47], ["coronaviruses", "ORGANISM", 34, 47], ["Other viruses", "PROBLEM", 0, 13], ["influenza", "PROBLEM", 20, 29], ["coronaviruses", "PROBLEM", 34, 47], ["organisms", "PROBLEM", 73, 82], ["viruses", "OBSERVATION", 6, 13], ["Gall", "ANATOMY", 157, 161]]], ["Besides, the COVID-19 virus has not been shown to be present in drinking water sources, and existing documentation indicate a low risk to water sources (WHO, 2020).Transmission by drinking waterExtreme numbers of viruses are excreted in fecal matter even in a symptomless manner.", [["fecal matter", "ANATOMY", 237, 249], ["COVID-19 virus", "ORGANISM", 13, 27], ["COVID-19 virus", "SPECIES", 13, 27], ["the COVID-19 virus", "PROBLEM", 9, 27], ["viruses", "PROBLEM", 213, 220], ["viruses", "OBSERVATION", 213, 220], ["fecal matter", "OBSERVATION_MODIFIER", 237, 249]]], ["For instance, up to 10 11 norovirus particles are detectable per gram of faeces (Gall et al., 2015) .Transmission by drinking waterAdditionally, non-enfold viruses can survive in water for prolonged time-periods (Firquet et al., 2015; Pinon and Vialette, 2018) .", [["norovirus", "ORGANISM", 26, 35], ["faeces", "ORGANISM_SUBSTANCE", 73, 79], ["non-enfold viruses", "PROBLEM", 145, 163], ["Gall", "ANATOMY", 81, 85]]], ["With taking account of these features, insufficient sanitization of faecal-infected drinking water facilitates endemics of viral gastroenteritis from consumption.Transmission by drinking waterRemarkably, drinking water is also capable of transmitting viruses through inhalation or aspiration (e.g., water-bathing) or contacting with skin and eyes (e.g., swimming), which cause respiratory and ophthalmic contaminations (Pinon and Vialette, 2018) .", [["skin", "ANATOMY", 333, 337], ["eyes", "ANATOMY", 342, 346], ["respiratory", "ANATOMY", 377, 388], ["viral gastroenteritis", "DISEASE", 123, 144], ["respiratory and ophthalmic contaminations", "DISEASE", 377, 418], ["faecal", "ORGANISM_SUBSTANCE", 68, 74], ["skin", "ORGAN", 333, 337], ["eyes", "ORGAN", 342, 346], ["these features", "PROBLEM", 23, 37], ["insufficient sanitization of faecal", "PROBLEM", 39, 74], ["viral gastroenteritis", "PROBLEM", 123, 144], ["aspiration", "PROBLEM", 281, 291], ["respiratory and ophthalmic contaminations", "PROBLEM", 377, 418], ["viral gastroenteritis", "OBSERVATION", 123, 144], ["aspiration", "OBSERVATION", 281, 291], ["skin", "ANATOMY", 333, 337], ["eyes", "ANATOMY", 342, 346], ["respiratory", "ANATOMY", 377, 388]]], ["COVID-19 virus is an encased virus with a brittle exterior membrane.", [["membrane", "ANATOMY", 59, 67], ["COVID-19 virus", "ORGANISM", 0, 14], ["exterior membrane", "CELLULAR_COMPONENT", 50, 67], ["COVID-19 virus", "SPECIES", 0, 14], ["COVID", "TEST", 0, 5], ["virus", "PROBLEM", 9, 14], ["an encased virus", "PROBLEM", 18, 34], ["a brittle exterior membrane", "PROBLEM", 40, 67], ["19 virus", "OBSERVATION_MODIFIER", 6, 14], ["encased", "OBSERVATION_MODIFIER", 21, 28], ["virus", "OBSERVATION", 29, 34], ["brittle", "OBSERVATION_MODIFIER", 42, 49], ["exterior membrane", "OBSERVATION", 50, 67]]], ["Encased viruses have in general less environmental stability with more susceptibility to such oxidants as chlorine (Pinon and Vialette, 2018) .", [["chlorine", "CHEMICAL", 106, 114], ["Pinon", "CHEMICAL", 116, 121], ["chlorine", "CHEMICAL", 106, 114], ["Pinon", "CHEMICAL", 116, 121], ["chlorine", "SIMPLE_CHEMICAL", 106, 114], ["Encased viruses", "PROBLEM", 0, 15], ["chlorine", "TREATMENT", 106, 114], ["viruses", "OBSERVATION", 8, 15], ["less environmental", "OBSERVATION_MODIFIER", 32, 50], ["stability", "OBSERVATION_MODIFIER", 51, 60]]], ["Although no documentation is available hitherto on the COVID-19 virus survivability in water or sewerage (WHO, 2020), the virus can probably be deactivated considerably quicker than non-encased human intestinal viruses (e.g., adenovirus, norovirus, rotavirus, and hepatitis A) with confirmed transmission ability through water.", [["intestinal", "ANATOMY", 200, 210], ["norovirus, rotavirus, and hepatitis A", "DISEASE", 238, 275], ["COVID-19 virus", "ORGANISM", 55, 69], ["human", "ORGANISM", 194, 199], ["intestinal viruses", "ORGANISM", 200, 218], ["adenovirus", "ORGANISM", 226, 236], ["norovirus", "ORGANISM", 238, 247], ["rotavirus", "ORGANISM", 249, 258], ["hepatitis A", "ORGANISM", 264, 275], ["human", "SPECIES", 194, 199], ["COVID-19 virus", "SPECIES", 55, 69], ["human", "SPECIES", 194, 199], ["adenovirus", "SPECIES", 226, 236], ["rotavirus", "SPECIES", 249, 258], ["hepatitis A", "SPECIES", 264, 275], ["the COVID", "TEST", 51, 60], ["the virus", "PROBLEM", 118, 127], ["non-encased human intestinal viruses", "PROBLEM", 182, 218], ["adenovirus", "PROBLEM", 226, 236], ["norovirus", "PROBLEM", 238, 247], ["rotavirus", "PROBLEM", 249, 258], ["intestinal viruses", "ANATOMY", 200, 218]]], ["Heller et al by considering the detection of SARS-CoV-2 in stools and sewage, proposed the faecal-oral transmission of COVID-19 from environment to human (Heller et al., 2020) .", [["oral", "ANATOMY", 98, 102], ["SARS", "DISEASE", 45, 49], ["COVID-19", "CHEMICAL", 119, 127], ["SARS-CoV-2", "ORGANISM", 45, 55], ["stools", "ORGANISM", 59, 65], ["faecal", "ORGANISM_SUBDIVISION", 91, 97], ["oral", "ORGANISM_SUBDIVISION", 98, 102], ["human", "ORGANISM", 148, 153], ["human", "SPECIES", 148, 153], ["SARS-CoV", "SPECIES", 45, 53], ["human", "SPECIES", 148, 153], ["SARS", "PROBLEM", 45, 49], ["CoV", "TEST", 50, 53], ["sewage", "TREATMENT", 70, 76], ["oral transmission of COVID", "TREATMENT", 98, 124]]], ["According to other concordant investigations, the human coronavirus illustrated a 99.9 % die-out from 2 days to 2 weeks at 23 \u00b0C and 25 \u00b0C, respectively, (WHO, 2020).", [["human", "ORGANISM", 50, 55], ["coronavirus", "ORGANISM", 56, 67], ["human", "SPECIES", 50, 55], ["human coronavirus", "SPECIES", 50, 67], ["the human coronavirus", "TEST", 46, 67]]], ["The die-out is facilitated by heat, high or low pH, sunshine, and commonly used sanitizers (e.g., chlorine) (Pinon and Vialette, 2018).Water treatment process against virusesCommonly used water purification methods globally are physical removal of pathogenic agents by treating conventionally and inactivation of pathogenic agents via application of ultraviolet light or chemical oxidizing agents including chlorine, chloramines, ozone, and chlorine dioxide.Water treatment process against virusesDue to the tiny size of viruses (mostly with a diameter ranging between 5 and 400 nm), though some paramyxoviruses may be up to 14,000 nm long, traditional purification, including filtration ( Fig. 2) , is not effective in physical removal of viruses.", [["chlorine", "CHEMICAL", 98, 106], ["ultraviolet light", "CHEMICAL", 350, 367], ["chlorine", "CHEMICAL", 407, 415], ["chloramines", "CHEMICAL", 417, 428], ["ozone", "CHEMICAL", 430, 435], ["chlorine dioxide", "CHEMICAL", 441, 457], ["chlorine", "CHEMICAL", 98, 106], ["chlorine", "CHEMICAL", 407, 415], ["chloramines", "CHEMICAL", 417, 428], ["ozone", "CHEMICAL", 430, 435], ["chlorine dioxide", "CHEMICAL", 441, 457], ["chlorine", "SIMPLE_CHEMICAL", 98, 106], ["chemical oxidizing agents", "SIMPLE_CHEMICAL", 371, 396], ["chlorine", "SIMPLE_CHEMICAL", 407, 415], ["chloramines", "SIMPLE_CHEMICAL", 417, 428], ["ozone", "SIMPLE_CHEMICAL", 430, 435], ["chlorine dioxide", "SIMPLE_CHEMICAL", 441, 457], ["high or low pH", "PROBLEM", 36, 50], ["chlorine", "TREATMENT", 98, 106], ["Water treatment process", "TREATMENT", 135, 158], ["viruses", "PROBLEM", 167, 174], ["water purification methods", "TREATMENT", 188, 214], ["physical removal", "TREATMENT", 228, 244], ["pathogenic agents", "TREATMENT", 248, 265], ["pathogenic agents", "TREATMENT", 313, 330], ["ultraviolet light", "TREATMENT", 350, 367], ["chemical oxidizing agents", "TREATMENT", 371, 396], ["chlorine", "TREATMENT", 407, 415], ["chloramines", "TREATMENT", 417, 428], ["ozone", "TREATMENT", 430, 435], ["chlorine dioxide", "TREATMENT", 441, 457], ["Water treatment process", "TREATMENT", 458, 481], ["viruses", "PROBLEM", 490, 497], ["the tiny size of viruses", "PROBLEM", 504, 528], ["some paramyxoviruses", "PROBLEM", 591, 611], ["traditional purification", "TEST", 641, 665], ["physical removal", "TREATMENT", 720, 736], ["viruses", "PROBLEM", 740, 747], ["tiny", "OBSERVATION_MODIFIER", 508, 512], ["size", "OBSERVATION_MODIFIER", 513, 517], ["viruses", "OBSERVATION", 521, 528], ["diameter", "OBSERVATION_MODIFIER", 544, 552], ["paramyxoviruses", "OBSERVATION", 596, 611], ["viruses", "OBSERVATION", 740, 747]]], ["Fujioka et al reported bacterial removal rates of 95\u00b72 %-99\u00b73 % during full-scale water filtering (Fujioka et al., 2019) .", [["bacterial removal rates", "TEST", 23, 46], ["bacterial removal", "OBSERVATION", 23, 40]]], ["Thus, viral removals are not expectedly lower than bacterial ones (> 0.2 \u03bcm in size) due to the size.", [["viral removals", "TREATMENT", 6, 20], ["viral removals", "OBSERVATION", 6, 20], ["size", "OBSERVATION_MODIFIER", 96, 100]]], ["The use of sanitizers is greatly dependent upon water chemistry and regional rules.", [["sanitizers", "TREATMENT", 11, 21], ["greatly dependent", "PROBLEM", 25, 42]]], ["Free chlorine (i.e., the sum of hypochlorous acid and hypochlorite ions produced by dissolving and hydrolysing chlorine gas in water) is the disinfection agent with the uppermost usage around the world (Hoseinzadeh, 2019) .", [["chlorine", "CHEMICAL", 5, 13], ["hypochlorous acid", "CHEMICAL", 32, 49], ["hypochlorite ions", "CHEMICAL", 54, 71], ["chlorine", "CHEMICAL", 111, 119], ["chlorine", "CHEMICAL", 5, 13], ["hypochlorous acid", "CHEMICAL", 32, 49], ["hypochlorite", "CHEMICAL", 54, 66], ["chlorine", "CHEMICAL", 111, 119], ["chlorine", "SIMPLE_CHEMICAL", 5, 13], ["hypochlorous acid", "SIMPLE_CHEMICAL", 32, 49], ["hypochlorite", "SIMPLE_CHEMICAL", 54, 66], ["chlorine", "SIMPLE_CHEMICAL", 111, 119], ["Free chlorine", "TREATMENT", 0, 13], ["hypochlorous acid", "TREATMENT", 32, 49], ["hypochlorite ions", "TREATMENT", 54, 71], ["hydrolysing chlorine gas", "TREATMENT", 99, 123], ["the disinfection agent", "TREATMENT", 137, 159], ["chlorine", "OBSERVATION", 5, 13]]], ["This powerful oxidizing agent inactivates the majority of viruses (Pinon and Vialette, 2018) .", [["This powerful oxidizing agent", "TREATMENT", 0, 29], ["viruses", "OBSERVATION", 58, 65]]], ["Nonetheless, treat with free chlorine may form regularized toxic disinfection by-products (DBPs).", [["chlorine", "CHEMICAL", 29, 37], ["chlorine", "CHEMICAL", 29, 37], ["chlorine", "SIMPLE_CHEMICAL", 29, 37], ["by-products", "SIMPLE_CHEMICAL", 78, 89], ["DBPs", "SIMPLE_CHEMICAL", 91, 95], ["free chlorine", "TREATMENT", 24, 37], ["regularized toxic disinfection", "TREATMENT", 47, 77], ["toxic disinfection", "OBSERVATION", 59, 77]]], ["Adenovirus has susceptibility to deactivation with free chlorine with high resistance to deactivation using both monochloramine and UV light (Pinon and Vialette, 2018) .", [["chlorine", "CHEMICAL", 56, 64], ["monochloramine", "CHEMICAL", 113, 127], ["chlorine", "CHEMICAL", 56, 64], ["monochloramine", "CHEMICAL", 113, 127], ["Adenovirus", "ORGANISM", 0, 10], ["chlorine", "SIMPLE_CHEMICAL", 56, 64], ["monochloramine", "SIMPLE_CHEMICAL", 113, 127], ["Adenovirus", "SPECIES", 0, 10], ["Adenovirus", "PROBLEM", 0, 10], ["free chlorine", "TREATMENT", 51, 64], ["both monochloramine", "TREATMENT", 108, 127], ["UV light", "TREATMENT", 132, 140], ["high resistance", "OBSERVATION", 70, 85]]], ["Chlorine dioxide and ozone are also robust oxidizing agents, both of which can effectively control viruses (Gall et al., 2015) .Water treatment process against virusesIrrespective of the sanitization utilized at a drinking water facility, the travel of purified water from the treatment plant to the tap can lead to cross-contamination all over the extent of water dissemination substructure because of cavitation and random depressurisation; thus, it is necessary to utilize alternative sanitizers in distribution systems.", [["Chlorine dioxide", "CHEMICAL", 0, 16], ["ozone", "CHEMICAL", 21, 26], ["Chlorine dioxide", "CHEMICAL", 0, 16], ["ozone", "CHEMICAL", 21, 26], ["Chlorine dioxide", "SIMPLE_CHEMICAL", 0, 16], ["ozone", "SIMPLE_CHEMICAL", 21, 26], ["Chlorine dioxide", "TREATMENT", 0, 16], ["ozone", "TREATMENT", 21, 26], ["robust oxidizing agents", "TREATMENT", 36, 59], ["Water treatment process", "TREATMENT", 128, 151], ["viruses", "PROBLEM", 160, 167], ["the treatment plant", "TREATMENT", 273, 292], ["the tap", "TREATMENT", 296, 303], ["cross-contamination", "PROBLEM", 316, 335], ["water dissemination substructure", "PROBLEM", 359, 391], ["cavitation", "PROBLEM", 403, 413], ["random depressurisation", "PROBLEM", 418, 441], ["alternative sanitizers", "TREATMENT", 476, 498], ["water dissemination", "OBSERVATION", 359, 378], ["cavitation", "OBSERVATION", 403, 413]]], ["Free chlorine and monochloramine are the only two sanitizers that can maintain remains in the distribution system.Water treatment process against virusesIn spite of more powerful disinfecting effect of free chlorine in terms of inactivating pathogens, monochloramine leaves residues with a higher stability in distribution systems hence both are useable.", [["chlorine", "CHEMICAL", 5, 13], ["monochloramine", "CHEMICAL", 18, 32], ["chlorine", "CHEMICAL", 207, 215], ["monochloramine", "CHEMICAL", 252, 266], ["chlorine", "CHEMICAL", 5, 13], ["monochloramine", "CHEMICAL", 18, 32], ["chlorine", "CHEMICAL", 207, 215], ["monochloramine", "CHEMICAL", 252, 266], ["chlorine", "SIMPLE_CHEMICAL", 5, 13], ["monochloramine", "SIMPLE_CHEMICAL", 18, 32], ["chlorine", "SIMPLE_CHEMICAL", 207, 215], ["monochloramine", "SIMPLE_CHEMICAL", 252, 266], ["Free chlorine", "TREATMENT", 0, 13], ["monochloramine", "TREATMENT", 18, 32], ["Water treatment process", "TREATMENT", 114, 137], ["viruses", "PROBLEM", 146, 153], ["free chlorine", "TREATMENT", 202, 215], ["inactivating pathogens", "PROBLEM", 228, 250], ["monochloramine leaves residues", "TREATMENT", 252, 282], ["a higher stability in distribution systems", "PROBLEM", 288, 330], ["free chlorine", "OBSERVATION", 202, 215], ["higher", "OBSERVATION_MODIFIER", 290, 296], ["stability", "OBSERVATION_MODIFIER", 297, 306]]], ["Human coronavirus can persist for only two days in dechlorinated tap water and hospital effluent at 20 \u00b0C (WHO, 2020).", [["Human", "ORGANISM", 0, 5], ["coronavirus", "ORGANISM", 6, 17], ["Human", "SPECIES", 0, 5], ["coronavirus", "SPECIES", 6, 17], ["Human coronavirus", "SPECIES", 0, 17], ["Human coronavirus", "PROBLEM", 0, 17], ["coronavirus", "OBSERVATION", 6, 17]]], ["A main barricade to extensive use of water quality settings is that not a single sanitization technique is effectual towards the whole viruses.", [["water quality settings", "TREATMENT", 37, 59], ["a single sanitization technique", "TREATMENT", 72, 103], ["main", "OBSERVATION_MODIFIER", 2, 6], ["extensive", "OBSERVATION_MODIFIER", 20, 29]]], ["To have efficient concentrated sanitization, free chlorine remaining concentration must be \u2265 0\u00b75 mg/L following a minimum of 30 min after contact time at pH < 8\u00b70 (WHO, 2011).", [["chlorine", "CHEMICAL", 50, 58], ["chlorine", "CHEMICAL", 50, 58], ["chlorine", "SIMPLE_CHEMICAL", 50, 58], ["efficient concentrated sanitization", "TREATMENT", 8, 43], ["free chlorine remaining concentration", "TREATMENT", 45, 82], ["efficient", "OBSERVATION_MODIFIER", 8, 17], ["concentrated", "OBSERVATION_MODIFIER", 18, 30], ["sanitization", "OBSERVATION", 31, 43]]], ["A chlorine residue should remain all over the distribution system.Detection of viruses in drinking waterWater purification facilities routinely examine the existence of faecal coliforms in water sources, but they do not examine the existence of infective viruses due to either impossibility or unfeasibility of detecting or propagating infective viral particles cost-effectively and in a welltimed fashion.", [["faecal coliforms", "ANATOMY", 169, 185], ["chlorine", "CHEMICAL", 2, 10], ["faecal coliforms", "DISEASE", 169, 185], ["chlorine", "CHEMICAL", 2, 10], ["chlorine", "SIMPLE_CHEMICAL", 2, 10], ["A chlorine residue", "TREATMENT", 0, 18], ["viruses", "PROBLEM", 79, 86], ["faecal coliforms", "PROBLEM", 169, 185], ["infective viruses", "PROBLEM", 245, 262], ["propagating infective viral particles", "PROBLEM", 324, 361], ["chlorine residue", "OBSERVATION", 2, 18], ["viruses", "OBSERVATION", 79, 86], ["infective", "OBSERVATION", 245, 254], ["infective", "OBSERVATION_MODIFIER", 336, 345], ["viral particles", "OBSERVATION", 346, 361]]], ["Whereas, viral proteins or genomes can be detected swiftly utilizing enzymelinked immunosorbent assay (ELISA) or quantitative polymerase chain reaction (qPCR)-based technologies, respectively, the techniques cannot discriminate between infective and noninfective viral particles.", [["viral proteins", "PROTEIN", 9, 23], ["viral proteins or genomes", "PROBLEM", 9, 34], ["enzymelinked immunosorbent assay", "TEST", 69, 101], ["ELISA", "TEST", 103, 108], ["quantitative polymerase chain reaction", "PROBLEM", 113, 151], ["infective and noninfective viral particles", "PROBLEM", 236, 278], ["viral particles", "OBSERVATION", 263, 278]]], ["Integrated cell culture-PCR (ICC-PCR) lowers the time demands of conventional plaque tests allowing infective viruses to proliferate in host cells, but a cell culture used in the technique is not even practical at water treatment facilities (Gall et al., 2015) .", [["cell", "ANATOMY", 11, 15], ["plaque", "ANATOMY", 78, 84], ["cells", "ANATOMY", 141, 146], ["cell", "ANATOMY", 154, 158], ["cell", "CELL", 11, 15], ["host cells", "CELL", 136, 146], ["cell", "CELL", 154, 158], ["host cells", "CELL_TYPE", 136, 146], ["Integrated cell culture", "TEST", 0, 23], ["PCR", "TEST", 24, 27], ["ICC", "TEST", 29, 32], ["PCR", "TEST", 33, 36], ["conventional plaque tests", "PROBLEM", 65, 90], ["infective viruses", "PROBLEM", 100, 117], ["host cells", "PROBLEM", 136, 146], ["a cell culture", "TEST", 152, 166], ["the technique", "TEST", 175, 188], ["plaque", "OBSERVATION", 78, 84], ["infective viruses", "OBSERVATION", 100, 117], ["host cells", "OBSERVATION", 136, 146], ["Gall", "ANATOMY", 242, 246]]], ["Despite advancements obtained in collecting viruses from huge volumes of water, it remains as a fast way of detecting survivable viruses.", [["survivable viruses", "PROBLEM", 118, 136], ["viruses", "OBSERVATION", 44, 51], ["huge", "OBSERVATION_MODIFIER", 57, 61], ["viruses", "OBSERVATION", 129, 136]]], ["Multiple existing barricades preclude detection of viruses in drinking water.", [["Multiple existing barricades", "TREATMENT", 0, 28], ["viruses", "PROBLEM", 51, 58], ["viruses", "OBSERVATION", 51, 58]]], ["To consider technologically, viral replication needs using tissue culture, a system requiring elevated time, workforce, skill, and costly apparatus.", [["tissue culture", "ANATOMY", 59, 73], ["tissue", "TISSUE", 59, 65], ["viral replication", "TREATMENT", 29, 46], ["tissue culture", "TEST", 59, 73]]], ["Additionally, some of these viruses are not culturable simply (adenovirus serotypes 40 and 41) or at all (human norovirus, hepatitis A virus) in culture media.", [["norovirus, hepatitis A virus", "DISEASE", 112, 140], ["adenovirus serotypes 40", "ORGANISM", 63, 86], ["human norovirus", "ORGANISM", 106, 121], ["hepatitis A virus", "ORGANISM", 123, 140], ["human", "SPECIES", 106, 111], ["hepatitis A virus", "SPECIES", 123, 140], ["human", "SPECIES", 106, 111], ["hepatitis A virus", "SPECIES", 123, 140], ["these viruses", "PROBLEM", 22, 35], ["adenovirus serotypes", "TEST", 63, 83], ["human norovirus", "PROBLEM", 106, 121], ["hepatitis A virus", "PROBLEM", 123, 140], ["culture media", "TEST", 145, 158], ["viruses", "OBSERVATION", 28, 35]]], ["Accordingly, conventional viral development tests (plaque assays) are either inaccessible or highly time-taking rendering them impractical for water treatment facilities.", [["plaque", "ANATOMY", 51, 57], ["conventional viral development tests", "TEST", 13, 49], ["plaque assays", "TEST", 51, 64], ["water treatment facilities", "TREATMENT", 143, 169]]], ["Generally, the potential of SARS-CoV-2 transmission via water sources is low(Cahill and Morris, 2020) but more research need to study the viability of the virus and contamination of water source that can transmit the SARS-CoV-2 to humans.Transmission by sewerage systemsThe majority of faecal-oral-spread viruses have high resistance in the water milieu, in which they are likely to present improved survival in spite of the sanitization procedures usually utilized to treat drinking water and sewerage (Hoseinzadeh, 2019) .", [["oral", "ANATOMY", 293, 297], ["SARS", "DISEASE", 28, 32], ["SARS", "DISEASE", 217, 221], ["SARS-CoV-2", "ORGANISM", 28, 38], ["SARS-CoV-2", "ORGANISM", 217, 227], ["humans", "ORGANISM", 231, 237], ["faecal-", "ORGANISM", 286, 293], ["oral", "ORGANISM_SUBDIVISION", 293, 297], ["humans", "SPECIES", 231, 237], ["SARS-CoV", "SPECIES", 28, 36], ["humans", "SPECIES", 231, 237], ["SARS", "PROBLEM", 28, 32], ["CoV", "TEST", 33, 36], ["the virus", "PROBLEM", 151, 160], ["faecal-oral-spread viruses", "PROBLEM", 286, 312], ["high resistance in the water milieu", "PROBLEM", 318, 353], ["the sanitization procedures", "TREATMENT", 421, 448], ["majority", "OBSERVATION_MODIFIER", 274, 282], ["faecal", "ANATOMY", 286, 292], ["high resistance", "OBSERVATION", 318, 333], ["water milieu", "OBSERVATION_MODIFIER", 341, 353], ["likely to", "UNCERTAINTY", 373, 382], ["improved", "OBSERVATION_MODIFIER", 391, 399], ["survival", "OBSERVATION", 400, 408]]], ["The bulk of such viruses are nonencased viruses, such as norovirus, enterovirus, Aichi virus, parechovirus, hepatitis A and E viruses (HAV and HEV, respectively), astrovirus, rotavirus, and adenovirus (Ad) (Gall et al., 2015) .", [["norovirus, enterovirus, Aichi virus", "DISEASE", 57, 92], ["hepatitis A", "DISEASE", 108, 119], ["astrovirus, rotavirus", "DISEASE", 163, 184], ["norovirus", "ORGANISM", 57, 66], ["enterovirus", "ORGANISM", 68, 79], ["Aichi virus", "ORGANISM", 81, 92], ["parechovirus,", "ORGANISM", 94, 107], ["hepatitis A and E viruses", "ORGANISM", 108, 133], ["HAV", "ORGANISM", 135, 138], ["HEV", "ORGANISM", 143, 146], ["astrovirus", "ORGANISM", 163, 173], ["rotavirus", "ORGANISM", 175, 184], ["adenovirus", "ORGANISM", 190, 200], ["Ad", "ORGANISM", 202, 204], ["Aichi virus", "SPECIES", 81, 92], ["Aichi virus", "SPECIES", 81, 92], ["hepatitis A", "SPECIES", 108, 119], ["E viruses", "SPECIES", 124, 133], ["HAV", "SPECIES", 135, 138], ["HEV", "SPECIES", 143, 146], ["rotavirus", "SPECIES", 175, 184], ["adenovirus", "SPECIES", 190, 200], ["Ad", "SPECIES", 202, 204], ["such viruses", "PROBLEM", 12, 24], ["nonencased viruses", "PROBLEM", 29, 47], ["norovirus", "PROBLEM", 57, 66], ["enterovirus", "PROBLEM", 68, 79], ["Aichi virus", "PROBLEM", 81, 92], ["parechovirus", "PROBLEM", 94, 106], ["hepatitis A and E viruses", "PROBLEM", 108, 133], ["HAV", "PROBLEM", 135, 138], ["HEV", "PROBLEM", 143, 146], ["astrovirus", "PROBLEM", 163, 173], ["rotavirus", "PROBLEM", 175, 184], ["adenovirus", "PROBLEM", 190, 200], ["bulk", "OBSERVATION_MODIFIER", 4, 8], ["viruses", "OBSERVATION", 17, 24], ["viruses", "OBSERVATION", 40, 47], ["Gall", "ANATOMY", 207, 211]]], ["These viruses are detectable in effluents as people excrete about 100g of stool daily, and 10 5 -10 9 intestinal viral particles per gram of stool are released every day from a diseased person (Wigginton et al., 2012) .", [["stool", "ANATOMY", 74, 79], ["stool", "ANATOMY", 141, 146], ["people", "ORGANISM", 45, 51], ["stool", "ORGANISM_SUBSTANCE", 74, 79], ["stool", "ORGANISM_SUBSTANCE", 141, 146], ["people", "SPECIES", 45, 51], ["person", "SPECIES", 186, 192], ["These viruses", "PROBLEM", 0, 13], ["viruses", "OBSERVATION", 6, 13], ["effluents", "OBSERVATION_MODIFIER", 32, 41], ["intestinal", "ANATOMY", 102, 112]]], ["Since 10 7 -10 13 viral particles are excreted daily from an diseased person (Wigginton et al., 2012) , a possibly helpful tool is to analyse entering effluent to disclose the existence and quantification of defecated human pathogenic agents, thereby providing an estimate of the numbers of diseased individuals(La Rosa et al., 2020) .", [["human", "ORGANISM", 218, 223], ["person", "SPECIES", 70, 76], ["human", "SPECIES", 218, 223], ["human", "SPECIES", 218, 223], ["diseased", "OBSERVATION", 61, 69]]], ["If the virus is present, it will not indicate a relation between the viral sequences in effluent and those from patients of the same sampling time and area (Hellm\u00e9r et al., 2014 (Hellm\u00e9r et al., 2014) .", [["patients", "ORGANISM", 112, 120], ["viral sequences", "DNA", 69, 84], ["patients", "SPECIES", 112, 120], ["the virus", "PROBLEM", 3, 12], ["the viral sequences", "TEST", 65, 84], ["virus", "OBSERVATION", 7, 12], ["viral", "OBSERVATION", 69, 74], ["effluent", "OBSERVATION", 88, 96]]], ["The virus is detectable prior to occurring an endemic, as reported by a research on norovirus, because the virus may be defecated in stool prior to the incidence of indications (Carter, 2005) , which is 1-2 days for norovirus GII and 4-5 days for astrovirus (Lee et al., 2013) whereas, the defecation duration is lengthier for hepatitis A and E viruses, occurring for about 7 weeks (Richardson et al., 2001) .", [["norovirus", "DISEASE", 84, 93], ["norovirus", "DISEASE", 216, 225], ["astrovirus", "DISEASE", 247, 257], ["hepatitis A and E viruses", "DISEASE", 327, 352], ["norovirus", "ORGANISM", 84, 93], ["stool", "ORGANISM_SUBSTANCE", 133, 138], ["norovirus GII", "ORGANISM", 216, 229], ["astrovirus", "ORGANISM", 247, 257], ["E viruses", "ORGANISM", 343, 352], ["hepatitis A", "SPECIES", 327, 338], ["E viruses", "SPECIES", 343, 352], ["The virus", "PROBLEM", 0, 9], ["an endemic", "PROBLEM", 43, 53], ["norovirus", "PROBLEM", 84, 93], ["the virus", "PROBLEM", 103, 112], ["norovirus GII", "TREATMENT", 216, 229], ["astrovirus", "PROBLEM", 247, 257], ["the defecation duration", "PROBLEM", 286, 309], ["hepatitis A and E viruses", "PROBLEM", 327, 352], ["virus", "OBSERVATION", 4, 9], ["endemic", "OBSERVATION", 46, 53], ["norovirus", "OBSERVATION", 84, 93]]], ["No documentation is available hitherto about the COVID-19 virus transmission through sewer systems, with or without wastewater treatment.", [["COVID-19 virus", "ORGANISM", 49, 63], ["COVID-19 virus", "SPECIES", 49, 63], ["the COVID", "TEST", 45, 54], ["wastewater treatment", "TREATMENT", 116, 136]]], ["Besides, no proof can be found regarding the counteraction with SARS by effluent and wastewater treatment staffs.", [["SARS", "DISEASE", 64, 68], ["SARS", "PROBLEM", 64, 68]]], ["Genetically compared effluent viruses with those from clinical periodic cases and endemics can put forward a model to understand the epidemiology of intestinal viral pathogens in the population.", [["intestinal", "ANATOMY", 149, 159], ["intestinal viral pathogens", "DISEASE", 149, 175], ["intestinal", "ORGAN", 149, 159], ["effluent viruses", "PROBLEM", 21, 37], ["intestinal viral pathogens", "PROBLEM", 149, 175], ["effluent", "OBSERVATION_MODIFIER", 21, 29], ["viruses", "OBSERVATION", 30, 37], ["intestinal", "ANATOMY", 149, 159], ["viral", "OBSERVATION", 160, 165]]], ["Thus, surveillance of effluent regularly for such viruses can offer an ahead-of-time alarm of a potential forthcoming outbreaks.", [["such viruses", "PROBLEM", 45, 57], ["effluent", "OBSERVATION", 22, 30]]], ["Based on a research work in Helsinki, Finland, poliovirus was detectable in effluent if only 1 in 10,000 residents defecated the virus (Hovi et al., 2001) .", [["poliovirus", "ORGANISM", 47, 57], ["poliovirus", "SPECIES", 47, 57], ["poliovirus", "PROBLEM", 47, 57]]], ["Even so, it may identify genomes from non-infective viral particles as well (Hellm\u00e9r et al., 2014) .", [["non-infective viral particles", "PROBLEM", 38, 67], ["non-infective", "OBSERVATION_MODIFIER", 38, 51], ["viral particles", "OBSERVATION", 52, 67]]], ["A study conducted in Spain on six wastewater treatment plants in an area with lowest COVID-19 prevalence revealed that two secondary water sample were polluted.", [["A study", "TEST", 0, 7], ["six wastewater treatment plants", "TREATMENT", 30, 61], ["lowest COVID", "TEST", 78, 90], ["two secondary water sample", "TREATMENT", 119, 145]]], ["Comparison of the data with data of confirmed COVID-19 cases at municipally level revealed that people were shedding SARS-CoV-2 RNA in their faeces even before the first cases were reported by local or national authorities (Randazzo et al., 2020) .", [["faeces", "ANATOMY", 141, 147], ["people", "ORGANISM", 96, 102], ["CoV-2", "ORGANISM", 122, 127], ["faeces", "ORGANISM_SUBDIVISION", 141, 147], ["people", "SPECIES", 96, 102], ["SARS-CoV", "SPECIES", 117, 125], ["the data", "TEST", 14, 22], ["COVID", "TEST", 46, 51]]], ["In case of identifying only viral segments, it will continue providing an acceptable denotation about the types of viruses circulating in the community and those infecting individuals not seeking therapeutic care.", [["viral segments", "PROBLEM", 28, 42], ["viruses", "PROBLEM", 115, 122], ["therapeutic care", "TREATMENT", 196, 212], ["viral segments", "OBSERVATION", 28, 42], ["viruses", "OBSERVATION", 115, 122]]], ["It is recommendable to utilize this procedure for forecasting COVID-19 in the public (Randazzo et al., 2020) .", [["this procedure", "TREATMENT", 31, 45], ["forecasting COVID", "TEST", 50, 67]]], ["As a fraction of a merged population health strategy, effluent passed through sewer systems should undergo ideal treatment in decently established and properly controlled consolidated wastewater treatment utilities.", [["ideal treatment", "TREATMENT", 107, 122]]], ["Finally, it is possible to consider a decontamination phase if available sewer water purification plants are not subjected to optimisation to for viral removal.", [["a decontamination phase", "TREATMENT", 36, 59], ["sewer water purification plants", "TREATMENT", 73, 104], ["viral removal", "TREATMENT", 146, 159]]], ["It is essential to follow the best applications to protect the professional health of labours at sanitisation treatment installations.", [["labours at sanitisation treatment installations", "TREATMENT", 86, 133]]], ["Labours need to put on suitable personal protective equipment (PPE), including protecting outer wear, gloves, boots, goggles, or face shields, masks, regularly hand hygiene, and avoiding the touch of the eyes, nose, and mouth with dirty hands.Transmission by healthcare wasteLeftovers created during health care activities possess great potentiality for contamination, and its insufficient managing practices exposes health care personnel (e.g., physicians, nurses, and laboratory staffs), waste carriers, and patients in hospitals to health risks both directly and indirectly (Amsalu et al., 2016) .", [["hand", "ANATOMY", 160, 164], ["eyes", "ANATOMY", 204, 208], ["nose", "ANATOMY", 210, 214], ["mouth", "ANATOMY", 220, 225], ["hand", "ORGANISM_SUBDIVISION", 160, 164], ["eyes", "ORGAN", 204, 208], ["nose", "ORGANISM_SUBDIVISION", 210, 214], ["mouth", "ORGANISM_SUBDIVISION", 220, 225], ["hands", "ORGANISM_SUBDIVISION", 237, 242], ["patients", "ORGANISM", 510, 518], ["patients", "SPECIES", 510, 518], ["suitable personal protective equipment (PPE)", "TREATMENT", 23, 67], ["protecting outer wear", "TREATMENT", 79, 100], ["gloves", "TREATMENT", 102, 108], ["boots", "TREATMENT", 110, 115], ["goggles", "TREATMENT", 117, 124], ["face shields", "TREATMENT", 129, 141], ["masks", "TREATMENT", 143, 148], ["health care activities", "TREATMENT", 300, 322], ["contamination", "PROBLEM", 354, 367], ["eyes", "ANATOMY", 204, 208], ["nose", "ANATOMY", 210, 214], ["mouth", "ANATOMY", 220, 225]]], ["Health-care waste (HCW) carries a vast array of pathogenic agents.", [["pathogenic agents", "TREATMENT", 48, 65]]], ["Professional risk associated with COVID-19 contact is a main concerning issue, particularly in developing countries in which people do not rigorously follow a protocol for waste treatment.", [["COVID-19", "CHEMICAL", 34, 42], ["people", "ORGANISM", 125, 131], ["people", "SPECIES", 125, 131], ["waste treatment", "TREATMENT", 172, 187]]], ["Documentations are absent about human exposure directly and insecurely throughout treatment of HCW resulting in the COVID-19 endemic.", [["human", "ORGANISM", 32, 37], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["the COVID", "TEST", 112, 121]]], ["A report by the WHO (2004) indicate that urban and solid HCW have identical contents of microorganisms, and that 2% of blood-stained waste tested positively for hepatitis viruses, poliovirus, and echovirus identified in the defiled diapers of household waste (WHO, 2004) .", [["blood", "ANATOMY", 119, 124], ["hepatitis viruses", "DISEASE", 161, 178], ["echovirus", "DISEASE", 196, 205], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["hepatitis viruses", "ORGANISM", 161, 178], ["poliovirus", "ORGANISM", 180, 190], ["hepatitis viruses", "SPECIES", 161, 178], ["poliovirus", "SPECIES", 180, 190], ["solid HCW", "PROBLEM", 51, 60], ["microorganisms", "PROBLEM", 88, 102], ["blood-stained waste", "TEST", 119, 138], ["hepatitis viruses", "PROBLEM", 161, 178], ["poliovirus", "PROBLEM", 180, 190], ["echovirus", "PROBLEM", 196, 205]]], ["Pathogenic viruses, such as NoVs and hepatitis B virus, have been identified in human tissue waste (WHO, 2004) (WHO, 2004) .", [["tissue", "ANATOMY", 86, 92], ["hepatitis B", "DISEASE", 37, 48], ["NoVs", "GENE_OR_GENE_PRODUCT", 28, 32], ["hepatitis B virus", "ORGANISM", 37, 54], ["human", "ORGANISM", 80, 85], ["tissue", "TISSUE", 86, 92], ["hepatitis B virus", "SPECIES", 37, 54], ["human", "SPECIES", 80, 85], ["hepatitis B virus", "SPECIES", 37, 54], ["human", "SPECIES", 80, 85], ["Pathogenic viruses", "PROBLEM", 0, 18], ["NoVs", "PROBLEM", 28, 32], ["hepatitis B virus", "PROBLEM", 37, 54], ["viruses", "OBSERVATION", 11, 18], ["hepatitis", "OBSERVATION", 37, 46], ["human tissue", "OBSERVATION_MODIFIER", 80, 92]]], ["There is little information suggesting that that viral RNA was detectable in the plasmas or sera of COVID-19 infected people (Chang et al., 2020) .", [["plasmas", "ANATOMY", 81, 88], ["sera", "ANATOMY", 92, 96], ["sera", "ORGANISM_SUBSTANCE", 92, 96], ["COVID-19", "ORGANISM", 100, 108], ["people", "ORGANISM", 118, 124], ["viral RNA", "RNA", 49, 58], ["people", "SPECIES", 118, 124], ["COVID-19", "SPECIES", 100, 108], ["viral RNA", "PROBLEM", 49, 58], ["COVID", "TEST", 100, 105], ["little information suggesting", "UNCERTAINTY", 9, 38]]], ["Even so, observations of researches conducted experimentally demonstrated that some viruses (e.g. respiratory syncytial virus) have partial survivability under settings possibly found in a variety of wastes (Park et al., 2009) , and that viral loads are usually low.", [["respiratory syncytial virus", "DISEASE", 98, 125], ["respiratory syncytial virus", "ORGANISM", 98, 125], ["respiratory syncytial virus", "SPECIES", 98, 125], ["respiratory syncytial virus", "SPECIES", 98, 125], ["some viruses (e.g. respiratory syncytial virus", "PROBLEM", 79, 125], ["viral loads", "TEST", 238, 249], ["viruses", "OBSERVATION", 84, 91], ["viral loads", "OBSERVATION", 238, 249]]], ["Thus, an essential issue is that labours follow group and personal protecting procedures including gloves, respiratory masks, glasses, and overalls that are previously supplied in all working environment security plans (Carducci et al., 2013) .", [["respiratory", "ANATOMY", 107, 118], ["personal protecting procedures", "TREATMENT", 58, 88], ["gloves", "TREATMENT", 99, 105], ["respiratory masks", "OBSERVATION", 107, 124]]], ["Since minor amounts of information are available from individual plants, it is necessary to perform more inclusive surveillance examinations.", [["inclusive surveillance examinations", "TEST", 105, 140]]], ["All HCW created throughout the care of COVID-19 patients need to be gathered securely in engineered vessels and bags, handled, and then carefully discarded and/or treated, preferably in situ (WHO, 2020) .", [["vessels", "ANATOMY", 100, 107], ["patients", "ORGANISM", 48, 56], ["vessels", "MULTI-TISSUE_STRUCTURE", 100, 107], ["patients", "SPECIES", 48, 56], ["COVID", "TEST", 39, 44], ["bags", "TREATMENT", 112, 116], ["vessels", "ANATOMY", 100, 107]]], ["In case of moving wastes ex situ, its treatment and destruction place and mechanism must be understood critically.", [["moving wastes ex situ", "TREATMENT", 11, 32], ["its treatment", "TREATMENT", 34, 47], ["destruction", "PROBLEM", 52, 63]]], ["Prior to treatment of HCW, it is necessary to wear suitable PPE (boots, apron, long-sleeved gown, thick gloves, mask, and goggles), and perform appropriate hand sanitation after elimination.", [["hand", "ANATOMY", 156, 160], ["hand", "ORGANISM_SUBDIVISION", 156, 160], ["treatment", "TREATMENT", 9, 18], ["HCW", "TREATMENT", 22, 25], ["suitable PPE (boots", "TREATMENT", 51, 70], ["apron", "TREATMENT", 72, 77], ["long-sleeved gown", "TREATMENT", 79, 96], ["thick gloves", "TREATMENT", 98, 110], ["mask", "TREATMENT", 112, 116], ["appropriate hand sanitation", "TREATMENT", 144, 171]]], ["An emphasis is placed on necessary trainings in preventing contagion, in particular concerning waste treatment and removal.", [["necessary trainings", "TREATMENT", 25, 44], ["waste treatment", "TREATMENT", 95, 110], ["removal", "TREATMENT", 115, 122]]], ["It is imperative to follow the most acceptable operations to safely manage HCW, such as assignment of accountability and providing adequate human and material resources for safe removal of waste.Transmission by inanimate surfacesNon-encased viruses (e.g. coxsackieviruses, rotavirus, or poliovirus) can be viable for prolonged times on surfaces whereas, encased viruses, such as H1N1 and human coronaviruses, are still infective on surfaces after few days.", [["human", "ORGANISM", 140, 145], ["rotavirus", "ORGANISM", 273, 282], ["human", "ORGANISM", 388, 393], ["coronaviruses", "ORGANISM", 394, 407], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 388, 393], ["human", "SPECIES", 140, 145], ["rotavirus", "SPECIES", 273, 282], ["poliovirus", "SPECIES", 287, 297], ["human coronaviruses", "SPECIES", 388, 407], ["adequate human and material resources", "TREATMENT", 131, 168], ["safe removal of waste", "TREATMENT", 173, 194], ["encased viruses", "PROBLEM", 233, 248], ["coxsackieviruses", "PROBLEM", 255, 271], ["rotavirus", "PROBLEM", 273, 282], ["poliovirus", "PROBLEM", 287, 297], ["encased viruses", "PROBLEM", 354, 369], ["H1N1", "PROBLEM", 379, 383], ["human coronaviruses", "PROBLEM", 388, 407], ["surfaces", "OBSERVATION_MODIFIER", 221, 229], ["encased", "OBSERVATION_MODIFIER", 233, 240], ["viruses", "OBSERVATION", 241, 248], ["viruses", "OBSERVATION", 362, 369], ["infective", "OBSERVATION", 419, 428]]], ["A variety of environmental situations and parameters including heat, moisture, pH, and surface type influence the viability of desiccated viruses (Firquet et al., 2015) .", [["surface", "ANATOMY", 87, 94], ["heat, moisture, pH", "TREATMENT", 63, 81], ["desiccated viruses", "PROBLEM", 127, 145]]], ["The ingredients of the media can affect the viability of viruses as well.Transmission by inanimate surfacesEnvironmental surfaces probably contribute to the spread of hospital-derived viral contaminations (Ryu et al., 2020; Wang et al., 2020b; Ye et al., 2020) .", [["viruses", "OBSERVATION", 57, 64]]], ["At times of endemics in health care services, samples taken from surfaces discovered SARS-CoV nucleic acids on surfaces and non-living substances (Casanova et al., 2010) , suggesting that surfaces could be sources of virus spread for SARS-CoV-2.", [["samples", "ANATOMY", 46, 53], ["SARS", "DISEASE", 85, 89], ["nucleic acids", "CHEMICAL", 94, 107], ["SARS", "DISEASE", 234, 238], ["SARS-CoV-2", "ORGANISM", 234, 244], ["SARS-CoV", "SPECIES", 85, 93], ["SARS-CoV", "SPECIES", 234, 242], ["SARS", "PROBLEM", 85, 89], ["CoV nucleic acids", "TREATMENT", 90, 107], ["virus spread", "PROBLEM", 217, 229], ["SARS", "PROBLEM", 234, 238], ["CoV", "TEST", 239, 242]]], ["Environmental viral tests identify them in proteinladen media (such as serum) and protein-poor media, including water.", [["serum", "ANATOMY", 71, 76], ["proteinladen", "CHEMICAL", 43, 55], ["proteinladen", "SIMPLE_CHEMICAL", 43, 55], ["serum", "ORGANISM_SUBSTANCE", 71, 76], ["Environmental viral tests", "TEST", 0, 25], ["serum", "TEST", 71, 76], ["protein", "TEST", 82, 89], ["poor media", "OBSERVATION_MODIFIER", 90, 100]]], ["Hydrophobic substances prevent the spread of droplets, and their non-porous feature improves viral survivability (Firquet et al., 2015) .", [["Hydrophobic substances", "TREATMENT", 0, 22]]], ["Survival duration of the COVID-19 causing virus on surfaces is not certainly known, but it apparently behaves the same as other coronaviruses.", [["COVID-19", "CHEMICAL", 25, 33], ["coronaviruses", "ORGANISM", 128, 141], ["COVID-19 causing virus", "SPECIES", 25, 47], ["the COVID", "TEST", 21, 30], ["virus", "PROBLEM", 42, 47], ["virus", "OBSERVATION", 42, 47], ["not certainly", "UNCERTAINTY", 63, 76]]], ["Recently, reviewing the viability of human coronaviruses on surfaces revealed high survivability, in the range of 2 h-9 days(WHO, 2020).", [["human", "ORGANISM", 37, 42], ["coronaviruses", "ORGANISM", 43, 56], ["human", "SPECIES", 37, 42], ["human coronaviruses", "SPECIES", 37, 56], ["high survivability", "PROBLEM", 78, 96], ["high", "OBSERVATION_MODIFIER", 78, 82], ["survivability", "OBSERVATION_MODIFIER", 83, 96]]], ["Casanova et al. (Casanova et al., 2010) demonstrated that infective SARS-CoV survived for a period of 28 days at 4 \u00b0C, and the deactivation was lowermost at 20% relative humidity (RH).", [["SARS", "DISEASE", 68, 72], ["SARS-CoV", "ORGANISM", 68, 76], ["SARS-CoV", "SPECIES", 68, 76], ["infective SARS", "PROBLEM", 58, 72], ["infective", "OBSERVATION_MODIFIER", 58, 67]]], ["Faster deactivation occurred at 20 \u00b0C than at 4 \u00b0C at all moisture levels; the viruses were viable for 5-28 days, and a low RH led to the slowest deactivation.", [["Faster deactivation", "PROBLEM", 0, 19], ["the viruses", "PROBLEM", 75, 86], ["a low RH", "PROBLEM", 118, 126], ["viruses", "OBSERVATION", 79, 86]]], ["Deactivation of viruses was more rapid at 40 \u00b0C than at 20 \u00b0C (Casanova et al., 2010) .", [["Deactivation of viruses", "PROBLEM", 0, 23], ["viruses", "OBSERVATION", 16, 23]]], ["The association between deactivation and RH was not monotone, and low RH (20 %) and high RH (80 %) resulted in better persistence or a higher protecting impact than at mild RH (50 %) (Casanova et al., 2010) .Transmission by inanimate surfacesDeactivation is dividable into two steps of initial represented by water loss because of evaporating free water from the surface (Zhao et al., 2012) , exposing viruses to a liquid-air interface, which leads to viral deactivation.", [["surface", "ANATOMY", 363, 370], ["surface", "CELLULAR_COMPONENT", 363, 370], ["RH", "TEST", 41, 43], ["mild RH", "PROBLEM", 168, 175], ["water loss", "PROBLEM", 309, 319], ["a liquid-air interface", "PROBLEM", 413, 435], ["viral deactivation", "PROBLEM", 452, 470], ["surfaces", "OBSERVATION_MODIFIER", 234, 242], ["water loss", "OBSERVATION", 309, 319], ["air interface", "OBSERVATION", 422, 435], ["viral deactivation", "OBSERVATION", 452, 470]]], ["The discrepancy can be attributed to rehydration, noticeably inactivating non-lipid viruses, including poliovirus (Zhao et al., 2012) .", [["rehydration", "TREATMENT", 37, 48], ["non-lipid viruses", "PROBLEM", 74, 91], ["poliovirus", "PROBLEM", 103, 113], ["can be attributed to", "UNCERTAINTY", 16, 36], ["rehydration", "OBSERVATION", 37, 48]]], ["Even so, iterative drying cannot influence non-encased viruses.", [["iterative drying", "TREATMENT", 9, 25], ["viruses", "OBSERVATION", 55, 62]]], ["Encased viruses showed more sensitivity than non-encased ones in the second stage of viral survival, which began once the liquid could not be seen on the lids anymore.", [["Encased viruses", "PROBLEM", 0, 15], ["viral survival", "TREATMENT", 85, 99], ["viruses", "OBSERVATION", 8, 15], ["more sensitivity", "OBSERVATION_MODIFIER", 23, 39], ["viral survival", "OBSERVATION", 85, 99]]], ["Probably, the viruses survived for days or even weeks on dry hydrophobic surfaces (Firquet et al., 2015; WHO, 2011) .", [["the viruses", "PROBLEM", 10, 21], ["viruses", "OBSERVATION", 14, 21]]], ["Media constituents and component contents had a clear contribution upon exposure of virus suspensions to desiccation (Firquet et al., 2015; WHO, 2011) .", [["component contents", "PROBLEM", 23, 41], ["virus suspensions", "TREATMENT", 84, 101], ["component", "OBSERVATION_MODIFIER", 23, 32], ["contents", "OBSERVATION", 33, 41]]], ["Coronaviruses are encased, positive-sense, and single-stranded RNA viruses.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["Coronaviruses", "PROBLEM", 0, 13], ["single-stranded RNA viruses", "PROBLEM", 47, 74], ["RNA viruses", "OBSERVATION", 63, 74]]], ["They typically show vulnerability to acid-pH, basic-pH, and heat, but apparently have more stability at 4 \u00b0C. The lipid bilayer casing of these viruses has rather sensitivity to dryness, heat, and detersives; thus, their sterilisation is simpler than non-encased viruses (Firquet et al., 2015; WHO, 2011) .", [["acid-pH", "TEST", 37, 44], ["The lipid bilayer casing", "TREATMENT", 110, 134], ["these viruses", "PROBLEM", 138, 151], ["dryness", "PROBLEM", 178, 185], ["more stability", "OBSERVATION_MODIFIER", 86, 100], ["lipid bilayer", "OBSERVATION", 114, 127], ["viruses", "OBSERVATION", 144, 151]]], ["Several studies report that a succeeding elevation in solute concentrations in droplets could modulate the survivability of viruses against desiccation.", [["solute", "SIMPLE_CHEMICAL", 54, 60], ["Several studies", "TEST", 0, 15], ["a succeeding elevation", "PROBLEM", 28, 50], ["solute concentrations in droplets", "TREATMENT", 54, 87], ["desiccation", "PROBLEM", 140, 151], ["elevation", "OBSERVATION_MODIFIER", 41, 50], ["solute concentrations", "OBSERVATION", 54, 75], ["viruses", "OBSERVATION", 124, 131]]], ["Because the contents of media has a contribution the survivability of viruses subjected to desiccation, further investigations are necessary on the viral viability in natural media (clinical or environmental), rather than determined media.", [["viruses", "PROBLEM", 70, 77], ["desiccation", "PROBLEM", 91, 102], ["further investigations", "TEST", 104, 126], ["the viral viability", "PROBLEM", 144, 163], ["viruses", "OBSERVATION", 70, 77]]], ["Contamination of surfaces in hospital was investigated by et al (Razzini et al., 2020) which reported that 35% of COVID-19 patient's ward, 50% undressing room and no clean areas were contaminated with COVID-19.", [["COVID-19", "CHEMICAL", 201, 209], ["COVID-19", "CHEMICAL", 201, 209], ["patient", "ORGANISM", 123, 130], ["patient", "SPECIES", 123, 130], ["COVID", "TEST", 114, 119], ["COVID", "TEST", 201, 206], ["surfaces", "OBSERVATION_MODIFIER", 17, 25]]], ["The most contaminated surfaces were hand sanitizer dispensers, medical equipment, medical equipment touch screens, and shelves for medical equipment, bedrails and door handles, respectively.", [["hand", "ANATOMY", 36, 40], ["medical equipment touch screens", "TEST", 82, 113], ["medical equipment", "TREATMENT", 131, 148]]], ["Kampf et al presented evidence that efficient inactivation of coronaviruses would be possible by surface sanitizers containing 62%-71 % ethanol, 0\u00b75 % hydrogen peroxide, or 0\u00b71 % sodium hypochlorite for approx.", [["surface", "ANATOMY", 97, 104], ["ethanol", "CHEMICAL", 136, 143], ["hydrogen peroxide", "CHEMICAL", 151, 168], ["sodium hypochlorite", "CHEMICAL", 179, 198], ["ethanol", "CHEMICAL", 136, 143], ["hydrogen peroxide", "CHEMICAL", 151, 168], ["sodium hypochlorite", "CHEMICAL", 179, 198], ["coronaviruses", "ORGANISM", 62, 75], ["ethanol", "SIMPLE_CHEMICAL", 136, 143], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 151, 168], ["sodium hypochlorite", "SIMPLE_CHEMICAL", 179, 198], ["efficient inactivation of coronaviruses", "PROBLEM", 36, 75], ["surface sanitizers", "TEST", 97, 115], ["ethanol", "TREATMENT", 136, 143], ["0\u00b75 % hydrogen peroxide", "TREATMENT", 145, 168], ["0\u00b71 % sodium hypochlorite", "TREATMENT", 173, 198]]], ["1 min, but other biocides, e.g. 0\u00b705%-0\u00b72% benzalkonium chloride or 0\u00b702 % chlorhexidine digluconate, presented lower effectiveness (Kampf et al., 2020) .Transmission by ambient airVarious pathogens c are present in the air and have the potential to be spread over extended spaces (Hoseinzadeh et al., 2017) , which comprise influenza virus, SARS virus, Mycobacterium tuberculosis, foot and mouth disease, and several other ones.", [["foot", "ANATOMY", 382, 386], ["mouth", "ANATOMY", 391, 396], ["benzalkonium chloride", "CHEMICAL", 43, 64], ["chlorhexidine digluconate", "CHEMICAL", 75, 100], ["influenza virus", "DISEASE", 325, 340], ["SARS virus", "DISEASE", 342, 352], ["Mycobacterium tuberculosis", "DISEASE", 354, 380], ["foot and mouth disease", "DISEASE", 382, 404], ["benzalkonium chloride", "CHEMICAL", 43, 64], ["chlorhexidine digluconate", "CHEMICAL", 75, 100], ["benzalkonium chloride", "SIMPLE_CHEMICAL", 43, 64], ["chlorhexidine digluconate", "SIMPLE_CHEMICAL", 75, 100], ["influenza virus", "ORGANISM", 325, 340], ["SARS virus", "ORGANISM", 342, 352], ["Mycobacterium tuberculosis", "ORGANISM", 354, 380], ["foot", "ORGANISM_SUBDIVISION", 382, 386], ["mouth", "ORGAN", 391, 396], ["influenza virus", "SPECIES", 325, 340], ["Mycobacterium tuberculosis", "SPECIES", 354, 380], ["influenza virus", "SPECIES", 325, 340], ["SARS virus", "SPECIES", 342, 352], ["Mycobacterium tuberculosis", "SPECIES", 354, 380], ["benzalkonium chloride", "TREATMENT", 43, 64], ["0\u00b702 % chlorhexidine digluconate", "TREATMENT", 68, 100], ["ambient airVarious pathogens", "PROBLEM", 170, 198], ["influenza virus", "PROBLEM", 325, 340], ["SARS virus", "PROBLEM", 342, 352], ["Mycobacterium tuberculosis", "PROBLEM", 354, 380], ["foot and mouth disease", "PROBLEM", 382, 404], ["air", "ANATOMY", 220, 223], ["spread", "OBSERVATION_MODIFIER", 253, 259], ["influenza virus", "OBSERVATION", 325, 340], ["Mycobacterium tuberculosis", "OBSERVATION", 354, 380], ["foot", "ANATOMY", 382, 386], ["mouth", "ANATOMY", 391, 396], ["disease", "OBSERVATION", 397, 404]]], ["The majority of patients with COVID-19 were affected severely by acute respiratory infection, including fever, cough, and shortness of breath, leading to death of most of such people.", [["respiratory", "ANATOMY", 71, 82], ["acute respiratory infection", "DISEASE", 65, 92], ["fever", "DISEASE", 104, 109], ["cough", "DISEASE", 111, 116], ["shortness of breath", "DISEASE", 122, 141], ["death", "DISEASE", 154, 159], ["patients", "ORGANISM", 16, 24], ["people", "ORGANISM", 176, 182], ["patients", "SPECIES", 16, 24], ["people", "SPECIES", 176, 182], ["COVID", "TEST", 30, 35], ["acute respiratory infection", "PROBLEM", 65, 92], ["fever", "PROBLEM", 104, 109], ["cough", "PROBLEM", 111, 116], ["shortness of breath", "PROBLEM", 122, 141], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["respiratory", "ANATOMY", 71, 82], ["infection", "OBSERVATION", 83, 92]]], ["Given that respiratory spread and the spread of survivable virus placed on the surfaces is possible, the viability of air-transmitted viral aerosolised should be importantly investigated in ambient air (Morawska and Cao, 2020) .Transmission by ambient airFelipe Falc\u00e3oSobral et al found the negative association between air temperature and COVID-19Transmission by ambient aircases.", [["respiratory", "ANATOMY", 11, 22], ["COVID-19Transmission", "CHEMICAL", 340, 360], ["respiratory spread", "PROBLEM", 11, 29], ["survivable virus", "PROBLEM", 48, 64], ["air-transmitted viral aerosolised", "PROBLEM", 118, 151], ["air temperature", "TEST", 320, 335], ["COVID", "TEST", 340, 345], ["respiratory spread", "OBSERVATION", 11, 29], ["negative", "OBSERVATION", 291, 299]]], ["In addition, they found rainfall as an important climate factor in SARS-CoV-2 transmission (Sobral et al., 2020) .", [["SARS", "DISEASE", 67, 71], ["CoV-2", "ORGANISM", 72, 77], ["SARS-CoV", "SPECIES", 67, 75]]], ["Furthermore, the impact of weather on COVID-19 pandemic in Turkey assessed by Mehmet \u015eahin.", [["COVID", "TREATMENT", 38, 43]]], ["He found inverse correlation between wind speed, air humidity and temperature as the weather parameters with COVID-19 cases (\u015eahin, 2020) .", [["air humidity", "TREATMENT", 49, 61], ["COVID", "TEST", 109, 114], ["air humidity", "OBSERVATION", 49, 61]]], ["A study (Xu et al., 2020a) showed a significant relation (Poisson regression model) between air quality index (AQI) that determine the ambient air quality with COVID-19 cases for Chinese cities.", [["A study", "TEST", 0, 7], ["a significant relation (Poisson regression model) between air quality index", "PROBLEM", 34, 109], ["COVID", "TEST", 160, 165]]], ["A recent extensive research has studied the persistence of diverse strains of air-conveyed influenza virus and (Pyankov et al., 2012) observed that infectious virus were present following 90 min of aerosolisation.", [["influenza", "DISEASE", 91, 100], ["air-conveyed influenza virus", "ORGANISM", 78, 106], ["air-conveyed influenza virus", "SPECIES", 78, 106], ["air-conveyed influenza virus", "SPECIES", 78, 106], ["diverse strains of air-conveyed influenza virus", "PROBLEM", 59, 106], ["infectious virus", "PROBLEM", 148, 164], ["aerosolisation", "PROBLEM", 198, 212], ["diverse strains", "OBSERVATION", 59, 74], ["influenza virus", "OBSERVATION", 91, 106], ["infectious virus", "OBSERVATION", 148, 164]]], ["Air temperature and humidity, microbial resistance to external physical and biological stresses, and solar intensity have been introduced to be some significant factors of air that affect the persistence and distribution of microorganisms (Pyankov et al., 2012) .", [["Air temperature", "TEST", 0, 15], ["humidity", "TREATMENT", 20, 28], ["microbial resistance to external physical and biological stresses", "PROBLEM", 30, 95], ["solar intensity", "PROBLEM", 101, 116], ["some significant factors of air", "PROBLEM", 144, 175], ["microorganisms", "PROBLEM", 224, 238], ["humidity", "OBSERVATION_MODIFIER", 20, 28], ["microbial resistance", "OBSERVATION", 30, 50], ["biological stresses", "OBSERVATION", 76, 95], ["solar intensity", "OBSERVATION_MODIFIER", 101, 116], ["air", "OBSERVATION", 172, 175]]], ["Cases may be transmitted continually and grow (exponentially) and rapidly within an spectrum of humidity varying from cold and dry provinces in China, including Jilin and Heilongjiang, to hot regions, such as Guangxi, and Singapore (Luo et al., 2020) .", [["cold", "PROBLEM", 118, 122], ["Jilin", "TREATMENT", 161, 166]]], ["A conclusion can be drawn that climatic changes lonely (i.e., rises of temperature and humidity upon reaching spring and summer months in the Northern Hemisphere) will not essentially result in reductions in case frequencies with no execution of widespread public health interventions.", [["widespread", "OBSERVATION_MODIFIER", 246, 256]]], ["Carducci et al. (Carducci et al., 2013) reported that totally 30% (12/40) of air samples and 13\u00b75% (5 / 37) of surface samples obtained from the solid waste removal location were positive for the virus.", [["air samples", "ANATOMY", 77, 88], ["surface samples", "ANATOMY", 111, 126], ["air samples", "CANCER", 77, 88], ["air samples", "TEST", 77, 88], ["surface samples", "TEST", 111, 126], ["the solid waste removal", "TREATMENT", 141, 164], ["the virus", "PROBLEM", 192, 201]]], ["Pyankov et al. (Pyankov et al., 2018) investigated the persistence of aerosolised MERS-CoV in ambient air.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 82, 90], ["MERS-CoV", "SPECIES", 82, 90], ["aerosolised MERS", "PROBLEM", 70, 86], ["ambient air", "OBSERVATION", 94, 105]]], ["They detected a rather high count of viral particles at 25 \u00b0C, as opposed to influenza strains, with over 63% of living particles staying in the air following 60 min of aerosolisation.", [["influenza", "DISEASE", 77, 86], ["a rather high count of viral particles", "PROBLEM", 14, 52], ["influenza strains", "PROBLEM", 77, 94], ["aerosolisation", "PROBLEM", 169, 183], ["viral particles", "OBSERVATION_MODIFIER", 37, 52], ["influenza strains", "OBSERVATION", 77, 94], ["air", "ANATOMY", 145, 148]]], ["The inactivation was much more effectual at 38 \u00b0C, with merely 4\u00b77% live viruses observed after completing the 60 min run.Transmission by ambient airThe reported findings illustrate that the strain is capable of surviving during prolonged times and has the potential of spreading because of respiratory contagion even under tropical and arid weather situations relating to the Middle Eastern area, the place of origin for this virus.Transmission by ambient airDoremalen et al found identical persistence of HCoV-19 and SARS-CoV under the settings examined experimentally (van Doremalen et al., 2020) .", [["respiratory contagion", "DISEASE", 291, 312], ["SARS", "DISEASE", 519, 523], ["HCoV-19", "GENE_OR_GENE_PRODUCT", 507, 514], ["SARS-CoV", "ORGANISM", 519, 527], ["HCoV-19", "SPECIES", 507, 514], ["SARS-CoV", "SPECIES", 519, 527], ["the strain", "PROBLEM", 187, 197], ["respiratory contagion", "PROBLEM", 291, 312], ["the Middle Eastern area", "PROBLEM", 373, 396], ["this virus", "PROBLEM", 422, 432], ["HCoV", "TEST", 507, 511], ["SARS", "PROBLEM", 519, 523], ["Middle", "ANATOMY_MODIFIER", 377, 383]]], ["According to their findings, HCoV-19 retained its viability in aerosols in the course of their experimental period (3 h) with a reduced in infective titre between 10 3.5 and 10 2.7 TCID 50 /L, to the same as that noticed for SARS-CoV, from 10 4.3 to 10 3.5 TCID 50 /mL.", [["HCoV-19", "CHEMICAL", 29, 36], ["SARS", "DISEASE", 225, 229], ["HCoV-19", "CHEMICAL", 29, 36], ["HCoV-19", "CELL", 29, 36], ["SARS-CoV", "SPECIES", 225, 233], ["HCoV", "TEST", 29, 33], ["a reduced in infective titre", "PROBLEM", 126, 154], ["SARS", "PROBLEM", 225, 229], ["CoV", "TEST", 230, 233], ["viability", "OBSERVATION_MODIFIER", 50, 59], ["reduced", "OBSERVATION_MODIFIER", 128, 135], ["infective", "OBSERVATION", 139, 148]]], ["The above surveys suggest that aerosol and fomite spread of HCoV-19 is probable because the virus is able to retain its viability in aerosols for several hours and on surfaces for a number of days.", [["HCoV-19", "CHEMICAL", 60, 67], ["HCoV-19", "CHEMICAL", 60, 67], ["HCoV-19", "ORGANISM", 60, 67], ["HCoV-19", "SPECIES", 60, 67], ["The above surveys", "TEST", 0, 17], ["aerosol", "TREATMENT", 31, 38], ["HCoV", "TEST", 60, 64], ["the virus", "PROBLEM", 88, 97], ["virus", "OBSERVATION", 92, 97]]], ["Ogen studied the nitrogen dioxide (NO 2 ) levels of ambient air as a causal factor to coronavirus (COVID-19) fatality in Turkey.", [["nitrogen dioxide", "CHEMICAL", 17, 33], ["NO", "CHEMICAL", 35, 37], ["coronavirus", "DISEASE", 86, 97], ["nitrogen dioxide", "CHEMICAL", 17, 33], ["NO 2", "CHEMICAL", 35, 39], ["nitrogen dioxide", "SIMPLE_CHEMICAL", 17, 33], ["NO 2", "SIMPLE_CHEMICAL", 35, 39], ["coronavirus", "ORGANISM", 86, 97], ["the nitrogen dioxide", "TEST", 13, 33], ["ambient air", "PROBLEM", 52, 63], ["coronavirus", "PROBLEM", 86, 97]]], ["The results showed as the NO 2 can lead to lung inflammatory and may be increasing susceptibility to air pollution, so chronic airway disease due to long-term exposure to air pollutants can increase the COVID-19 fatality (Ogen, 2020) .", [["lung", "ANATOMY", 43, 47], ["airway", "ANATOMY", 127, 133], ["NO", "CHEMICAL", 26, 28], ["chronic airway disease", "DISEASE", 119, 141], ["NO 2", "CHEMICAL", 26, 30], ["NO 2", "GENE_OR_GENE_PRODUCT", 26, 30], ["lung", "ORGAN", 43, 47], ["airway", "MULTI-TISSUE_STRUCTURE", 127, 133], ["lung inflammatory", "PROBLEM", 43, 60], ["increasing susceptibility to air pollution", "PROBLEM", 72, 114], ["chronic airway disease", "PROBLEM", 119, 141], ["long-term exposure", "PROBLEM", 149, 167], ["air pollutants", "PROBLEM", 171, 185], ["the COVID", "TEST", 199, 208], ["lung", "ANATOMY", 43, 47], ["inflammatory", "OBSERVATION", 48, 60], ["may be", "UNCERTAINTY", 65, 71], ["increasing", "OBSERVATION_MODIFIER", 72, 82], ["air pollution", "OBSERVATION", 101, 114], ["chronic", "OBSERVATION_MODIFIER", 119, 126], ["airway", "ANATOMY", 127, 133], ["disease", "OBSERVATION", 134, 141], ["long-term", "OBSERVATION_MODIFIER", 149, 158], ["air pollutants", "OBSERVATION", 171, 185]]], ["In regard with impact of particulate matter, Mehmood et al stated that although the short-and long-term exposure with PM 2.5 resulted in higher incidence of lethality of COVID-19, however, estimation of PM 2.5 incidence is required to experimental and epidemiological studies (Mehmood et al., 2020) .", [["lethality", "PROBLEM", 157, 166], ["COVID", "TEST", 170, 175], ["epidemiological studies", "TEST", 252, 275]]], ["Correia et al addressed indoor and environmental transmission of the SARS-CoV-2 through Heating, Ventilation and Air Conditioning Systems (HVAC) (Correia et al., 2020) .", [["SARS", "DISEASE", 69, 73], ["the SARS", "TEST", 65, 73], ["CoV", "TEST", 74, 77], ["Ventilation", "TREATMENT", 97, 108]]], ["By controlling this transmission routs the pandemic control of COVID-19 can be more effective.", [["COVID-19", "CHEMICAL", 63, 71], ["COVID-19", "CHEMICAL", 63, 71], ["COVID-19", "DNA", 63, 71], ["COVID", "TREATMENT", 63, 68]]], ["However, Faridi et al (Faridi et al., 2020) did not found viral RNA in air samples taken from patient room with confirmed COVID-19 at distance of 2 to 5 m from the beds.New ways of SARS-CoV-2 transmission that maybe facilitated by angiotensinconverting enzyme 2 (ACE2)The commonly observed indications of COVID-19 at disease incidence are fever, fatigue, dry cough, myalgia, and dyspnoea (Wang et al., 2020a) .", [["air samples", "ANATOMY", 71, 82], ["SARS", "DISEASE", 181, 185], ["fever", "DISEASE", 339, 344], ["fatigue", "DISEASE", 346, 353], ["dry cough", "DISEASE", 355, 364], ["myalgia", "DISEASE", 366, 373], ["dyspnoea", "DISEASE", 379, 387], ["air samples", "ORGANISM_SUBSTANCE", 71, 82], ["patient", "ORGANISM", 94, 101], ["CoV-2", "ORGANISM", 186, 191], ["angiotensinconverting enzyme 2", "GENE_OR_GENE_PRODUCT", 231, 261], ["ACE2", "GENE_OR_GENE_PRODUCT", 263, 267], ["COVID-19", "GENE_OR_GENE_PRODUCT", 305, 313], ["viral RNA", "RNA", 58, 67], ["angiotensinconverting enzyme 2", "PROTEIN", 231, 261], ["ACE2", "PROTEIN", 263, 267], ["patient", "SPECIES", 94, 101], ["viral RNA in air samples", "PROBLEM", 58, 82], ["COVID", "TEST", 122, 127], ["SARS", "PROBLEM", 181, 185], ["COVID", "TEST", 305, 310], ["fever", "PROBLEM", 339, 344], ["fatigue", "PROBLEM", 346, 353], ["dry cough", "PROBLEM", 355, 364], ["myalgia", "PROBLEM", 366, 373], ["dyspnoea", "PROBLEM", 379, 387], ["viral RNA", "OBSERVATION", 58, 67], ["beds", "ANATOMY", 164, 168], ["SARS", "OBSERVATION", 181, 185], ["myalgia", "OBSERVATION", 366, 373]]], ["Few patients could also present headache, dizziness, abdominal pain, diarrhoea, nausea, and vomiting (Wang et al., 2020a) .", [["abdominal", "ANATOMY", 53, 62], ["headache", "DISEASE", 32, 40], ["dizziness", "DISEASE", 42, 51], ["abdominal pain", "DISEASE", 53, 67], ["diarrhoea", "DISEASE", 69, 78], ["nausea", "DISEASE", 80, 86], ["vomiting", "DISEASE", 92, 100], ["patients", "ORGANISM", 4, 12], ["abdominal", "ORGANISM_SUBDIVISION", 53, 62], ["patients", "SPECIES", 4, 12], ["headache", "PROBLEM", 32, 40], ["dizziness", "PROBLEM", 42, 51], ["abdominal pain", "PROBLEM", 53, 67], ["diarrhoea", "PROBLEM", 69, 78], ["nausea", "PROBLEM", 80, 86], ["vomiting", "PROBLEM", 92, 100], ["headache", "OBSERVATION", 32, 40], ["abdominal", "ANATOMY", 53, 62], ["pain", "OBSERVATION", 63, 67], ["diarrhoea", "OBSERVATION", 69, 78], ["nausea", "OBSERVATION", 80, 86]]], ["Illness incidence may result in continuous respiratory inability because of alveolar harm and even demise.", [["respiratory", "ANATOMY", 43, 54], ["alveolar", "ANATOMY", 76, 84], ["alveolar harm", "DISEASE", 76, 89], ["alveolar", "MULTI-TISSUE_STRUCTURE", 76, 84], ["Illness incidence", "PROBLEM", 0, 17], ["continuous respiratory inability", "PROBLEM", 32, 64], ["alveolar harm", "PROBLEM", 76, 89], ["even demise", "PROBLEM", 94, 105], ["alveolar", "ANATOMY", 76, 84]]], ["The expression and dissemination of angiotensin-converting enzyme 2 (ACE2) in the human body can be indicative of the possible entrance of SARS-CoV-2 that play as a receptor (Bosso et al., 2020) .", [["body", "ANATOMY", 88, 92], ["angiotensin", "CHEMICAL", 36, 47], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 36, 67], ["ACE2", "GENE_OR_GENE_PRODUCT", 69, 73], ["human", "ORGANISM", 82, 87], ["body", "ORGANISM_SUBDIVISION", 88, 92], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 139, 149], ["angiotensin-converting enzyme 2", "PROTEIN", 36, 67], ["ACE2", "PROTEIN", 69, 73], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 82, 87], ["angiotensin", "TEST", 36, 47], ["converting enzyme", "TEST", 48, 65]]], ["High ACE2 expression was detected in type II alveolar cells (AT2) of the lung, oesophagus, upper and stratified epithelial cells, absorptive enterocytes from the ileum and colon, cholangiocytes, myocardial cells, kidney proximal tubule cells, and bladder urothelial cells (Xu et al., 2020b; Zhang et al., 2020) .", [["type II alveolar cells", "ANATOMY", 37, 59], ["lung", "ANATOMY", 73, 77], ["oesophagus", "ANATOMY", 79, 89], ["upper", "ANATOMY", 91, 96], ["epithelial cells", "ANATOMY", 112, 128], ["absorptive enterocytes", "ANATOMY", 130, 152], ["ileum", "ANATOMY", 162, 167], ["colon", "ANATOMY", 172, 177], ["cholangiocytes", "ANATOMY", 179, 193], ["myocardial cells", "ANATOMY", 195, 211], ["kidney proximal tubule cells", "ANATOMY", 213, 241], ["bladder urothelial cells", "ANATOMY", 247, 271], ["ACE2", "GENE_OR_GENE_PRODUCT", 5, 9], ["type II alveolar cells", "CELL", 37, 59], ["AT2", "CELL", 61, 64], ["lung", "ORGAN", 73, 77], ["oesophagus", "ORGAN", 79, 89], ["upper", "ORGAN", 91, 96], ["epithelial cells", "CELL", 112, 128], ["absorptive enterocytes", "TISSUE", 130, 152], ["ileum", "MULTI-TISSUE_STRUCTURE", 162, 167], ["colon", "ORGAN", 172, 177], ["cholangiocytes", "CELL", 179, 193], ["myocardial cells", "CELL", 195, 211], ["kidney proximal tubule cells", "CELL", 213, 241], ["bladder urothelial cells", "CELL", 247, 271], ["ACE2", "PROTEIN", 5, 9], ["type II alveolar cells", "CELL_TYPE", 37, 59], ["upper and stratified epithelial cells", "CELL_TYPE", 91, 128], ["absorptive enterocytes", "CELL_TYPE", 130, 152], ["myocardial cells", "CELL_TYPE", 195, 211], ["kidney proximal tubule cells", "CELL_TYPE", 213, 241], ["bladder urothelial cells", "CELL_TYPE", 247, 271], ["High ACE2 expression", "PROBLEM", 0, 20], ["upper and stratified epithelial cells", "PROBLEM", 91, 128], ["absorptive enterocytes from the ileum and colon", "PROBLEM", 130, 177], ["myocardial cells", "PROBLEM", 195, 211], ["kidney proximal tubule cells", "PROBLEM", 213, 241], ["bladder urothelial cells", "PROBLEM", 247, 271], ["ACE2 expression", "OBSERVATION", 5, 20], ["type II", "OBSERVATION_MODIFIER", 37, 44], ["alveolar cells", "OBSERVATION", 45, 59], ["lung", "ANATOMY", 73, 77], ["oesophagus", "ANATOMY", 79, 89], ["upper", "ANATOMY_MODIFIER", 91, 96], ["epithelial cells", "OBSERVATION", 112, 128], ["absorptive enterocytes", "OBSERVATION", 130, 152], ["ileum", "ANATOMY", 162, 167], ["colon", "ANATOMY", 172, 177], ["cholangiocytes", "ANATOMY", 179, 193], ["myocardial cells", "OBSERVATION", 195, 211], ["kidney", "ANATOMY", 213, 219], ["proximal", "ANATOMY_MODIFIER", 220, 228], ["tubule cells", "OBSERVATION", 229, 241], ["bladder urothelial", "ANATOMY", 247, 265]]], ["These observations revealed that the organs with high ACE2-expressing cells would be regarded as those with high potential risk for SARS-CoV-2 contamination (Xu et al., 2020b) .", [["organs", "ANATOMY", 37, 43], ["cells", "ANATOMY", 70, 75], ["SARS", "DISEASE", 132, 136], ["organs", "ORGAN", 37, 43], ["ACE2", "GENE_OR_GENE_PRODUCT", 54, 58], ["cells", "CELL", 70, 75], ["ACE2", "PROTEIN", 54, 58], ["expressing cells", "CELL_TYPE", 59, 75], ["These observations", "TEST", 0, 18], ["high ACE2-expressing cells", "PROBLEM", 49, 75], ["SARS", "PROBLEM", 132, 136], ["CoV", "PROBLEM", 137, 140]]], ["Xu et al. modelled the spike protein of the receptor for SARS-CoV-2 and found that ACE2 might be the receptor for this viral strain (Xu et al., 2020b) .New ways of SARS-CoV-2 transmission that maybe facilitated by angiotensinconverting enzyme 2 (ACE2)Likewise, ACE2 is a receptor for SARS-nCoV and NL63 .", [["SARS", "DISEASE", 164, 168], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 57, 67], ["ACE2", "GENE_OR_GENE_PRODUCT", 83, 87], ["CoV-2", "ORGANISM", 169, 174], ["angiotensinconverting enzyme 2", "GENE_OR_GENE_PRODUCT", 214, 244], ["ACE2", "GENE_OR_GENE_PRODUCT", 246, 250], ["ACE2", "GENE_OR_GENE_PRODUCT", 261, 265], ["SARS-nCoV", "GENE_OR_GENE_PRODUCT", 284, 293], ["NL63", "GENE_OR_GENE_PRODUCT", 298, 302], ["spike protein", "PROTEIN", 23, 36], ["ACE2", "PROTEIN", 83, 87], ["angiotensinconverting enzyme 2", "PROTEIN", 214, 244], ["ACE2", "PROTEIN", 246, 250], ["ACE2", "PROTEIN", 261, 265], ["nCoV", "PROTEIN", 289, 293], ["NL63", "PROTEIN", 298, 302], ["SARS-CoV", "SPECIES", 57, 65], ["SARS", "PROBLEM", 57, 61], ["CoV", "TEST", 62, 65], ["ACE2", "PROBLEM", 83, 87], ["this viral strain", "PROBLEM", 114, 131], ["SARS", "PROBLEM", 164, 168], ["ACE2", "TEST", 261, 265], ["SARS", "PROBLEM", 284, 288], ["nCoV", "TREATMENT", 289, 293], ["NL63", "TREATMENT", 298, 302], ["SARS", "OBSERVATION", 164, 168]]], ["Based on their model, the coupling strength is greater between SARS-CoV-2 and ACE2 than the limit needed for viral contamination, though it is poorer than that between SARS-nCoV and ACE2.", [["ACE2", "GENE_OR_GENE_PRODUCT", 78, 82], ["SARS-nCoV", "GENE_OR_GENE_PRODUCT", 168, 177], ["ACE2", "GENE_OR_GENE_PRODUCT", 182, 186], ["ACE2", "PROTEIN", 78, 82], ["nCoV", "PROTEIN", 173, 177], ["ACE2", "PROTEIN", 182, 186], ["the coupling strength", "TEST", 22, 43], ["SARS", "TEST", 63, 67], ["CoV", "TEST", 68, 71], ["ACE2", "TEST", 78, 82], ["viral contamination", "PROBLEM", 109, 128], ["ACE2", "TREATMENT", 182, 186], ["greater", "OBSERVATION_MODIFIER", 47, 54]]], ["Zhou et al. carried out viral contamination assays and detected that ACE2 would be necessary for entering SARS-CoV-2 into HeLa cells (Zhao et al., 2020) .", [["HeLa cells", "ANATOMY", 122, 132], ["SARS", "DISEASE", 106, 110], ["ACE2", "GENE_OR_GENE_PRODUCT", 69, 73], ["HeLa cells", "CELL", 122, 132], ["ACE2", "PROTEIN", 69, 73], ["HeLa cells", "CELL_LINE", 122, 132], ["SARS-CoV", "SPECIES", 106, 114], ["viral contamination assays", "TEST", 24, 50], ["ACE2", "TEST", 69, 73]]], ["Such information demonstrate that ACE2 may be the receptor for SARS-CoV-2.", [["ACE2", "GENE_OR_GENE_PRODUCT", 34, 38], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 63, 73], ["ACE2", "PROTEIN", 34, 38], ["SARS", "TEST", 63, 67], ["CoV", "TEST", 68, 71]]], ["Zhao et al. examined normal lung tissue cells of eight healthy persons and noticed that the only Asian donor presented over five times the ACE2 expressing cell ratio as white and African American donors.", [["lung tissue cells", "ANATOMY", 28, 45], ["cell", "ANATOMY", 155, 159], ["lung tissue cells", "CELL", 28, 45], ["persons", "ORGANISM", 63, 70], ["ACE2", "GENE_OR_GENE_PRODUCT", 139, 143], ["cell", "CELL", 155, 159], ["donors", "ORGANISM", 196, 202], ["normal lung tissue cells", "CELL_TYPE", 21, 45], ["ACE2", "PROTEIN", 139, 143], ["persons", "SPECIES", 63, 70], ["lung", "ANATOMY", 28, 32], ["tissue cells", "OBSERVATION", 33, 45]]], ["These findings suggest that the Asian population is likely to be increasingly susceptible, though such a conclusion requires further documentation.", [["the Asian population", "PROBLEM", 28, 48], ["likely to be", "UNCERTAINTY", 52, 64]]], ["Hao Xu et al. (Xu et al., 2020b) presented evidence of ACE2 expression on the mucosa of the oral cavity.", [["mucosa", "ANATOMY", 78, 84], ["oral cavity", "ANATOMY", 92, 103], ["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["mucosa", "MULTI-TISSUE_STRUCTURE", 78, 84], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 92, 103], ["ACE2", "PROTEIN", 55, 59], ["ACE2 expression on the mucosa of the oral cavity", "PROBLEM", 55, 103], ["ACE2 expression", "OBSERVATION", 55, 70], ["mucosa", "ANATOMY", 78, 84], ["oral cavity", "ANATOMY", 92, 103]]], ["It is interesting that this receptor contained a high bulk of epithelial cells of the tongue, which have justified the basic mode of action by which the oral cavity has the potential of a high risk for SARS-CoV-2 contamination sensitivity; such discoveries also present proof of forthcoming preventing policies in dental clinical practice (Peng et al., 2020b) and everyday life.", [["epithelial cells", "ANATOMY", 62, 78], ["tongue", "ANATOMY", 86, 92], ["oral cavity", "ANATOMY", 153, 164], ["SARS", "DISEASE", 202, 206], ["epithelial cells", "CELL", 62, 78], ["tongue", "ORGAN", 86, 92], ["oral cavity", "ORGANISM_SUBDIVISION", 153, 164], ["epithelial cells", "CELL_TYPE", 62, 78], ["epithelial cells of the tongue", "PROBLEM", 62, 92], ["SARS", "PROBLEM", 202, 206], ["CoV", "TEST", 207, 210], ["2 contamination sensitivity", "PROBLEM", 211, 238], ["high bulk", "OBSERVATION_MODIFIER", 49, 58], ["epithelial cells", "OBSERVATION", 62, 78], ["tongue", "ANATOMY", 86, 92]]], ["The observations also imply that ACE2 has a significant contribution to cellular entrance (Choi et al., 2020) ; hence, ACE2-expressing cells can serve as target cells, and have susceptibility to SARS-CoV-2 contamination.", [["cellular", "ANATOMY", 72, 80], ["cells", "ANATOMY", 135, 140], ["cells", "ANATOMY", 161, 166], ["SARS", "DISEASE", 195, 199], ["ACE2", "GENE_OR_GENE_PRODUCT", 33, 37], ["cellular", "CELL", 72, 80], ["ACE2", "GENE_OR_GENE_PRODUCT", 119, 123], ["cells", "CELL", 135, 140], ["cells", "CELL", 161, 166], ["CoV-2", "ORGANISM", 200, 205], ["ACE2", "PROTEIN", 33, 37], ["ACE2", "PROTEIN", 119, 123], ["expressing cells", "CELL_TYPE", 124, 140], ["target cells", "CELL_TYPE", 154, 166], ["ACE2", "TEST", 119, 123], ["SARS", "TEST", 195, 199], ["CoV", "TEST", 200, 203], ["significant", "OBSERVATION_MODIFIER", 44, 55]]], ["It may be the SARS-COV-2 virus uses the ACE2 receptor to improvement access the cell interior that the virus can do replication there easily (Li et al., 2020) .ConclusionThe accessible data about environmental spread paths for SARS-CoV-2 that have not been earlier investigated to date were reviewed here, indicating the availability of scarce or unavailable documentation concerning thereof.", [["cell", "ANATOMY", 80, 84], ["SARS", "DISEASE", 227, 231], ["SARS-COV-2 virus", "ORGANISM", 14, 30], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 40, 53], ["cell", "CELL", 80, 84], ["SARS-CoV-2", "ORGANISM", 227, 237], ["ACE2 receptor", "PROTEIN", 40, 53], ["SARS-COV-2 virus", "SPECIES", 14, 30], ["SARS-CoV", "SPECIES", 227, 235], ["the SARS-COV-2 virus", "PROBLEM", 10, 30], ["the ACE2 receptor", "TREATMENT", 36, 53], ["the virus", "PROBLEM", 99, 108], ["SARS-CoV", "TEST", 227, 235]]], ["Despite the unconfirmed contagion of SARS-CoV-2 via drinking water, sewer systems, and ambient air revealed by accessible guidelines, reviewed data strengthen the suspicion by highlighting the robust potential of environmental spread via these paths hence necessitating extra studies.", [["SARS", "DISEASE", 37, 41], ["CoV-2", "ORGANISM", 42, 47], ["SARS", "PROBLEM", 37, 41], ["CoV", "TEST", 42, 45], ["extra studies", "TEST", 270, 283]]], ["Moreover, the ACE2 that was recognised as a cellular doorway for SARS-CoV-2 entrance the cells by some studies, which may be usable for identifying novel paths of SARS-CoV-2 contagion.", [["cellular", "ANATOMY", 44, 52], ["cells", "ANATOMY", 89, 94], ["SARS", "DISEASE", 163, 167], ["ACE2", "GENE_OR_GENE_PRODUCT", 14, 18], ["cellular", "CELL", 44, 52], ["cells", "CELL", 89, 94], ["ACE2", "PROTEIN", 14, 18], ["SARS", "PROBLEM", 65, 69], ["some studies", "TEST", 98, 110], ["SARS", "PROBLEM", 163, 167]]]], "56bd30d2d40d31e2237dbcd0712d347b9bb18556": [["Neurobiological Insights Into Stress-Induced Attention DeficitEmily C. WrightNeurobiological Insights Into Stress-Induced Attention DeficitAt the start of the COVID-19 quarantine I found myself in the unenviable position of having to shut down my research.", [["the COVID", "TREATMENT", 155, 164]]], ["I told myself I would make the most of it by tackling my backlog of writing and data analysis.", [["data analysis", "TEST", 80, 93]]], ["In times of stress and turmoil, attentional control can become disrupted, hindering an individual's ability to function.", [["stress", "PROBLEM", 12, 18], ["turmoil", "PROBLEM", 23, 30], ["attentional control", "TREATMENT", 32, 51]]], ["This disruption, also referred to as an attention deficit, is a hallmark trait of several neurological conditions such as attention-deficit/hyperactivity disorder (ADHD).", [["neurological", "ANATOMY", 90, 102], ["attention deficit", "DISEASE", 40, 57], ["neurological conditions", "DISEASE", 90, 113], ["attention-deficit/hyperactivity disorder", "DISEASE", 122, 162], ["ADHD", "DISEASE", 164, 168], ["This disruption", "PROBLEM", 0, 15], ["an attention deficit", "PROBLEM", 37, 57], ["several neurological conditions", "PROBLEM", 82, 113], ["hyperactivity disorder", "PROBLEM", 140, 162]]], ["Despite the prominent importance of attentional ability, much is still unknown about how stress impacts the neural circuits of attention.", [["neural", "ANATOMY", 108, 114], ["prominent", "OBSERVATION_MODIFIER", 12, 21]]], ["Narrowing gaps in the current understanding of attentional control, Eck et al. (1) discovered that stress-induced attention deficits are linked with distinct neurobiological and molecular changes in major cortical regions.Neurobiological Insights Into Stress-Induced Attention DeficitIn the current issue of Biological Psychiatry, Eck et al.Neurobiological Insights Into Stress-Induced Attention Deficit(1) investigated the role of stress on the attention system in adult male and female rats.", [["cortical regions", "ANATOMY", 205, 221], ["stress-induced attention deficits", "DISEASE", 99, 132], ["cortical regions", "MULTI-TISSUE_STRUCTURE", 205, 221], ["rats", "ORGANISM", 488, 492], ["rats", "SPECIES", 488, 492], ["Narrowing gaps", "PROBLEM", 0, 14], ["attentional control", "TREATMENT", 47, 66], ["stress-induced attention deficits", "PROBLEM", 99, 132], ["distinct neurobiological and molecular changes in major cortical regions", "PROBLEM", 149, 221], ["Attention Deficit", "PROBLEM", 386, 403], ["gaps", "OBSERVATION_MODIFIER", 10, 14], ["molecular changes", "OBSERVATION", 178, 195], ["major", "ANATOMY_MODIFIER", 199, 204], ["cortical", "ANATOMY_MODIFIER", 205, 213], ["regions", "ANATOMY_MODIFIER", 214, 221]]], ["Variable stressors were administered via a daily episode of restraint, predator odor, or forced swim stressors for a total of 6 days.", [["Variable stressors", "PROBLEM", 0, 18], ["restraint", "TREATMENT", 60, 69], ["predator odor", "PROBLEM", 71, 84]]], ["Control rats received comparable handling.", [["rats", "ORGANISM", 8, 12], ["rats", "SPECIES", 8, 12]]], ["Attention was evaluated via a sustained attention task that was designed for rats to learn to distinguish between signal trials, when a signal light indicated the availability of food reward versus nonsignal conditions ( Figure 1 ).", [["rats", "ORGANISM", 77, 81], ["rats", "SPECIES", 77, 81], ["a sustained attention task", "TREATMENT", 28, 54], ["nonsignal conditions", "PROBLEM", 198, 218]]], ["The sustained attention task was administered 30 minutes after the cessation of variable stress (or control handling) across all 6 days of experimentation.Neurobiological Insights Into Stress-Induced Attention DeficitExposure to variable stressors impaired attention in both male and female rats.", [["rats", "ORGANISM", 291, 295], ["rats", "SPECIES", 291, 295], ["variable stress", "PROBLEM", 80, 95], ["variable stressors", "PROBLEM", 229, 247]]], ["This fits within a larger body of literature demonstrating that stress impairs a wide array of executive functions.", [["stress impairs", "PROBLEM", 64, 78]]], ["The authors performed several experiments to investigate how stress impacts neural functions of attention.", [["neural", "ANATOMY", 76, 82]]], ["They focused their investigation on the nucleus basalis of Meynert (NBM), which promotes attention through the activity of cholinergic neurons (1).", [["nucleus basalis", "ANATOMY", 40, 55], ["NBM", "ANATOMY", 68, 71], ["cholinergic neurons", "ANATOMY", 123, 142], ["nucleus basalis", "CELLULAR_COMPONENT", 40, 55], ["Meynert", "CELLULAR_COMPONENT", 59, 66], ["NBM", "MULTI-TISSUE_STRUCTURE", 68, 71], ["cholinergic neurons", "CELL", 123, 142], ["cholinergic neurons", "CELL_TYPE", 123, 142]]], ["Most excitingly they found that stressed males and females had a significant increase in Dusp1 expression.", [["Dusp1", "GENE_OR_GENE_PRODUCT", 89, 94], ["Dusp1", "PROTEIN", 89, 94], ["a significant increase in Dusp1 expression", "PROBLEM", 63, 105], ["significant", "OBSERVATION_MODIFIER", 65, 76], ["increase", "OBSERVATION_MODIFIER", 77, 85], ["Dusp1 expression", "OBSERVATION", 89, 105]]], ["DUSP1 is a phosphatase that induces dendritic hypertrophy.", [["dendritic", "ANATOMY", 36, 45], ["dendritic hypertrophy", "DISEASE", 36, 57], ["DUSP1", "GENE_OR_GENE_PRODUCT", 0, 5], ["DUSP1", "PROTEIN", 0, 5], ["phosphatase", "PROTEIN", 11, 22], ["a phosphatase", "TEST", 9, 22], ["dendritic hypertrophy", "PROBLEM", 36, 57], ["dendritic hypertrophy", "OBSERVATION", 36, 57]]], ["Increased cortical expression of Dusp1 has been found in rodent models of ADHD (2) .", [["cortical", "ANATOMY", 10, 18], ["ADHD", "DISEASE", 74, 78], ["cortical", "MULTI-TISSUE_STRUCTURE", 10, 18], ["Dusp1", "GENE_OR_GENE_PRODUCT", 33, 38], ["Dusp1", "PROTEIN", 33, 38], ["Increased cortical expression of Dusp1", "PROBLEM", 0, 38], ["cortical expression", "OBSERVATION", 10, 29], ["Dusp1", "OBSERVATION", 33, 38]]], ["More broadly, differential expression of transcripts in the Dusp family have also been linked to depression and anxiety (3) and are an exciting new target for novel pharmaceuticals.", [["depression", "DISEASE", 97, 107], ["anxiety", "DISEASE", 112, 119], ["Dusp", "GENE_OR_GENE_PRODUCT", 60, 64], ["Dusp family", "PROTEIN", 60, 71], ["depression", "PROBLEM", 97, 107], ["anxiety", "PROBLEM", 112, 119], ["novel pharmaceuticals", "TREATMENT", 159, 180]]], ["While increased Dusp1 expression is traditionally associated with hypertrophy of dopaminergic neurons, its role in the regulation of cholinergic neurons has yet to be investigated.", [["dopaminergic neurons", "ANATOMY", 81, 101], ["cholinergic neurons", "ANATOMY", 133, 152], ["Dusp1", "GENE_OR_GENE_PRODUCT", 16, 21], ["dopaminergic neurons", "CELL", 81, 101], ["cholinergic neurons", "CELL", 133, 152], ["Dusp1", "PROTEIN", 16, 21], ["dopaminergic neurons", "CELL_TYPE", 81, 101], ["cholinergic neurons", "CELL_TYPE", 133, 152], ["hypertrophy of dopaminergic neurons", "PROBLEM", 66, 101], ["increased", "OBSERVATION_MODIFIER", 6, 15], ["Dusp1 expression", "OBSERVATION", 16, 32], ["hypertrophy", "OBSERVATION", 66, 77], ["dopaminergic neurons", "OBSERVATION", 81, 101]]], ["The authors examined stress-induced changes in dendritic branching of cholinergic neurons in NBM and found increased length and complexity for both sexes.", [["dendritic", "ANATOMY", 47, 56], ["cholinergic neurons", "ANATOMY", 70, 89], ["NBM", "ANATOMY", 93, 96], ["dendritic", "CELL", 47, 56], ["cholinergic neurons", "CELL", 70, 89], ["NBM", "CELL", 93, 96], ["cholinergic neurons", "CELL_TYPE", 70, 89], ["NBM", "CELL_TYPE", 93, 96], ["stress", "PROBLEM", 21, 27], ["dendritic branching of cholinergic neurons in NBM", "PROBLEM", 47, 96], ["increased length", "PROBLEM", 107, 123], ["dendritic", "OBSERVATION_MODIFIER", 47, 56], ["branching", "OBSERVATION_MODIFIER", 57, 66], ["cholinergic neurons", "OBSERVATION", 70, 89], ["NBM", "ANATOMY", 93, 96], ["increased", "OBSERVATION_MODIFIER", 107, 116], ["length", "OBSERVATION_MODIFIER", 117, 123]]], ["Taken together, these findings provide compelling evidence for an investigation into the relationship between DUSP1 and cholinergic hypertrophy.", [["hypertrophy", "DISEASE", 132, 143], ["DUSP1", "GENE_OR_GENE_PRODUCT", 110, 115], ["DUSP1", "PROTEIN", 110, 115], ["an investigation", "TEST", 63, 79], ["DUSP1 and cholinergic hypertrophy", "PROBLEM", 110, 143], ["cholinergic hypertrophy", "OBSERVATION", 120, 143]]], ["Further research into this relationship may also hold valuable information for researchers linking Dusp activity and anxiety behavior.Neurobiological Insights Into Stress-Induced Attention DeficitAlthough stressed male and female rats showed overall attention deficits, there were subtle sex differences on individual days.", [["anxiety", "DISEASE", 117, 124], ["attention deficits", "DISEASE", 250, 268], ["Dusp", "GENE_OR_GENE_PRODUCT", 99, 103], ["rats", "ORGANISM", 230, 234], ["rats", "SPECIES", 230, 234], ["anxiety behavior", "PROBLEM", 117, 133], ["overall attention deficits", "PROBLEM", 242, 268], ["subtle", "OBSERVATION_MODIFIER", 281, 287]]], ["Notably, on the sixth day of testing stressed females no longer showed attention deficits while stressed males continued to have poor performance.", [["attention deficits", "DISEASE", 71, 89], ["attention deficits", "PROBLEM", 71, 89]]], ["This finding suggests that there may be sex differences in the effects of acute versus chronic stress on attention.", [["acute versus chronic stress", "PROBLEM", 74, 101], ["may be", "UNCERTAINTY", 33, 39], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["chronic", "OBSERVATION_MODIFIER", 87, 94], ["stress", "OBSERVATION", 95, 101]]], ["This hypothesis is particularly compelling in light of findings at the neural circuit level and complements other research finding stronger negative impacts of stress on certain executive functions in males than in females (4, 5) .Neurobiological Insights Into Stress-Induced Attention DeficitThe NBM has strong projections to the prefrontal cortex (PFC), which enhances attention through acetylcholine binding to nicotinic receptors (6) .", [["neural", "ANATOMY", 71, 77], ["prefrontal cortex", "ANATOMY", 331, 348], ["PFC", "ANATOMY", 350, 353], ["Attention Deficit", "DISEASE", 276, 293], ["acetylcholine", "CHEMICAL", 389, 402], ["acetylcholine", "CHEMICAL", 389, 402], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 331, 348], ["PFC", "CANCER", 350, 353], ["acetylcholine", "SIMPLE_CHEMICAL", 389, 402], ["NBM", "PROTEIN", 297, 300], ["nicotinic receptors", "PROTEIN", 414, 433], ["stress", "PROBLEM", 160, 166], ["Attention Deficit", "PROBLEM", 276, 293], ["acetylcholine binding to nicotinic receptors", "TREATMENT", 389, 433], ["prefrontal cortex", "ANATOMY", 331, 348]]], ["When examining performance of this pathway in stressed rats, the authors found decreased acetylcholine output in stressed males only, matching their impaired attention.", [["acetylcholine", "CHEMICAL", 89, 102], ["acetylcholine", "CHEMICAL", 89, 102], ["rats", "ORGANISM", 55, 59], ["acetylcholine", "SIMPLE_CHEMICAL", 89, 102], ["rats", "SPECIES", 55, 59], ["decreased acetylcholine output", "PROBLEM", 79, 109], ["decreased", "OBSERVATION_MODIFIER", 79, 88], ["acetylcholine output", "OBSERVATION", 89, 109]]], ["This projection showed no change from baseline in females, running contrary to their overall attention deficits.", [["attention deficits", "DISEASE", 93, 111], ["This projection", "TEST", 0, 15], ["no", "UNCERTAINTY", 23, 25], ["change", "OBSERVATION_MODIFIER", 26, 32]]], ["It is possible that neuroadaptation in females rescued NBM to PFC acetylcholine release by this time point.", [["NBM", "ANATOMY", 55, 58], ["PFC", "ANATOMY", 62, 65], ["acetylcholine", "CHEMICAL", 66, 79], ["acetylcholine", "CHEMICAL", 66, 79], ["NBM", "CELL", 55, 58], ["PFC", "GENE_OR_GENE_PRODUCT", 62, 65], ["acetylcholine", "SIMPLE_CHEMICAL", 66, 79], ["PFC acetylcholine release", "TREATMENT", 62, 87]]], ["Another option is that because control females have lower baseline levels of acetylcholine activity, a floor effect occurred, preventing stress from lowering output any further.", [["acetylcholine", "CHEMICAL", 77, 90], ["acetylcholine", "CHEMICAL", 77, 90], ["acetylcholine", "SIMPLE_CHEMICAL", 77, 90], ["acetylcholine activity", "TREATMENT", 77, 99], ["stress from lowering output", "PROBLEM", 137, 164]]], ["In nonstressed rats, Eck et al. (1) discovered that males have a higher baseline acetylcholine release than females.", [["acetylcholine", "CHEMICAL", 81, 94], ["acetylcholine", "CHEMICAL", 81, 94], ["rats", "ORGANISM", 15, 19], ["acetylcholine", "SIMPLE_CHEMICAL", 81, 94], ["rats", "SPECIES", 15, 19]]], ["There are no sex differences in baseline attention, and therefore it is likely that further sex differences, such as increased nicotinic receptor density, may compensate for the decrease in cholinergic input in females.", [["nicotinic receptor", "GENE_OR_GENE_PRODUCT", 127, 145], ["increased nicotinic receptor density", "PROBLEM", 117, 153], ["the decrease in cholinergic input in females", "PROBLEM", 174, 218], ["no", "UNCERTAINTY", 10, 12], ["is likely", "UNCERTAINTY", 69, 78], ["increased", "OBSERVATION_MODIFIER", 117, 126], ["nicotinic receptor density", "OBSERVATION", 127, 153], ["decrease", "OBSERVATION_MODIFIER", 178, 186], ["cholinergic input", "OBSERVATION", 190, 207]]], ["This is an interesting finding because it highlights sex differences in a neural mechanism of attention both at baseline and in reaction to stress.", [["neural", "ANATOMY", 74, 80], ["stress", "PROBLEM", 140, 146]]], ["Attention encompasses many important aspects of behavior; understanding the neural mechanism for attention in both males and females can provide a wealth of valuable knowledge when trying to understand both neurotypical and neurodiverse behavior.Neurobiological Insights Into Stress-Induced Attention DeficitThe findings outlined are interesting not only from a perspective of stress response and attention but also for a better understanding of the role of the cholinergic system in ADHD.", [["neural", "ANATOMY", 76, 82], ["Attention Deficit", "DISEASE", 291, 308], ["ADHD", "DISEASE", 484, 488], ["Attention Deficit", "PROBLEM", 291, 308], ["stress response", "PROBLEM", 377, 392]]], ["Genetic variability in Dusp1 is associated with ADHD in humans (7), and cortical upregulation of Dusp1 is found in rodent models of ADHD (2) .", [["cortical", "ANATOMY", 72, 80], ["ADHD", "DISEASE", 48, 52], ["ADHD", "DISEASE", 132, 136], ["Dusp1", "GENE_OR_GENE_PRODUCT", 23, 28], ["humans", "ORGANISM", 56, 62], ["cortical", "MULTI-TISSUE_STRUCTURE", 72, 80], ["Dusp1", "GENE_OR_GENE_PRODUCT", 97, 102], ["Dusp1", "DNA", 23, 28], ["Dusp1", "PROTEIN", 97, 102], ["humans", "SPECIES", 56, 62], ["humans", "SPECIES", 56, 62], ["Genetic variability in Dusp1", "PROBLEM", 0, 28], ["ADHD in humans", "PROBLEM", 48, 62], ["cortical upregulation of Dusp1", "PROBLEM", 72, 102], ["variability", "OBSERVATION_MODIFIER", 8, 19], ["Dusp1", "OBSERVATION", 23, 28], ["cortical upregulation", "OBSERVATION", 72, 93], ["Dusp1", "OBSERVATION", 97, 102]]], ["Because of the prominent role the dopamine system plays in ADHD, previous work has focused on the relationship between Dusp1 and hypertrophy of the dopamine system.", [["dopamine", "CHEMICAL", 34, 42], ["ADHD", "DISEASE", 59, 63], ["hypertrophy", "DISEASE", 129, 140], ["dopamine", "CHEMICAL", 148, 156], ["dopamine", "CHEMICAL", 34, 42], ["dopamine", "CHEMICAL", 148, 156], ["dopamine", "SIMPLE_CHEMICAL", 34, 42], ["Dusp1", "GENE_OR_GENE_PRODUCT", 119, 124], ["dopamine", "SIMPLE_CHEMICAL", 148, 156], ["Dusp1", "PROTEIN", 119, 124], ["the dopamine system", "TREATMENT", 30, 49], ["ADHD", "PROBLEM", 59, 63], ["Dusp1", "TEST", 119, 124], ["hypertrophy of the dopamine system", "PROBLEM", 129, 163], ["prominent", "OBSERVATION_MODIFIER", 15, 24], ["hypertrophy", "OBSERVATION", 129, 140], ["dopamine system", "OBSERVATION", 148, 163]]], ["Eck et al.'s findings (1) give cause for investigation into the relationship between Dusp1 and cholinergic neurons as well.", [["cholinergic neurons", "ANATOMY", 95, 114], ["Dusp1", "GENE_OR_GENE_PRODUCT", 85, 90], ["cholinergic neurons", "CELL", 95, 114], ["Dusp1", "PROTEIN", 85, 90], ["cholinergic neurons", "CELL_TYPE", 95, 114], ["Dusp1 and cholinergic neurons", "PROBLEM", 85, 114], ["cholinergic neurons", "ANATOMY", 95, 114]]], ["The MBN is one of the most prominent sites of acetylcholine production and projection in the forebrain (8), a system linked to ADHD.", [["forebrain", "ANATOMY", 93, 102], ["acetylcholine", "CHEMICAL", 46, 59], ["ADHD", "DISEASE", 127, 131], ["acetylcholine", "CHEMICAL", 46, 59], ["MBN", "GENE_OR_GENE_PRODUCT", 4, 7], ["acetylcholine", "SIMPLE_CHEMICAL", 46, 59], ["forebrain", "ORGAN", 93, 102], ["MBN", "PROTEIN", 4, 7], ["ADHD", "PROBLEM", 127, 131], ["MBN", "OBSERVATION", 4, 7], ["one", "OBSERVATION_MODIFIER", 11, 14], ["most prominent", "OBSERVATION_MODIFIER", 22, 36], ["acetylcholine production", "OBSERVATION", 46, 70], ["forebrain", "ANATOMY", 93, 102]]], ["Sparked by the relationship between nicotine consumption and the reduction of ADHD symptomatology, researchers have found nicotinic receptor agonists to have modest clinical benefits (9) .", [["nicotine", "CHEMICAL", 36, 44], ["ADHD symptomatology", "DISEASE", 78, 97], ["nicotine", "CHEMICAL", 36, 44], ["nicotine", "SIMPLE_CHEMICAL", 36, 44], ["nicotine consumption", "TREATMENT", 36, 56], ["ADHD symptomatology", "PROBLEM", 78, 97], ["nicotinic receptor agonists", "TREATMENT", 122, 149]]], ["While these results have not produced pharmaceutical interventions with the same efficacy as stimulant-based therapies, they do provide additional evidence clearly linking attention modulation and the cholinergic system.", [["pharmaceutical interventions", "TREATMENT", 38, 66], ["stimulant-based therapies", "TREATMENT", 93, 118]]], ["ADHD is classified into 3 major subgroups: hyperactive/ impulsive, inattentive, and combined.", [["ADHD", "DISEASE", 0, 4], ["hyperactive/ impulsive, inattentive", "DISEASE", 43, 78], ["hyperactive/ impulsive", "PROBLEM", 43, 65], ["inattentive", "PROBLEM", 67, 78], ["hyperactive", "OBSERVATION", 43, 54], ["impulsive", "OBSERVATION", 56, 65]]], ["Females are more likely to be diagnosed with inattentive type ADHD than males (10) , suggesting that there could be neurological sex differences contributing to how ADHD manifests behaviorally.", [["inattentive type ADHD", "DISEASE", 45, 66], ["ADHD", "DISEASE", 165, 169], ["inattentive type ADHD", "PROBLEM", 45, 66]]], ["The cholinergic system presents itself as an interesting point to consider in this context.", [["cholinergic system", "OBSERVATION", 4, 22]]], ["Acetylcholine binds to both nicotinic and muscarinic receptors in the PFC.", [["PFC", "ANATOMY", 70, 73], ["Acetylcholine", "CHEMICAL", 0, 13], ["Acetylcholine", "CHEMICAL", 0, 13], ["Acetylcholine", "SIMPLE_CHEMICAL", 0, 13], ["nicotinic", "SIMPLE_CHEMICAL", 28, 37], ["PFC", "CANCER", 70, 73], ["nicotinic and muscarinic receptors", "PROTEIN", 28, 62], ["Acetylcholine binds", "TREATMENT", 0, 19], ["muscarinic receptors", "TREATMENT", 42, 62], ["PFC", "ANATOMY", 70, 73]]], ["Activation of nicotinic receptors improves attention while activation of muscarinic receptors increases impulsive behaviors (6).", [["nicotinic receptors", "GENE_OR_GENE_PRODUCT", 14, 33], ["nicotinic receptors", "PROTEIN", 14, 33], ["muscarinic receptors", "PROTEIN", 73, 93], ["Activation of nicotinic receptors", "TREATMENT", 0, 33]]], ["Eck et al. (1) showed that male rats have higher acetylcholine release from the NBM to the PFC.", [["NBM", "ANATOMY", 80, 83], ["PFC", "ANATOMY", 91, 94], ["acetylcholine", "CHEMICAL", 49, 62], ["acetylcholine", "CHEMICAL", 49, 62], ["rats", "ORGANISM", 32, 36], ["acetylcholine", "SIMPLE_CHEMICAL", 49, 62], ["NBM", "CELLULAR_COMPONENT", 80, 83], ["PFC", "CANCER", 91, 94], ["rats", "SPECIES", 32, 36], ["higher acetylcholine release", "TREATMENT", 42, 70], ["PFC", "OBSERVATION", 91, 94]]], ["While the sex difference in this projection was not associated with a difference in baseline attentional performance in a neurotypical rat brain, it may interact differently with other neurological phenotypes associated with ADHD.", [["brain", "ANATOMY", 139, 144], ["neurological", "ANATOMY", 185, 197], ["ADHD", "DISEASE", 225, 229], ["rat", "ORGANISM", 135, 138], ["brain", "ORGAN", 139, 144], ["rat", "SPECIES", 135, 138], ["rat", "SPECIES", 135, 138], ["other neurological phenotypes", "PROBLEM", 179, 208], ["ADHD", "PROBLEM", 225, 229], ["brain", "ANATOMY", 139, 144]]], ["Findings also showed that stress decreased cholinergic activity in males but not females.", [["stress decreased cholinergic activity", "PROBLEM", 26, 63], ["stress", "OBSERVATION_MODIFIER", 26, 32], ["decreased", "OBSERVATION_MODIFIER", 33, 42], ["cholinergic activity", "OBSERVATION", 43, 63]]], ["As ADHD is often coupled with increased anxiety and is frequently comorbid with anxiety disorders (10), the study of circuit function under stress conditions can also lead to valuable insights into ADHD neurofunction.", [["ADHD", "DISEASE", 3, 7], ["anxiety", "DISEASE", 40, 47], ["anxiety disorders", "DISEASE", 80, 97], ["ADHD", "DISEASE", 198, 202], ["ADHD", "PROBLEM", 3, 7], ["increased anxiety", "PROBLEM", 30, 47], ["anxiety disorders", "PROBLEM", 80, 97], ["the study", "TEST", 104, 113], ["stress conditions", "PROBLEM", 140, 157]]], ["Understanding how sex differences in this system under control and stress conditions could provide key insights into mechanisms contributing to diversity in phenotypes observed with ADHD.", [["ADHD", "DISEASE", 182, 186], ["stress conditions", "PROBLEM", 67, 84], ["diversity in phenotypes", "PROBLEM", 144, 167], ["ADHD", "PROBLEM", 182, 186]]], ["Building off Eck et al.'s discovery, further investigation into nicotinic versus muscarinic receptor cell types in the PFC, coupled with mapping of NBM cholinergic projections onto the two receptor types, would be invaluable to our continued research into potential mechanisms of sex differences in ADHD.", [["cell", "ANATOMY", 101, 105], ["PFC", "ANATOMY", 119, 122], ["ADHD", "DISEASE", 299, 303], ["cell", "CELL", 101, 105], ["PFC", "MULTI-TISSUE_STRUCTURE", 119, 122], ["further investigation", "TEST", 37, 58], ["muscarinic receptor cell types", "TREATMENT", 81, 111], ["NBM cholinergic projections", "TREATMENT", 148, 175], ["ADHD", "PROBLEM", 299, 303], ["PFC", "ANATOMY", 119, 122]]], ["Stressinduced upregulation of Dusp1 in the NBM coupled with growth in cholinergic dendrites highlights a need for research into the function of DUSP1 in cholinergic neurons.", [["NBM", "ANATOMY", 43, 46], ["cholinergic dendrites", "ANATOMY", 70, 91], ["cholinergic neurons", "ANATOMY", 153, 172], ["Dusp1", "GENE_OR_GENE_PRODUCT", 30, 35], ["NBM", "CELL", 43, 46], ["cholinergic dendrites", "CELLULAR_COMPONENT", 70, 91], ["DUSP1", "GENE_OR_GENE_PRODUCT", 144, 149], ["cholinergic neurons", "CELL", 153, 172], ["Dusp1", "PROTEIN", 30, 35], ["DUSP1", "PROTEIN", 144, 149], ["cholinergic neurons", "CELL_TYPE", 153, 172], ["Dusp1", "PROBLEM", 30, 35], ["growth in cholinergic dendrites", "PROBLEM", 60, 91], ["Dusp1", "OBSERVATION", 30, 35], ["NBM", "ANATOMY", 43, 46], ["growth", "OBSERVATION_MODIFIER", 60, 66], ["cholinergic neurons", "ANATOMY", 153, 172]]], ["Empirical evidence of DUSP1-induced hypertrophy in cholinergic neurons would suggest new roles of the cholinergic system in the presentation of DUSP-related neural conditions.", [["cholinergic neurons", "ANATOMY", 51, 70], ["neural", "ANATOMY", 157, 163], ["DUSP1", "CHEMICAL", 22, 27], ["hypertrophy", "DISEASE", 36, 47], ["DUSP1", "GENE_OR_GENE_PRODUCT", 22, 27], ["cholinergic neurons", "CELL", 51, 70], ["DUSP", "GENE_OR_GENE_PRODUCT", 144, 148], ["DUSP1", "PROTEIN", 22, 27], ["cholinergic neurons", "CELL_TYPE", 51, 70], ["DUSP", "PROTEIN", 144, 148], ["DUSP1", "PROBLEM", 22, 27], ["induced hypertrophy in cholinergic neurons", "PROBLEM", 28, 70], ["DUSP", "PROBLEM", 144, 148], ["neural conditions", "PROBLEM", 157, 174], ["DUSP1", "OBSERVATION", 22, 27], ["hypertrophy", "OBSERVATION", 36, 47], ["cholinergic neurons", "OBSERVATION", 51, 70], ["new", "OBSERVATION_MODIFIER", 85, 88], ["cholinergic system", "OBSERVATION", 102, 120], ["neural conditions", "OBSERVATION", 157, 174]]], ["Investigation into NBM to PFC projecting cholinergic neurons revealed higher output at baseline in males, coupled with a stress-triggered decreased in male output.", [["NBM", "ANATOMY", 19, 22], ["PFC", "ANATOMY", 26, 29], ["cholinergic neurons", "ANATOMY", 41, 60], ["NBM", "CELL", 19, 22], ["PFC", "CELL", 26, 29], ["cholinergic neurons", "CELL", 41, 60], ["PFC projecting cholinergic neurons", "CELL_TYPE", 26, 60], ["higher output", "PROBLEM", 70, 83], ["a stress", "PROBLEM", 119, 127], ["higher", "OBSERVATION_MODIFIER", 70, 76], ["output", "OBSERVATION_MODIFIER", 77, 83], ["decreased", "OBSERVATION_MODIFIER", 138, 147]]], ["The sex-dependent activity of this circuit, in both control and stressed rats, warrants further investigation into the information of continuing circuits of attentional control, particularly via activity at nicotinic versus muscarinic receptors.", [["rats", "ORGANISM", 73, 77], ["muscarinic receptors", "PROTEIN", 224, 244], ["rats", "SPECIES", 73, 77], ["this circuit", "TREATMENT", 30, 42], ["further investigation", "TEST", 88, 109], ["continuing circuits of attentional control", "TREATMENT", 134, 176], ["dependent activity", "OBSERVATION_MODIFIER", 8, 26]]], ["Given that the cholinergic system is a modulator of both attention and impulsion, sex differences in this pathway may contribute to the differentiation of ADHD subtypes.Neurobiological Insights Into Stress-Induced Attention DeficitWhen faced with stressful conditions such as a pandemic, many of us will experience deficits in attentional control.", [["ADHD", "DISEASE", 155, 159], ["pandemic", "DISEASE", 278, 286], ["deficits in attentional control", "DISEASE", 315, 346], ["ADHD subtypes", "PROBLEM", 155, 168], ["stressful conditions", "PROBLEM", 247, 267], ["deficits", "PROBLEM", 315, 323], ["attentional control", "TREATMENT", 327, 346]]], ["The findings by Eck et al. (1) provide insights into the real physical changes that stress induces in the brain.", [["brain", "ANATOMY", 106, 111], ["brain", "ORGAN", 106, 111], ["stress induces in the brain", "PROBLEM", 84, 111], ["brain", "ANATOMY", 106, 111]]], ["A better understanding of these neurological responses adds insight that may help us all adapt more quickly to the next challenge that comes our way.", [["neurological", "ANATOMY", 32, 44]]]], "PMC7184145": [["To the Editor\u2014In March 2020, a call to action was issued for antimicrobial stewardship programs (ASP) to assist in the SARS-CoV-2/COVID-19 response.1 Specific attention was focused on the common ASP infrastructures of prospective audit, existing partnerships with microbiology laboratories, and experience in stewarding medication resources as justification for ASP involvement.", [["SARS", "DISEASE", 119, 123], ["antimicrobial stewardship programs", "TREATMENT", 61, 95], ["the SARS", "TEST", 115, 123], ["CoV", "TEST", 124, 127], ["COVID", "TEST", 130, 135], ["microbiology laboratories", "TEST", 264, 289], ["stewarding medication resources", "TREATMENT", 309, 340], ["ASP involvement", "PROBLEM", 362, 377]]], ["We leveraged our existing Enterprise ASP prospective audit platform to contribute to the response.", [["Enterprise ASP prospective audit platform", "TREATMENT", 26, 67]]], ["Here we describe the logic and development of COVID-19 ASP flags, which were rapidly operationalized in the enterprise electronic medical record (EMR).", [["COVID", "TEST", 46, 51], ["19 ASP flags", "PROBLEM", 52, 64]]]], "PMC7115623": [["IntroductionAvian infectious bronchitis virus (IBV) is a gammacoronavirus that causes an economically significant upper respiratory tract disease in chickens [1].", [["upper respiratory tract", "ANATOMY", 114, 137], ["infectious bronchitis virus", "DISEASE", 18, 45], ["gammacoronavirus", "DISEASE", 57, 73], ["upper respiratory tract disease", "DISEASE", 114, 145], ["IntroductionAvian infectious bronchitis virus", "ORGANISM", 0, 45], ["IBV", "ORGANISM", 47, 50], ["upper", "ORGANISM_SUBDIVISION", 114, 119], ["respiratory tract", "ORGANISM_SUBDIVISION", 120, 137], ["chickens", "ORGANISM", 149, 157], ["infectious bronchitis virus", "SPECIES", 18, 45], ["chickens", "SPECIES", 149, 157], ["IntroductionAvian infectious bronchitis virus", "SPECIES", 0, 45], ["IBV", "SPECIES", 47, 50], ["chickens", "SPECIES", 149, 157], ["IntroductionAvian infectious bronchitis virus", "PROBLEM", 0, 45], ["a gammacoronavirus", "PROBLEM", 55, 73], ["an economically significant upper respiratory tract disease", "PROBLEM", 86, 145], ["infectious", "OBSERVATION_MODIFIER", 18, 28], ["economically", "OBSERVATION_MODIFIER", 89, 101], ["significant", "OBSERVATION_MODIFIER", 102, 113], ["upper", "ANATOMY_MODIFIER", 114, 119], ["respiratory tract", "ANATOMY", 120, 137]]], ["Because of its prevalence and infectivity, nearly all commercial poultry in the U.S. are vaccinated for IBV in a serotype-specific manner [2], [3].", [["IBV", "ORGANISM", 104, 107], ["IBV", "SPECIES", 104, 107], ["infectivity", "PROBLEM", 30, 41], ["IBV", "PROBLEM", 104, 107]]], ["IBV vaccines are developed by passaging a pathogenic field virus in embryonated eggs until the virus has lost its pathogenicity in chickens.", [["eggs", "ANATOMY", 80, 84], ["IBV", "ORGANISM", 0, 3], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 80, 84], ["chickens", "ORGANISM", 131, 139], ["chickens", "SPECIES", 131, 139], ["IBV", "SPECIES", 0, 3], ["chickens", "SPECIES", 131, 139], ["IBV vaccines", "TREATMENT", 0, 12], ["a pathogenic field virus", "PROBLEM", 40, 64], ["embryonated eggs", "TREATMENT", 68, 84], ["the virus", "PROBLEM", 91, 100], ["pathogenicity", "OBSERVATION_MODIFIER", 114, 127]]], ["During these repeated rounds of embryo passage, the pathogenic field virus will accumulate mutations that result in an adaptation for replication in embryos.", [["embryo", "ANATOMY", 32, 38], ["embryos", "ANATOMY", 149, 156], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 32, 38], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 149, 156], ["embryo passage", "TREATMENT", 32, 46], ["the pathogenic field virus", "PROBLEM", 48, 74], ["mutations", "PROBLEM", 91, 100], ["replication in embryos", "TREATMENT", 134, 156]]], ["Conversely, the outcome of this adaptation is a decreased affinity for chicken tissues and therefore a reduced virulence in chickens [4], [5], [6].", [["tissues", "ANATOMY", 79, 86], ["chicken", "ORGANISM", 71, 78], ["tissues", "TISSUE", 79, 86], ["chickens", "ORGANISM", 124, 132], ["[5]", "SIMPLE_CHEMICAL", 138, 141], ["chicken", "SPECIES", 71, 78], ["chickens", "SPECIES", 124, 132], ["chicken", "SPECIES", 71, 78], ["chickens", "SPECIES", 124, 132], ["a decreased affinity", "PROBLEM", 46, 66], ["chicken tissues", "PROBLEM", 71, 86], ["a reduced virulence", "PROBLEM", 101, 120]]], ["Live attenuated vaccines stimulate both humoral and cellular immunity, resulting in high levels of protection, and can be mass applied by spray [3], [7].", [["cellular", "ANATOMY", 52, 60], ["cellular", "CELL", 52, 60], ["Live attenuated vaccines", "TREATMENT", 0, 24]]], ["Immunity resulting from vaccination with live attenuated IBV vaccines prevents replication of homologous virulent challenge virus within only a short time following vaccination [7].IntroductionOf the vaccines used in the U.S., the Arkansas Delmarva Poultry Industry (ArkDPI) serotype vaccine has been shown to be highly variable in its protective ability and is frequently isolated from vaccinated chicks [8], [9], [10].", [["ArkDPI", "CHEMICAL", 267, 273], ["IBV", "ORGANISM", 57, 60], ["virulent challenge virus", "ORGANISM", 105, 129], ["IBV", "SPECIES", 57, 60], ["vaccination", "TREATMENT", 24, 35], ["live attenuated IBV vaccines", "TREATMENT", 41, 69], ["homologous virulent challenge virus", "TREATMENT", 94, 129], ["IntroductionOf the vaccines", "TREATMENT", 181, 208], ["the Arkansas Delmarva Poultry Industry (ArkDPI) serotype vaccine", "TREATMENT", 227, 291]]], ["Ideally, when mass applying an IBV vaccine, a high percentage of chicks should be infected with actively replicating virus (vaccine coverage) by days 7\u201310 post-vaccination, followed by a gradual decline in viral load.", [["IBV", "ORGANISM", 31, 34], ["chicks", "ORGANISM", 65, 71], ["IBV", "SPECIES", 31, 34], ["mass", "PROBLEM", 14, 18], ["an IBV vaccine", "TREATMENT", 28, 42], ["actively replicating virus (vaccine coverage", "TREATMENT", 96, 140], ["a gradual decline in viral load", "PROBLEM", 185, 216], ["viral load", "OBSERVATION", 206, 216]]], ["However, it has been shown that the ArkDPI vaccine has an atypical vaccine coverage and replication pattern when mass applied by spray, and previous data from our laboratory suggests that the percentage of chicks infected with vaccine virus by 10 days post-vaccination only reaches 15\u201325% [11], [12].", [["ArkDPI", "CHEMICAL", 36, 42], ["ArkDPI", "GENE_OR_GENE_PRODUCT", 36, 42], ["chicks", "ORGANISM", 206, 212], ["vaccine virus", "ORGANISM", 227, 240], ["chicks", "SPECIES", 206, 212], ["the ArkDPI vaccine", "TREATMENT", 32, 50], ["an atypical vaccine coverage", "TREATMENT", 55, 83], ["mass", "PROBLEM", 113, 117], ["chicks infected", "PROBLEM", 206, 221], ["vaccine virus", "TREATMENT", 227, 240]]], ["Multiple replication cycles also occur in the bird (indicated by viral load and clinical signs in chicks), resulting in \u201crolling\u201d reactions at different time points post-vaccination [13].", [["chicks", "SPECIES", 98, 104], ["Multiple replication cycles", "TREATMENT", 0, 27], ["viral load", "PROBLEM", 65, 75], ["clinical signs in chicks)", "PROBLEM", 80, 105], ["replication cycles", "OBSERVATION", 9, 27], ["viral load", "OBSERVATION", 65, 75]]], ["Our previous research has shown that to achieve an adequate proportion of infected chicks with ArkDPI vaccine and eliminate rolling replication cycles, a 100x dose is required [12].IntroductionThe atypical vaccine coverage and cycling observed following ArkDPI vaccination is a product of the multiple minor genetic subpopulations in the vaccine bottle [14].", [["ArkDPI", "CHEMICAL", 95, 101], ["ArkDPI", "CHEMICAL", 254, 260], ["chicks", "ORGANISM", 83, 89], ["ArkDPI", "SIMPLE_CHEMICAL", 95, 101], ["ArkDPI", "SPECIES", 95, 101], ["infected chicks", "TREATMENT", 74, 89], ["ArkDPI vaccine", "TREATMENT", 95, 109], ["rolling replication cycles", "TREATMENT", 124, 150], ["The atypical vaccine coverage", "TREATMENT", 193, 222], ["ArkDPI vaccination", "TREATMENT", 254, 272], ["infected", "OBSERVATION", 74, 82]]], ["It has been previously shown that several serotypes of IBV vaccines contain genetic subpopulations and the subpopulations are often recovered in chickens following vaccination, even though these vaccines show a typical infection and replication cycle and protect from challenge [15].", [["infection", "DISEASE", 219, 228], ["IBV", "ORGANISM", 55, 58], ["chickens", "ORGANISM", 145, 153], ["chickens", "SPECIES", 145, 153], ["IBV", "SPECIES", 55, 58], ["chickens", "SPECIES", 145, 153], ["IBV vaccines", "TREATMENT", 55, 67], ["genetic subpopulations", "TREATMENT", 76, 98], ["vaccination", "TREATMENT", 164, 175], ["these vaccines", "TREATMENT", 189, 203], ["a typical infection", "PROBLEM", 209, 228], ["subpopulations", "OBSERVATION_MODIFIER", 84, 98], ["subpopulations", "OBSERVATION_MODIFIER", 107, 121], ["typical", "OBSERVATION_MODIFIER", 211, 218], ["infection", "OBSERVATION", 219, 228]]], ["With ArkDPI, the major population in the vaccine contains multiple, distinct amino acid changes in the spike protein that increase binding affinity in the embryonated egg but decrease binding affinity to mature chicken cells [9], [16].", [["egg", "ANATOMY", 167, 170], ["cells", "ANATOMY", 219, 224], ["ArkDPI", "CHEMICAL", 5, 11], ["amino acid", "CHEMICAL", 77, 87], ["amino acid", "CHEMICAL", 77, 87], ["ArkDPI", "GENE_OR_GENE_PRODUCT", 5, 11], ["amino acid", "AMINO_ACID", 77, 87], ["egg", "ORGANISM_SUBDIVISION", 167, 170], ["chicken", "ORGANISM", 211, 218], ["cells", "CELL", 219, 224], ["ArkDPI", "PROTEIN", 5, 11], ["spike protein", "PROTEIN", 103, 116], ["mature chicken cells", "CELL_TYPE", 204, 224], ["chicken", "SPECIES", 211, 218], ["chicken", "SPECIES", 211, 218], ["ArkDPI", "TREATMENT", 5, 11], ["the vaccine", "TREATMENT", 37, 48], ["distinct amino acid changes", "PROBLEM", 68, 95], ["the spike protein", "PROBLEM", 99, 116], ["binding affinity", "PROBLEM", 131, 147], ["the embryonated egg", "PROBLEM", 151, 170], ["decrease binding affinity", "PROBLEM", 175, 200], ["major", "OBSERVATION_MODIFIER", 17, 22], ["population", "OBSERVATION", 23, 33], ["multiple", "OBSERVATION_MODIFIER", 58, 66], ["distinct", "OBSERVATION_MODIFIER", 68, 76], ["amino acid", "OBSERVATION", 77, 87]]], ["Conversely, the minor populations, which have the opposite spike protein binding profile, are more suited to infect and replicate in chickens [16], [17].", [["chickens", "ORGANISM", 133, 141], ["chickens", "SPECIES", 133, 141], ["chickens", "SPECIES", 133, 141], ["the minor populations", "PROBLEM", 12, 33]]], ["However, these minor subpopulations are only a fraction of the total genetic population contained in the vaccine bottle.", [["the total genetic population", "TREATMENT", 59, 87], ["the vaccine bottle", "TREATMENT", 101, 119], ["minor", "OBSERVATION_MODIFIER", 15, 20], ["subpopulations", "OBSERVATION_MODIFIER", 21, 35], ["fraction", "OBSERVATION_MODIFIER", 47, 55]]], ["Thus, the proportion of infected chicks is very low and the time to reach peak infection and replication is delayed [12].", [["infection", "DISEASE", 79, 88], ["chicks", "ORGANISM", 33, 39], ["infected chicks", "PROBLEM", 24, 39], ["very low", "PROBLEM", 43, 51], ["peak infection", "PROBLEM", 74, 88], ["infected", "OBSERVATION", 24, 32], ["infection", "OBSERVATION", 79, 88]]], ["For these reasons, chickens do not develop adequate immunity following ArkDPI vaccination.", [["ArkDPI", "CHEMICAL", 71, 77], ["chickens", "ORGANISM", 19, 27], ["ArkDPI", "SIMPLE_CHEMICAL", 71, 77], ["chickens", "SPECIES", 19, 27], ["chickens", "SPECIES", 19, 27], ["ArkDPI vaccination", "TREATMENT", 71, 89]]], ["Although using one of the viral subpopulations with binding affinity for chicken cells directly as a vaccine will induce a protective immune response, these subpopulations cannot be maintained through multiple passages in embryonated chicken eggs, which is required to propagate IBV vaccine.", [["cells", "ANATOMY", 81, 86], ["eggs", "ANATOMY", 242, 246], ["chicken", "ORGANISM", 73, 80], ["cells", "CELL", 81, 86], ["chicken", "ORGANISM", 234, 241], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 242, 246], ["IBV", "ORGANISM", 279, 282], ["chicken cells", "CELL_TYPE", 73, 86], ["chicken", "SPECIES", 73, 80], ["chicken", "SPECIES", 234, 241], ["chicken", "SPECIES", 73, 80], ["chicken", "SPECIES", 234, 241], ["IBV", "SPECIES", 279, 282], ["chicken cells", "TREATMENT", 73, 86], ["a vaccine", "TREATMENT", 99, 108], ["embryonated chicken eggs", "TREATMENT", 222, 246], ["IBV vaccine", "TREATMENT", 279, 290]]], ["Research has been performed to homogenize the ArkDPI viral population by adapting it for growth in chicken embryo kidney cells, however this vaccine model has not yet been shown to be commercially feasible [18].IntroductionWhile ArkDPI is the only commercially available Ark-type IBV vaccine today, it is not the only Ark-type IBV vaccine ever produced.", [["embryo kidney cells", "ANATOMY", 107, 126], ["ArkDPI", "CHEMICAL", 229, 235], ["chicken", "ORGANISM", 99, 106], ["embryo kidney cells", "CELL", 107, 126], ["ArkDPI", "SIMPLE_CHEMICAL", 229, 235], ["Ark-type", "ORGANISM", 271, 279], ["IBV", "ORGANISM", 280, 283], ["Ark-type IBV", "ORGANISM", 318, 330], ["chicken embryo kidney cells", "CELL_TYPE", 99, 126], ["chicken", "SPECIES", 99, 106], ["chicken", "SPECIES", 99, 106], ["IBV", "SPECIES", 280, 283], ["IBV", "SPECIES", 327, 330], ["the ArkDPI viral population", "TREATMENT", 42, 69], ["chicken embryo kidney cells", "TREATMENT", 99, 126], ["this vaccine model", "TREATMENT", 136, 154], ["Ark-type IBV vaccine", "TREATMENT", 271, 291], ["Ark-type IBV vaccine", "TREATMENT", 318, 338], ["kidney", "ANATOMY", 114, 120]]], ["The Arkansas 99 (Ark99) strain was the first Ark-type virus to be attenuated for use as a vaccine.", [["Arkansas 99", "ORGANISM", 4, 15], ["Ark99", "GENE_OR_GENE_PRODUCT", 17, 22], ["Ark-type virus", "ORGANISM", 45, 59], ["Ark-type virus", "SPECIES", 45, 59], ["The Arkansas", "TEST", 0, 12], ["strain", "PROBLEM", 24, 30], ["type virus", "PROBLEM", 49, 59], ["a vaccine", "TREATMENT", 88, 97]]], ["When originally mass applied in the field, it caused a severe vaccine reaction in young broilers, and was therefore discontinued when ArkDPI was developed [19], [20].", [["ArkDPI", "CHEMICAL", 134, 140], ["ArkDPI", "CHEMICAL", 134, 140], ["broilers", "ORGANISM", 88, 96], ["ArkDPI", "SIMPLE_CHEMICAL", 134, 140], ["a severe vaccine reaction", "PROBLEM", 53, 78], ["mass", "OBSERVATION", 16, 20], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["vaccine", "OBSERVATION", 62, 69]]], ["The purpose of this study was to reevaluate the original and additionally attenuated Ark99 vaccine by multiple serial passaged in embryonated eggs as a potential Ark-type vaccine candidate.", [["eggs", "ANATOMY", 142, 146], ["Ark99", "GENE_OR_GENE_PRODUCT", 85, 90], ["this study", "TEST", 15, 25], ["attenuated Ark99 vaccine", "TREATMENT", 74, 98], ["embryonated eggs", "TREATMENT", 130, 146], ["a potential Ark-type vaccine", "TREATMENT", 150, 178]]], ["In addition, we investigated the mechanisms of attenuation of this vaccine by sequencing the genome and performing SNP analysis during the subsequent embryo passages.", [["embryo", "ANATOMY", 150, 156], ["SNP", "CHEMICAL", 115, 118], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 150, 156], ["this vaccine", "TREATMENT", 62, 74], ["performing SNP analysis", "TEST", 104, 127], ["the subsequent embryo passages", "TREATMENT", 135, 165], ["embryo passages", "OBSERVATION", 150, 165]]], ["This study led to development of a new, more attenuated yet still efficacious vaccine strain designated Arkansas Georgia (ArkGA).Vaccine and challenge viruses ::: Materials and methodsArk99 vaccine is no longer produced nor is USDA license maintained by any vaccine manufacturer.", [["This study", "TEST", 0, 10], ["a new, more attenuated", "PROBLEM", 33, 55], ["Materials and methodsArk99 vaccine", "TREATMENT", 163, 197], ["new", "OBSERVATION_MODIFIER", 35, 38], ["more attenuated", "OBSERVATION_MODIFIER", 40, 55], ["no longer", "UNCERTAINTY", 201, 210]]], ["An archived reference sample of live Ark99 vaccine was obtained from a commercial source and passaged once in 9-to-11 days of incubation specific-pathogen free (SPF) chicken embryos as described below.", [["embryos", "ANATOMY", 174, 181], ["Ark99", "CHEMICAL", 37, 42], ["Ark99", "ORGANISM", 37, 42], ["chicken", "ORGANISM", 166, 173], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 174, 181], ["chicken", "SPECIES", 166, 173], ["chicken", "SPECIES", 166, 173], ["live Ark99 vaccine", "TREATMENT", 32, 50], ["incubation", "TREATMENT", 126, 136], ["pathogen free (SPF) chicken embryos", "TREATMENT", 146, 181]]], ["The University of Georgia egg-passaged virus, now designated ArkGA, was then used for further experimentation.", [["Georgia egg", "ORGANISM", 18, 29], ["Georgia egg", "TEST", 18, 29], ["passaged virus", "PROBLEM", 30, 44]]], ["Different egg passages, beginning at egg passage 1 (P1) and going to P60, were used in this study for consecutive experiments.", [["egg", "ANATOMY", 10, 13], ["Different egg passages", "PROBLEM", 0, 22], ["this study", "TEST", 87, 97], ["egg passages", "OBSERVATION", 10, 22]]], ["A pathogenic Arkansas serotype challenge virus from our laboratory was also used in this study.Embryonated chicken eggs and chickens ::: Materials and methodsSPF embryonated chicken eggs were purchased from Charles River Laboratories (North Franklin, CT) and incubated to 9-to-11 days of development for virus passage, titration, and isolation experiments.", [["eggs", "ANATOMY", 115, 119], ["eggs", "ANATOMY", 182, 186], ["Arkansas serotype", "ORGANISM", 13, 30], ["chicken", "ORGANISM", 107, 114], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 115, 119], ["chickens", "ORGANISM", 124, 132], ["chicken", "ORGANISM", 174, 181], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 182, 186], ["chicken", "SPECIES", 107, 114], ["chickens", "SPECIES", 124, 132], ["chicken", "SPECIES", 174, 181], ["Arkansas serotype challenge virus", "SPECIES", 13, 46], ["chicken", "SPECIES", 107, 114], ["chickens", "SPECIES", 124, 132], ["chicken", "SPECIES", 174, 181], ["A pathogenic Arkansas serotype challenge virus", "PROBLEM", 0, 46], ["this study", "TEST", 84, 94], ["Materials", "TREATMENT", 137, 146], ["methodsSPF embryonated chicken eggs", "TREATMENT", 151, 186], ["CT", "TEST", 251, 253], ["virus passage", "TREATMENT", 304, 317], ["titration", "TREATMENT", 319, 328], ["isolation experiments", "TREATMENT", 334, 355]]], ["Commercial non-vaccinated broiler chickens were used in the vaccination experiments as described below.Virus attenuation ::: Materials and methodsArkGA was serially passaged 60 times by inoculating 9-to-11-day-old SPF embryonated chicken eggs in a 0.1 ml volume via the chorioallantoic sac (CAS) route [21].", [["eggs", "ANATOMY", 238, 242], ["chorioallantoic sac", "ANATOMY", 270, 289], ["chickens", "ORGANISM", 34, 42], ["Virus", "ORGANISM", 103, 108], ["ArkGA", "GENE_OR_GENE_PRODUCT", 146, 151], ["SPF", "ORGANISM", 214, 217], ["chicken", "ORGANISM", 230, 237], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 238, 242], ["chorioallantoic sac", "MULTI-TISSUE_STRUCTURE", 270, 289], ["chickens", "SPECIES", 34, 42], ["chicken", "SPECIES", 230, 237], ["chickens", "SPECIES", 34, 42], ["chicken", "SPECIES", 230, 237], ["Commercial non-vaccinated broiler chickens", "TREATMENT", 0, 42], ["the vaccination experiments", "TREATMENT", 56, 83], ["methodsArkGA", "TREATMENT", 139, 151], ["SPF embryonated chicken eggs", "TREATMENT", 214, 242], ["the chorioallantoic sac (CAS", "TREATMENT", 266, 294], ["broiler chickens", "OBSERVATION", 26, 42], ["chorioallantoic sac", "ANATOMY", 270, 289]]], ["Inoculated eggs were incubated at 37 \u00b0C for 48 h, at which point the embryos were humanely euthanized, and chorioallantoic fluid was collected for subsequent passage into additional 9-to-11-day-old embryos.", [["eggs", "ANATOMY", 11, 15], ["embryos", "ANATOMY", 69, 76], ["chorioallantoic fluid", "ANATOMY", 107, 128], ["embryos", "ANATOMY", 198, 205], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 69, 76], ["chorioallantoic fluid", "ORGANISM_SUBSTANCE", 107, 128], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 198, 205], ["Inoculated eggs", "PROBLEM", 0, 15], ["chorioallantoic fluid", "TEST", 107, 128], ["embryos", "ANATOMY", 69, 76]]], ["Embryos were candled daily and mortality determined to be from non-viral origin was discarded.Virus titration ::: Materials and methodsViruses were titrated at different egg passage levels using the following protocol: 10-fold serial dilutions of the virus were made in sterile deionized water and each dilution was inoculated into five 10-day-old embryonated SPF chicken eggs (0.1 ml/egg).", [["Embryos", "ANATOMY", 0, 7], ["egg", "ANATOMY", 170, 173], ["eggs", "ANATOMY", 372, 376], ["Embryos", "ORGANISM", 0, 7], ["Virus", "ORGANISM", 94, 99], ["chicken", "ORGANISM", 364, 371], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 372, 376], ["chicken", "SPECIES", 364, 371], ["SPF", "SPECIES", 360, 363], ["chicken", "SPECIES", 364, 371], ["Embryos", "TREATMENT", 0, 7], ["Viruses", "PROBLEM", 135, 142], ["the virus", "TREATMENT", 247, 256], ["sterile deionized water", "TREATMENT", 270, 293], ["each dilution", "TREATMENT", 298, 311], ["embryonated SPF chicken eggs", "TREATMENT", 348, 376]]], ["Inoculated eggs were incubated at 37 \u00b0C for 7-days and embryos were examined for IBV-specific lesions.", [["eggs", "ANATOMY", 11, 15], ["embryos", "ANATOMY", 55, 62], ["lesions", "ANATOMY", 94, 101], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 55, 62], ["IBV", "ORGANISM", 81, 84], ["lesions", "PATHOLOGICAL_FORMATION", 94, 101], ["IBV", "SPECIES", 81, 84], ["Inoculated eggs", "PROBLEM", 0, 15], ["embryos", "PROBLEM", 55, 62], ["IBV-specific lesions", "PROBLEM", 81, 101], ["specific", "OBSERVATION_MODIFIER", 85, 93], ["lesions", "OBSERVATION", 94, 101]]], ["Embryo mortality within 24-h post-inoculation was considered nonspecific and not included in virus titer calculations.", [["Embryo", "ANATOMY", 0, 6], ["Embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 0, 6], ["Embryo mortality", "PROBLEM", 0, 16], ["virus titer calculations", "TEST", 93, 117]]], ["Virus titers were calculated by the method of Reed and Muench [22] and expressed as the 50% embryo infectious dose (EID50).", [["embryo", "ANATOMY", 92, 98], ["Virus", "ORGANISM", 0, 5], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 92, 98], ["Virus titers", "TEST", 0, 12]]], ["In addition to titration of embryo passages, vaccine and challenge viruses for the ArkGA P1 and P60 experiments were also titrated following dilution for inoculation into chickens to confirm the inoculation dose.Experiment 1.", [["embryo", "ANATOMY", 28, 34], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 28, 34], ["ArkGA P1", "ORGANISM", 83, 91], ["chickens", "ORGANISM", 171, 179], ["chickens", "SPECIES", 171, 179], ["chickens", "SPECIES", 171, 179], ["embryo passages", "TREATMENT", 28, 43], ["vaccine", "TREATMENT", 45, 52], ["challenge viruses", "TREATMENT", 57, 74], ["the ArkGA P1", "TREATMENT", 79, 91], ["inoculation into chickens", "TREATMENT", 154, 179], ["the inoculation dose", "TREATMENT", 191, 211]]], ["Evaluation of infection and replication of ArkGA P1 and protection from challenge ::: Materials and methodsOne hundred one-day-old broiler chicks were vaccinated with the ArkGA P1 vaccine candidate in a 7 ml spray volume using a commercial vaccine spray cabinet and placed in an isolation house on fresh litter.", [["infection", "DISEASE", 14, 23], ["ArkGA", "CHEMICAL", 171, 176], ["chicks", "ORGANISM", 139, 145], ["chicks", "SPECIES", 139, 145], ["Evaluation", "TEST", 0, 10], ["infection", "PROBLEM", 14, 23], ["ArkGA P1", "TREATMENT", 43, 51], ["old broiler chicks", "TREATMENT", 127, 145], ["the ArkGA P1 vaccine", "TREATMENT", 167, 187], ["a 7 ml spray volume", "TREATMENT", 201, 220], ["a commercial vaccine spray cabinet", "TREATMENT", 227, 261], ["infection", "OBSERVATION", 14, 23], ["fresh litter", "OBSERVATION", 298, 310]]], ["Ten additional non-vaccinated chicks were placed in Horsfal-Bauer isolation units as controls.", [["chicks", "ORGANISM", 30, 36], ["chicks", "SPECIES", 30, 36], ["Ten additional non-vaccinated chicks", "TREATMENT", 0, 36], ["Horsfal-Bauer isolation units", "TREATMENT", 52, 81], ["non-vaccinated chicks", "OBSERVATION", 15, 36]]], ["At 7, 10, 14, 17, 21, 24, and 28 days post-vaccination, all vaccinated chicks were swabbed in the choanal cleft for qRT-PCR analysis of viral load.", [["choanal cleft", "ANATOMY", 98, 111], ["choanal cleft", "DISEASE", 98, 111], ["chicks", "ORGANISM", 71, 77], ["chicks", "SPECIES", 71, 77], ["all vaccinated chicks", "PROBLEM", 56, 77], ["qRT", "TEST", 116, 119], ["PCR analysis", "TEST", 120, 132], ["viral load", "PROBLEM", 136, 146], ["choanal cleft", "ANATOMY", 98, 111], ["viral load", "OBSERVATION", 136, 146]]], ["Clinical signs corresponding to IBV vaccine reactions were also recorded on those days [3].", [["IBV", "ORGANISM", 32, 35], ["IBV", "SPECIES", 32, 35], ["Clinical signs", "PROBLEM", 0, 14], ["IBV vaccine reactions", "TREATMENT", 32, 53]]], ["On day 30 post-vaccination, 20 vaccinated and 5 non-vaccinated chickens were challenged with pathogenic Arkansas serotype virus in a 0.1 ml eyedrop application, while an additional 5 vaccinated and 5 non-vaccinated chickens were held as non-challenged controls.", [["chickens", "ORGANISM", 63, 71], ["Arkansas serotype virus", "ORGANISM", 104, 127], ["chickens", "ORGANISM", 215, 223], ["chickens", "SPECIES", 63, 71], ["Arkansas serotype virus", "SPECIES", 104, 127], ["chickens", "SPECIES", 215, 223], ["chickens", "SPECIES", 63, 71], ["Arkansas serotype virus", "SPECIES", 104, 127], ["chickens", "SPECIES", 215, 223], ["vaccination", "TREATMENT", 15, 26], ["5 non-vaccinated chickens", "TREATMENT", 46, 71], ["pathogenic Arkansas serotype virus", "PROBLEM", 93, 127], ["a 0.1 ml eyedrop application", "TREATMENT", 131, 159], ["an additional 5 vaccinated", "TREATMENT", 167, 193], ["5 non-vaccinated chickens", "TREATMENT", 198, 223]]], ["Five days post-challenge, clinical signs were scored and all chickens were swabbed and euthanized for necropsy.", [["chickens", "ORGANISM", 61, 69], ["chickens", "SPECIES", 61, 69], ["chickens", "SPECIES", 61, 69], ["clinical signs", "TEST", 26, 40], ["necropsy", "TREATMENT", 102, 110]]], ["Tracheas were collected at necropsy for ciliostasis scoring.Trial 1.", [["Tracheas", "ANATOMY", 0, 8], ["Tracheas", "CANCER", 0, 8], ["Tracheas", "TREATMENT", 0, 8]]], ["Evaluation of infection and replication of ArkGA P20, P40, and P60 vaccine candidates and protection from challenge ::: Materials and methodsThe ArkGA P1 vaccine candidate was further attenuated by 19 additional embryonated egg passages, yielding the ArkGA P20 vaccine candidate.", [["infection", "DISEASE", 14, 23], ["ArkGA P20", "GENE_OR_GENE_PRODUCT", 43, 52], ["P40", "GENE_OR_GENE_PRODUCT", 54, 57], ["P60 vaccine", "ORGANISM", 63, 74], ["ArkGA P1", "GENE_OR_GENE_PRODUCT", 145, 153], ["egg", "ORGANISM", 224, 227], ["Evaluation", "TEST", 0, 10], ["infection", "PROBLEM", 14, 23], ["ArkGA P20", "TEST", 43, 52], ["P40", "TEST", 54, 57], ["The ArkGA P1 vaccine", "TREATMENT", 141, 161], ["additional embryonated egg passages", "TREATMENT", 201, 236], ["the ArkGA P20 vaccine", "TREATMENT", 247, 268], ["infection", "OBSERVATION", 14, 23]]], ["One hundred one-day-old broiler chicks were vaccinated using a spray cabinet with the ArkGA P20 vaccine candidate in an 18 ml spray volume and placed in an isolation house on fresh litter.", [["ArkGA", "CHEMICAL", 86, 91], ["chicks", "ORGANISM", 32, 38], ["chicks", "SPECIES", 32, 38], ["old broiler chicks", "TREATMENT", 20, 38], ["a spray cabinet", "TREATMENT", 61, 76], ["the ArkGA P20 vaccine", "TREATMENT", 82, 103], ["an 18 ml spray volume", "TREATMENT", 117, 138], ["fresh litter", "OBSERVATION", 175, 187]]], ["Ten additional non-vaccinated chicks were placed in isolators as controls.", [["chicks", "ORGANISM", 30, 36], ["chicks", "SPECIES", 30, 36], ["Ten additional non-vaccinated chicks", "TREATMENT", 0, 36]]], ["Swabs were taken at 3, 5, 7, 10, and 14 days post-vaccination to assess viral load and vaccine coverage in chicks, and clinical signs were recorded.Trial 2.", [["Swabs", "ANATOMY", 0, 5], ["chicks", "ORGANISM", 107, 113], ["chicks", "SPECIES", 107, 113], ["Swabs", "TEST", 0, 5], ["viral load", "PROBLEM", 72, 82], ["vaccine coverage", "TREATMENT", 87, 103], ["clinical signs", "TEST", 119, 133]]], ["Evaluation of infection and replication of ArkGA P20, P40, and P60 vaccine candidates and protection from challenge ::: Materials and methodsThe ArkGA P20 vaccine candidate was passaged an additional 20 times in embryonated eggs to produce the ArkGA P40 vaccine candidate and another vaccination trial was conducted as described in Trial 1.Trial 3.", [["eggs", "ANATOMY", 224, 228], ["infection", "DISEASE", 14, 23], ["ArkGA", "CHEMICAL", 145, 150], ["ArkGA P20", "GENE_OR_GENE_PRODUCT", 43, 52], ["P40", "GENE_OR_GENE_PRODUCT", 54, 57], ["P60 vaccine", "ORGANISM", 63, 74], ["ArkGA", "GENE_OR_GENE_PRODUCT", 145, 150], ["P40", "GENE_OR_GENE_PRODUCT", 250, 253], ["Evaluation", "TEST", 0, 10], ["infection", "PROBLEM", 14, 23], ["ArkGA P20", "TEST", 43, 52], ["P40", "TEST", 54, 57], ["The ArkGA P20 vaccine", "TREATMENT", 141, 162], ["embryonated eggs", "TREATMENT", 212, 228], ["the ArkGA P40 vaccine", "TREATMENT", 240, 261], ["another vaccination trial", "TREATMENT", 276, 301], ["infection", "OBSERVATION", 14, 23]]], ["Evaluation of infection and replication of ArkGA P20, P40, and P60 vaccine candidates and protection from challenge ::: Materials and methodsThe ArkGA P40 vaccine candidate was passaged an additional 20 times in embryonated eggs to further attenuate the virus, producing ArkGA P60.", [["eggs", "ANATOMY", 224, 228], ["infection", "DISEASE", 14, 23], ["ArkGA P20", "GENE_OR_GENE_PRODUCT", 43, 52], ["P40", "GENE_OR_GENE_PRODUCT", 54, 57], ["P60 vaccine", "ORGANISM", 63, 74], ["ArkGA P40", "ORGANISM", 145, 154], ["ArkGA P60", "GENE_OR_GENE_PRODUCT", 271, 280], ["Evaluation", "TEST", 0, 10], ["infection", "PROBLEM", 14, 23], ["ArkGA P20", "TEST", 43, 52], ["P40", "TEST", 54, 57], ["Materials", "TREATMENT", 120, 129], ["methods", "TREATMENT", 134, 141], ["The ArkGA P40 vaccine", "TREATMENT", 141, 162], ["embryonated eggs", "TREATMENT", 212, 228], ["the virus", "PROBLEM", 250, 259], ["infection", "OBSERVATION", 14, 23]]], ["One hundred one-day-old broiler chicks were spray vaccinated with the ArkGA P60 vaccine candidate in an 18 ml spray volume and placed in an isolation house on fresh litter.", [["ArkGA", "CHEMICAL", 70, 75], ["chicks", "ORGANISM", 32, 38], ["chicks", "SPECIES", 32, 38], ["old broiler chicks", "TREATMENT", 20, 38], ["the ArkGA P60 vaccine", "TREATMENT", 66, 87], ["an 18 ml spray volume", "TREATMENT", 101, 122]]], ["Ten additional non-vaccinated chicks were placed in isolation units as controls.", [["chicks", "ORGANISM", 30, 36], ["chicks", "SPECIES", 30, 36], ["Ten additional non-vaccinated chicks", "TREATMENT", 0, 36], ["non-vaccinated chicks", "OBSERVATION", 15, 36]]], ["At 3, 5, 7, 10, 14, 17, 21, 24, and 28 days post-vaccination, all vaccinated chicks were swabbed in the choanal cleft for qRT-PCR analysis of viral load as previously described.", [["choanal cleft", "ANATOMY", 104, 117], ["choanal cleft", "DISEASE", 104, 117], ["chicks", "ORGANISM", 77, 83], ["chicks", "SPECIES", 77, 83], ["all vaccinated chicks", "PROBLEM", 62, 83], ["qRT", "TEST", 122, 125], ["PCR analysis", "TEST", 126, 138], ["viral load", "PROBLEM", 142, 152], ["choanal cleft", "ANATOMY", 104, 117], ["viral load", "OBSERVATION", 142, 152]]], ["Clinical signs corresponding to vaccine reactions were also recorded on those days.", [["Clinical signs", "PROBLEM", 0, 14], ["vaccine reactions", "PROBLEM", 32, 49]]], ["On day 30 post-vaccination, 20 vaccinated and 5 non-vaccinated chickens were challenged with pathogenic Ark-type IBV in a 0.1 ml eyedrop application, while an additional 5 vaccinated and 5 non-vaccinated chickens were held non-challenged as controls.", [["chickens", "ORGANISM", 63, 71], ["Ark-type IBV", "ORGANISM", 104, 116], ["chickens", "ORGANISM", 204, 212], ["chickens", "SPECIES", 63, 71], ["chickens", "SPECIES", 204, 212], ["chickens", "SPECIES", 63, 71], ["Ark-type IBV", "SPECIES", 104, 116], ["chickens", "SPECIES", 204, 212], ["vaccination", "TREATMENT", 15, 26], ["5 non-vaccinated chickens", "TREATMENT", 46, 71], ["pathogenic Ark-type IBV", "TREATMENT", 93, 116], ["a 0.1 ml eyedrop application", "TREATMENT", 120, 148], ["an additional 5 vaccinated", "TREATMENT", 156, 182], ["5 non-vaccinated chickens", "TREATMENT", 187, 212]]], ["Five days post-challenge, clinical signs were recorded, and all chickens were swabbed in the choanal cleft palate and euthanized for necropsy.", [["choanal cleft palate", "ANATOMY", 93, 113], ["choanal cleft palate", "DISEASE", 93, 113], ["chickens", "ORGANISM", 64, 72], ["palate", "ORGAN", 107, 113], ["chickens", "SPECIES", 64, 72], ["chickens", "SPECIES", 64, 72], ["clinical signs", "TEST", 26, 40], ["necropsy", "TREATMENT", 133, 141], ["choanal", "ANATOMY", 93, 100], ["cleft palate", "ANATOMY", 101, 113]]], ["Tracheas were collected at necropsy for ciliostasis scoring.Virus detection using quantitative real-time RT-PCR ::: Materials and methodsViral RNA was extracted from 50 \u03bcl of choanal swab fluid using the MagMAX-96 RNA Isolation Kit (Ambion Inc., Austin TX) on a KingFisher Flex magnetic particle processor (Thermo Scientific, Waltham, MA) per the manufacturer\u2019s protocol.", [["Tracheas", "ANATOMY", 0, 8], ["choanal swab fluid", "ANATOMY", 175, 193], ["Tracheas", "CANCER", 0, 8], ["Virus", "ORGANISM", 60, 65], ["Viral", "ORGANISM", 137, 142], ["Viral RNA", "RNA", 137, 146], ["MagMAX-96", "SPECIES", 204, 213], ["Tracheas", "TREATMENT", 0, 8], ["Virus detection", "TEST", 60, 75], ["methodsViral RNA", "PROBLEM", 130, 146], ["choanal swab fluid", "TREATMENT", 175, 193], ["the MagMAX", "TREATMENT", 200, 210], ["Austin TX", "TREATMENT", 246, 255], ["a KingFisher Flex magnetic particle processor", "TREATMENT", 260, 305]]], ["Quantitative real-time RT-PCR (qRT-PCR) was conducted using an Applied Biosystems 7500 Fast Real-Time PCR System (Life Technologies, Carlsbad, CA) and the AgPath-IDtm One-Step RT-PCR kit (Ambion Inc.) per the manufacturer\u2019s recommendations.", [["PCR", "TEST", 26, 29], ["qRT", "TEST", 31, 34], ["PCR", "TEST", 35, 38], ["an Applied Biosystems", "TEST", 60, 81], ["the AgPath", "TEST", 151, 161]]], ["Primers and probe for the qRT-PCR were previously published [23] and consist of a forward primer IBV5\u2032GU391 (5\u2032-GCT TTT GAG CCT AGC GTT-3\u2032), a reverse primer IBV5\u2032GL533 (5\u2032-GCC ATG TTG TCA CTG TCT ATT G-3\u2032) and a Taqman\u00ae dual-labeled probe IBV5\u2032G probe (5\u2032 \u2013FAM-CAC CAC CAG AAC CTG TCA CCT C-BHQ1-3\u2032).", [["qRT", "DNA", 26, 29], ["forward primer IBV5", "DNA", 82, 101], ["reverse primer IBV5\u2032GL533", "DNA", 143, 168], ["5\u2032-GCC ATG TTG TCA CTG TCT ATT G-3\u2032", "DNA", 170, 205], ["Taqman\u00ae dual-labeled probe IBV5\u2032G probe", "DNA", 213, 252], ["5\u2032 \u2013FAM", "DNA", 254, 261], ["CAC CAC CAG", "DNA", 262, 273], ["CCT C", "DNA", 286, 291], ["BHQ1", "DNA", 292, 296], ["the qRT-PCR", "TEST", 22, 33], ["a forward primer IBV5", "TEST", 80, 101], ["GU391", "TEST", 102, 107], ["GCT", "TEST", 112, 115], ["TTT", "TEST", 116, 119], ["GAG", "TEST", 120, 123], ["CCT", "TEST", 124, 127], ["AGC", "TEST", 128, 131], ["GTT", "TEST", 132, 135], ["a reverse primer IBV5", "TEST", 141, 162], ["GL533", "TEST", 163, 168], ["GCC", "TEST", 173, 176], ["ATG", "TEST", 177, 180], ["TTG", "TEST", 181, 184], ["TCA", "TEST", 185, 188], ["CTG", "TEST", 189, 192], ["TCT", "TEST", 193, 196], ["G", "TEST", 201, 202], ["a Taqman\u00ae dual", "TEST", 211, 225], ["G probe", "TEST", 245, 252], ["\u2013FAM", "TEST", 257, 261], ["CAC", "TEST", 262, 265], ["CAC", "TEST", 266, 269], ["CAG", "TEST", 270, 273], ["AAC", "TEST", 274, 277], ["CTG", "TEST", 278, 281], ["TCA", "TEST", 282, 285], ["CCT", "TEST", 286, 289], ["C", "TEST", 290, 291], ["BHQ1", "TEST", 292, 296]]], ["Cycle-threshold (CT) values above the limit of detection for each run (determined by a standard curve) were considered negative [24].", [["Cycle-threshold (CT) values", "TEST", 0, 27], ["a standard curve", "TEST", 85, 101]]], ["All positive samples were used to determine the total percent positive for each group.", [["samples", "ANATOMY", 13, 20], ["All positive samples", "TEST", 0, 20]]], ["Post-challenge viral load data was presented as relative viral load values made between the groups within an experiment and were not absolute virus genome copy numbers.Clinical sign scoring ::: Materials and methodsClinical signs were scored based on a method described by Jackwood et al. [25].", [["challenge viral load data", "TEST", 5, 30], ["relative viral load values", "PROBLEM", 48, 74], ["Clinical signs", "TEST", 215, 229], ["viral load", "OBSERVATION", 57, 67]]], ["Scoring was conducted on a scale from 0 to 3, where 0 = negative, 1 = mild signs, 2 = watery eyes and some mucus in the nares, and 3 = watery eyes, mucus in the nares, and tracheal rales.Ciliostasis scoring ::: Materials and methodsCiliostasis scoring was conducted by examining five rings approximately 1 mm thick cut from each chicken trachea representing the proximal, middle and distal portion.", [["eyes", "ANATOMY", 93, 97], ["mucus", "ANATOMY", 107, 112], ["nares", "ANATOMY", 120, 125], ["eyes", "ANATOMY", 142, 146], ["mucus", "ANATOMY", 148, 153], ["nares", "ANATOMY", 161, 166], ["tracheal rales", "ANATOMY", 172, 186], ["trachea", "ANATOMY", 337, 344], ["eyes", "ORGAN", 93, 97], ["nares", "ORGANISM_SUBDIVISION", 120, 125], ["eyes", "ORGAN", 142, 146], ["mucus", "MULTI-TISSUE_STRUCTURE", 148, 153], ["nares", "ORGANISM_SUBDIVISION", 161, 166], ["chicken", "ORGANISM", 329, 336], ["trachea", "ORGAN", 337, 344], ["chicken", "SPECIES", 329, 336], ["chicken", "SPECIES", 329, 336], ["a scale", "TEST", 25, 32], ["mild signs, 2 = watery eyes", "PROBLEM", 70, 97], ["some mucus in the nares", "PROBLEM", 102, 125], ["mucus in the nares", "PROBLEM", 148, 166], ["tracheal rales", "PROBLEM", 172, 186], ["watery eyes", "ANATOMY", 86, 97], ["mucus", "OBSERVATION", 107, 112], ["nares", "ANATOMY", 120, 125], ["watery eyes", "ANATOMY", 135, 146], ["mucus", "OBSERVATION", 148, 153], ["nares", "ANATOMY", 161, 166], ["tracheal", "ANATOMY", 172, 180], ["rales", "OBSERVATION", 181, 186], ["1 mm", "OBSERVATION_MODIFIER", 304, 308], ["trachea", "ANATOMY", 337, 344], ["proximal", "ANATOMY_MODIFIER", 362, 370], ["middle", "ANATOMY_MODIFIER", 372, 378], ["distal", "ANATOMY_MODIFIER", 383, 389]]], ["Cilia activity was observed with an inverted microscope (Olympus, Center Valley, PA).", [["Cilia", "ANATOMY", 0, 5], ["Cilia", "MULTI-TISSUE_STRUCTURE", 0, 5], ["an inverted microscope", "TEST", 33, 55]]], ["Scoring was conducted based on the method by Cook et al. wherein: 0, all cilia beating; 1, 75% of cilia beating; 2, 50% of cilia beating; 3, 25% of cilia beating; 4, no cilia beating.", [["cilia", "ANATOMY", 73, 78], ["cilia", "ANATOMY", 98, 103], ["cilia", "ANATOMY", 123, 128], ["cilia", "ANATOMY", 148, 153], ["cilia", "ANATOMY", 169, 174], ["cilia", "CELL", 123, 128], ["cilia", "CELL", 148, 153], ["cilia beating", "TEST", 98, 111], ["cilia beating", "TEST", 123, 136], ["cilia beating", "TEST", 148, 161], ["cilia beating", "PROBLEM", 169, 182], ["no", "UNCERTAINTY", 166, 168], ["cilia beating", "OBSERVATION", 169, 182]]], ["Mean scores per group were calculated and relationships between groups were analyzed statistically [26].Challenge virus detection in embryonated eggs ::: Materials and methodsRoutine virus isolation techniques were used for detection of IBV challenge virus in 9-to-11 days of incubation embryonated SPF chicken eggs.", [["eggs", "ANATOMY", 311, 315], ["IBV", "ORGANISM", 237, 240], ["chicken", "ORGANISM", 303, 310], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 311, 315], ["chicken", "SPECIES", 303, 310], ["IBV challenge virus", "SPECIES", 237, 256], ["SPF", "SPECIES", 299, 302], ["chicken", "SPECIES", 303, 310], ["Mean scores", "TEST", 0, 11], ["Materials", "TREATMENT", 154, 163], ["Routine virus isolation techniques", "TREATMENT", 175, 209], ["IBV challenge virus", "TREATMENT", 237, 256]]], ["Briefly, 2 ml of ice-cold PBS were added to the choanal swab fluid to match the stipulations of the U.S. Code of Federal Regulations, title IX (9-CFR) [27].", [["choanal swab fluid", "ANATOMY", 48, 66], ["ice-cold PBS", "TREATMENT", 17, 29], ["the choanal swab fluid", "TEST", 44, 66], ["choanal", "ANATOMY", 48, 55]]], ["PBS from the swabs was filter sterilized and 0.2 ml of each sample were inoculated into the CAS of 6 embryonated chicken eggs.", [["swabs", "ANATOMY", 13, 18], ["sample", "ANATOMY", 60, 66], ["eggs", "ANATOMY", 121, 125], ["chicken", "ORGANISM", 113, 120], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 121, 125], ["chicken", "SPECIES", 113, 120], ["chicken", "SPECIES", 113, 120], ["PBS", "TEST", 0, 3], ["the swabs", "TEST", 9, 18], ["filter", "TREATMENT", 23, 29]]], ["Eggs were candled daily (24\u201372 h deaths were discarded) for 7 days and the number of deaths and embryo lesions consistent with IBV infection was recorded.Genome sequencing ::: Materials and methodsComplete genome sequencing was performed on ArkGA P1, P20, P40, and P60 to detect changes occurring within the viral genome during attenuation.", [["Eggs", "ANATOMY", 0, 4], ["embryo lesions", "ANATOMY", 96, 110], ["deaths", "DISEASE", 33, 39], ["deaths", "DISEASE", 85, 91], ["IBV infection", "DISEASE", 127, 140], ["Eggs", "ORGANISM_SUBSTANCE", 0, 4], ["embryo lesions", "PATHOLOGICAL_FORMATION", 96, 110], ["IBV", "ORGANISM", 127, 130], ["ArkGA P1", "GENE_OR_GENE_PRODUCT", 241, 249], ["P40", "GENE_OR_GENE_PRODUCT", 256, 259], ["ArkGA P1, P20, P40, and P60", "DNA", 241, 268], ["viral genome", "DNA", 308, 320], ["IBV", "SPECIES", 127, 130], ["Eggs", "TEST", 0, 4], ["embryo lesions", "PROBLEM", 96, 110], ["IBV infection", "PROBLEM", 127, 140], ["ArkGA P1", "TREATMENT", 241, 249], ["P40", "TEST", 256, 259], ["embryo", "ANATOMY", 96, 102], ["lesions", "OBSERVATION", 103, 110], ["consistent with", "UNCERTAINTY", 111, 126], ["IBV", "OBSERVATION_MODIFIER", 127, 130], ["infection", "OBSERVATION", 131, 140], ["viral genome", "OBSERVATION", 308, 320], ["attenuation", "OBSERVATION_MODIFIER", 328, 339]]], ["Virus stock was filtered with a 0.2 \u03bcm syringe filter.", [["Virus", "ORGANISM", 0, 5], ["Virus stock", "TREATMENT", 0, 11], ["a 0.2 \u03bcm syringe filter", "TREATMENT", 30, 53]]], ["Viral RNA was extracted from samples using the Direct-Zol RNA MiniPrep Kit (Zymo Research) and treated with DNase I (New England Biolabs).", [["samples", "ANATOMY", 29, 36], ["Viral", "ORGANISM", 0, 5], ["DNase I", "GENE_OR_GENE_PRODUCT", 108, 115], ["Biolabs", "GENE_OR_GENE_PRODUCT", 129, 136], ["Viral RNA", "RNA", 0, 9], ["DNase I", "PROTEIN", 108, 115], ["Viral RNA", "PROBLEM", 0, 9], ["the Direct-Zol RNA", "TREATMENT", 43, 61], ["DNase I", "TREATMENT", 108, 115], ["New England Biolabs)", "TREATMENT", 117, 137], ["RNA", "OBSERVATION", 6, 9]]], ["The SISPA method was used for random amplification of RNA as previously described [28].", [["SISPA", "DNA", 4, 9], ["The SISPA method", "TREATMENT", 0, 16], ["random amplification of RNA", "PROBLEM", 30, 57]]], ["Complementary DNA (cDNA) was synthesized using SuperScript IV (Invitrogen/Thermo Scientific).", [["DNA", "CELLULAR_COMPONENT", 14, 17], ["cDNA", "CELLULAR_COMPONENT", 19, 23], ["Complementary DNA", "DNA", 0, 17], ["cDNA", "DNA", 19, 23], ["SuperScript IV", "DNA", 47, 61], ["SuperScript IV", "TREATMENT", 47, 61]]], ["Double stranded cDNA (dsDNA) was generated from cDNA templates using Second Strand cDNA Synthesis Kit (Applied Biological Materials Inc.).", [["dsDNA", "CELLULAR_COMPONENT", 22, 27], ["Double stranded cDNA", "DNA", 0, 20], ["dsDNA", "DNA", 22, 27], ["cDNA templates", "DNA", 48, 62], ["Double stranded cDNA (dsDNA)", "TREATMENT", 0, 28], ["cDNA templates", "TREATMENT", 48, 62], ["Second Strand cDNA Synthesis Kit", "TREATMENT", 69, 101]]], ["Complete genome sequencing at a 50\u00d7 depth of coverage was conducted using the Nextera XT DNA Sample Preparation Kit (Illumina) and MiSeq sequencer (Illumina) according to manufacturer\u2019s instructions.", [["coverage", "TREATMENT", 45, 53], ["the Nextera XT DNA Sample Preparation Kit (Illumina)", "TREATMENT", 74, 126], ["MiSeq sequencer (Illumina)", "TREATMENT", 131, 157]]], ["De Novo and directed assembly of genome sequences was carried out using the MIRA3 sequence assembler and Geneious r8 program (www.geneious.com).", [["genome sequences", "DNA", 33, 49], ["MIRA3 sequence assembler", "DNA", 76, 100], ["genome sequences", "TEST", 33, 49]]], ["Non-synonymous substitutions in the assembled sequence reads were compared to consensus sequence at 5% of minimum variant frequency using Geneious r8 program.", [["consensus sequence", "DNA", 78, 96], ["Non-synonymous substitutions", "PROBLEM", 0, 28], ["consensus sequence", "TEST", 78, 96], ["Geneious r8 program", "TREATMENT", 138, 157]]], ["Whole genome consensus sequences were entered into the GenBank database, with accession numbers as follows: Ark99 pathogenic field virus MH779860, ArkGA P1 MH779856, ArkGA P20 MH779857, ArkGA P40 MH779858, ArkGA P60 MH779859.Sequence analysis of the S1 gene of viral RNA isolated from vaccinated chickens ::: Materials and methodsFor ArkGA P1, P20, P40, and P60 vaccination trials, viral RNA from 5 choanal cleft palate swabs each from days 7, 10, and 14 post-vaccination was purified and amplified for sequencing of the S1 region of the genome.", [["choanal cleft palate swabs", "ANATOMY", 399, 425], ["Ark99 pathogenic field virus", "ORGANISM", 108, 136], ["S1", "GENE_OR_GENE_PRODUCT", 250, 252], ["chickens", "ORGANISM", 296, 304], ["P40", "GENE_OR_GENE_PRODUCT", 349, 352], ["genome", "CELLULAR_COMPONENT", 538, 544], ["Whole genome consensus sequences", "DNA", 0, 32], ["S1 gene", "DNA", 250, 257], ["viral RNA", "RNA", 261, 270], ["viral RNA", "RNA", 382, 391], ["S1 region", "DNA", 521, 530], ["chickens", "SPECIES", 296, 304], ["chickens", "SPECIES", 296, 304], ["Whole genome consensus sequences", "TEST", 0, 32], ["ArkGA", "TEST", 147, 152], ["ArkGA", "TEST", 166, 171], ["ArkGA", "TEST", 186, 191], ["ArkGA", "TEST", 206, 211], ["Sequence analysis", "TEST", 225, 242], ["viral RNA", "PROBLEM", 261, 270], ["methods", "TEST", 323, 330], ["ArkGA P1", "TEST", 334, 342], ["P20", "TEST", 344, 347], ["P40", "TEST", 349, 352], ["P60 vaccination trials", "TREATMENT", 358, 380], ["viral RNA", "PROBLEM", 382, 391], ["5 choanal cleft palate swabs", "PROBLEM", 397, 425], ["viral RNA", "OBSERVATION", 261, 270], ["viral RNA", "OBSERVATION", 382, 391], ["cleft palate", "ANATOMY", 407, 419], ["S1", "ANATOMY", 521, 523], ["region", "ANATOMY_MODIFIER", 524, 530], ["genome", "OBSERVATION", 538, 544]]], ["Briefly, viral RNA was purified using the Zymo Direct-zol RNA miniprep kit (Zymo Research, Irvine CA).", [["Zymo", "ORGANISM", 76, 80], ["viral RNA", "RNA", 9, 18], ["viral RNA", "PROBLEM", 9, 18], ["the Zymo Direct-zol RNA", "TREATMENT", 38, 61]]], ["S1 gene sequences were amplified by RT-PCR using the Titan One-Step RT-PCR system (Roche Diagnostics, Indianapolis, IN) and previously published primers: NEWS1OLIGO5\u2032 [29] and Degenerate3\u2032 [30].", [["S1", "GENE_OR_GENE_PRODUCT", 0, 2], ["S1 gene sequences", "DNA", 0, 17], ["S1 gene sequences", "TEST", 0, 17], ["PCR", "TEST", 39, 42], ["the Titan", "TREATMENT", 49, 58]]], ["RT-PCR reactions were analyzed on a 1% w/v agarose gel and bands of the correct size were excised and DNA was purified from the gel fragment using the GeneJET Gel Extraction Kit (Thermo Scientific, Waltham, MA).", [["DNA", "CELLULAR_COMPONENT", 102, 105], ["RT-PCR reactions", "TEST", 0, 16], ["a 1% w/v agarose gel", "TREATMENT", 34, 54], ["DNA", "PROBLEM", 102, 105], ["the gel fragment", "PROBLEM", 124, 140], ["the GeneJET Gel Extraction", "TREATMENT", 147, 173], ["size", "OBSERVATION_MODIFIER", 80, 84]]], ["Sanger sequencing was performed by the Georgia Genomics Facility, University of Georgia, Athens, GA.", [["Sanger sequencing", "TEST", 0, 17]]], ["The S1 sequences were assembled and compared using the DNAStar suite of programs (DNAStar, Madison WI).", [["S1 sequences", "DNA", 4, 16], ["The S1 sequences", "TEST", 0, 16]]], ["The S1 amino acid sequences of viral RNA isolated from vaccinated chickens was compared to the consensus S1 sequences of the vaccine virus for P1, P20, P40, and P60 obtained from whole genome sequencing to detect changes in the viral population after replication in chicken tissues.Statistical analysis ::: Materials and methodsStatistical analysis was performed using Prism v.6.0.", [["tissues", "ANATOMY", 274, 281], ["amino acid", "CHEMICAL", 7, 17], ["amino acid", "CHEMICAL", 7, 17], ["amino acid", "AMINO_ACID", 7, 17], ["chickens", "ORGANISM", 66, 74], ["P40", "GENE_OR_GENE_PRODUCT", 152, 155], ["chicken", "ORGANISM", 266, 273], ["tissues", "TISSUE", 274, 281], ["S1 amino acid sequences", "PROTEIN", 4, 27], ["viral RNA", "RNA", 31, 40], ["consensus S1 sequences", "DNA", 95, 117], ["P1, P20, P40, and P60", "DNA", 143, 164], ["chickens", "SPECIES", 66, 74], ["chicken", "SPECIES", 266, 273], ["chickens", "SPECIES", 66, 74], ["chicken", "SPECIES", 266, 273], ["The S1 amino acid sequences", "TEST", 0, 27], ["viral RNA", "PROBLEM", 31, 40], ["vaccinated chickens", "PROBLEM", 55, 74], ["the consensus S1 sequences", "TEST", 91, 117], ["P1", "TEST", 143, 145], ["P20", "TEST", 147, 150], ["P40", "TEST", 152, 155], ["whole genome sequencing", "TEST", 179, 202], ["the viral population", "PROBLEM", 224, 244], ["Statistical analysis", "TEST", 328, 348], ["Prism", "TEST", 369, 374], ["viral RNA", "OBSERVATION", 31, 40], ["viral population", "OBSERVATION", 228, 244], ["chicken tissues", "OBSERVATION", 266, 281]]], ["(GraphPad Software, Inc., La Jolla, CA).", [["GraphPad Software", "TEST", 1, 18]]], ["For experiments 1 and 2, post-vaccination viral load determined by qRT-PCR was compared between all vaccinated chickens within each collection time point via analysis of the mean and standard error of the mean (SEM).", [["chickens", "ORGANISM", 111, 119], ["chickens", "SPECIES", 111, 119], ["chickens", "SPECIES", 111, 119], ["experiments", "TEST", 4, 15], ["post-vaccination viral load", "TEST", 25, 52], ["qRT", "TEST", 67, 70], ["PCR", "TEST", 71, 74], ["all vaccinated chickens", "TREATMENT", 96, 119]]], ["Post-challenge clinical signs, ciliostasis, and viral load between challenge groups were analyzed using an alpha of 0.05 with ordinary one-way ANOVA and Tukey\u2019s multiple comparisons test.ArkGA P1 whole genome sequence analysis and comparison with Ark99 pathogenic field virus ::: ArkGA P1 ::: ResultsThe reference sequence used for comparison of the ArkGA passages was the full genome of the Ark99 pathogenic field virus (unpublished sequence).", [["ciliostasis", "DISEASE", 31, 42], ["Ark99 pathogenic field virus", "ORGANISM", 247, 275], ["Ark99 pathogenic field virus", "ORGANISM", 392, 420], ["ArkGA P1 whole genome sequence", "DNA", 187, 217], ["ArkGA", "DNA", 350, 355], ["challenge clinical signs", "TEST", 5, 29], ["ciliostasis", "PROBLEM", 31, 42], ["viral load between challenge groups", "TREATMENT", 48, 83], ["an alpha", "TEST", 104, 112], ["multiple comparisons test", "TEST", 161, 186], ["ArkGA P1 whole genome sequence analysis", "TEST", 187, 226], ["The reference sequence", "TEST", 300, 322], ["the ArkGA passages", "TEST", 346, 364], ["viral load", "OBSERVATION", 48, 58]]], ["In the ArkGA P1 vaccine consensus sequence, mutations occurred in polyprotein 1a, the spike gene, and in a non-coding region (Fig. 1).", [["ArkGA P1", "GENE_OR_GENE_PRODUCT", 7, 15], ["polyprotein 1a", "GENE_OR_GENE_PRODUCT", 66, 80], ["ArkGA P1 vaccine consensus sequence", "DNA", 7, 42], ["polyprotein 1a", "DNA", 66, 80], ["spike gene", "DNA", 86, 96], ["non-coding region", "DNA", 107, 124], ["mutations", "PROBLEM", 44, 53]]], ["Only the mutation occurring in the spike gene resulted in an amino acid change (Table 1).ArkGA P1 vaccination study ::: ArkGA P1 ::: ResultsArkGA P1 was titrated in embryos prior to vaccination and was determined to have an EID50 of 1x106/ml.", [["embryos", "ANATOMY", 165, 172], ["amino acid", "CHEMICAL", 61, 71], ["amino acid", "CHEMICAL", 61, 71], ["amino acid", "AMINO_ACID", 61, 71], ["ResultsArkGA P1", "GENE_OR_GENE_PRODUCT", 133, 148], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 165, 172], ["spike gene", "DNA", 35, 45], ["the mutation", "PROBLEM", 5, 17], ["an amino acid change", "TREATMENT", 58, 78], ["ResultsArkGA P1", "TREATMENT", 133, 148], ["vaccination", "TREATMENT", 182, 193]]], ["Appropriate dilutions were performed to achieve the desired vaccination dose of 1x103.5 EID50 per bird, and this was confirmed by back-titration in embryonating eggs.", [["eggs", "ANATOMY", 161, 165]]], ["Fig. 2shows viral load and vaccine infection rate (coverage) post-vaccination with ArkGA P1.", [["infection", "DISEASE", 35, 44], ["ArkGA P1", "DNA", 83, 91], ["Fig", "TEST", 0, 3], ["viral load", "PROBLEM", 12, 22], ["vaccine infection rate (coverage) post-vaccination with ArkGA P1", "TREATMENT", 27, 91], ["viral load", "OBSERVATION", 12, 22]]], ["Viral load in chickens was high by day 7 post-vaccination, and remained constant until 14-days post-vaccination, when it began to decrease (Fig. 2A).", [["Viral", "ORGANISM", 0, 5], ["chickens", "ORGANISM", 14, 22], ["chickens", "SPECIES", 14, 22], ["chickens", "SPECIES", 14, 22], ["Viral load in chickens", "PROBLEM", 0, 22], ["vaccination", "TREATMENT", 46, 57], ["high", "OBSERVATION_MODIFIER", 27, 31]]], ["ArkGA P1 vaccine candidate coverage was 100% by day 7 post-vaccination and remained constant throughout the course of the experiment (Fig. 2B).", [["ArkGA", "CHEMICAL", 0, 5], ["ArkGA P1 vaccine candidate coverage", "TREATMENT", 0, 35], ["vaccination", "TREATMENT", 59, 70]]], ["Clinical signs were also recorded at these time points and tracheal rales were observed in 60% of the chicks vaccinated with ArkGA P1 vaccine candidate at 10 days post-vaccination, which is consistent with previous reports for Ark99.ArkGA P1 vaccination study ::: ArkGA P1 ::: ResultsTitration of pathogenic Ark type challenge virus showed an EID50 of 1x107/ml.", [["tracheal", "ANATOMY", 59, 67], ["ArkGA", "CHEMICAL", 125, 130], ["tracheal rales", "MULTI-TISSUE_STRUCTURE", 59, 73], ["chicks", "ORGANISM", 102, 108], ["Ark99", "GENE_OR_GENE_PRODUCT", 227, 232], ["Ark type challenge virus", "ORGANISM", 308, 332], ["Ark99", "PROTEIN", 227, 232], ["Clinical signs", "TEST", 0, 14], ["tracheal rales", "PROBLEM", 59, 73], ["ArkGA P1 vaccine", "TREATMENT", 125, 141], ["pathogenic Ark type challenge virus", "PROBLEM", 297, 332], ["an EID50", "TEST", 340, 348], ["tracheal", "ANATOMY", 59, 67], ["rales", "OBSERVATION", 68, 73], ["consistent with", "UNCERTAINTY", 190, 205]]], ["Challenge virus was diluted to a dose of 1x103.5 per bird prior to inoculation and confirmed by back-titration in embryos.", [["embryos", "ANATOMY", 114, 121], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 114, 121], ["Challenge virus", "TREATMENT", 0, 15], ["inoculation", "TREATMENT", 67, 78]]], ["All groups showed significantly less clinical signs than the non-vaccinated and challenged group (Fig. 3A), and all groups had significantly reduced ciliostasis scores compared to the non-vaccinated and challenged group (Fig. 3B), as expected.", [["significantly reduced ciliostasis scores", "PROBLEM", 127, 167]]], ["Relative viral load was also significantly reduced in all groups when compared to the non-vaccinated and challenged group (Fig. 3C).", [["Relative viral load", "PROBLEM", 0, 19], ["viral load", "OBSERVATION", 9, 19], ["significantly", "OBSERVATION_MODIFIER", 29, 42], ["reduced", "OBSERVATION_MODIFIER", 43, 50]]], ["Plotting the Ct values from individual samples taken from each group shows that 4/20 chickens in the ArkGA P1 vaccinated and challenged group were positive by qRT-PCR (Fig. 3D).", [["samples", "ANATOMY", 39, 46], ["ArkGA", "CHEMICAL", 101, 106], ["chickens", "ORGANISM", 85, 93], ["ArkGA P1", "ORGANISM", 101, 109], ["chickens", "SPECIES", 85, 93], ["chickens", "SPECIES", 85, 93], ["Plotting the Ct values", "TEST", 0, 22], ["individual samples", "TEST", 28, 46], ["4/20 chickens", "PROBLEM", 80, 93], ["PCR", "TEST", 163, 166]]], ["Virus isolation was not performed for this trial.Analysis of the ArkGA P1 S1 sequence isolated from vaccinated birds ::: ArkGA P1 ::: Results", [["Virus", "ORGANISM", 0, 5], ["ArkGA P1 S1", "GENE_OR_GENE_PRODUCT", 65, 76], ["birds", "ORGANISM", 111, 116], ["ArkGA P1 S1 sequence", "DNA", 65, 85], ["Virus isolation", "TREATMENT", 0, 15], ["Analysis", "TEST", 49, 57], ["the ArkGA P1 S1 sequence", "TEST", 61, 85]]]], "PMC6491439": [["IntroductionChronic obstructive pulmonary disease (COPD) characteristically involves an airflow limitation that is not fully reversible.", [["pulmonary", "ANATOMY", 32, 41], ["IntroductionChronic obstructive pulmonary disease", "DISEASE", 0, 49], ["COPD", "DISEASE", 51, 55], ["pulmonary", "ORGAN", 32, 41], ["IntroductionChronic obstructive pulmonary disease (COPD)", "PROBLEM", 0, 56], ["an airflow limitation", "PROBLEM", 85, 106], ["obstructive", "OBSERVATION_MODIFIER", 20, 31], ["pulmonary", "ANATOMY", 32, 41], ["disease", "OBSERVATION", 42, 49], ["COPD", "OBSERVATION", 51, 55], ["airflow limitation", "OBSERVATION", 88, 106], ["not", "UNCERTAINTY", 115, 118], ["fully reversible", "OBSERVATION_MODIFIER", 119, 135]]], ["Its worldwide prevalence is increasing, and the Global Burden of Disease Study has estimated that COPD will be the fourth leading cause of death by 20301.", [["COPD", "DISEASE", 98, 102], ["death", "DISEASE", 139, 144], ["Disease Study", "TEST", 65, 78], ["COPD", "PROBLEM", 98, 102], ["death", "PROBLEM", 139, 144], ["worldwide", "OBSERVATION_MODIFIER", 4, 13], ["prevalence", "OBSERVATION_MODIFIER", 14, 24], ["increasing", "OBSERVATION_MODIFIER", 28, 38], ["Global", "OBSERVATION_MODIFIER", 48, 54], ["Burden", "OBSERVATION_MODIFIER", 55, 61], ["Disease", "OBSERVATION", 65, 72], ["COPD", "OBSERVATION", 98, 102]]], ["Although pharmacotherapies for COPD have improved, many patients still experience exacerbations of COPD, during which respiratory symptoms worsen acutely, and which determine disease-associated morbidity, mortality, resource burden, and healthcare costs2.", [["respiratory", "ANATOMY", 118, 129], ["COPD", "DISEASE", 31, 35], ["COPD", "DISEASE", 99, 103], ["respiratory symptoms", "DISEASE", 118, 138], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["pharmacotherapies", "TREATMENT", 9, 26], ["COPD", "PROBLEM", 31, 35], ["COPD", "PROBLEM", 99, 103], ["respiratory symptoms", "PROBLEM", 118, 138], ["COPD", "OBSERVATION", 31, 35], ["improved", "OBSERVATION_MODIFIER", 41, 49], ["COPD", "OBSERVATION", 99, 103]]], ["After exacerbations, the patients\u2019 symptomatic and pulmonary function recovery takes several weeks, and their quality of life may be seriously degraded.", [["pulmonary", "ANATOMY", 51, 60], ["patients", "ORGANISM", 25, 33], ["pulmonary", "ORGAN", 51, 60], ["patients", "SPECIES", 25, 33], ["exacerbations", "PROBLEM", 6, 19], ["the patients\u2019 symptomatic and pulmonary function recovery", "PROBLEM", 21, 78], ["symptomatic", "OBSERVATION_MODIFIER", 35, 46], ["pulmonary", "ANATOMY", 51, 60]]], ["In a large study of commercially insured COPD patients, the total medical and pharmaceutical costs per patient admitted to an emergency department or as a hospital inpatient was approximately $2,000\u2013$40,0003.", [["COPD", "DISEASE", 41, 45], ["patients", "ORGANISM", 46, 54], ["patient", "ORGANISM", 103, 110], ["patients", "SPECIES", 46, 54], ["patient", "SPECIES", 103, 110], ["large", "OBSERVATION_MODIFIER", 5, 10], ["COPD", "OBSERVATION", 41, 45]]], ["Hence, it is extremely important to prevent acute exacerbation in COPD patients, but this requires identification of the factors associated with exacerbation.IntroductionTo date, most research on COPD-exacerbating factors has relied on cohort data.", [["COPD", "DISEASE", 66, 70], ["COPD", "DISEASE", 196, 200], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["acute exacerbation", "PROBLEM", 44, 62], ["COPD patients", "PROBLEM", 66, 79], ["exacerbation", "PROBLEM", 145, 157], ["COPD", "PROBLEM", 196, 200], ["exacerbating factors", "PROBLEM", 201, 221], ["cohort data", "TEST", 236, 247], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["exacerbation", "OBSERVATION", 50, 62], ["COPD", "OBSERVATION", 66, 70], ["COPD", "OBSERVATION", 196, 200]]], ["Moreover, most studies have focused on factors inherent to the COPD patients themselves, rather than external factors4\u20136.", [["COPD", "DISEASE", 63, 67], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["external factors", "TEST", 101, 117], ["COPD", "OBSERVATION", 63, 67]]], ["Although external factors, such as air pollution and viral infection, are known to contribute to COPD exacerbation7\u20139, few studies have analysed the factors associated with COPD based on cohort as well as external data.IntroductionKorea has a compulsory universal health insurance system that includes medical reimbursement records for the entire Korean population.", [["viral infection", "DISEASE", 53, 68], ["COPD", "DISEASE", 97, 101], ["COPD", "DISEASE", 173, 177], ["IntroductionKorea", "CHEMICAL", 219, 236], ["external factors", "PROBLEM", 9, 25], ["air pollution", "PROBLEM", 35, 48], ["viral infection", "PROBLEM", 53, 68], ["COPD exacerbation7\u20139", "PROBLEM", 97, 117], ["few studies", "TEST", 119, 130], ["COPD", "PROBLEM", 173, 177], ["external data", "TEST", 205, 218], ["external factors", "OBSERVATION", 9, 25], ["air pollution", "OBSERVATION", 35, 48], ["viral", "OBSERVATION_MODIFIER", 53, 58], ["infection", "OBSERVATION", 59, 68], ["COPD", "OBSERVATION", 97, 101]]], ["The Korean Health Insurance Review and Assessment Service (HIRA) database contains detailed information about diagnosis, health care use, and medication, and is a reliable source for nationwide epidemiological evaluations10.", [["medication", "TREATMENT", 142, 152], ["epidemiological evaluations", "TEST", 194, 221]]], ["Merging these claims data with cohort data provides a powerful research resource.", [["cohort data", "TEST", 31, 42]]], ["Cohort data contain very detailed and accurate information regarding COPD, such as lung function, quality of life, and smoking status, which are usually lacking in claims data.", [["lung", "ANATOMY", 83, 87], ["COPD", "DISEASE", 69, 73], ["lung", "ORGAN", 83, 87], ["Cohort data", "TEST", 0, 11], ["COPD", "PROBLEM", 69, 73], ["COPD", "OBSERVATION", 69, 73], ["lung", "ANATOMY", 83, 87]]], ["Furthermore, in Korea, big data on factors that can potentially influence acute exacerbations, such as air pollution, social network services, weather data, and respiratory virus detection rates, are available.IntroductionHowever, no previous study has collected and integrated all these potential factors in COPD research.", [["COPD", "DISEASE", 309, 313], ["acute exacerbations", "PROBLEM", 74, 93], ["weather data", "TEST", 143, 155], ["respiratory virus detection rates", "TEST", 161, 194], ["previous study", "TEST", 234, 248], ["COPD research", "PROBLEM", 309, 322], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["exacerbations", "OBSERVATION", 80, 93], ["COPD", "OBSERVATION", 309, 313]]], ["We therefore analysed such combined big data in order to identify factors associated with acute exacerbation of COPD.Baseline patient characteristics ::: ResultsSupplementary Table S1 shows the baseline characteristics of the COPD patients who were included in this study.", [["COPD", "DISEASE", 112, 116], ["COPD", "DISEASE", 226, 230], ["patient", "ORGANISM", 126, 133], ["patients", "ORGANISM", 231, 239], ["patient", "SPECIES", 126, 133], ["patients", "SPECIES", 231, 239], ["big data", "TEST", 36, 44], ["acute exacerbation", "PROBLEM", 90, 108], ["COPD", "PROBLEM", 112, 116], ["this study", "TEST", 261, 271], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["exacerbation", "OBSERVATION", 96, 108], ["COPD", "OBSERVATION", 112, 116], ["COPD", "OBSERVATION", 226, 230]]], ["Almost all patients (98.8%) were current or former smokers.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19]]], ["The post-bronchodilator FEV1 was 55.9 \u00b1 17.2% predicted, and the FEV1/FVC ratio was 48.3 \u00b1 12.0.", [["The post-bronchodilator FEV1", "TEST", 0, 28], ["the FEV1/FVC ratio", "TEST", 61, 79]]], ["The mean CAT score was 15.8 \u00b1 7.4 and the CAT score was \u226510 in 79.0% of the patients.", [["patients", "ORGANISM", 76, 84], ["CAT", "PROTEIN", 9, 12], ["CAT", "PROTEIN", 42, 45], ["patients", "SPECIES", 76, 84], ["The mean CAT score", "TEST", 0, 18], ["the CAT score", "TEST", 38, 51]]], ["Of the total study population, the percentages of patients in GOLD stages I, II, III, and IV were 6.7 (n = 38), 53.9 (n = 305), 33.9 (n = 192), and 5.5 (n = 31).Patient characteristics associated with COPD acute exacerbation during a 5-year follow-up period ::: ResultsUnivariate analysis was used to examine the influence of patient characteristics on COPD acute exacerbations during a 5-year follow-up period, and the results are shown in Supplementary Table S2.", [["COPD", "DISEASE", 201, 205], ["COPD", "DISEASE", 353, 357], ["patients", "ORGANISM", 50, 58], ["patient", "ORGANISM", 326, 333], ["patients", "SPECIES", 50, 58], ["Patient", "SPECIES", 161, 168], ["patient", "SPECIES", 326, 333], ["the total study population", "TEST", 3, 29], ["IV", "TEST", 90, 92], ["COPD acute exacerbation", "PROBLEM", 201, 224], ["ResultsUnivariate analysis", "TEST", 262, 288], ["COPD acute exacerbations", "PROBLEM", 353, 377], ["associated with", "UNCERTAINTY", 185, 200], ["COPD", "OBSERVATION", 201, 205], ["acute", "OBSERVATION_MODIFIER", 206, 211], ["exacerbation", "OBSERVATION", 212, 224], ["acute", "OBSERVATION_MODIFIER", 358, 363], ["exacerbations", "OBSERVATION", 364, 377]]], ["Old age, female sex, smoking status, high CAT score, low FEV1, higher grade of COPD, number of exacerbations during the previous year (2007), and number of visits to the ER during the previous year (2007) were all associated with COPD acute exacerbation.Meteorological factors associated with COPD acute exacerbation during a 5-year follow-up period ::: ResultsTable 1 shows the influence of environmental factors on COPD acute exacerbation in terms of univariate analysis.", [["COPD", "DISEASE", 79, 83], ["COPD", "DISEASE", 230, 234], ["COPD", "DISEASE", 293, 297], ["COPD", "DISEASE", 417, 421], ["ER", "GENE_OR_GENE_PRODUCT", 170, 172], ["CAT", "PROTEIN", 42, 45], ["ER", "PROTEIN", 170, 172], ["high CAT score", "PROBLEM", 37, 51], ["low FEV1", "PROBLEM", 53, 61], ["COPD", "PROBLEM", 79, 83], ["exacerbations", "PROBLEM", 95, 108], ["COPD acute exacerbation", "PROBLEM", 230, 253], ["COPD acute exacerbation", "PROBLEM", 293, 316], ["COPD acute exacerbation", "PROBLEM", 417, 440], ["univariate analysis", "TEST", 453, 472], ["higher grade", "OBSERVATION_MODIFIER", 63, 75], ["COPD", "OBSERVATION", 79, 83], ["exacerbations", "OBSERVATION", 95, 108], ["COPD", "OBSERVATION", 230, 234], ["acute", "OBSERVATION_MODIFIER", 235, 240], ["exacerbation", "OBSERVATION", 241, 253], ["COPD", "OBSERVATION", 293, 297], ["acute", "OBSERVATION_MODIFIER", 298, 303], ["exacerbation", "OBSERVATION", 304, 316], ["acute", "OBSERVATION_MODIFIER", 422, 427], ["exacerbation", "OBSERVATION", 428, 440]]], ["Humidity, variation of diurnal temperature, lowest temperature, and cumulative amount of rainfall during the 7 days before an acute exacerbation were associated with acute exacerbations.", [["Humidity", "TREATMENT", 0, 8], ["diurnal temperature", "PROBLEM", 23, 42], ["lowest temperature", "PROBLEM", 44, 62], ["an acute exacerbation", "PROBLEM", 123, 144], ["acute exacerbations", "PROBLEM", 166, 185], ["cumulative", "OBSERVATION_MODIFIER", 68, 78], ["amount", "OBSERVATION_MODIFIER", 79, 85], ["acute", "OBSERVATION_MODIFIER", 126, 131], ["exacerbation", "OBSERVATION", 132, 144], ["associated with", "UNCERTAINTY", 150, 165], ["acute", "OBSERVATION_MODIFIER", 166, 171], ["exacerbations", "OBSERVATION", 172, 185]]], ["Figure 1 shows the effect of the lowest temperature 1 day prior to a COPD acute exacerbation.", [["COPD", "DISEASE", 69, 73], ["the lowest temperature", "PROBLEM", 29, 51], ["a COPD acute exacerbation", "PROBLEM", 67, 92], ["COPD", "OBSERVATION", 69, 73], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["exacerbation", "OBSERVATION", 80, 92]]], ["The lowest temperature was also correlated with PM10 and the virus detection rate (as detailed in Supplementary Table S3).Air pollution factors associated with COPD acute exacerbation during a 5-year follow-up period ::: ResultsThe results of univariate analyses, showing the relationship between air pollution and COPD exacerbation, are shown in Table 2.", [["PM10", "CHEMICAL", 48, 52], ["COPD", "DISEASE", 160, 164], ["COPD", "DISEASE", 315, 319], ["The lowest temperature", "TEST", 0, 22], ["the virus detection rate", "TEST", 57, 81], ["Air pollution factors", "PROBLEM", 122, 143], ["COPD acute exacerbation", "PROBLEM", 160, 183], ["univariate analyses", "TEST", 243, 262], ["air pollution", "PROBLEM", 297, 310], ["COPD exacerbation", "PROBLEM", 315, 332], ["COPD", "OBSERVATION_MODIFIER", 160, 164], ["acute", "OBSERVATION_MODIFIER", 165, 170], ["exacerbation", "OBSERVATION", 171, 183], ["air pollution", "OBSERVATION", 297, 310], ["COPD", "OBSERVATION", 315, 319]]], ["PM10 levels 1 day before acute exacerbation was associated with acute exacerbation.", [["PM10", "CHEMICAL", 0, 4], ["PM10", "CHEMICAL", 0, 4], ["PM10", "SIMPLE_CHEMICAL", 0, 4], ["PM10 levels", "TEST", 0, 11], ["acute exacerbation", "PROBLEM", 25, 43], ["acute exacerbation", "PROBLEM", 64, 82], ["acute", "OBSERVATION_MODIFIER", 25, 30], ["exacerbation", "OBSERVATION", 31, 43], ["associated with", "UNCERTAINTY", 48, 63], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["exacerbation", "OBSERVATION", 70, 82]]], ["The monthly mean incidence rate of COPD acute exacerbation showed a similar tendency with PM10 1 day prior to the acute exacerbation (Fig. 2).Web query data associated with COPD acute exacerbation during a 5-year follow-up period ::: ResultsThe results of GEE model analysis of the relationship between web search data and COPD exacerbations are shown in Supplementary Table S4.", [["COPD", "DISEASE", 35, 39], ["PM10", "CHEMICAL", 90, 94], ["COPD", "DISEASE", 173, 177], ["COPD", "DISEASE", 323, 327], ["COPD acute exacerbation", "PROBLEM", 35, 58], ["the acute exacerbation", "PROBLEM", 110, 132], ["COPD acute exacerbation", "PROBLEM", 173, 196], ["GEE model analysis", "TEST", 256, 274], ["web search data", "TEST", 303, 318], ["COPD exacerbations", "PROBLEM", 323, 341], ["COPD", "OBSERVATION", 35, 39], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["exacerbation", "OBSERVATION", 46, 58], ["acute", "OBSERVATION_MODIFIER", 114, 119], ["exacerbation", "OBSERVATION", 120, 132], ["acute", "OBSERVATION_MODIFIER", 178, 183], ["exacerbation", "OBSERVATION", 184, 196], ["COPD", "OBSERVATION", 323, 327]]], ["In univariate analysis, the number of logs of online web search queries about COPD, containing the words \u201cflu\u201d, \u201cdyspnea\u201d, \u201casthma\u201d, \u201cCOPD\u201d, \u201cacute exacerbation\u201d, \u201cemphysema\u201d and \u201cchronic bronchitis\u201d at 1 and 2 weeks prior to exacerbation correlated positively with COPD exacerbation.Viral factors associated with COPD acute exacerbation during a 5-year follow-up period ::: ResultsUnivariate analysis results indicating the relationship between viral factors and COPD acute exacerbation are shown in Table 3.", [["COPD", "DISEASE", 78, 82], ["flu\u201d", "DISEASE", 106, 110], ["dyspnea", "DISEASE", 113, 120], ["asthma", "DISEASE", 124, 130], ["COPD", "DISEASE", 134, 138], ["emphysema", "DISEASE", 164, 173], ["bronchitis", "DISEASE", 188, 198], ["COPD", "DISEASE", 266, 270], ["COPD", "DISEASE", 314, 318], ["COPD", "DISEASE", 464, 468], ["Viral factors", "PROTEIN", 284, 297], ["viral factors", "PROTEIN", 446, 459], ["univariate analysis", "TEST", 3, 22], ["COPD", "PROBLEM", 78, 82], ["dyspnea", "PROBLEM", 113, 120], ["asthma", "PROBLEM", 124, 130], ["COPD", "PROBLEM", 134, 138], ["acute exacerbation", "PROBLEM", 142, 160], ["emphysema", "PROBLEM", 164, 173], ["chronic bronchitis", "PROBLEM", 180, 198], ["exacerbation", "PROBLEM", 226, 238], ["COPD exacerbation", "PROBLEM", 266, 283], ["Viral factors", "PROBLEM", 284, 297], ["COPD acute exacerbation", "PROBLEM", 314, 337], ["ResultsUnivariate analysis", "TEST", 375, 401], ["viral factors", "PROBLEM", 446, 459], ["COPD acute exacerbation", "PROBLEM", 464, 487], ["asthma", "OBSERVATION", 124, 130], ["COPD", "OBSERVATION", 134, 138], ["acute", "OBSERVATION_MODIFIER", 142, 147], ["exacerbation", "OBSERVATION", 148, 160], ["emphysema", "OBSERVATION", 164, 173], ["chronic", "OBSERVATION_MODIFIER", 180, 187], ["bronchitis", "OBSERVATION", 188, 198], ["COPD", "OBSERVATION", 266, 270], ["COPD", "OBSERVATION", 314, 318], ["acute", "OBSERVATION_MODIFIER", 319, 324], ["exacerbation", "OBSERVATION", 325, 337], ["COPD", "OBSERVATION_MODIFIER", 464, 468], ["acute", "OBSERVATION_MODIFIER", 469, 474], ["exacerbation", "OBSERVATION", 475, 487]]], ["The detection rate of IFV, hCoV, hRV, and COPD acute exacerbation correlated positively.", [["COPD", "DISEASE", 42, 46], ["IFV", "SPECIES", 22, 25], ["hRV", "SPECIES", 33, 36], ["The detection rate", "TEST", 0, 18], ["IFV", "PROBLEM", 22, 25], ["hRV", "PROBLEM", 33, 36], ["COPD acute exacerbation", "PROBLEM", 42, 65], ["COPD", "OBSERVATION", 42, 46], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["exacerbation", "OBSERVATION", 53, 65]]], ["Figure 3 shows the relationship between the detection rate of viruses and COPD acute exacerbation.Viral factors associated with COPD acute exacerbation during a 5-year follow-up period ::: ResultsTable 4 shows multivariate associations between potential predictor variables and exacerbations.", [["COPD", "DISEASE", 74, 78], ["COPD", "DISEASE", 128, 132], ["Viral factors", "PROTEIN", 98, 111], ["viruses", "PROBLEM", 62, 69], ["COPD acute exacerbation", "PROBLEM", 74, 97], ["Viral factors", "PROBLEM", 98, 111], ["COPD acute exacerbation", "PROBLEM", 128, 151], ["exacerbations", "PROBLEM", 278, 291], ["viruses", "OBSERVATION", 62, 69], ["COPD", "OBSERVATION_MODIFIER", 74, 78], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["exacerbation", "OBSERVATION", 85, 97], ["COPD", "OBSERVATION", 128, 132], ["acute", "OBSERVATION_MODIFIER", 133, 138], ["exacerbation", "OBSERVATION", 139, 151]]], ["Female sex, number of exacerbations in the baseline year, COPD grade, and detection rate of IFV 2 weeks before acute exacerbation were significantly positively correlated with COPD acute exacerbation.", [["exacerbations", "DISEASE", 22, 35], ["COPD", "DISEASE", 58, 62], ["COPD", "DISEASE", 176, 180], ["exacerbations", "PROBLEM", 22, 35], ["COPD grade", "PROBLEM", 58, 68], ["acute exacerbation", "PROBLEM", 111, 129], ["COPD acute exacerbation", "PROBLEM", 176, 199], ["exacerbations", "OBSERVATION", 22, 35], ["COPD", "OBSERVATION", 58, 62], ["acute", "OBSERVATION_MODIFIER", 111, 116], ["exacerbation", "OBSERVATION", 117, 129], ["acute", "OBSERVATION_MODIFIER", 181, 186], ["exacerbation", "OBSERVATION", 187, 199]]], ["Multivariate analysis revealed that the number of exacerbations in the preceding year, female sex, COPD grade, and IFV detection rate, and lowest temperature showed significant association with exacerbationDiscussionWe merged clinical data from cohort and 6 years\u2019 follow-up claims data with external factors, such as air pollution and viral infection rates, to identify factors that were associated with acute COPD exacerbation.", [["exacerbations", "DISEASE", 50, 63], ["COPD", "DISEASE", 99, 103], ["viral infection", "DISEASE", 336, 351], ["COPD", "DISEASE", 411, 415], ["Multivariate analysis", "TEST", 0, 21], ["exacerbations", "PROBLEM", 50, 63], ["COPD grade", "PROBLEM", 99, 109], ["IFV detection rate", "TEST", 115, 133], ["lowest temperature", "PROBLEM", 139, 157], ["exacerbation", "PROBLEM", 194, 206], ["external factors", "PROBLEM", 292, 308], ["air pollution", "PROBLEM", 318, 331], ["viral infection rates", "PROBLEM", 336, 357], ["acute COPD exacerbation", "PROBLEM", 405, 428], ["exacerbations", "OBSERVATION", 50, 63], ["COPD", "OBSERVATION", 99, 103], ["viral infection", "OBSERVATION", 336, 351], ["acute", "OBSERVATION_MODIFIER", 405, 410], ["COPD", "OBSERVATION", 411, 415]]], ["The possible factors associated with exacerbation were female sex, a history of frequent exacerbations in the previous year, a higher COPD grade, the IFV detection rate in the period before an acute exacerbation, and a low lowest temperature before an acute exacerbation (Fig. 4).DiscussionMany other predictive studies have focused only on factors inherent to COPD patients4\u20136,11, or only on external factors, such as environmental or viral factors8,9,12\u201315.", [["COPD", "DISEASE", 134, 138], ["COPD", "DISEASE", 361, 365], ["viral factors", "PROTEIN", 436, 449], ["exacerbation", "PROBLEM", 37, 49], ["frequent exacerbations", "PROBLEM", 80, 102], ["a higher COPD grade", "PROBLEM", 125, 144], ["the IFV detection rate", "TEST", 146, 168], ["an acute exacerbation", "PROBLEM", 190, 211], ["a low lowest temperature", "PROBLEM", 217, 241], ["an acute exacerbation", "PROBLEM", 249, 270], ["other predictive studies", "TEST", 295, 319], ["possible factors associated with", "UNCERTAINTY", 4, 36], ["frequent", "OBSERVATION_MODIFIER", 80, 88], ["exacerbations", "OBSERVATION", 89, 102], ["acute", "OBSERVATION_MODIFIER", 193, 198], ["exacerbation", "OBSERVATION", 199, 211], ["low lowest temperature", "OBSERVATION_MODIFIER", 219, 241], ["acute", "OBSERVATION_MODIFIER", 252, 257], ["exacerbation", "OBSERVATION", 258, 270]]], ["In the present study, we integrated factors related to the COPD patients with external potentially contributing factors.DiscussionPrevious studies on predictors of COPD exacerbation have commonly identified airway obstruction (FEV1% predicted, or FEV1, or GOLD stage), previous exacerbations, age, and smoking as the causes of COPD exacerbation16.", [["airway", "ANATOMY", 207, 213], ["COPD", "DISEASE", 59, 63], ["COPD", "DISEASE", 164, 168], ["airway obstruction", "DISEASE", 207, 225], ["COPD", "DISEASE", 327, 331], ["patients", "ORGANISM", 64, 72], ["airway", "MULTI-TISSUE_STRUCTURE", 207, 213], ["patients", "SPECIES", 64, 72], ["the present study", "TEST", 3, 20], ["the COPD patients", "PROBLEM", 55, 72], ["DiscussionPrevious studies", "TEST", 120, 146], ["COPD exacerbation", "PROBLEM", 164, 181], ["airway obstruction", "PROBLEM", 207, 225], ["FEV1", "TEST", 227, 231], ["FEV1", "TEST", 247, 251], ["GOLD stage)", "PROBLEM", 256, 267], ["previous exacerbations", "PROBLEM", 269, 291], ["COPD exacerbation16", "PROBLEM", 327, 346], ["COPD", "OBSERVATION", 59, 63], ["COPD", "OBSERVATION", 164, 168], ["airway", "ANATOMY", 207, 213], ["obstruction", "OBSERVATION", 214, 225], ["COPD", "OBSERVATION", 327, 331]]], ["Similar to previous studies, a higher grade of COPD and the number of exacerbations were identified as significant predictors; older age and smoking status were significant in the present univariate, but not multivariate analyses.DiscussionA lower lowest temperature and the viral detection rate were related with COPD exacerbation.", [["COPD", "DISEASE", 47, 51], ["COPD", "DISEASE", 314, 318], ["previous studies", "TEST", 11, 27], ["COPD", "PROBLEM", 47, 51], ["exacerbations", "PROBLEM", 70, 83], ["DiscussionA lower lowest temperature", "PROBLEM", 230, 266], ["the viral detection rate", "TEST", 271, 295], ["COPD exacerbation", "PROBLEM", 314, 331], ["higher grade", "OBSERVATION_MODIFIER", 31, 43], ["COPD", "OBSERVATION", 47, 51], ["number", "OBSERVATION_MODIFIER", 60, 66], ["exacerbations", "OBSERVATION", 70, 83], ["significant", "OBSERVATION_MODIFIER", 103, 114], ["COPD", "OBSERVATION", 314, 318]]], ["COPD exacerbations were more common in the winter months, with colder temperature, when respiratory viral infections are more prevalent in the community9,17.", [["COPD", "DISEASE", 0, 4], ["respiratory viral infections", "DISEASE", 88, 116], ["COPD exacerbations", "PROBLEM", 0, 18], ["colder temperature", "PROBLEM", 63, 81], ["respiratory viral infections", "PROBLEM", 88, 116], ["viral infections", "OBSERVATION", 100, 116]]], ["A two-fold increase in the COPD exacerbation rate in winter has previously been reported18,19, and a previous nationwide study has shown that cold temperature increased COPD exacerbation14, in agreement with the present findings.DiscussionViral infection is a major cause of COPD exacerbations; the respiratory viruses most frequently involved in COPD exacerbations are rhinoviruses, IFVs, coronaviruses, and respiratory syncytial virus9,20\u201322.", [["COPD", "DISEASE", 27, 31], ["COPD", "DISEASE", 169, 173], ["DiscussionViral infection", "DISEASE", 229, 254], ["COPD", "DISEASE", 275, 279], ["respiratory viruses", "DISEASE", 299, 318], ["COPD", "DISEASE", 347, 351], ["rhinoviruses, IFVs, coronaviruses", "DISEASE", 370, 403], ["respiratory syncytial virus", "DISEASE", 409, 436], ["rhinoviruses", "ORGANISM", 370, 382], ["respiratory syncytial virus", "ORGANISM", 409, 436], ["respiratory syncytial virus", "SPECIES", 409, 436], ["A two-fold increase", "PROBLEM", 0, 19], ["the COPD exacerbation rate", "PROBLEM", 23, 49], ["a previous nationwide study", "TEST", 99, 126], ["cold temperature increased COPD exacerbation14", "PROBLEM", 142, 188], ["DiscussionViral infection", "PROBLEM", 229, 254], ["COPD exacerbations", "PROBLEM", 275, 293], ["the respiratory viruses", "PROBLEM", 295, 318], ["COPD exacerbations", "PROBLEM", 347, 365], ["rhinoviruses", "PROBLEM", 370, 382], ["IFVs", "PROBLEM", 384, 388], ["coronaviruses", "PROBLEM", 390, 403], ["respiratory syncytial virus", "TEST", 409, 436], ["two", "OBSERVATION_MODIFIER", 2, 5], ["-fold", "OBSERVATION_MODIFIER", 5, 10], ["increase", "OBSERVATION_MODIFIER", 11, 19], ["COPD", "OBSERVATION_MODIFIER", 27, 31], ["exacerbation", "OBSERVATION", 32, 44], ["cold temperature", "OBSERVATION_MODIFIER", 142, 158], ["increased", "OBSERVATION_MODIFIER", 159, 168], ["COPD", "OBSERVATION", 169, 173], ["infection", "OBSERVATION", 245, 254], ["COPD", "OBSERVATION", 275, 279], ["respiratory viruses", "OBSERVATION", 299, 318], ["COPD", "OBSERVATION", 347, 351], ["rhinoviruses", "OBSERVATION", 370, 382], ["respiratory syncytial", "ANATOMY", 409, 430]]], ["Papi et al. have reported that viral infection played a role in 48% of COPD exacerbations; based on polymerase chain reaction analyses, rhinovirus infections were the most common, followed by IFVs, accounting for 23% of virus-associated exacerbations22.", [["viral infection", "DISEASE", 31, 46], ["COPD", "DISEASE", 71, 75], ["rhinovirus infections", "DISEASE", 136, 157], ["IFVs", "DISEASE", 192, 196], ["rhinovirus", "ORGANISM", 136, 146], ["viral infection", "PROBLEM", 31, 46], ["COPD exacerbations", "PROBLEM", 71, 89], ["polymerase chain reaction analyses", "TEST", 100, 134], ["rhinovirus infections", "PROBLEM", 136, 157], ["virus", "PROBLEM", 220, 225], ["viral", "OBSERVATION_MODIFIER", 31, 36], ["infection", "OBSERVATION", 37, 46], ["COPD", "OBSERVATION", 71, 75], ["most common", "OBSERVATION_MODIFIER", 167, 178]]], ["The present univariate analysis implicated various viruses in COPD exacerbation, as in previous studies.", [["COPD", "DISEASE", 62, 66], ["various viruses", "PROBLEM", 43, 58], ["COPD exacerbation", "PROBLEM", 62, 79], ["previous studies", "TEST", 87, 103], ["various viruses", "OBSERVATION", 43, 58], ["COPD", "OBSERVATION_MODIFIER", 62, 66], ["exacerbation", "OBSERVATION", 67, 79]]], ["However, in multivariate analysis, the correlation between viruses other than IFV and COPD exacerbation was not statistically significant, perhaps due to the confounding effect of temperature, which is a very powerful factor in COPD exacerbation.DiscussionIn this study, PM10 was identified as a significant predictor in univariate analysis, and the monthly mean trend of PM10 showed a similar tendency as that of the COPD exacerbation incidence rate.", [["COPD", "DISEASE", 86, 90], ["COPD", "DISEASE", 228, 232], ["PM10", "CHEMICAL", 271, 275], ["PM10", "CHEMICAL", 372, 376], ["COPD", "DISEASE", 418, 422], ["PM10", "SIMPLE_CHEMICAL", 271, 275], ["multivariate analysis", "TEST", 12, 33], ["viruses", "PROBLEM", 59, 66], ["IFV", "PROBLEM", 78, 81], ["COPD exacerbation", "PROBLEM", 86, 103], ["the confounding effect of temperature", "PROBLEM", 154, 191], ["COPD exacerbation", "PROBLEM", 228, 245], ["this study", "TEST", 259, 269], ["univariate analysis", "TEST", 321, 340], ["the COPD exacerbation incidence rate", "PROBLEM", 414, 450], ["COPD", "OBSERVATION", 86, 90], ["COPD", "OBSERVATION", 228, 232], ["COPD", "OBSERVATION", 418, 422]]], ["Due to the rapid urbanization of the world population, air pollution has become a major health problem.", [["air pollution", "PROBLEM", 55, 68], ["rapid", "OBSERVATION_MODIFIER", 11, 16], ["urbanization", "OBSERVATION_MODIFIER", 17, 29], ["air pollution", "OBSERVATION", 55, 68]]], ["Outdoor air pollution also seems to be an important environmental trigger for acute exacerbation of COPD23.", [["COPD23", "CHEMICAL", 100, 106], ["COPD23", "GENE_OR_GENE_PRODUCT", 100, 106], ["COPD23", "PROTEIN", 100, 106], ["Outdoor air pollution", "PROBLEM", 0, 21], ["acute exacerbation of COPD23", "PROBLEM", 78, 106], ["seems to be", "UNCERTAINTY", 27, 38]]], ["A few studies have reported the relationship between air pollution, such as particulate matters (PM10, PM2.5) and harmful gases (NO2, SO2, and O3), and COPD exacerbation7,24\u201326.", [["PM10", "CHEMICAL", 97, 101], ["PM2.5", "CHEMICAL", 103, 108], ["NO2", "CHEMICAL", 129, 132], ["SO2", "CHEMICAL", 134, 137], ["O3", "CHEMICAL", 143, 145], ["COPD", "DISEASE", 152, 156], ["NO2", "CHEMICAL", 129, 132], ["SO2", "CHEMICAL", 134, 137], ["O3", "CHEMICAL", 143, 145], ["NO2", "SIMPLE_CHEMICAL", 129, 132], ["SO2", "SIMPLE_CHEMICAL", 134, 137], ["O3", "SIMPLE_CHEMICAL", 143, 145], ["A few studies", "TEST", 0, 13], ["air pollution", "PROBLEM", 53, 66], ["harmful gases", "TEST", 114, 127], ["NO2", "TEST", 129, 132], ["SO2", "TEST", 134, 137], ["COPD exacerbation", "PROBLEM", 152, 169], ["air pollution", "OBSERVATION", 53, 66], ["COPD", "OBSERVATION", 152, 156]]], ["The deposition of PM in the respiratory tract depends on the size of the particles, and its insufficient clearance may cause a chronic, low-grade inflammatory response, which is known to cause COPD exacerbations27.", [["respiratory tract", "ANATOMY", 28, 45], ["COPD", "DISEASE", 193, 197], ["PM", "MULTI-TISSUE_STRUCTURE", 18, 20], ["respiratory tract", "ORGANISM_SUBDIVISION", 28, 45], ["the respiratory tract", "PROBLEM", 24, 45], ["a chronic, low-grade inflammatory response", "PROBLEM", 125, 167], ["COPD exacerbations", "PROBLEM", 193, 211], ["deposition", "OBSERVATION_MODIFIER", 4, 14], ["respiratory tract", "ANATOMY", 28, 45], ["size", "OBSERVATION_MODIFIER", 61, 65], ["particles", "OBSERVATION_MODIFIER", 73, 82], ["may cause", "UNCERTAINTY", 115, 124], ["chronic", "OBSERVATION_MODIFIER", 127, 134], ["low-grade", "OBSERVATION_MODIFIER", 136, 145], ["inflammatory response", "OBSERVATION", 146, 167], ["known to cause", "UNCERTAINTY", 178, 192], ["COPD", "OBSERVATION", 193, 197]]], ["Currently, there is insufficient evidence that air pollution is a causative factor of COPD, further studies on this topic are therefore recommended.", [["COPD", "DISEASE", 86, 90], ["air pollution", "PROBLEM", 47, 60], ["COPD", "PROBLEM", 86, 90], ["further studies", "TEST", 92, 107], ["air pollution", "OBSERVATION", 47, 60], ["COPD", "OBSERVATION", 86, 90]]], ["Although multivariate analysis showed that the correlation between PM10 and COPD exacerbation was not statistically significant in this study, this discrepancy could also be attributed to the powerful factor of temperature.DiscussionLower temperature, a higher virus detection rate, and a higher concentration of PM10 were significantly correlated with COPD exacerbation in the present study.", [["PM10", "CHEMICAL", 67, 71], ["COPD", "DISEASE", 76, 80], ["PM10", "CHEMICAL", 313, 317], ["COPD", "DISEASE", 353, 357], ["PM10", "SIMPLE_CHEMICAL", 313, 317], ["multivariate analysis", "TEST", 9, 30], ["COPD exacerbation", "PROBLEM", 76, 93], ["this study", "TEST", 131, 141], ["a higher virus detection rate", "PROBLEM", 252, 281], ["a higher concentration of PM10", "TREATMENT", 287, 317], ["COPD exacerbation", "PROBLEM", 353, 370], ["the present study", "TEST", 374, 391], ["COPD", "OBSERVATION", 76, 80], ["COPD", "OBSERVATION", 353, 357]]], ["This result suggested that cold weather eventually increases viral infection and air pollution.", [["infection", "DISEASE", 67, 76], ["cold weather", "PROBLEM", 27, 39], ["viral infection", "PROBLEM", 61, 76], ["air pollution", "PROBLEM", 81, 94], ["viral", "OBSERVATION_MODIFIER", 61, 66], ["infection", "OBSERVATION", 67, 76], ["air pollution", "OBSERVATION", 81, 94]]], ["Multivariate analysis showed that COPD exacerbations are not related to viruses other than influenza, and air pollution, but this is assumed to have been due to the temperature factor, which affects viral infection and air pollution, rather than due to their actual irrelevance.DiscussionOur study demonstrated that the number of exacerbations during the previous year is a significant predictive factor, which was in accord with the findings of previous studies.", [["COPD", "DISEASE", 34, 38], ["influenza", "DISEASE", 91, 100], ["infection", "DISEASE", 205, 214], ["exacerbations", "DISEASE", 330, 343], ["Multivariate analysis", "TEST", 0, 21], ["COPD exacerbations", "PROBLEM", 34, 52], ["viruses", "PROBLEM", 72, 79], ["influenza", "PROBLEM", 91, 100], ["air pollution", "PROBLEM", 106, 119], ["the temperature factor", "PROBLEM", 161, 183], ["viral infection", "PROBLEM", 199, 214], ["air pollution", "PROBLEM", 219, 232], ["DiscussionOur study", "TEST", 278, 297], ["exacerbations", "PROBLEM", 330, 343], ["previous studies", "TEST", 446, 462], ["COPD", "OBSERVATION", 34, 38], ["not related to", "UNCERTAINTY", 57, 71], ["viruses", "OBSERVATION", 72, 79], ["air pollution", "OBSERVATION", 106, 119], ["viral", "OBSERVATION_MODIFIER", 199, 204], ["infection", "OBSERVATION", 205, 214], ["air pollution", "OBSERVATION", 219, 232], ["exacerbations", "OBSERVATION", 330, 343]]], ["Make et al. reported that a history of prior exacerbations and more exacerbations during a previous year were strong predictors for future exacerbations28.", [["prior exacerbations", "PROBLEM", 39, 58], ["future exacerbations", "PROBLEM", 132, 152], ["exacerbations", "OBSERVATION", 45, 58]]], ["M\u00fcllerov\u00e1 et al. also reported that patients with only one prior moderate exacerbation were at increased risk of future exacerbation events29.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["one prior moderate exacerbation", "PROBLEM", 55, 86], ["future exacerbation events", "PROBLEM", 113, 139], ["moderate", "OBSERVATION_MODIFIER", 65, 73], ["exacerbation", "OBSERVATION", 74, 86]]], ["A large observational cohort study also demonstrated that the single best predictor of exacerbations was a history of previous exacerbations30.", [["A large observational cohort study", "TEST", 0, 34], ["exacerbations", "PROBLEM", 87, 100], ["previous exacerbations", "PROBLEM", 118, 140], ["large", "OBSERVATION_MODIFIER", 2, 7], ["exacerbations", "OBSERVATION", 87, 100]]], ["The findings of these studies were consistent with those reported in the present study.DiscussionOur study had several strengths.", [["these studies", "TEST", 16, 29], ["the present study", "TEST", 69, 86], ["DiscussionOur study", "TEST", 87, 106], ["consistent with", "UNCERTAINTY", 35, 50]]], ["First, this study analysed both patient factors and external factors.", [["patient", "ORGANISM", 32, 39], ["external factors", "PROTEIN", 52, 68], ["patient", "SPECIES", 32, 39], ["this study", "TEST", 7, 17], ["external factors", "TREATMENT", 52, 68]]], ["Furthermore, we merged our cohort data with claims data.", [["claims data", "TEST", 44, 55]]], ["Cohort data contained detailed and accurate information regarding COPD, such as lung function and CAT score, while claims data included medical reimbursement records for the entire Korean population, and allowed us to obtain the exact date of COPD exacerbation.", [["lung", "ANATOMY", 80, 84], ["COPD", "DISEASE", 66, 70], ["COPD", "DISEASE", 243, 247], ["lung", "ORGAN", 80, 84], ["CAT", "PROTEIN", 98, 101], ["Cohort data", "TEST", 0, 11], ["COPD", "PROBLEM", 66, 70], ["lung function", "TEST", 80, 93], ["CAT score", "TEST", 98, 107], ["COPD exacerbation", "PROBLEM", 243, 260], ["COPD", "OBSERVATION", 66, 70], ["lung", "ANATOMY", 80, 84], ["COPD", "OBSERVATION", 243, 247]]], ["Using this information, we could precisely match COPD exacerbations with external factors, which included information on the weather, air pollution, and viruses.", [["COPD", "DISEASE", 49, 53], ["COPD exacerbations", "PROBLEM", 49, 67], ["external factors", "PROBLEM", 73, 89], ["viruses", "PROBLEM", 153, 160], ["air pollution", "OBSERVATION", 134, 147]]], ["Moreover, no previous study had analysed COPD patients using nationwide big data or long-term follow-up (5 years) data.DiscussionThe study had some limitations.", [["COPD", "DISEASE", 41, 45], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["previous study", "TEST", 13, 27], ["COPD", "PROBLEM", 41, 45], ["The study", "TEST", 129, 138]]], ["First, COPD exacerbation might be under or overestimated in this study, because the exacerbation data analysed were based on claims data, rather than being acquired via an exacerbation diary or patient interview.", [["COPD", "DISEASE", 7, 11], ["patient", "ORGANISM", 194, 201], ["patient", "SPECIES", 194, 201], ["COPD exacerbation", "PROBLEM", 7, 24], ["this study", "TEST", 60, 70], ["the exacerbation data", "PROBLEM", 80, 101], ["COPD", "OBSERVATION", 7, 11]]], ["Second, since the concentration of PM and the detection rate of viruses vary according to region, consideration should be given to the local distribution of patients.", [["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["viruses", "PROBLEM", 64, 71]]], ["We had, in fact, attempted to adjust for the local distributions of patients based on claims data.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["claims data", "TEST", 86, 97]]], ["It is possible to identify the location of the hospital from the HIRA data; however, this adjustment is not perfect, since the patient may visit a hospital far from home.", [["patient", "ORGANISM", 127, 134], ["patient", "SPECIES", 127, 134]]], ["A further study that considers the regional distribution is therefore required.", [["A further study", "TEST", 0, 15]]], ["Third, some of the baseline data were adopted from the cohort data, and there was a time difference between cohort data and HIRA data.", [["the cohort data", "TEST", 51, 66], ["cohort data", "TEST", 108, 119], ["HIRA data", "TEST", 124, 133]]], ["Thus, CAT, PFT, BMI, smoking status were actually measured after the follow-up period.", [["CAT", "GENE_OR_GENE_PRODUCT", 6, 9], ["CAT", "PROTEIN", 6, 9], ["PFT", "TEST", 11, 14], ["BMI", "PROBLEM", 16, 19]]], ["Also, difference of data measurement period (e.g., daily mean PM10 and weekly viral infection status) should be considered as the limitation of this study.", [["PM10", "CHEMICAL", 62, 66], ["viral infection", "DISEASE", 78, 93], ["weekly viral infection status", "PROBLEM", 71, 100], ["this study", "TEST", 144, 154]]], ["Finally, we did not weight on any variables in multivariate analysis.", [["multivariate analysis", "TEST", 47, 68]]], ["The methodology we developed in this study is the first attempt in the world, and there has been no reference how to weight in equation.", [["this study", "TEST", 32, 42]]], ["Further study with large number of patients will be needed.DiscussionIn conclusion, in this study, we merged factors inherent to COPD patients and external factors, such as environmental, viral, and web search data, to identify factors associated with acute exacerbation of COPD.", [["COPD", "DISEASE", 129, 133], ["COPD", "DISEASE", 274, 278], ["patients", "ORGANISM", 35, 43], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 134, 142], ["Further study", "TEST", 0, 13], ["this study", "TEST", 87, 97], ["COPD patients", "PROBLEM", 129, 142], ["external factors", "PROBLEM", 147, 163], ["acute exacerbation", "PROBLEM", 252, 270], ["COPD", "PROBLEM", 274, 278], ["large", "OBSERVATION_MODIFIER", 19, 24], ["acute", "OBSERVATION_MODIFIER", 252, 257], ["exacerbation", "OBSERVATION", 258, 270], ["COPD", "OBSERVATION", 274, 278]]], ["Univariate analysis showed that patient factors, air pollution, various types of viruses, temperature, and the number of web queries about COPD were associated with COPD exacerbation.", [["COPD", "DISEASE", 139, 143], ["COPD", "DISEASE", 165, 169], ["patient", "ORGANISM", 32, 39], ["patient", "SPECIES", 32, 39], ["Univariate analysis", "TEST", 0, 19], ["patient factors", "PROBLEM", 32, 47], ["air pollution", "PROBLEM", 49, 62], ["viruses", "PROBLEM", 81, 88], ["COPD", "PROBLEM", 139, 143], ["COPD exacerbation", "PROBLEM", 165, 182], ["air pollution", "OBSERVATION", 49, 62], ["viruses", "OBSERVATION", 81, 88], ["COPD", "OBSERVATION", 165, 169]]], ["We demonstrated that the number of exacerbations in the preceding year, being female, a high grade of COPD, the IFV detection rate, and a low lowest temperature were significantly associated with future exacerbation events, according to multivariate analysis.", [["exacerbations", "DISEASE", 35, 48], ["COPD", "DISEASE", 102, 106], ["exacerbations", "PROBLEM", 35, 48], ["COPD", "PROBLEM", 102, 106], ["the IFV detection rate", "TEST", 108, 130], ["a low lowest temperature", "PROBLEM", 136, 160], ["future exacerbation events", "PROBLEM", 196, 222], ["multivariate analysis", "TEST", 237, 258], ["number", "OBSERVATION_MODIFIER", 25, 31], ["exacerbations", "OBSERVATION", 35, 48], ["COPD", "OBSERVATION", 102, 106]]], ["Since exacerbations can negatively impact health status and disease progression31,32, these findings may help to identify the COPD patients who are at risk of exacerbation and to provide intervention as early as possible.Study design and data source ::: MethodsWe investigated data from 594 COPD patients who were enrolled in the Korean COPD subgroup study (KOCOSS) cohort between December 2011 and March 2014.", [["COPD", "DISEASE", 126, 130], ["COPD", "DISEASE", 291, 295], ["COPD", "DISEASE", 337, 341], ["patients", "ORGANISM", 131, 139], ["patients", "ORGANISM", 296, 304], ["patients", "SPECIES", 131, 139], ["patients", "SPECIES", 296, 304], ["exacerbations", "PROBLEM", 6, 19], ["disease progression", "PROBLEM", 60, 79], ["exacerbation", "PROBLEM", 159, 171], ["intervention", "TREATMENT", 187, 199]]], ["Patients were eligible if they had been diagnosed with COPD by a pulmonologist, were aged \u226540 years, had post-bronchodilator FEV1/FVC < 0.7, and if respiratory symptoms, such as cough, sputum, or dyspnoea, were present.", [["respiratory", "ANATOMY", 148, 159], ["sputum", "ANATOMY", 185, 191], ["COPD", "DISEASE", 55, 59], ["respiratory symptoms", "DISEASE", 148, 168], ["cough", "DISEASE", 178, 183], ["dyspnoea", "DISEASE", 196, 204], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["COPD", "PROBLEM", 55, 59], ["post-bronchodilator FEV1", "TEST", 105, 129], ["FVC", "TEST", 130, 133], ["respiratory symptoms", "PROBLEM", 148, 168], ["cough", "PROBLEM", 178, 183], ["sputum", "PROBLEM", 185, 191], ["dyspnoea", "PROBLEM", 196, 204], ["COPD", "OBSERVATION", 55, 59]]], ["Detailed information regarding KOCOSS cohort is described in a previous publication33.Study design and data source ::: MethodsWe obtained four data items from KOCOSS cohort, i.e., smoking status, lung function, body mass index (BMI), and COPD assessment test (CAT) scores.", [["lung", "ANATOMY", 196, 200], ["body", "ANATOMY", 211, 215], ["COPD", "DISEASE", 238, 242], ["lung", "ORGAN", 196, 200], ["body", "ORGANISM_SUBDIVISION", 211, 215], ["lung function", "TEST", 196, 209], ["body mass index", "TEST", 211, 226], ["COPD assessment test", "TEST", 238, 258], ["lung", "ANATOMY", 196, 200]]], ["We then merged these items with their HIRA data from between 2007 and 2012; the latter data included details on comorbidity, medication, and health care utilization.", [["medication", "TREATMENT", 125, 135]]], ["Moderate exacerbation was defined as when COPD patients visited outpatient clinics with an ICD-10 code of COPD (J43.x\u221244.x, except J430, as the primary or within the fifth secondary diagnosis) and systemic steroid medication with or without antibiotics were prescribed.", [["COPD", "DISEASE", 42, 46], ["COPD", "DISEASE", 106, 110], ["steroid", "CHEMICAL", 206, 213], ["steroid", "CHEMICAL", 206, 213], ["patients", "ORGANISM", 47, 55], ["steroid", "SIMPLE_CHEMICAL", 206, 213], ["patients", "SPECIES", 47, 55], ["Moderate exacerbation", "PROBLEM", 0, 21], ["an ICD", "TREATMENT", 88, 94], ["COPD", "PROBLEM", 106, 110], ["systemic steroid medication", "TREATMENT", 197, 224], ["antibiotics", "TREATMENT", 241, 252], ["exacerbation", "OBSERVATION", 9, 21], ["ICD", "OBSERVATION", 91, 94], ["COPD", "OBSERVATION", 106, 110]]], ["Severe exacerbation was defined as when COPD patients visited the emergency room or were admitted to hospital with an ICD-10 code of COPD and were prescribed steroid medication with or without antibiotics.", [["COPD", "DISEASE", 40, 44], ["COPD", "DISEASE", 133, 137], ["steroid", "CHEMICAL", 158, 165], ["steroid", "CHEMICAL", 158, 165], ["patients", "ORGANISM", 45, 53], ["steroid", "SIMPLE_CHEMICAL", 158, 165], ["patients", "SPECIES", 45, 53], ["Severe exacerbation", "PROBLEM", 0, 19], ["COPD", "PROBLEM", 40, 44], ["an ICD", "TREATMENT", 115, 121], ["COPD", "PROBLEM", 133, 137], ["steroid medication", "TREATMENT", 158, 176], ["antibiotics", "TREATMENT", 193, 204], ["exacerbation", "OBSERVATION", 7, 19], ["ICD", "OBSERVATION", 118, 121], ["COPD", "OBSERVATION", 133, 137]]], ["A high COPD grade was arbitrarily defined as patients who were (1) tertiary hospital care patients meeting the above definition of COPD, and (2) regularly used triple inhaler therapy (inhaled corticosteroids [ICS] + long acting beta-2 agonists [LABA] + long acting muscarinic antagonists [LAMA]) or used of systemic steroid therapy at least twice per year with COPD inhaler therapy (LAMA or ICS + LABA)34.", [["COPD", "DISEASE", 7, 11], ["COPD", "DISEASE", 131, 135], ["LABA", "CHEMICAL", 245, 249], ["steroid", "CHEMICAL", 316, 323], ["LABA", "CHEMICAL", 397, 401], ["steroid", "CHEMICAL", 316, 323], ["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 90, 98], ["beta-2 agonists", "GENE_OR_GENE_PRODUCT", 228, 243], ["LABA", "SIMPLE_CHEMICAL", 245, 249], ["long acting muscarinic antagonists", "SIMPLE_CHEMICAL", 253, 287], ["LAMA", "SIMPLE_CHEMICAL", 289, 293], ["steroid", "SIMPLE_CHEMICAL", 316, 323], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 90, 98], ["A high COPD grade", "PROBLEM", 0, 17], ["tertiary hospital care", "TREATMENT", 67, 89], ["COPD", "PROBLEM", 131, 135], ["triple inhaler therapy", "TREATMENT", 160, 182], ["inhaled corticosteroids [ICS", "TREATMENT", 184, 212], ["long acting beta-2 agonists", "TREATMENT", 216, 243], ["LABA", "TREATMENT", 245, 249], ["long acting muscarinic antagonists", "TREATMENT", 253, 287], ["LAMA])", "TREATMENT", 289, 295], ["systemic steroid therapy", "TREATMENT", 307, 331], ["COPD inhaler therapy", "TREATMENT", 361, 381], ["LAMA or ICS + LABA)", "TREATMENT", 383, 402], ["high", "OBSERVATION_MODIFIER", 2, 6], ["COPD", "OBSERVATION", 7, 11]]], ["The HIRA 2007\u20132012 data were used to analyse utilization of COPD medication, comorbidity, and hospital admission.", [["COPD", "DISEASE", 60, 64], ["COPD medication", "TREATMENT", 60, 75], ["comorbidity", "PROBLEM", 77, 88]]], ["The 2007 data were used to identify the history of COPD exacerbation over the past year, and the 2008\u20132012 data were used to analyse the relationship between COPD exacerbation and putative predictive factors.Study design and data source ::: MethodsWe also collected primary weather variables, including levels of particulate matter <10 microns in diameter (PM10, \u00b5g/m3), daily minimum ambient temperature (\u00b0C), and daily precipitation for 2007\u20132012.", [["COPD", "DISEASE", 51, 55], ["COPD", "DISEASE", 158, 162], ["putative predictive factors", "PROTEIN", 180, 207], ["COPD exacerbation", "PROBLEM", 51, 68], ["COPD exacerbation", "PROBLEM", 158, 175], ["putative predictive factors", "PROBLEM", 180, 207], ["COPD", "OBSERVATION", 51, 55], ["COPD", "OBSERVATION", 158, 162]]], ["All the information amassed was matched to the patients\u2019 addresses.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55]]], ["The area of the respective provinces (n = 16) ranged from 501 to 19,031 km2 (median: 6,628 km2, interquartile range: 827\u201310,362 km2).Study design and data source ::: MethodsThe Korean National Institute of Health (KNIH) monitors the trends of virus activity on a nation level.", [["Methods", "TREATMENT", 166, 173], ["virus activity", "PROBLEM", 243, 257], ["area", "OBSERVATION_MODIFIER", 4, 8], ["respective", "OBSERVATION_MODIFIER", 16, 26], ["provinces", "OBSERVATION_MODIFIER", 27, 36], ["virus activity", "OBSERVATION", 243, 257]]], ["KNIH has surveyed respiratory viral infection status since 2000 and provided information to the public on a weekly basis (detection rate, %).", [["KNIH", "CHEMICAL", 0, 4], ["respiratory viral infection", "DISEASE", 18, 45], ["respiratory viral infection", "PROBLEM", 18, 45], ["detection rate", "TEST", 122, 136], ["respiratory", "ANATOMY", 18, 29], ["viral infection", "OBSERVATION", 30, 45]]], ["Data on the activities of influenza adenovirus, parainfluenza virus, respiratory syncytial virus, influenza virus (IFV), human coronavirus (hCoV), human rhinovirus (hRV), human bocavirus, and human enterovirus were collected from the KNIH database for the 2007\u20132012 period.Study design and data source ::: MethodsAdditionally, we tracked the tendencies of online web search queries (normalized search volume index, 0\u2013100), containing the key terms \u201cflu\u201d, \u201cdyspnea\u201d, \u201casthma\u201d, \u201cCOPD\u201d, \u201cacute exacerbation\u201d, \u201cemphysema,\u201d and \u201cchronic bronchitis\u201d on Naver (www.naver.com; the biggest search engine site in Korea), for the period 2007 to 2012.Statistical analysis ::: MethodsDescriptive statistics were used to characterize the study population (mean and standard deviation [SD], and percent).", [["influenza adenovirus", "DISEASE", 26, 46], ["parainfluenza virus", "DISEASE", 48, 67], ["respiratory syncytial virus", "DISEASE", 69, 96], ["influenza virus", "DISEASE", 98, 113], ["human coronavirus", "DISEASE", 121, 138], ["flu", "DISEASE", 449, 452], ["dyspnea", "DISEASE", 456, 463], ["asthma", "DISEASE", 467, 473], ["COPD", "DISEASE", 477, 481], ["emphysema", "DISEASE", 507, 516], ["bronchitis", "DISEASE", 532, 542], ["influenza adenovirus", "ORGANISM", 26, 46], ["parainfluenza virus", "ORGANISM", 48, 67], ["respiratory syncytial virus", "ORGANISM", 69, 96], ["influenza virus", "ORGANISM", 98, 113], ["human coronavirus", "ORGANISM", 121, 138], ["hCoV", "GENE_OR_GENE_PRODUCT", 140, 144], ["human rhinovirus", "ORGANISM", 147, 163], ["hRV", "ORGANISM", 165, 168], ["human", "ORGANISM", 171, 176], ["bocavirus", "ORGANISM", 177, 186], ["human", "ORGANISM", 192, 197], ["enterovirus", "ORGANISM", 198, 209], ["influenza adenovirus", "SPECIES", 26, 46], ["parainfluenza virus", "SPECIES", 48, 67], ["respiratory syncytial virus", "SPECIES", 69, 96], ["influenza virus", "SPECIES", 98, 113], ["human", "SPECIES", 121, 126], ["coronavirus", "SPECIES", 127, 138], ["human", "SPECIES", 147, 152], ["rhinovirus", "SPECIES", 153, 163], ["human", "SPECIES", 171, 176], ["human", "SPECIES", 192, 197], ["parainfluenza virus", "SPECIES", 48, 67], ["respiratory syncytial virus", "SPECIES", 69, 96], ["influenza virus", "SPECIES", 98, 113], ["IFV", "SPECIES", 115, 118], ["human coronavirus", "SPECIES", 121, 138], ["hCoV", "SPECIES", 140, 144], ["human rhinovirus", "SPECIES", 147, 163], ["hRV", "SPECIES", 165, 168], ["human", "SPECIES", 171, 176], ["human", "SPECIES", 192, 197], ["influenza adenovirus", "PROBLEM", 26, 46], ["parainfluenza virus", "PROBLEM", 48, 67], ["respiratory syncytial virus", "PROBLEM", 69, 96], ["influenza virus", "PROBLEM", 98, 113], ["human coronavirus (hCoV", "PROBLEM", 121, 144], ["human rhinovirus", "PROBLEM", 147, 163], ["human bocavirus", "PROBLEM", 171, 186], ["human enterovirus", "PROBLEM", 192, 209], ["volume index", "TEST", 401, 413], ["dyspnea", "PROBLEM", 456, 463], ["asthma", "PROBLEM", 467, 473], ["COPD", "PROBLEM", 477, 481], ["acute exacerbation", "PROBLEM", 485, 503], ["emphysema", "PROBLEM", 507, 516], ["chronic bronchitis", "PROBLEM", 524, 542], ["the study population", "TEST", 720, 740], ["syncytial virus", "OBSERVATION", 81, 96], ["flu", "OBSERVATION", 449, 452], ["asthma", "OBSERVATION", 467, 473], ["COPD", "OBSERVATION", 477, 481], ["acute", "OBSERVATION_MODIFIER", 485, 490], ["exacerbation", "OBSERVATION", 491, 503], ["emphysema", "OBSERVATION", 507, 516], ["chronic", "OBSERVATION_MODIFIER", 524, 531], ["bronchitis", "OBSERVATION", 532, 542]]], ["Independent t-tests were used to compare continuous variables and chi-square tests were used for categorical variable comparisons.", [["Independent t-tests", "TEST", 0, 19], ["continuous variables", "TEST", 41, 61], ["chi-square tests", "TEST", 66, 82], ["categorical variable comparisons", "TEST", 97, 129]]], ["Because all longitudinal data related to these patients are measured repeatedly, it violates the independency assumption of general statistical techniques.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55]]], ["Therefore, the occurrence of acute exacerbation was investigated using generalized estimating equations (GEEs)35.", [["acute exacerbation", "PROBLEM", 29, 47], ["generalized estimating equations", "PROBLEM", 71, 103], ["acute", "OBSERVATION_MODIFIER", 29, 34], ["exacerbation", "OBSERVATION", 35, 47]]], ["Univariate analysis was performed by GEE between COPD exacerbation and single factor one by one.", [["COPD", "DISEASE", 49, 53], ["Univariate analysis", "TEST", 0, 19], ["COPD exacerbation", "PROBLEM", 49, 66], ["COPD", "OBSERVATION", 49, 53]]], ["Then, multivariable analysis was performed with all factors included.", [["multivariable analysis", "TEST", 6, 28]]], ["Factors included in multivariable analysis were time variables, sex, smoking history, CAT score, FEV1(%), prescription of COPD medication, ICD-10 code for comorbidities, number of hospital admissions during the previous year (2007), number of ER visits during the previous year (2007), the history of acute exacerbations during the previous year (2007), grade of COPD, activities of viruses, cumulative exposures to PM10, meteorological factors, and online web search query logs.", [["COPD", "DISEASE", 122, 126], ["COPD", "DISEASE", 363, 367], ["PM10", "CHEMICAL", 416, 420], ["ER", "GENE_OR_GENE_PRODUCT", 243, 245], ["CAT", "PROTEIN", 86, 89], ["ER", "PROTEIN", 243, 245], ["multivariable analysis", "TEST", 20, 42], ["CAT score", "TEST", 86, 95], ["FEV1", "TEST", 97, 101], ["COPD medication", "TREATMENT", 122, 137], ["ICD", "TREATMENT", 139, 142], ["comorbidities", "PROBLEM", 155, 168], ["acute exacerbations", "PROBLEM", 301, 320], ["COPD", "PROBLEM", 363, 367], ["activities of viruses", "PROBLEM", 369, 390], ["acute", "OBSERVATION_MODIFIER", 301, 306], ["exacerbations", "OBSERVATION", 307, 320], ["COPD", "OBSERVATION", 363, 367]]], ["Subsequently, backward elimination of significant variables was performed.", [["significant variables", "PROBLEM", 38, 59], ["significant", "OBSERVATION_MODIFIER", 38, 49]]], ["All analyses were performed with SAS software, version 9.4 (SAS Institute, Cary, NC).", [["All analyses", "TEST", 0, 12], ["SAS software", "TEST", 33, 45], ["version", "TEST", 47, 54]]]]}